legemiddel-
statistikk 2015:2

Reseptregisteret 2010–2014

The Norwegian Prescription Database 2010–2014

Tema: Antibiotika

Topic: Antibiotics

folkehelseinstituttet

legemiddel-
statistikk 2015:2

Reseptregisteret 2010–2014

The Norwegian Prescription Database 2010–2014

Christian Berg
Hege Salvesen Blix
Olaug Fenne
Kari Jansdotter Husabø
Irene Litleskare
Ingvild Odsbu

Tema: Antibiotika

Topic: Antibiotics

folkehelseinstituttet

Rapport 2015:2
Nasjonalt folkehelseinstitutt /
The Norwegian Institute of Public Health

Tittel/Title:
Reseptregisteret 2010–2014

The Norwegian Prescription Database 2010–2014

Redaktør/Editor:
Christian Berg

Forfattere/Authors:
Christian Berg
Hege Salvesen Blix
Olaug Fenne
Kari Jansdotter Husabø
Irene Litleskare
Ingvild Odsbu

Publisert av / Published by:
Folkehelseinstituttet
Postboks 4404 Nydalen
NO-0403
Norway

Tel: + 47 21 07 70 00
E-mail: folkehelseinstituttet@fhi.no
www.fhi.no

Design/Layout
Houston911

Acknowledgement:
Julie D.W. Johansen (English version)

Forsideillustrasjon / Front page illustration:
iStockPhoto

Trykk/Print:
www.wj.no

Opplag / Number printed:
300

Bestilling/Order:
publikasjon@fhi.no
Fax: +47-21 07 81 05
Tel: +47-21 07 82 00

ISSN: 1890-9647
ISBN: 978-82-8082-665-7 trykt utgave /printed version
ISBN: 978-82-8082-666-4 elektronisk utgave /electronic version

Tidligere utgaver / Previous editions:
2008: Reseptregisteret 2004–2007 / The Norwegian Prescription Database 2004–2007
2009: Legemiddelstatistikk 2009:2: Reseptregisteret 2004–2008 / The Norwegian Prescription Database 2004–2008
2010: Legemiddelstatistikk 2010:2: Reseptregisteret 2005–2009. Tema:Vanedannende legemidler / The Norwegian Prescription Database 2005–2009. Topic: Addictive drugs
2011: Legemiddelstatistikk 2011:2: Reseptregisteret 2006–2010 / The Norwegian Prescription Database 2006–2010
2012: Legemiddelstatistikk 2012:2: Reseptregisteret 2007–2011 / The Norwegian Prescription Database 2007–2011
2013: Legemiddelstatistikk 2013:2: Reseptregisteret 2008–2012 / The Norwegian Prescription Database 2008–2012
2014: Legemiddelstatistikk 2014:2: Reseptregisteret 2009–2013. / The Norwegian Prescription Database 2009–2013.

Forord

Bruken av legemidler i befolkningen er økende. En viktig målsetting for norsk legemiddelpolitikk er rasjonell legemiddelbruk. En forutsetning for arbeidet med å optimalisere legemiddelbruken i befolkningen er kunnskap om hvilke legemidler som brukes, hvem som bruker legemidlene og hvordan de brukes. For å få bedre kunnskap på dette området, vedtok Stortinget i desember 2002 å etablere et nasjonalt reseptbasert legemiddelregister (Reseptregisteret). Oppgaven med å etablere registeret ble gitt til Folkehelseinstituttet som fra 1. januar 2004 har mottatt månedlige opplysninger fra alle apotek om utlevering av legemidler til pasienter, leger og institusjoner.

Denne rapporten er åttende utgave av den årlige statistikken fra Reseptregisteret. Årets utgave er et temanummer med fokus på bruk av antibiotika i Norge. Temakapitlet (del 1 i rapporten) inneholder bl.a. en del nøkkeltall om antibiotikabruk og fokus på bruken hos enkelte utvalgte grupper. Generell informasjon om Reseptregisteret, legemiddelstatistikk, klassifikasjon av legemidler og målemetoder finnes i rapportens del 2. Del 3 inneholder noen nøkkeltall fra Reseptregisteret og et omfattende tabellverk med opplysninger om antall individer som har fått utlevert legemidler etter resept fra apotekene i Norge i siste femårsperiode (2010–2014). Opplysningene er fordelt på enkeltlegemidler og legemiddelgrupper. ATC (Anatomisk Terapeutisk Kjemisk) -klassifikasjon er benyttet i tabellene. For 2014 er informasjon om alders- og kjønnsfordeling og kostnader inkludert i tabellene.
ATC-/DDD-versjon gjeldende fra januar 2015 er benyttet i rapporten, se også www.whocc.no

Reseptregisteret har også en nettside der man kan finne kompletterende informasjon: www.norpd.no (engelsk versjon) eller www.reseptregisteret.no (norsk versjon).
Det er også mulig å søke om utlevering av data fra Reseptregisteret til forskning eller til andre formål som er i henhold til formålet for Reseptregisteret. Mer informasjon om dette finnes i rapportens del 3 og på nettsiden til Folkehelseinstituttet (www.fhi.no).

Avdeling for legemiddelepidemiologi
Folkehelseinstituttet
April 2015

Preface

The use of drugs in the population is increasing. An important goal of the health policies regarding pharmaceuticals in Norway is rational drug use. In order to improve drug use, knowledge about which drugs are used, how they are used and who uses them is vital. In December 2002, the Parliament decided to establish a national prescription database in Norway (NorPD). The task of building up the register was given to the Norwegian Institute of Public Health (NIPH). Since 1st January 2004, the institute has received monthly data on prescriptions from all Norwegian pharmacies.

This report is the eigth edition of the annual statistics from NorPD. This year's report is a theme issue focusing on the usage of antibiotics in Norway. The theme issue (part 1 of the report) presents some key figures regarding use of antibiotics and focus on the usage in selected groups of the population. General information about NorPD, drug statistics, classification of drugs and measurement methods is included in part 2 of the report. Part 3 contains some key figures from NorPD and the main tables with information about the number of individuals who had prescriptions dispensed from pharmacies in Norway during the latest five years period (2010–2014). The information includes particular drug substances as well as drug groups. ATC (Anatomical Therapeutic Chemical) classification is used in the tables. For 2014, information about age, gender and costs are included in the tables.
The ATC/DDD version of January 2015 has been used in the report, see also www.whocc.no

NorPD also has a website where you can find complementary information: www.norpd.no (English version) or www.reseptregisteret.no (Norwegian version). It is also possible to apply for data from NorPD for research or for other purposes which are according to the objectives of NorPD. More information about this can be found in part 3 of the report, and at the website of the Norwegian Institute of Public Health (www.fhi.no).

Department of Pharmacoepidemiology
Norwegian Institute of Public Health
April 2015

Innhold

Forord 6

1. Bruk av antibiotika i Norge 13

Introduksjon 13

1.1 Sammendrag 14

1.2 Bruk av antibiotika basert på tall fra Grossistbasert legemiddelstatistikk 15

1.3 Bruk av antibakterielle midler – nøkkeltall fra Reseptregisteret 18

1.3.1 Mest brukte antibakterielle midler 18

1.3.2 Andel brukere (prevalens) i 2014 fordelt på aldersgrupper og kjønn 19

1.3.3 Regionale forskjeller i antibiotikabruk 20

1.4 Antibiotika ved urinveisinfeksjoner, luftveisinfeksjoner og akne/hudproblemer, fordelt på aldersgrupper 21

1.5 Antibiotikabruk hos barn 23

1.5.1 Bruk av systemiske antibiotika hos barn 23

1.5.2 Behandling av bakterielle konjunktivitter (øyekatarr) hos barn. 24

1.6 Antibiotika til 19-åringer 27

1.7 Bruk av antibiotika i Norge sammenlignet med Sverige og Danmark 28

2. Generelt om Reseptregisteret og legemiddelstatistikk 31

2.1 Reseptregisteret (NorPD) 31

2.2 Nordiske reseptregistre 34

2.3 Grossistbasert legemiddelstatistikk 35

2.4 Anatomisk Terapeutisk Kjemisk (ATC)-klassifikasjon 35

2.5 Definert Døgndose (DDD) 36

2.6 WHO Collaborating Centre for Drug Statistics Methodology 37

3. Reseptregisteret 2010–2014 39

3.1 Utvalgte nøkkeltall fra Reseptregisteret 39

3.2 Reseptkategorier og refusjon av utgifter til legemidler 43

3.3 Beskrivelse av hovedtabellene 47

3.4 ATC main groups 51

3.5 ATC group A – Alimentary tract and metabolism 52

3.6 ATC group B – Blood and bloodforming organs 63

3.7 ATC group C – Cardiovascular system 66

3.8 ATC group D – Dermatologicals 74

3.9 ATC group G – Genito urinary system and sex hormones 80

3.10 ATC group H – Systemic hormonal preparations, excl. sex hormones and insulins 85

3.11 ATC group J – Antiinfectives for systemic use 88

3.12 ATC group L – Antineoplastic and immunomodulating agents 94
3.14 ATC group N – Nervous system 100
3.15 ATC group P – Antiparasitic products, insecticides and repellents 110
3.16 ATC group R – Respiratory system 112
3.17 ATC group S – Sensory organs 117
3.18 ATC group V – Various 121

Noen forkortelser og definisjoner 122

Folkemengde i Norge 2010–2014 (per 1. juli) 123
Folkemengde etter alder i 2014 (per 1. juli) 123

Liste over publikasjoner basert på data fra Reseptregisteret per mars 2015 124

Contents

Preface 6

1. Use of antibiotics in Norway **13**
Introduction 13
1.1 Summary 14
1.2 Use of antibiotics based on figures from the Norwegian Drug Wholesale Statistics 15
1.3 Use of antibacterials – key figures from NorPD 18
1.3.1 The most used antibacterials 18
1.3.2 Proportion of users (prevalence) in 2014 by age and gender 19
1.3.3 Regional differences in antibiotic use 20
1.4 Antibiotics used in urinary tract infections, respiratory infections and acne/skin problems, by age 21
1.5 Antibiotikabruk hos barn 23
1.5.1 Use of systemic antibiotics in children 23
1.5.2 Treatment of bacterial conjunctivitis in children 24
1.6 Antibiotics among 19-years old 27
1.7 Use of antibiotics in Norway compared to Sweden and Denmark 28

2. General information about the Norwegian Prescription Database and drug statistics **31**
2.1 About the NorPD 31
2.2 Prescription statistic in the other Nordic countries 34
2.3 The Norwegian Drug Wholesales Statistics 35
2.4 The Anatomical Therapeutic Chemical (ATC) classification system 35
2.5 The Defined Daily Dose (DDD) 36
2.6 The WHO Collaborating Centre for Drug Statistics Methodology 37

3. The Norwegian Prescription Database (NorPD) 2010–2014 ..... **39**
3.1 Selected key figures from NorPD 39
3.2 Prescription categories and reimbursement of medicinal expenses 43
3.3 Description of the main tables 47
3.4 ATC main groups 51
3.5 ATC group A – Alimentary tract and metabolism 52
3.6 ATC group B – Blood and bloodforming organs 63
3.7 ATC group C – Cardiovascular system 66
3.8 ATC group D – Dermatologicals 74
3.9 ATC group G – Genito urinary system and sex hormones 80
3.10 ATC group H – Systemic hormonal preparations, excl. sex hormones and insulins 85
3.11 ATC group J – Antiinfectives for systemic use 88

3.12 ATC group L – Antineoplastic and immunomodulating agents 94
3.13 ATC group M – Musculo-skeletal system 97
3.14 ATC group N – Nervous system 100
3.15 ATC group P – Antiparasitic products, insecticides and repellents 110
3.16 ATC group R – Respiratory system 112
3.17 ATC group S – Sensory organs 117
3.18 ATC group V – Various 121

Some abbreviations and definitions 122

Population in Norway 2010–2014 (as of 1st July) 123
Population by age in 2014 (as of 1st July) 123

List of publications based on data from the Norwegian Prescription Database (NorPD) as of March 2015 124

Del 1 Part 1

1. Bruk av antibiotika i Norge

Introduksjon

Antibiotika er betegnelsen på stoffer som hemmer eller dreper sykdomsskapende mikroorganismer. I denne rapporten anvendes betegnelsen antibiotika om antibakterielle legemidler.

De fleste antibiotika på markedet i dag ble utviklet i forrige århundre, og det er få nye antibiotika under utvikling. Bakterier kan ved eksponering for antibiotika utvikle resistens, det vil si bli motstandsdyktige mot virkningen av antibiotika. Utvikling og spredning av antibiotikaresistens representerer en alvorlig trussel mot global folkehelse. Det er høy forekomst av antibiotikaresistens i bakterier som forårsaker vanlige infeksjoner som urinveisinfeksjoner og lungebetennelse i alle regioner av verden. Flere land rapporterer om behandlingssvikt på grunn av antibiotikaresistens, også ved bruk av bredspektret antibiotika.

Norge er en del av det internasjonale samfunn der antibiotikaresistens er et stadig større problem. Selv om smalspektret antibiotika fremdeles kan brukes mot vanlige infeksjoner i Norge, er multiresistens også observert hos oss.

Det er et overordnet mål å redusere bruken av antibiotika og unngå unødvendig bruk, som uttrykt i *Nasjonal faglig retningslinje for antibiotikabruk i primærhelsetjenesten* (1) og *Nasjonal faglig retningslinje for bruk av antibiotika i sykehus* (2). Et viktig ledd i strategien mot antibiotikaresistens er kunnskap om forbruket i befolkningen. Reseptregisteret og Grossistbasert legemiddelstatistikk er viktige kilder for overvåkning og analyse av antibiotikabruk i Norge.

I denne delen av rapporten omtaler vi spesielt bruken av antibiotika og presenterer data fra Reseptregisteret

1. Use of antibiotics in Norway

Introduction

Antibiotics are substances that inhibit or kill microorganisms. In this report the term antibiotics is used for antibacterial agents.

Most antibiotics on the market today were developed in the last century, and there are few new antibiotics under development. When exposed to antibiotics, bacteria may develop resistance, a feature that makes them resistant to the effect of antibiotics. The development and spread of antibiotic resistance represents a serious threat to global public health. There is a high prevalence of antibiotic resistance in bacterias that cause common infections like urinary tract infections and pneumonia in all regions of the world. Treatment failure due to resistance to broad spectrum antibiotics has been reported from several countries.

Norway is a part of the international community where antibiotic resistance is an increasing problem. Even though narrow spectrum antibiotics can still be used for common infections in Norway, multi-resistance is also observed here.

It is an overall goal to reduce the use of antibiotics and avoid unnecessary use, as expressed in *Guidelines for the use of antibiotics in primary care* (1) and *Guidelines for the use of antibiotics in hospitals* (2). A key part of the strategy against antibiotic resistance is knowledge of the consumption in the population. The Norwegian Prescription Registry (NorPD) and the Norwegian Drug Wholesale Statistics are important sources for monitoring and analysing antibiotic use in Norway.

In this part of the report we look specifically at the use of antibiotics and present data from the NorPD and the Norwegian Drug Wholesale Statistics. Both historical

og Grossistbasert legemiddelstatistikk. Både historisk utvikling og aktuell bruk av antibiotika presenteres. For detaljer om Reseptregisteret, se del 2. Det er ikke forsøkt å gi en fullstendig analyse, men en presentasjon av nøkkeltall og eksempler på analyser fra registrene. For en mer detaljert analyse av bruken av antibiotika i Norge, viser vi til den årlige rapporten fra NORM/NORMvet *(3)* med mer data fra Reseptregisteret og Grossistbasert legemiddelstatistikk.

1.1 Sammendrag

Bruken av antibiotika i Norge har økt i perioden 1999–2014. Reseptregisteret viser at 28 % av kvinner og 19 % av menn fikk utlevert et systemisk antibiotikum (ATC-gruppe J01) på resept minst én gang i 2014. Bruken varierer mellom aldersgrupper og kjønn. Kvinner bruker mer enn menn. Det er en høy andel brukere blant unge voksne, men den høyeste andelen brukere finner man blant de eldste i befolkningen (> 80 år).

I Norge utgjør få antibiotika hovedandelen av all bruk. I 2014 representerte smalspektrede penicilliner 25 % av bruken, men også tetrasykliner (bredspektrede antibiotika) brukes i stort omfang. Det er store fylkesvise forskjeller i bruken. Østfold har høyest andel brukere av antibiotika, mens Troms og Finnmark har den laveste andelen.

Antibiotika som hovedsakelig brukes ved luftveisinfeksjoner bidrar mest til antibiotikabruken hos barn og voksne under 65 år. Hos de eldre dominerer antibiotika som brukes ved urinveisinfeksjoner.

Bruken av antibiotika hos barn (0–12 år) i perioden 2010 til 2014 har vært relativt stabil, men har gått ned de siste to årene. I 2014 hadde Nord-Trøndelag det høyeste forbruket av antibiotika og Finnmark det laveste forbruk blant barn i aldersgruppen 0–5 år. Antibiotika til behandling av øyeinfeksjoner hos barn i alderen 0–5 år varierer også, men med annen fylkesvariasjon. Andelen som fikk utlevert kloramfenikol eller fusidinsyre var nesten dobbelt så høyt i de to fylkene med høyest forbruk (Aust-Agder og Vestfold) sammenlignet med de to fylkene med lavest forbruk (Rogaland og Sogn og Fjordane).

I mai bruker 19-åringer svært mye antibiotika. Dette har sannsynligvis sammenheng med russefeiringen.

Forbruksmønsteret av antibiotika er ganske likt i Skandinavia, men Sverige har et lavere forbruk av antibiotika per innbygger enn i Norge og Danmark.

trends and current antibiotic use are presented. For details about NorPD, see part 2. We have not endeavoured to give a full analysis, but to present key figures and examples of analysis from the registries. For a more detailed analysis of the use of antibiotics in Norway, we refer to the annual report from NORM/NORMvet *(3)* with more data from the NorPD and the Norwegian Drug Wholesale Statistics.

1.1 Summary

The use of antibiotics in Norway has increased from1999 to 2014. Data from the NorPD shows that 28% of women and 19 % of men were dispensed at a systemic antibiotic (ATC group J01) on prescription at least one time in 2014. The use of antibiotics varies across age and gender. Women use more than men. Young adults have a high proportion of users, but the highest proportion of users is among the oldest age group (> 80 years).

A small number of antibiotics account for the majority of the total antibiotic usage. The narrow spectrum penicillins represented 25% of the use in 2014, but also tetracyclines (broad spectrum antibiotics) were extensively used. There are large regional differences in use. Østfold has the highest proportion of users of antibiotics, while Troms and Finnmark has the lowest proportion.

Antibiotics used primarily for respiratory infections contribute most to the use of antibiotics in children and adults under 65 years. In the older age groups, antibiotics used for urinary tract infections dominate the prescriptions.

The use of antibiotics in children (0–12 years) has been relatively stable between 2010 and 2014, but has decreased over the last two years. Nord-Trøndelag had the highest consumption of antibiotics in children aged 0–5 years in 2014 and Finnmark the lowest consumption. Antibiotics for the treatment of eye infections in children aged 0–5 years also vary, but with a differing variation between the counties. The proportion receiving prescriptions were almost twice as high in the two counties with the highest consumption (Aust-Agder and Vestfold) compared with the two counties with the lowest consumption (Rogaland and Sogn og Fjordane).

In May, 19-year-olds are dispensed a high number of antibiotics. This is a likely consequence of the celebration "russefeiring" in connection with graduation from high school.

The use of antibiotics in the Scandinavian countries is quite similar, but Sweden has a lower consumption of antibiotics per capita than Norway and Denmark.

1.2 Bruk av antibiotika basert på tall fra Grossistbasert legemiddelstatistikk

Tabell 1.2. gir en oversikt over antibakterielle midler (ATC gruppe J01) på markedet i Norge.

Informasjon om totalt salg av legemidler fra grossist til apotek i Norge har vært tilgjengelig siden 1970-årene. Denne statistikken er en viktig kilde til en overordnet oversikt over hva som brukes av legemidler. Den gir

1.2 Use of antibiotics based on figures from the Norwegian Drug Wholesale Statistics

Table 1.2. gives an overview of antibacterial agents (ATC group J01) on the market in Norway.

Information about total sales of drugs from wholesalers to pharmacies in Norway has been available since the 1970s. These statistics are an important

Table 1.2. Antibacterials for systemic use (ATC group J01) on the market in Norway 2014.

ATC code		Brand names
J01A	**Tetracyclines**	
J01AA02	Doxycycline	Doksycyklin, Doxylin, Oracea,Vibranord
J01AA04	Lymecycline	Lymecyclin,Tetralysal
J01AA07	Tetracycline	Tetracyclin
J01AA12	Tigecycline	Tygacil
J01C	**Beta-lactam antibacterials, penicillins**	
J01CA01	Ampicillin	Ampicillin, Pentrexyl
J01CA04	Amoxicillin	Amoxicillin, Imacillin
J01CA08	Pivmecillinam	Penomax, Selexid
J01CA11	Mecillinam	Selexid (for injection)
J01CE01	Benzylpenicillin	Benzylpenicillin, Penicillin
J01CE02	Phenoxymethyl-penicillin	Apocillin, Weifapenin
J01CF01	Dicloxacillin	Diclin, Diclocil, Dicloxacillin
J01CF02	Cloxacillin	Cloxacillin, Ekvacillin
J01CR05	Piperacillin and enzyme inhibitor	Pipercillin/Tazobactam, Piptazira, Tazocin
J01D	**Other beta-lactam antibacterials**	
J01DB01	Cefalexin	Keflex
J01DB03	Cefalotin	Cefalotin, Keflin
J01DC02	Cefuroxime	Cefuroxim, Zinacef
J01DD01	Cefotaxime	Cefotaxim
J01DD02	Ceftazidime	Ceftazidim, Fortum
J01DD04	Ceftriaxone	Ceftriaxon
J01DF01	Aztreonam	Azactam, Cayston
J01DH02	Meropenem	Meropenem
J01DH03	Ertapenem	Invanz
J01DH51	Imipenem and enzyme inhibitor	Imipenem/Cilastatin, Tienam
J01DI02	Ceftaroline fosamil	Zinforo

ATC code		Brand names
J01E	**Sulfonamides and trimethoprim**	
J01EA01	Trimethoprim	Trimetoprim
J01EE01	Sulfameth-oxazole and trimethoprim	Bactrim
J01F	**Macrolides, lincosamides and streptogramins**	
J01FA01	Erythromycin	Abboticin, Ery-Max
J01FA02	Spiramycin	Rovamycin
J01FA09	Clarithromycin	Clarithromycin, Klacid
J01FA10	Azithromycin	Azitromax
J01FF01	Clindamycin	Dalacin
J01G	**Aminoglycoside antibacterials**	
J01GB01	Tobramycin	Nebcina, Tobi, Tobramycin
J01GB03	Gentamicin	Gensumycin, Gentamicin, Septopal
J01M	**Quinolone antibacterials**	
J01MA01	Ofloxacin	Tarivid
J01MA02	Ciprofloxacin	Ciprofloxacin, Ciproxin
J01MA12	Levofloxacin	Levofloxacin
J01X	**Other antibacterials**	
J01XA01	Vancomycin	Vancomycin
J01XA02	Teicoplanin	Targocid
J01XB01	Colistin	Colobreathe, Promixin
J01XC01	Fusidic acid	Fucidin
J01XD01	Metronidazole	Flagyl, Metronidazol
J01XE01	Nitrofurantoin	Furadantin
J01XX05	Methenamine	Hiprex
J01XX08	Linezolid	Zyvoxid
J01XX09	Daptomycin	Cubicin



Figure 1.2: Sales of antibacterials for systemic use (ATC group J01) in Norway in 1999–2014 measured in DDD/1000 inhabitants/day. Source: The Norwegian Drug Wholesales Statistics

oss muligheten til å følge bruken over tid og i ulike deler av landet. I henhold til grossistforskriften er alle legemiddelgrossister pålagt å rapportere det månedlige salget til Folkehelseinstituttet. Grossiststatistikken omfatter alt salg av antibiotika, også til sykehus og sykehjem. Databasen gir imidlertid ikke informasjon om forbruket knyttet til individer (pasient eller forskriver). Se også del 2.3 om Grossistbasert legemiddelstatistikk. For opplysninger om klassifikasjonssystemet for legemidler (ATC) og måleenheten definert døgndose (DDD), se del 2.4 og 2.5.

Historiske data for ATC gruppe J01 Antibakterielle midler til systemisk bruk fra Grossistbasert legemiddelstatistikk for perioden 1999 til 2014 presenteres som antall DDD per 1 000 innbyggere per døgn (Figur 1.2). Dette gir et grovt bilde av bruken i befolkningen. For eksempel indikerer 10 DDD/1 000 innbyggere/døgn at 1 % av befolkningen bruker legemidlet daglig. Dette stemmer likevel bare dersom det er godt samsvar mellom DDD og dosen som faktisk brukes i behandlingen. For antibiotika som hovedsakelig brukes i korte kurer, vil DDD/1 000 innbyggere/døgn gi et usikkert estimat av antall brukere. Måleenheten er derimot godt egnet til å følge trender i legemiddelbruken over tid.

source to obtain an overview over drug consumption. It gives us the opportunity to follow usage over time and in different parts of the country. According to the Regulation about wholesalers, all drug wholesalers are required to report monthly sales to the Norwegian Institute of Public Health. The wholesales statistics include all sales of antibiotics, also to hospitals and nursing homes. However, the database provides no information on individuals (patient or prescriber). See also section 2.3 regarding the Norwegian Drug Wholesale Statistics. For information about classification of drug substances (ATC) and the unit of measurement, Defined Daily Dose (DDD), see section 2.4 and 2.5.

Historical data for ATC group J01 Antibacterials for systemic use from the wholesale statistics for the period 1999 to 2014 are presented as the number of DDD per 1000 inhabitants per day (Figure 1.2). This gives a rough overview of the use in the population. For example 10 DDD/1000 inhabitants/day indicates that 1% of the population uses drugs daily. This estimate is only valid if there is a good correlation between the DDD and the actual dose consumed. Antibiotics are mainly used in short courses. Thus DDD/1000 inhabitants/day gives an uncertain esti-

I 2014 var totalsalget av antibakterielle midler til humant bruk 19,3 DDD/1 000 innbyggere/døgn. Bruken av antibiotika var noe redusert i 2014 sammenlignet med de foregående årene. I 2011 og 2012 forårsaket en Mycoplasma epidemi høyere forskrivning av makrolider og tetrasykliner.

Økt salg av antibakterielle midler i perioden 1999–2010 skyldes hovedsakelig en økning i bruken av penicilliner og urinveisantiseptikumet metenamin. Dersom vi ser bort fra metenamin, var antibiotikabruken på 15,7 DDD/1 000 innbyggere/døgn i 2014.

Bruk av smalspektrede antibiotika kan dempe utviklingen av antibiotikaresistente bakterier. I Norge bruker vi mer smalspektrede antibiotika som penicilliner, sammenlignet med mange andre land. I 2014 utgjorde penicillinene (J01C) 42 % av totalforbruket av antibiotika. I løpet av årene har det likevel vært en dreining mot bruk av mer bredspektrede penicilliner i Norge, men beta-laktamase sensitive penicilliner (J01CE) (smalspektret) er fortsatt den største undergruppen av penicillinene.

Bruken av makrolider, linkosamider og streptograminer (J01F) har variert noe fra år til år, men andelen gruppen har utgjort av totalforbruket er relativt stabil. Makrolider, brukt ved luftveisinfeksjoner, utgjør den største andelen av denne gruppen.

Kinoloner er bredspektrede midler som skal forbeholdes alvorlige infeksjoner. Økende bruk av kinoloner også ved mindre alvorlige infeksjoner har gitt økt resistens mot disse midlene. I 2013 ble bruken av kinoloner for første gang redusert siden fluorokinoloner (J01MA) kom på markedet i Norge tidlig på 1990-tallet, og nedgangen fortsatte i 2014. Kinoloner representerer kun 3 % av totalt antibakterielt salg i 2014, men salget målt i DDD/1 000 innbygger/døgn er doblet siden 1999.

Økningen i bruk av andre antibakterielle midler (J01X) skyldes hovedsakelig metenamin som brukes profylaktisk mot urinveisinfeksjon. Metenamin stod for 19 % av total antibakteriell bruk i 2014.

mate of the number of users. This unit of measure, however, will be suitable to follow trends in drug use over time.

In 2014, total sales of antibacterials for human use were 19.3 DDD/1000 inhabitants/day. The use of antibiotics was somewhat reduced in 2014 compared with previous years. In 2011 and 2012 a Mycoplasma epidemic caused increased prescribing of macrolides and tetracyclines.

Increased sales of antibacterials in the period 1999–2010 were mainly due to an increase in the consumption of penicillins and the urinary tract antiseptic methenamine. When excluding methenamine, the use of antibiotics in 2014 was 15.7 DDD/1000 inhabitants/day.

The use of narrow-spectrum antibiotics is important to avoid development of antibiotic resistance. In Norway, more narrow-spectrum antibiotics, such as penicillins, are used compared to many other countries. In 2014, penicillins (J01C) accounted for 42% of the total consumption of antibiotics in Norway. Over the years there has been a shift towards the use of more broad-spectrum penicillins. However, beta-lactamase sensitive penicillins (J01CE) (narrow spectrum) are still the largest subgroup of penicillins.

The use of macrolides, lincosamides and streptogramins (J01F) has varied from year to year, but the group still represents a relatively stable share of the total consumption. Macrolides used for respiratory tract infections represent the largest share of this group.

Quinolones are broad-spectrum agents which should be reserved for serious infections. Increasing use of quinolones in less serious infections has increased resistance to these agents. In 2013, the use of quinolones decreased for the first time since the fluoroquinolones (J01MA) were introduced on the market in Norway in the early 1990s, and the decline continued in 2014. Quinolones represent only 3% of the total antibacterial sales in 2014, but sales measured in DDD/1000 inhabitants/day have doubled since 1999.

The increased use of other antibacterials (J01X) is mainly due to methenamine, which is used prophylactically against urinary tract infections. Methenamine accounted for 19% of the total antibacterial consumption in 2014.

Table 1.3.1.a The 10 most used antibacterials for systemic use (ATC group J01, excl. methenamine) in 2014 according to the number of prescriptions per 100 inhabitants. Source: NorPD

Active ingredient (ATC code)	Number of prescriptions per 100 individuals	Proportion of the total number of prescriptions (%)	Proportion of the population (%)
Phenoxymethylpenicillin (J01CE02)	9,9	24,9	8,2
Pivmecillinam (J01CA08)	5,5	14,0	4,0
Doxycycline (J01AA02)	3,3	8,4	2,7
Amoxicillin (J01CA04)	3,2	8,1	2,6
Erythromycin (J01FA01)	2,5	6,4	2,2
Dicloxacillin (J01CF01)	2,4	6,1	1,9
Trimethoprim (J01EA01)	2,1	5,4	1,5
Azithromycin (J01FA10)	1,8	4,6	1,5
Ciprofloxacin (J01MA02)	1,7	4,3	1,2
Clindamycin (J01FF01)	1,6	4,0	1,2

1.3 Bruk av antibakterielle midler – nøkkeltall fra Reseptregisteret

1.3.1 Mest brukte antibakterielle midler

Tabellene 1.3.1.a og 1.3.1.b viser de ti mest brukte systemiske antibakterielle midlene (ATC-gruppe J01, ekskl. metenamin) i Norge i 2014, målt henholdsvis i antall resepter og antall definerte døgndoser (DDD) per 100 innbyggere.

Fenoksymetylpenicillin var det mest brukte antibiotikumet i 2014 og står for omtrent 25 % av forbruket både med hensyn på andel av totalt antall resepter og med hensyn på total andel av DDD. I alt 8,2 % av den norske befolkningen hentet ut fenoksymetylpenicillin minst èn gang på resept i 2014. De tre mest brukte tetrasyklinene (doksysyklin, lymesyklin og tetrasyklin) står samlet for nesten 25 % av antibiotikaforbruket målt i DDD. Tetrasyklinene brukes ofte som lengre kurer, noe som gjenspeiles ved at bare doksysyklin er inkludert på listen over de ti mest solgte med hensyn til antall resepter per 100 individ, mens alle de tre tetrasyklinene er inkludert på listen over forbruk målt i DDD. Erytromycin er det mest brukte makrolidet. Erytromycin utgjør cirka 5 % av totalforbruket i ATC gruppe J01, målt i DDD.

1.3 Use of antibacterials – key figures from NorPD

1.3.1 The most used antibacterials

Table 1.3.1.a and 1.3.1.b shows the ten most commonly used antibacterials (ATC-group J01, excl. methenamine) in 2014, measured by the number of prescriptions and the number of defined daily doses (DDDs) per 100 inhabitants.

Phenoxymethylpenicillin was the most commonly used antibiotic in 2014 and accounts for approximately 25 % of the consumption in terms of both proportion of total prescriptions and the proportion of the total DDD. 8.2% of the Norwegian population were dispensed phenoxymethylpenicillin on prescription at least once in 2014. The three most commonly used tetracyclines (doxycycline, lymecykline and tetracycline) account for almost 25% of antibiotics measured in DDD. Tetracycline is often used in long treatment courses, which is reflected by the fact that only doxycycline is seen among the top ten antibiotics in terms of number of users and the number of prescriptions per 100 individuals, while all three tetracyclines are among the top ten antibiotics in terms of consumption, measured in number of DDDs. Erythromycin is the most used macrolide. Erythromycin represents approximately 5% of total consumption in ATC group J01 measured in DDDs.

Table 1.3.1.b The 10 most used antibacterials for systemic use (ATC J01, excl. methenamine) in 2014 according to the number of DDDs per 100 inhabitants. Source: NorPD

Active ingredient (ATC code)	Number of DDDs per 100 individuals	Proportion of total number of DDDs (%)	Proportion of the population (%)
Phenoxymethylpenicillin (J01CE02)	113	25,1	8,2
Doxycycline (J01AA02)	60	13,2	2,7
Pivmecillinam (J01CA08)	54	12,0	4,0
Amoxicillin (J01CA04)	40	8,8	2,6
Lymecycline (J01AA04)	35	7,7	0,5
Erythromycin (J01FA01)	24	5,3	2,2
Dicloxacillin(J01CF01)	21	4,6	1,9
Tetracycline (J01AA07)	17	3,9	0,4
Ciprofloxacin (J01MA02)	17	3,9	1,2
Trimethoprim (J01EA01)	13	3,0	1,5

1.3.2 Andel brukere (prevalens) i 2014 fordelt på aldersgrupper og kjønn

Reseptregisteret viser at i 2014 fikk 28 % av norske kvinner og 19 % av norske menn utlevert systemiske antibakterielle midler (ATC-gruppe J01) på resept minst én gang. Ved beregning av andel brukere (prevalens) i Reseptregisteret benyttes hele befolkningen som nevner. Legemidler til pasienter på sykehus eller sykehjem er ikke tilgjengelig på individnivå i Reseptregisteret og konsekvensen for de eldste aldersgruppene, der en stor andel av befolkningen bor på sykehjem, er for lave tall for andel av legemiddelbrukere. I figur1.2.a er det derfor gjort en justering for beboere i institusjon for aldersgruppene over 80 år. Vi har benyttet informasjon fra Statistisk Sentralbyrå om beboere i institusjoner i 2010.

Figur 1.3.2 viser andel brukere av antibiotika hos menn og kvinner i forhold til alder. Det er relativt store alders- og kjønnsforskjeller. Bruk av antibiotika øker med økende alder, og andelen brukere er størst hos den eldre delen av befolkningen (> 80 år). En relativt høy andel av barn i småbarnsalderen har fått forskrevet antibiotika. Andelen synker hos eldre barn, men øker igjen i tenårene.

1.3.2 Proportion of users (prevalence) in 2014 by age and gender

In 2014, the NorPD shows that 28 % of Norwegian women and 19 % of Norwegian men had at least one prescription of systemic antibiotics (ATC group J01) dispensed. The entire population is used as denominator when calculating prevalence in the NorPD. Drugs dispensed to patients in hospitals or nursing homes are not available at an individual level in the NorPD. The consequence for the oldest age groups, where a large proportion of the population lives in a nursing home, is too low figures for the proportion (prevalence) of drug users. In figure1.2.a we have therefore adjusted for residents in institutions for the age groups > 80 years. Data from Statistics Norway about residents in institutions in 2010 were used.

Figure 1.3.2 shows the proportion of users of antibiotics by gender and age. There are relativeliy large age and gender differences. Use of antibiotics increases with age, and the proportion of users is greatest in the older part of the population (> 80 years). A relatively high proportion of children in early childhood have had antibiotics dispensed. The proportion drops in older children, but rises again in early adulthood.



Figure 1.3.2: Proportion of users (prevalence) of antibacterials for systemic use (ATC group J01, excl. methenamine) in 2014 by age and gender. For the older part of the population (>80), the prevalence is based on the population living outside institutions. Source: NorPD

Figuren viser også at kjønnsfordelingen er relativt lik i småbarnsalderen, men fra 15–16-årsalderen øker kjønnsforskjellene. Den største forskjellen sees i 19-årsalderen. For alle aldersgrupper er andelen kvinner som bruker antibiotika større enn andelen menn, med unntak av aldersgruppen 1–2 år. En av årsakene til at flere kvinner enn menn bruker antibiotika er at urinveisinfeksjoner forekommer hyppigere hos kvinner. Den økende bruken både hos kvinner og menn i tidlig voksen alder kan ha sammenheng med bruk av antibiotika til behandling av akne. En høyere forekomst av f.eks. klamydia i denne aldersgruppen vil også gi utslag på antibiotikabruken.

1.3.3 Regionale forskjeller i antibiotikabruk

Figur 1.3.3 viser fylkesvise forskjeller når det gjelder antall brukere av systemiske antibiotika i 2014. Østfold hadde den største andelen brukere både blant kvinner og menn, mens Troms hadde den laveste andelen blant kvinner og Finnmark den laveste andelen blant menn.

The figure also shows that gender ratios are relatively equal in early childhood, but from 15 to 16 years of age, the gender differences increase and the biggest difference is observed at the age of 19. For all age groups, the proportion of women who use antibiotics is greater than the proportion of men, with the exception of the age group 1–2 years. One of the reasons why more women than men use antibiotics is that urinary tract infections occur more frequently in women. The increased use of antibiotics among both women and men in early adulthood may to some extent be related to the use of antibiotics to treat acne. A higher incidence of e.g. chlamydia will also be reflected in the consumption figures in this age group.

1.3.3 Regional differences in antibiotic use

Figure 1.3.3 shows regional differences in terms of number of users of systemic antibiotics in 2014. Østfold county had the largest proportion of users, both among women and men, while Troms had the lowest proportion among women and Finnmark had the lowest proportion among men.



Figure 1.3.3: Proportion of users (prevalence) of antibacterials for systemic use (ATC group J01, excl. methenamine) in 2014 by gender and county. Source: NorPD

Table 1.4 Definition and grouping of antibiotics according to indications.

Indication group	Substances (ATC code)
Antibiotics mainly used in respiratory tract infections	Phenoxymetylpenicillin (J01CE02), amoxicillin (J01CA04), doxycycline (J01AA02), macrolides (J01FA: erythromycin, spiramycin, clarithromycin, azithromycin)
Antibiotics mainly used in urinary tract infections	Pivmecillinam (J01CA08), trimethoprim (J01EA01), sulfamethoxazole and trimethoprim (J01EE01), ofloxacin (J01MA01), ciprofloxacin (J01MA02), nitrofurantoin (J01XE01)
Tetracyclines often used for acne/skin problems	Lymecycline (J01AA04), oxytetracycline (J01AA06), tetracykline (J01AA07)
Methenamine (prophylactic urinary antiseptic)	Methenamine (J01XX05)
All other antibiotics	All other substances included in ATC group J01

1.4 Antibiotika ved urinveisinfeksjoner, luftveisinfeksjoner og akne/hudproblemer, fordelt på aldersgrupper

I Reseptregisteret er det foreløpig ingen informasjon om indikasjoner for antibiotika. Dette gjør det utfordrende å forstå bruksmønstre i henhold til retningslinjene for behandling. Antibiotika kan anvendes for forskjellige infeksjonstyper, men de fleste antibiotika kan plasseres i grovt definerte grupper av infeksjoner. I tabell 1.4 er de mest brukte antibiotika fordelt på de vanligste indikasjonene.

1.4 Antibiotics used in urinary tract infections, respiratory infections and acne/skin problems, by age

The NorPD does currently not include information about indications for antibiotics which makes it challenging to understand drug consumption patterns based on treatment guidelines. Antibiotics may be used for different infection types, but most antibiotics can be allocated into roughly defined groups of infections. Table 1.4 shows the most used antibiotics allocated to common indications.



Figure 1.4: Antibiotic therapy profiles in four age groups in 2014; children (0–12 years), young adults (13–29 years), adults (30–64 years) and elderly (65+ years). Proportion of prescriptions is grouped into indication groups according to the dispensed antibiotic. Source: NorPD

Figur 1.4 viser at antibiotika som hovedsakelig brukes ved luftveisinfeksjoner bidrar mest til antibiotikabruken hos barn og voksne under 65 år. Hos de eldre dominerer antibiotika som brukes for urinveisinfeksjoner. Sammen med den høye andelen som bruker metenamin (et profylaktisk urinveisantiseptisk middel) viser dette at urinveisinfeksjoner er et problem hos de eldre. Figuren gir kun et estimat siden de fleste antibiotika kan brukes ved andre indikasjoner enn indikasjonsgruppen den er plassert i her. Amoxicillin kan f.eks. brukes både ved urinveis- og luftveis-infeksjoner, men er her plassert i gruppen «luftveisantibiotika».

Figure 1.4 shows that antibiotics mainly used for respiratory tract infections contribute most to the total amount of antibiotics used in children and adults under 65 years. Antibiotics used for urinary tract infections dominate in the elderly. Together with the high proportion of methenamine prescriptions (prophylactic urinary antiseptic), this shows that urinary tract infections are problematic in older age. The figure is only an estimate since most antibiotics can be used for other indications, e.g. amoxicillin, which can be used for both urinary and respiratory tract infections, but is allocated to the respiratory tract antibiotics in this setting.



Figure 1.5.1.a: Proportion of users (prevalence) of antibacterials for systemic use (ATC-group J01) by gender and age among children aged 0–5 and 6–12 years in Norway for the years 2010–2014. Source: NorPD

1.5 Antibiotikabruk hos barn

1.5.1 Bruk av systemiske antibiotika hos barn

En relativt høy andel av de aller yngste barna får utlevert antibiotika på resept, mens andelen blant de litt eldre barna er betydelig mindre. Ser man nærmere på utviklingen i aldersgruppene 0–5 år og 6–12 år over de siste fem årene (figur 1.5.1.a), viser denne at andelen brukere har vært relativt stabil, men at det var en nedgang i antall brukere i 2013 og 2014 sammenlignet med 2011 og 2012 i begge aldersgrupper. Dette kan trolig tilskrives økt bruk i forbindelse med en Mycoplasma epidemi i 2011 og 2012.

Ifølge *Nasjonal faglig retningslinje for antibiotikabruk i primærhelsetjenesten (1)* er fenoksymetylpenicillin (J01CE02) førstevalg ved luftveisinfeksjoner hos barn. Figur 1.5.1.b viser at det er fylkesvise forskjeller både når det gjelder mengden antibiotika og andelen fenoksymetylpenicillin som utleveres til barn i alderen 0–5 år. I 2014 hadde Nord-Trøndelag det høyeste forbruket av antibiotika (6,4 DDD per 1000 barn per dag) og Finnmark laveste forbruk (2,6 DDD per 1000 barn per dag). Landsgjennomsnittet var 5,2 DDD per 1000 barn per dag. Andelen fenoksymetylpenicillin varierte fra 24 % i Nord-Trøndelag til 47 % i Troms og Finnmark. Landsgjennomsnittet var 38 %. Antall anti-

1.5 Use of antibiotics in children

1.5.1 Use of systemic antibiotics in children

A high proportion of toddlers were dispensed antibiotics, while the proportion among older children is significantly lower. Looking closer at the development in the age groups 0–5 years and 6–12 years over the last five years, figure 1.5.1.a shows that the proportion of users has been relatively stable, but that there was a decline in the number of users in 2013 and 2014 compared with 2011 and 2012 in both age groups. This can probably be attributed to a Mycoplasma epidemic in 2011 and 2012.

According to the *Guidelines for the use of antibiotics in primary care (1)* phenoxymethylpenicillin (J01CE02) is the drug of choice for treatment of respiratory infections in children. Figure 1.5.1.b shows regional differences both in terms of the amount of antibiotics dispensed and the proportion of phenoxymethylpenicillin dispensed to children aged 0–5 years. In 2014, Nord-Trøndelag had the highest consumption of antibiotics (6.4 DDD per 1000 children per day) and Finnmark had the lowest consumption (2.6 DDD per 1,000 children per day). The average in Norway was 5.2 DDD per 1000 children per day. The proportion of phenoxymethylpenicillin dispensed ranged from 24%



Figure 1.5.1.b: Consumption of antibacterials for systemic use (ATC group J01) in children aged 0–5 years by county 2014. Source: NorPD

biotikaresepter til barn i alderen 0–5 år varierte også mellom de ulike fylkene, fra 517 resepter per 1000 barn per år i Nord-Trøndelag til 210 resepter per 1000 barn per år i Finnmark. Landsgjennomsnittet var 397 resepter per 1000 barn per år.

1.5.2 Behandling av bakterielle konjunktivitter (øyekatarr) hos barn.

Bakterielle konjunktivitter er en vanlig øyelidelse, spesielt hos barn i barnehagealder, og behandles i Norge ofte med lokal antibiotika. Vanligvis benyttes kloramfenikol eller fusidinsyre, som dråper eller salve.

Figur 1.5.2.a viser andelen barn i aldersgruppen 0–5 år som har fått utlevert kloramfenikol eller fusidinsyre øyedråper/-salve på resept i 2014, fordelt på fylker. Figuren viser også antall resepter som er hentet ut per 100 barn i samme aldersgruppe. Antall resepter per 100 barn er nesten dobbelt så høyt i de tre fylkene med høyest forbruk (28–29 resepter per 100 barn i

in Nord-Trøndelag to 47% in Troms and Finnmark. The average in Norway was 38%. The number of antibiotic prescriptions dispensed to children aged 0–5 years also varied between counties, from 517 prescriptions per 1 000 children per year in Nord-Trøndelag to 210 prescriptions per 1 000 children per year in Finnmark. The average in Norway was 397 prescriptions per 1 000 children per year.

1.5.2 Treatment of bacterial conjunctivitis in children

Bacterial conjunctivitis is a common eye disease, especially among children in pre-school age, and is often treated with local antibiotics in Norway. Chloramphenicol or fusidic acid are commonly used antibacterials as drops or ointment.

Figure 1.5.2.a shows the proportion of children aged 0–5 years who have had chloramphenicol or fusidic acid eye drops or ointment dispensed in 2014 by



Figure 1.5.2.a: Use of chloramphenicol and fusidic acid eye drops/ointments in children aged 0–5 years in 2014 by county measured in number of prescriptions per 100 children and proportion (%) of users. Source: NorPD

Aust-Agder, Vestfold og Oslo) sammenlignet med de to fylkene med lavest forbruk (15 resepter per 100 barn i Rogaland og Sogn og Fjordane). Variasjonen i andel behandlede barn mellom fylkene viser nesten samme tendens som variasjonen i antall resepter.

Figur 1.5.2.b viser variasjonen i forbruket til gutter og jenter i aldersgruppen 0 til 5 år i perioden 2005 til 2014. Forbruket var spesielt høyt i 2010. Forbruket har gått gradvis nedover siden 2010, og 2014 var det året med lavest andel brukere i hele perioden. Andelen gutter som behandles er høyere enn andelen jenter for alle år.

county. The figure also shows the number of prescriptions per 100 children in the same age group. The number of prescriptions per 100 children is almost twice as high in the three counties with the highest consumption (28 to 29 prescriptions per 100 children in Aust-Agder, Vestfold and Oslo) compared with the two counties with the lowest consumption (15 prescriptions per 100 children in Rogaland and Sogn og Fjordane). The variation in the proportion of children treated between counties shows almost the same tendency as the variation in the number of prescriptions.

Figure 1.5.2.b shows the variation in consumption for boys and girls aged 0 to 5 years in the period 2005 to 2014. The consumption was particularly high in 2010. There has been a gradual reduction in consumption since 2010, and 2014 was the year with the lowest proportion of users in the entire period. The proportion of boys being treated is higher than the proportion of girls for all years.



Figure 1.5.2.b: Use of chloramphenicol and fusidic acid eye drops/ointments in boys and girls aged 0–5 years in 2005–2014. Source: NorPD



Figure 1.6: The number of 17-, 19-, and 21-year-olds who were dispensed antibiotics mainly used for respiratory tract infections (see table 1.5) from mid-April to mid-June. For each date, except May 1st and May 17th, the figure shows the number of individuals who had at least one antibiotic dispensed, averaged over the years 2005–2014 where the actual date was not a Sunday or a public holiday. Source: NorPD

1.6 Antibiotika til 19-åringer

Bruken av antibiotika hos 19-åringer i mai er langt høyere enn bruken hos 17- og 21-åringer i samme periode. Bruken hos 19-åringer gjenspeiler russefeiringen og avslutningen av videregående skole. Ungdommene feirer fra begynnelsen av mai og frem til 17. mai. Figur 1.6 viser økningen i dag-til-dag-utlevering av antibiotika som vanligvis brukes for luftveisinfeksjoner. Det er ingen salg 1. mai og 17. mai ettersom apotekene er stengt. Den kraftige økningen etter 17. mai kan forklares med økt forskrivning av antibiotika for luftveisinfeksjoner i etterkant av russefeiringen *(4)*.

1.6 Antibiotics among 19-years old

The use of antibiotics among 19-year-olds in May is far higher than among 17- and 21-year-olds in the same period. The use among 19-year-olds reflects «russefeiringen», the traditional celebration at the end of 12 years education. The celebration begins in early May and continues until May 17th – the Norwegian Constitution Day. Figure 1.6 shows an increased day-to-day dispensing of antibiotics typically used for respiratory tract infections. Pharmacies are closed on May 1st and May 17th which are public holidays. The steep increase after May 17th can be explained by increased prescribing of antibiotics for respiratory tract infections after «russefeiringen» *(4)*.



Figure1.7 : Proportion of users (prevalence) of antibacterials for systemic use (ATC group J01) according to gender and age in 2013, Norway compared to Sweden and Denmark .
Source: Socialstyrelsen, http://www.socialstyrelsen.se/statistik/statistikdatabas/lakemedel og Statens Serum Institut, Lægemiddelstatistik, http://www.medstat.dk/

1.7 Bruk av antibiotika i Norge sammenlignet med Sverige og Danmark

Bruken av antibiotika i Skandinavia er generelt lav i forhold til de fleste land i Europa. Figur 1.7 sammenligner antibiotikabruk i Norge, Sverige og Danmark. Forbruket følger samme mønster når det gjelder alder og kjønn i de tre landene. Kvinner bruker generelt mer antibiotika enn menn. Sverige ligger lavere i bruk enn Norge og Danmark for begge kjønn i de fleste aldersgrupper. Danmark har høyere forbruk enn Norge. Forbrukstoppen i begynnelsen av 20-årene er mindre uttalt i Sverige.

I alle land er det en betydelig økning i bruken av antibiotika fra 50-årsalderen hos både kvinner og menn. I befolkningen over 70 år er andelen som har fått forskrevet antibiotika høyere enn i småbarnsgruppen (0–4 år) for begge kjønn i alle tre land.

1.7 Use of antibiotics in Norway compared to Sweden and Denmark

The use of antibiotics in Scandinavia is generally low compared to most countries in Europe. Figure 1.7 compares use of antibiotics in Norway, Sweden and Denmark. The consumption follows the same pattern in terms of age and gender in the three countries. Women generally use more antibiotics than men. Sweden has a lower consumption than Norway and Denmark for both genders in almost all age groups. Denmark has a higher consumption than Norway. The peak in proportion of users in the beginning of their twenties is less pronounced in Sweden.

In all countries there is a significant increase in the use of antibiotics from the age of 50 among both women and men. In the population over 70 years, the proportion prescribed antibiotics is higher than in the group of young children (0–4 years) for both genders in all three countries.

Referanser/References:

1. Nasjonal faglig retningslinje for antibiotikabruk i primærhelsetjenesten, (Guidelines for the use of antibiotics in primary) https://helsedirektoratet.no/retningslinjer/nasjonal-faglig-retningslinje-for-antibiotikabruk-i-primerhelsetjenesten)
2. Nasjonal faglig retningslinje for bruk av antibiotika i sykehus, (Guidelines for use of antibiotics in hospitals) https://sites.helsedirektoratet.no/sites/antibiotikabruk-i-sykehus/Sider/default.aspx
3. NORM NORM-VET. Usage of Antimicrobial Agents and Occurrence of Antimicrobial Resistance in Norway, Oslo 2014 http://www.vetinst.no/Publikasjoner/NORM-NORM-VET)
4. Blix H S, Hjellvik V. Økt bruk av antibiotika blant 19-åringer i mai (Increased use of antibiotics among nineteen-year-olds in May). Tidsskr Nor Legeforen 2012; 132:1084 – 8. doi: 10.4045/tidsskr.11.1122

Del 2 Part 2

2. Generelt om Reseptregisteret og legemiddelstatistikk

2.1 Reseptregisteret (NorPD)

Datainnsamling og variabler i Reseptregisteret
Ny apoteklov trådte i kraft 1. mars 2001, og ifølge den nye loven ble apotek forpliktet til å videresende reseptdata til en ny nasjonal legemiddeldatabase. I oktober 2003 ble ny detaljert forskrift for Reseptregisteret (hjemlet i Helseregisterloven) vedtatt av Kongen i Statsråd (1). Formålet med Reseptregisteret (jf. forskriftens § 1-3) er å samle inn og behandle data om legemiddelbruk hos mennesker og dyr for å:

1. kartlegge forbruket i landet og belyse endringer over tid
2. fremme og gi grunnlag for forskning og utredning for å kunne belyse positive og negative effekter av legemiddelbruk
3. gi myndighetene et statistisk grunnlag for kvalitetssikring av legemiddelbruk og overordnet tilsyn, styring og planlegging
4. gi legemiddelrekvirenter et grunnlag for internkontroll og kvalitetsforbedring

Forskriftens formål bestemmer hva Reseptregisteret kan brukes til. Forskriften bestemmer også hva slags data som kan samles inn fra apotek og administrative registre.

2. General information about the Norwegian Prescription Database and drug statistics

2.1 About the NorPD

Data collection and variables in NorPD
New legislation in the Norwegian pharmacy sector came into force on March 1st 2001. According to the new act, pharmacies were obliged to forward prescription data to a new national drug database. In October 2003, new, detailed regulations for the NorPD were approved (1). The objectives of the NorPD, as defined in authoritative regulations, are to collect and prepare data on drug use in individuals and animals in order to:

1. describe drug use patterns, highlighting changes over time
2. promote and form a basis for research and review of the safety and effectiveness of drug use
3. serve as a management tool for the authorities in order to assure prescribing quality in addition to general surveillance, control and planning
4. give the prescribing doctors a basis for internal control, as part of an audit method to improve the quality of prescribing practices

All NorPD data use must be in accordance with these objectives. The regulation also determines what kind of data can be collected from the pharmacies and administrative registers.

Reseptregisteret inneholder følgende variabler:

Pasient

Personidentifikasjon (kryptert), fødselsmåned /-år, dødsmåned/- år, kjønn, bosted (kommune og fylke)

Forskriver

Personidentifikasjon (kryptert), fødselsår, kjønn, yrke, spesialitet

Legemiddel

Nordisk varenummer (handelsnavn, styrke, legemiddelform, pakningsstørrelse), antall pakninger, ATC-kode, antall definerte døgndoser (DDD), reseptkategori, kode for refusjon (fra mars 2008: ICD10, ICPC-2-koder og enkelte koder definert av Legemiddelverket, fullstendig implementert fra mars 2009), bruksområde og forskrevet dose (fritekst), utleveringsdato, pris (apotekets utsalgspris)

Apotek

Apoteknavn, konsesjonsnummer, kommune og fylke

Det nordiske varenummeret er en unik identifikasjon for hver pakning av et legemiddel og muliggjør kobling til andre registre som gir detaljert informasjon om legemidlene. Indikasjon for forskrivning ble de første årene ikke registrert i databasen, kun overordnede refusjonskoder som for enkelte legemidler fungerte som grov diagnosekode. Fra mars 2008 ble forskriver pålagt å angi mer spesifikke diagnosekoder på blåresepter som erstatning for de gamle sykdomspunktene. Det skal benyttes enten International Classification of Diseases versjon 10 (ICD-10) eller International Classification of Primary Care versjon 2 (ICPC). I tillegg har Legemiddelverket på enkelte områder definert egne koder. Ordningen er fullstendig implementert fra mars 2009.

Fra 1. januar 2004 har Folkehelseinstituttet mottatt månedlig informasjon om reseptutleveringer fra alle apotek i Norge (2). I alle apotek er det tilrettelagt for automatisk innsending av rapport til Reseptregisteret til fast tidspunkt hver måned, slik at apotekene kan oppfylle sin rapporteringsplikt uten vesentlig ekstra arbeid. Reseptregisteret inneholder informasjon om alle legemidler som er forskrevet og utlevert til enkeltpasienter utenom sykehus og institusjoner. Legemidler forskrevet på godkjenningsfritak er også inkludert, men legemidler som selges reseptfritt er ikke registrert i Reseptregisteret. Hvis reseptfrie legemidler er forskrevet på resept vil de imidlertid bli registrert i databasen.

De viktigste dataene i Reseptregisteret er basert på resepter forskrevet til enkeltpersoner, men også forskrivning av legemidler fra veterinærer til dyr og forskrivning til egen praksis registreres i Reseptregisteret. Når det gjelder pasienter som er innlagt i sykehus eller sykehjem, samler registeret kun inn

The NorPD contains the following variables:

Patient

Person-identifier (encrypted), month/year of birth, month/year of death, gender, place of residence (municipality & county)

Prescriber

Person-identifier (encrypted), year of birth, gender, profession, speciality

Drug

Nordic article number (unique product identifier stating brand name, strength, pharmaceutical form and pack size), number of packs, ATC code, number of Defined Daily Doses (DDD), prescription category, reimbursement code (from March 2008: ICD10, ICPC-2 codes or codes defined by the Norwegian Medicines Agency, completely implemented from March 2009), intended use and prescribed dose (free-text according to pharmacy label), dispensing date, price (pharmacy retail price)

Pharmacy

Name, licence number, municipality and county

The Nordic article number is the important link to other registries providing detailed information about the drugs. The indication for prescribing was in the first years not recorded in the database, only the code of reimbursement which in some cases, acted as a proxy of diagnosis. From March 2008, prescribers had to use either the International Classification of Diseases version 10 (ICD10), or the International Classification of Primary Care Codes version 2 (ICPC) or special codes assigned by the Norwegian Medicines Agency as the code of reimbursement on the prescriptions. This was fully implemented from March 2009.

Since 1st January 2004, the NIPH has received monthly data on prescriptions from all Norwegian pharmacies (2). Monthly electronically reports are automatically generated in all pharmacies, thus avoiding extra work for the pharmacy. NorPD contains information about all drugs prescribed (reimbursed or not) and dispensed at pharmacies to individual patients living outside institutions, i.e. ambulant care. Unlicensed drugs are also included, but drugs sold over-the-counter (OTC) are not recorded in NorPD. However, if the OTC drugs are prescribed by a physician and dispensed, then they will be recorded in the database.

The main data in NorPD are based on prescriptions to individual humans, but also prescribed drugs by veterinarians to animals and prescribing to a physician's own practice are collected in NorPD. For patients in nursing homes and hospitals, the register collects figures on drug use at the level of the institution or the department, i.e. on an aggregate level.

Figure 2.1: Data flow, the Norwegian Prescription Database (NorPD)

aggregerte data på institusjons- eller avdelingsnivå, basert på informasjon som apotekene registrerer når de leverer legemidler til institusjoner.

Datasikkerhet
Som illustrert i figur 2.1 blir registreringer av utleverte legemidler fra apotek elektronisk og automatisk overført til Statistisk sentralbyrå (SSB) før de kommer til FHI og inkluderes i Reseptregisteret. SSB fungerer som en såkalt tiltrodd tredjepart og er en del av datasikkerheten for å ivareta konfidensialitet og informasjonssikkerhet for all personlig informasjon. SSB har tilgang til pasientens personnummer og forskrivers helsepersonellnummer, og erstatter begge med et pseudonym. SSB kan ikke lese noen annen informasjon fra reseptene, fordi denne informasjonen er kryptert før SSB mottar dataene. Når SSB sender data er fødselsnummer og forskrivers helsepersonell-nummer fjernet, og FHI kan dekryptere helseopply-sningene som fremgår av resepten igjen. Prinsippet for pseudonymisering er at ingen, heller ikke den som tildeler og forvalter pseudonymer, skal kunne ha samtidig tilgang til både pseudonym, helseop-plysninger og personens identitet. Begrepet "Pseud-onymiserte helsedata" er definert i Helseregisterloven: "Personlig helsedata som identitet er kryptert, eller på annen måte skjult, men likevel individuell, slik at det er mulig å følge hver person gjennom helsesystemet uten at vedkommendes identitet blir avslørt" (3). Dette betyr at identiteten til pasienter og forskrivere har blitt kryptert i henhold til norsk lovgivning, men likevel er individuell, slik at det er mulig å følge enkeltpersoner over tid, og gjøre registerkoblingsstudier.

Kvalitetssikring
For kvalitetssikring blir et antall søk gjennomført månedlig eller halvårlig for å identifisere mulige feil eller uoverensstemmelser. FHI gjør ulike rutinemessige

Data protection
As illustrated in figure 2.1 the pharmacy records of dispensed drugs are electronically and automatically transferred through Statistics Norway before they arrive at NIPH and are included in NorPD. Statistics Norway acts as a so-called "trusted third part centre" and is a part of the data protection to ensure confi-dentiality of personal information. Statistics Norway only has access to the patient personal identification number and the prescriber's health personnel number and replaces both with a pseudonymised identifier. Statistics Norway cannot read any other prescription data because this information is encrypted before Statistics Norway receives the data. When Statistics Norway sends the data including the pseudonymised identifiers to the NIPH, the NIPH is allowed to decrypt the prescription information again. The term "Pseud-onymous health data" is defined in the Personal Health Data Filing System Act (in Norwegian: Helseregister-loven): *"personal health data in which the identity has been encrypted or otherwise concealed, but nonetheless individualized so that it is possible to follow each person through the health system without his identity being revealed"* (3). This means that the identity of patients and prescribers has been encrypted according to Norwegian legislation, but nonetheless individualized, so that it is possible to follow individuals over time and perform record-linkage studies. Data linkage is based on the unique identification number system which is available in all the Nordic countries.

Quality checks
For quality assurance, a number of queries are carried out monthly or half-yearly to identify possible errors or inconsistencies. NIPH performs different routine checks on the data before they are transferred to the NorPD. In the NorPD, the Nordic article number is linked to the national register of medicinal products with validated

kontroller på data før de overføres til Reseptregisterets database. I Reseptregisteret er det nordiske varenummeret knyttet til det nasjonale vareregisteret for legemidler med gyldige ATC-koder og DDD-verdier (4). Dette registeret oppdateres månedlig. FHI sjekker også om dataleveranser fra hvert apotek er av rimelig størrelse. Det totale antallet reseptbelagte poster, totalt antall pasienter og forskrivere blir sjekket hver måned. Statistikk for apotekene blir rutinemessig kjørt. Denne rutinen vil identifisere uvanlige variasjoner i størrelsen på dataleveranser fra måned til måned, og fange opp manglende leveranser av spesielle typer data, eller hvis en datalevering fra ett apotek er tom i en måned på grunn av tekniske feil på apoteket eller hos tiltrodd tredjepart (SSB). Fødselsnummeret kontrolleres hos SSB mot Folkeregisteret. Når fødselsnummeret er ugyldig eller mangler, lager SSB et spesielt pseudonym. Disse personene er ikke mulig å følge over tid, og heller ikke mulig å koble til andre datakilder, men det rapporterte antall ordinasjoner og DDD knyttet til disse personene kan likevel inkluderes i totalstatistikken.

2.2 Nordiske reseptregistre

På slutten av 1980-tallet, tok apotek i de nordiske landene gradvis i bruk elektroniske systemer ved ekspedering av resepter. Dette gjorde det mulig å samle inn reseptdata fra apotek på en enklere og mer effektiv måte. Selv om helsevesenet ikke er organisert likt i de nordiske landene, har alle fem land et helsevesen med universell dekning for helseutgifter. Alle borgere, uavhengig av sosioøkonomisk status, har ubegrenset tilgang til helsetjenester, inkludert delvis eller fullstendig refusjon av kjøpte legemidler. Nasjonale reseptdatabaser, som er basert på data fra ekspederte og utleverte legemidler fra apotek til individer utenfor sykehus/sykehjem, har vært tilgjengelig siden 1994 i Finland og Danmark, siden 2004 i Norge, siden 2005 i Sverige og siden 2006 på Island. Databasene dekker til sammen 25 millioner innbyggere (Danmark: 5,6 millioner, Finland: 5,4 millioner; Island: 0,3 millioner; Norge: 5,1 millioner og Sverige: 9,6 millioner). Det er mulig å koble disse dataene til ulike helseutfall og andre data basert på det unike fødselsnummeret/-koden som alle innbyggere i disse landene har. Databasene er en viktig ressurs for å kunne gjennomføre longitudinelle og registerkoblede studier med helseundersøkelser og andre registre. Databasene representerer også et godt kunnskapsgrunnlag for nasjonale beslutninger innen legemiddelbruk. En artikkel fra 2010 gir en oversikt over datainnsamlingsprosedyrer og innhold i de nordiske landenes reseptregistre (5).

ATC codes and DDD values (4). This register is updated monthly. NIPH also checks if the data deliveries from each pharmacy are of a reasonable size. The total number of prescription records and the total number of patients and prescribers are checked every month. Statistics for the pharmacies are checked by routine. Unusual variations in size of data files from month to month are identified and any missing data is caught, such as missing special data type deliveries or empty data files caused by technical error at the pharmacy or at the trusted third part. The Personal Identification Number is checked in Statistics Norway against the Central Population Registry. If the Personal Identification Number is invalid or missing, Statistics Norway creates a special pseudonym, but it is not possible to track these individuals or link them to other data sources. However, the reported total number of ordinations and DDDs can be included in the total statistics.

2.2 Prescription statistic in the other Nordic countries

During the late 1980s, pharmacies in the Nordic countries gradually computerized their records of dispensed prescriptions which made it possible to collect data efficiently. Although healthcare systems are not organized identically in the Nordic countries, all five countries have a tax-supported public health service with universal coverage. All citizens, independent of socioeconomic status, have unrestricted access to health services, including partial or complete reimbursement of purchased medicines. National prescription databases, containing data on drugs dispensed at pharmacies (exposure data) to individuals receiving ambulatory care, have been available since 1994 in Finland and Denmark, since 2004 in Norway, since 2005 in Sweden and since 2006 in Iceland.
The databases together cover 25 million inhabitants (Denmark: 5.6 million; Finland: 5.4 million; Iceland: 0.3 million; Norway: 5.1 million; and Sweden: 9.6 million) and have the potential to link these data to different health outcomes and other data based on the unique personal identity code which all residents in these countries have. The databases serve as a resource for conducting longitudinal and record-linkage studies with health surveys and other registries. They also offer a sound evidence base for national decision-making in the field of drug utilization. An article from 2010 provides an overview of the data collection procedures and content of the Nordic countries' prescription databases (5). In addition, the article discusses their unique potential for cross-national record linkage and for analytical pharmacoepidemiological studies.

2.3 Grossistbasert legemiddelstatistikk

Statistikk basert på totalt salg av legemidler fra grossist til apotek, sykehus/sykehjem har vært tilgjengelig i Norge siden 1970-tallet. Grossistbasert legemiddelstatistikk omfatter alt salg av legemidler fra grossist til apotek, sykehus/sykehjem, dagligvaredetaljister og andre med tillatelse til å omsette legemidler. Legemidler til dyr og mennesker, både reseptfrie og reseptbelagte, er inkludert i statistikken. Statistikken gir en oversikt over utviklingen i legemiddelomsetningen over tid, både totalt og på fylkesnivå. Statistikken inneholder imidlertid ikke opplysninger om den enkelte legemiddelbruker.

Legemiddelforbruket i Norge – årlig publikasjon
Årlig publiseres data fra den Grossistbaserte legemiddelstatistikken i publikasjonen *Legemiddelforbruket i Norge*. Hver utgave omfatter 5-årsoversikter over totalsalget av reseptfrie og reseptbelagte legemidler i Norge (6). Boken er tilgjengelig på nettsiden www.legemiddelforbruk.no. Nærmere informasjon vedrørende utlevering av data fra den grossistbaserte legemiddelstatistikken finnes på Folkehelseinstituttets nettside www.fhi.no.

2.4 Anatomisk Terapeutisk Kjemisk (ATC)-klassifikasjon

Alle legemidler som er registrert i Norge er gruppert etter ATC-systemet. I ATC-systemet inndeles legemidlene i grupper på 5 nivåer: På 1. nivå fordeles legemidlene på 14 anatomiske hovedgrupper. Det neste nivået (2. nivå) er en terapeutisk eller farmakologisk undergruppe. 3. nivå og 4. nivå er terapeutiske, farmakologiske eller kjemiske undergrupper, mens 5. nivå representerer den kjemiske substansen.

ATC- koden
En fullstendig klassifikasjon av legemiddelsubstansen spironolakton (vanndrivende middel) med ATC-koden C03DA01 kan illustrere oppbyggingen av ATC-systemet:

C	Hjerte og kretsløp (1. nivå, anatomisk hovedgruppe)
C03	Diuretika (2. nivå, terapeutisk undergruppe)
C03D	Kaliumsparende midler (3. nivå, farmakologisk undergruppe)
C03DA	Aldosteronantagonister (4. nivå, farmakologisk undergruppe)
C03DA01	Spironolakton (5. nivå, kjemisk substans)

2.3 The Norwegian Drug Wholesales Statistics

Statistics based on total sales of drugs from wholesalers to pharmacies, hospitals/nursing homes has been available in Norway since the 1970s. The Norwegian Drug Wholesales Statistics database includes total sales of drugs from wholesalers to pharmacies, hospitals/nursing homes and non-pharmacy outlets and others with permission to sell medicines. Total sales of prescription and non-prescription human and veterinary medicines are included in the statistics. The statistics give an overview of developments in drug consumption over time, both at county and country level. The statistics, however, contain no information about the individual drug user.

Drug Consumption in Norway – published annually
Data from the Norwegian Drug Wholesales Statistics Database have been published annually in *Drug Consumption in Norway (6)* since 1977. Each issue includes total sales data for 5 year periods for both prescription- and non-prescription drugs in Norway. The book is available from the website www.drugconsumption.no. Further information on the Norwegian Drug Wholesales Statistics database, including how to apply for data, can be found at the Norwegian Institute of Public Health's website www.fhi.no.

2.4 The Anatomical Therapeutic Chemical (ATC) classification system

In the ATC system the drug substances are classified into groups at 5 different levels. The drugs are divided into fourteen main groups (1st level), with pharmacological/ therapeutic sub-groups (2nd levels). The 3rd and 4th levels are chemical/pharmacological/ therapeutic sub-groups and the 5th level is the chemical substance.

The ATC code
A complete classification of the drug spironolactone (diuretic) with the ATC code C03DA01 illustrates the structure of the ATC system:

C	Cardiovascular system (1st level, anatomical main group)
C03	Diuretics (2nd level, therapeutic sub-group).
C03D	Potassium-sparing agents (3rd level, pharmacological sub-group)
C03DA	Aldosterone antagonists (4th level, pharmacological sub-group)
C03DA01	Spironolactone (5th level, chemical substance)

Alle spironolakton preparater (Aldactone® og Spirix®) gis i dette systemet koden C03DA01.

Ved hjelp av dette klassifikasjonssystemet kan man lage statistikker over legemiddelforbruk gruppert på fem ulike nivåer, fra tall som viser totalforbruket av alle preparater klassifisert f.eks. under hovedgruppe C – *Hjerte og kretsløp* (1. nivå), tall for de ulike undergruppene (2., 3. og 4. nivå) og ned til tall som viser forbruket av det enkelte virkestoff.

ATC-kode for hvert enkelt preparat er angitt i *apotekenes vareregister*, og i preparatomtalene (SPC) som er publisert i *Felleskatalogen*. Ved å bruke "Anatomisk terapeutisk kjemisk legemiddelregister" (Felleskatalogens gule del), vil man få en oversikt over hvilke produktnavn hver enkelt ATC-kode omfatter.

2.5 Definert Døgndose (DDD)

I enkelte tabeller i del 2 i boken er volum av legemiddelbruk angitt i antall DDD. Ved å benytte definerte døgndoser (DDD) som måleenhet, får man bedre mulighet for sammenligninger mellom alternative legemidler uavhengig av prisdifferanser. Vurdering av volum av legemiddelforbruket gjennom lengre tidsperioder, nasjonalt og internasjonalt, blir enklere og bedre ved bruk av definerte døgndoser. Måleenheten DDD er definert som *den antatt gjennomsnittlige døgndose brukt ved preparatets hovedindikasjon hos voksne*.

Døgndosene fastsettes på bakgrunn av en vurdering av bruken internasjonalt, selv om de nasjonale terapitradisjonene kan variere fra et land til et annet (f.eks. bruksområde og doseringsanbefalinger). Den definerte døgndose (DDD) bør derfor betraktes som en teknisk måleverdi.

Legemidler som benyttes ved forskjellige indikasjoner kan by på spesielle problemer som det må tas hensyn til ved vurdering av døgndosestatistikk. Dosen ved hovedindikasjonen benyttes normalt ved fastsettelse av DDD. Med unntak for noen få spesielle barnepreparater benyttes doseringer for voksne. Ofte vil DDD for ulike administrasjonsformer være like med unntak av der biotilgjengeligheten er svært forskjellig. For preparater der man benytter en støtdose og en vedlikeholdsdose, vil døgndosen være basert på vedlikeholdsdosen. Hvis mulig er DDD angitt i mengde aktiv substans. Er det umulig, som f.eks. ved kombinasjonspreparater og enkelte flytende preparater, angis DDD som antall enkeltdoser (antall tabletter, kapsler, milliliter osv.).

All medicinal products containing plain spironolactone (Aldactone® and Spirix®) are thus assigned the code C03DA01.

The ATC classification system makes it possible to compile drug consumption statistics on 5 different levels, i.e., figures showing total consumption of all preparations classified in main group C – *Cardiovascular system* (1st level), figures for the various subgroups (2nd, 3rd and 4th levels), and down to figures showing consumption of each active ingredient.

The ATC code for all pharmaceuticals on the Norwegian market can be retrieved from *the pharmacy medicinal product register* and in the monographs of the national drug catalogue "*Felleskatalogen*". The yellow section of the latter, entitled *The Anatomical Therapeutic Chemical Medicines Register*, lists all medicinal products belonging to each of the ATC 5th level codes.

2.5 The Defined Daily Dose (DDD)

In some tables in part 2 in this book the sales volume of drug consumption is given in number of DDDs. Using DDDs as the unit of measurement allows better comparison between alternative medications, regardless of price differences. The evaluation of drug consumption volumes over time, nationally and internationally, is simplified and improved by the use of DDDs. A DDD is defined as *the assumed average maintenance dose per day for a drug used on its main indication in adults*.

The DDDs are determined on the basis of evaluation of international use of the substance in question, bearing in mind that national therapy traditions (indications, dosages) often differ greatly. Each DDD should therefore be regarded as a technical measuring unit.

Drugs used for more than one indication may cause particular problems which are important to consider when evaluating statistics based on DDDs. With the exception of a very few specially formulated pediatric preparations, adult dosages are used. The DDD for a substance will often be one and the same, irrespective of the route of administration. However, drugs with different bioavailabilities depending on their administration route will have more than one DDD, each of them linked to a specific dosage form. For medications where a booster dose is followed by a smaller maintenance dosage, the maintenance dose will form the basis for determining the DDD. Whenever possible, the DDD is indicated as the quantity of active substance.

DDD representer ikke nødvendigvis den mest forskrevne eller brukte dose, noe som må tas i betraktning når tallene vurderes. Det vil derfor ofte være vanskelig å beregne antall brukere ved kun å bruke DDD som måleenhet. Dette gjelder særlig der doseringsanbefalingene kan variere mye etter bruksområde. Salgstallene kan angis i DDD/1 000 innbyggere/døgn og beregnes på følgende måte:

$$\frac{\text{Samlet forbruk i antall DDD x 1000}}{\text{365 x antall innbyggere}}$$

Dette tallet vil gi et estimat av andelen av befolkningen i promille som får en bestemt medikamentell behandling. Et estimert salg av et legemiddel på 10 DDD/1 000 innbyggere/døgn indikerer at 10 av 1000 personer (dvs. 1 % av befolkningen) daglig kan bruke dette legemidlet. Dette estimatet blir imidlertid kun riktig dersom det er samsvar mellom DDD og dosen som faktisk brukes.

2.6 WHO Collaborating Centre for Drug Statistics Methodology

ATC/DDD systemet administreres og videreutvikles av WHO Collaborating Centre for Drug Statistics Methodology. Dette senteret er en del av Avdeling for legemiddelepidemiologi ved Nasjonalt folkehelseinstitutt. Nærmere beskrivelse av systemet finnes i publikasjonen Guidelines for ATC classification and DDD assignment (7). ATC Index with DDDs, som inneholder en liste over alle fastsatte DDD, kan bestilles fra WHO senteret (8). Begge publikasjonene finnes i engelsk og spansk versjon. Senterets webside har følgende adresse: www.whocc.no. ATC og DDD endringer som er vedtatt blir publisert årlig og gjort gjeldende ved årsskiftet. ATC/DDD versjon gjeldende fra januar 2015 er benyttet i rapporten. Publikasjonene kan bestilles fra WHO Collaborating Centre for Drug Statistics Methodology.

When this is impossible, as is the case with combination preparations and some liquid preparations, the DDD is indicated as the number of single doses (number of tablets, capsules, millilitres etc.). The DDDs are not necessarily the most frequently prescribed or used doses. This must be considered when evaluating the data. Accordingly it will often be difficult to estimate the number of users by using the DDD as the measuring unit. The sales can be given as the number of DDDs/1000 inhabitants/day, calculated as follows:

$$\frac{\text{Total consumption measured in number of DDDs x 1000}}{\text{365 x number of inhabitants}}$$

This figure offers an estimation of what proportion of the population that may receive a certain drug treatment. An estimated drug consumption of 10 DDDs/1000 inhabitants/day corresponds to a daily use of this drug by 1% of the population. This estimate is, however, only valid if there is good correlation between the DDD and the actual consumed dose.

2.6 The WHO Collaborating Centre for Drug Statistics Methodology

The WHO Collaborating Centre for Drug Statistics Methodology is responsible for the administration and development of the ATC/DDD system. The Centre is located at the Department of Pharmacoepidemiology at the NIPH. Further information about the ATC/DDD system is given in the publication Guidelines for ATC classification and DDD assignment (7). The ATC Index with DDDs which includes a list of all assigned DDDs can be ordered from the Centre (8). Both publications are available in English and Spanish. The website for the Centre is www.whocc.no.ATC and DDD changes are published annually and are made official by the end of the year. ATC/DDD version from January 2015 has been used in the book. The ATC/DDD publications can be ordered from the WHO Collaborating Centre for Drug Statistics Methodology.

Referanser/References:

1. Forskrift om innsamling og behandling av helseopplysninger i Reseptbasert legemiddelregister (Reseptregisteret). 20-10-2003.
2. Strøm H. Reseptbasert legemiddelregister: et viktig verktøy for å oppnå detaljert legemiddelstatistikk. Nor J Epidemiol. 2004;14 (1):53-55.
3. Helseregisterloven [Personal Health Data Filing System Act]. Lov av 18.mai 2001
4. Rønning M, Litleskare I, Addis A et al. Recommendations for national registers of medicinal products with validated ATC codes and DDD values. Italian J Public Health 2006;3(1):30-35.
5. Furu K, Wettermark B, Andersen M, Martikainen JE, Almarsdottir AB, Sørensen HT. The Nordic countries as a cohort for pharmacoepidemiological research. Basic Clin Pharmacol Toxicol 2010;106(2):86-94.
6. Sakshaug S (Ed). Drug Consumption in Norway 2010–2014. [Legemiddelforbruket i Norge 2010–2014] Oslo: Norwegian Institute of Public Health, 2015.
7. WHO Collaborating Centre for Drug Statistics Methodology, Guidelines for ATC classification and DDD assignment 2015. Oslo, 2014.
8. WHO Collaborating Centre for Drug Statistics Methodology, ATC classification index with DDDs 2015. Oslo 2014.


adol Ac
hydrochlorid.
10 mg
NYCOMED

Del 3 Part 3

3. Reseptregisteret 2010–2014

3.1 Utvalgte nøkkeltall fra Reseptregisteret

Reseptregisteret inneholder opplysninger fra alle landets apotek om utlevering av legemidler på resept, til forskriveres egen praksis og til institusjoner. I 2014 ble rundt 95,5 % av legemidlene i Reseptregisteret (målt i DDD) utlevert til enkeltpersoner. Leveransene til institusjoner (sykehus og sykehjem) utgjorde 4 % av det totale antall DDD og ca. 0,4 % av totalt antall DDD ble utlevert til bruk i forskrivers egen praksis. Salg av reseptfrie legemidler er ikke inkludert i Reseptregisteret. Reseptfritt salg utgjorde i 2014 14 % av totalt salg av legemidler i Norge målt i DDD (Kilde: Grossistbasert legemiddelstatistikk, Folkehelseinstituttet).

3. The Norwegian Prescription Database (NorPD) 2010–2014

3.1 Selected key figures from NorPD

NorPD contains information from all Norwegian pharmacies of prescriptions to individuals, to a prescriber's own practice and to institutions. In 2014, about 95.5% of DDDs in NorPD were dispensed to individuals in ambulatory care. Deliveries to institutions (hospitals and nursing homes) amounted to 4% of the DDDs and about 0.4% of the DDDs were dispensed for use in the physician's practice. Sales of OTC medicines are not included in NorPD. OTC sales constitute 14% of total sales of pharmaceuticals in Norway in 2014, measured in DDDs (source: Norwegian Drug Wholesale Statistics, Norwegian Institute of Public Health).

Table 3.1.a: Number of individuals and one-year prevalence (%) of the population who had at least one prescription dispensed in Norway 2010–2014

	Women n (%)	Men n (%)	Both genders n (%)
2010	1 842 575 (75,4)	1 510 186 (61,8)	3 352 761 (68,6)
2011	1 879 445 (76,0)	1 551 598 (62,6)	3 431 043 (69,3)
2012	1 897 957 (75,9)	1 571 092 (62,4)	3 469 049 (69,1)
2013	1 910 199 (75,5)	1 574 389 (61,7)	3 484 588 (68,6)
2014	1 937 562 (75,9)	1 603 688 (62,1)	3 541 250 (68,9)



Figure 3.1: One-year prevalence (%) of the population who had at least one prescription dispensed in 2014 in Norway according to age and gender

Reseptregisteret ble opprettet 1. januar 2004 og i perioden 2004–2014 har 5,3 millioner individer blitt inkludert i NorPD med minst ett legemiddel utlevert på resept fra apotek. Antall legemiddelutleveringer etter resept til pasienter i samme periode er 424 millioner.

I 2014 fikk 68,9 % av den norske befolkningen utlevert minst ett legemiddel på resept, 75,9 % av kvinnene og 62,1 % av mennene (tabell 3.1.a). Krav om at pasientens fødselsnummer skal påføres resepten ble innført 1. oktober 2003. I 2004, det første driftsåret for NorPD, var andelen av resepter med ugyldig eller manglende 11-sifret fødselsnummer 3,7 %. I årene 2006–2007 lå denne andelen på rundt 2 %, og i 2008 og 2009 har den ligget på i underkant av 1,4 %. I 2010–2014 var andelen uten gyldig fødselsnummer under 1 % (0,36 % i 2014).

Ettårsprevalensen for å få utlevert legemiddel etter resept i 2014 var lavest for kvinner i aldersgruppen 5–9 år of for menn i aldersgruppen 10–14 år (figur 3.1). Rundt 93 % av individene i alderen 70 år og eldre fikk utlevert medisiner etter resept. Hvis vi ekskluderer kvinner som kun fikk utlevert hormonelle prevensjonsmidler (ATC-kode G03A), blir prevalensen av legemiddelbruk redusert med ca. 10–15 prosentpoeng hos kvinner i alderen 15–29 år, men fortsatt var andelen av legemiddelbrukere blant kvinner over 15 år høyere enn blant menn.

Since January 2004 5.3 million individuals have been included in NorPD with at least one prescription medication dispensed from a pharmacy. The number of prescriptions dispensed to patients in the same period (2004–2014) is 424 million.

In 2014, 68.9% of the Norwegian population had at least one prescription dispensed, 75.9% of women and 62.1% of men (table 3.1.a). In 2004, the first operational year of NorPD, the proportion of prescriptions having invalid or missing personal identification number was 3.7%. In the period 2005–2007, the proportion was around 2%. The proportion of prescriptions with an invalid personal identification number has declined further to just below 1.4 % in 2008 and 2009. In 2010–2014 the proportion was less than 1% (0.36% in 2014).

The age-specific one year prevalence for having a drug dispensed in 2014 was lowest for women at about 5–9 years of age and for men at about 10–14 years of age (figure 3.1). About 93 % of individuals aged 70 years and older received prescription medications. Excluding women who received only hormonal contraception for systemic use (ATC code G03A), the prevalence of drug use was reduced by about 10–15 percentage points in women aged 15–29, although the proportion of drug users among women over 15 years of age was still higher than in men.

Table 3.1.b: One-year prevalence (%) of the population who had at least one prescription dispensed in Norway in 2014 according to the main ATC groups

	ATC	Women %	Men %	Both genders %
A	Alimentary tract and metabolism	19,6	14,8	17,2
B	Blood and blood forming organs	12,4	12,5	12,5
C	Cardiovascular system	21,0	20,3	20,6
D	Dermatologicals	14,4	11,9	13,1
G	Genito urinary system and sex hormones	25,4	6,5	15,9
H	Systemic hormonal preparations, excl. sex hormones and insulins	11,4	5,6	8,5
J	Anti-infectives for systemic use	29,2	19,5	24,3
L	Anti-neoplastic and immunomodulating agents	2,0	1,7	1,9
M	Musculo-skeletal system	20,8	15,4	18,1
N	Nervous system	31,4	21,3	26,3
P	Anti-parasitic products, insecticides and repellents	2,4	1,4	1,9
R	Respiratory system	27,6	21,4	24,5
S	Sensory organs	14,4	11,0	12,7
V	Various	0,5	0,5	0,5

Tabell 3.1.b viser ettårsprevalens for hele befolkningen som har fått utlevert minst ett legemiddel etter resept innen hver av de 14 ATC-hovedgruppene, totalt og fordelt på kvinner og menn. De tre legemiddelgruppene som er mest brukt blant begge kjønn er midler mot infeksjoner til systemisk bruk (ATC-gruppe J), legemidler med virkning på nervesystemet (ATC-gruppe N) og legemidler som brukes for sykdommer i luftveiene (ATC-gruppe R).

Tabell 3.1.c viser en oversikt over legemidler (definert som ATC 5.nivåer) med flest brukere i Norge i 2014. Fenoxymetylpenicillin (antibakterielt middel) har flest brukere etterfulgt av paracetamol (smertestillende). Diklofenak har falt fra første plass i 2012, andre plass i 2013 og til femte plass i 2014. Paracetamol og diklofenak selges også i reseptfrie pakninger. Denne bruken registreres ikke i Reseptregisteret. Listen inneholder i hovedsak de samme legemidlene som tidligere år, men det er noen endringer i rekkefølgen. Ny på listen sammenlignet med i fjor er østradiol (hormonpreparat, forebyggende mot osteoporose) (28. plass) og escitalopram (mot depresjoner) (30. plass).

Table 3.1.b shows the one-year prevalence of the entire population, and among men and women, who received at least one prescription in each of the main ATC groups. The three drug groups most used in both men and women are anti-infectives (ATC group J), drugs affecting the nervous system (ATC group N) and drugs used for respiratory diseases (ATC group R).

Table 3.1.c shows an overview of medicines (defined as ATC 5th levels) with the most users in Norway in 2014. Phenoxymethylpenicillin (antibacterial) is used by the highest numbers of individuals followed by paracetamol (analgesic). Diclofenac has fallen from first place in 2012, second in 2013 and fifth in 2014. Paracetamol and diclofenac are also sold OTC. This use is not covered by the NorPD. The list contains essentially the same drugs as in previous years, but there are some changes in order. New on the list compared with last year is oestradiol (hormon replacement and postmenopausal osteoporosis) (28th place) and escitalopram (antidepressants) (30th place).

Table 3.1.c: Drugs with the highest number of users in Norway 2014

	ATC code	Active ingredient	Use	Number of individuals	Proportion (%) of the population
1	J01CE02	phenoxymethylpenicillin	Antibacterial	420 665	8,2
2	N02BE01	paracetamol *	Analgesic	414 747	8,1
3	B01AC06	acetylsalicylic acid	Antithrobotic	373 993	7,3
4	N02AA59	codeine, combinations excl. psycholeptics	Analgesic	373 320	7,3
5	M01AB05	diclofenac *	NSAID/analgestic	372 017	7,2
6	N05CF01	zopiclone	Hypnotic	304 096	5,9
7	R06AE07	cetirizine *	Anti-allergic	293 591	5,7
8	C07AB02	metoprolol	Antihypertensive/ cardiac disease	274 761	5,3
9	C10AA01	simvastatin	Lipid modifying	271 531	5,3
10	R05DA01	ethylmorphine	Cough suppresant	238 475	4,6
11	R03AC02	salbutamol	Asthma/COPD	231 782	4,5
12	M01AE01	ibuprofen *	NSAID/analgestic	223 845	4,4
13	C10AA05	atorvastatin	Lipid modifying	211 725	4,1
14	J01CA08	pivmecillinam	Antibacterial	203 619	4,0
15	H03AA01	levothyroxine sodium	Thyroxine supplement	196 810	3,8
16	A02BC02	pantoprazole *	Reflux oesofagitis	193 341	3,8
17	S01AA01	chloramphenicol	Antibacterial eye drops	191 810	3,7
18	N02AX02	tramadol	Analgesic	187 091	3,6
19	H02AB06	prednisolone	Antiinflammatory/corticosteroid	172 913	3,4
20	R06AX27	desloratadine	Anti-allergic	168 993	3,3
21	R01AD09	mometasone	Inflammatory skin disorders / eczema/psoriasis	160 704	3,1
22	A02BC05	esomeprazole	Reflux oesofagitis	148 787	2,9
23	G03AA07	levonorgestrel and ethinylestradiol	Hormonal contraception	138 446	2,7
24	J01AA02	doxycycline	Antibacterial	138 194	2,7
25	N05BA04	oxazepam	Anxiolytic	134 613	2,6
26	J01CA04	amoxicillin	Antibacterial	132 716	2,6
27	C08CA01	amlodipine	Antihypertensive/ cardiac disease	129 556	2,5
28	G03CA03	estradiol	Hormon replacement and postmenopausal osteoporosis	118 075	2,3
29	N05BA01	diazepam	Anxiolytic	116 548	2,3
30	N06AB10	escitalopram	Antidepressant	110 848	2,2

* The ATC level comprises OTC medicinal products. The number of individuals is registered for prescription sales only.

3.2 Reseptkategorier og refusjon av utgifter til legemidler

Reseptregisteret inneholder opplysninger om utlevering av legemidler fordelt på ulike reseptkategorier. Reseptkategorier har følgende hovedinndeling:

- Hvit resept
- Blå resept (i henhold til Forskrift om stønad til dekning av utgifter til viktige legemidler mv. (Blåreseptforskriften) FOR-2007-06-28-814)
- Helseforetaksresept

Informasjon om følgende reseptkategorier er ikke inkludert i tabellene:

- Bidragsordningen (hjemlet i Lov om folketrygd (folketrygdloven) § 5-22)
- Støtte til legemidler for vernepliktige og ved yrkesskade (hjemlet i Lov om folketrygd § 5-25)
- Spesielle refusjonsordninger som f.eks. medlemskap i Jernbanepersonalets Helsefond

Hvit resept
Resept hvor pasienten betaler hele beløpet selv.

Blå resept
I tabellene er refusjon i henhold til de ulike paragrafene i blåreseptforskriften slått sammen (§§ 2, 3a, 3b, 4).

Refusjon etter blåreseptforskriftens § 2
Legemidler som er ført opp på refusjonslista tilknyttet § 2 refunderes pliktmessig når de brukes ved diagnoser (angitt med ICPC eller ICD koder) spesifisert i refusjonslista. Statens legemiddelverk avgjør hvilke legemidler som skal føres opp i refusjonslista, og hvilke diagnosekoder/vilkår legemidlet skal underlegges ved rekvirering på blå resept.

Refusjon etter blåreseptforskriftens §§ 3a og 3b
HELFO kan fatte vedtak om individuell refusjon av utgifter til legemidler som ikke har forhåndsgodkjent refusjon etter § 2. Individuell refusjon forutsetter enten at indikasjonen for bruken av legemidlet er dekket av en diagnosekode i refusjonslista (§3a) eller at legemidlet skal benyttes til behandling av en sjelden eller alvorlig kronisk sykdom som ikke er nevnt i refusjonslista (§ 3b). Vedtak fattes for hver enkelt pasient på grunnlag av søknad fra behandlende lege. Reseptregisteret gir ikke en komplett oversikt over refusjon etter §§ 3a og 3b.

Refusjon etter blåreseptforskriftens § 4
Legemidler som benyttes ved allmennfarlige smittsomme sykdommer, refunderes etter § 4 etter en nærmere angitt sykdomsliste. Det ytes stønad til utgifter til legemidler mot infeksjoner, immunstimulerende legemidler og vaksiner. Denne støtten ytes til alle som bor i Norge, uavhengig av medlemskap i folketrygden.

3.2 Prescription categories and reimbursement of medicinal expenses

NorPD contains information about dispensed prescriptions based on the following prescription categories:

- Non-reimbursed prescriptions
- General reimbursement prescriptions according to the "Blue Prescription Regulation" (FOR-2007-06-28-814)
- Health trust prescription

The following prescription categories are not included in the tables:

- Contribution to cover the cost of healthcare when expenses are not otherwise covered by other laws (according to the National Insurance Act § 5.22).
- Contribution to conscripted military and individuals with occupational injury (according to the National Insurance Act § 5-25)
- Special contribution, for instance membership in Jernbanepersonalets Helsefond (Railways Workers Health Fund)

Non-reimbursed prescriptions
Prescriptions paid in full by the patient.

General reimbursement prescriptions
The costs under the various reimbursement schemes (§§ 2, 3a, 3b, 4) according to the "Blue Prescription Regulation" are combined in the tables.

Reimbursement according to § 2
Drugs listed on the reimbursement list § 2 will always be reimbursed when prescribed for the diagnoses (indicated by the ICPC and ICD codes) specified in the reimbursement list. The Norwegian Medicines Agency decides which medicines are included in the list and which diagnostic codes/conditions should be subject to reimbursement prescribing.

Individual reimbursement according to § § 3a and 3b
The Health Economics Administration (HELFO) will make decisions regarding individual reimbursement for drugs not included in the reimbursement list according to § 2. Individual reimbursement requires either that the indication for use of the drug is covered by a diagnostic code in the reimbursement list (§ 3a) or the drug will be used to treat a rare or serious chronic disease not listed in the reimbursement list (§ 3b). Decisions are made for each patient on the basis of application from the treating physician. NorPD does not provide a complete overview of reimbursement according to §§ 3a and 3b.

Legen har mulighet til å rekvirere flere av legemidlene i denne paragrafen til seg selv for å bevare pasientenes anonymitet, disse reseptene vil ikke kunne følges på individnivå i Reseptregisteret.

Helseforetaksresept

De regionale helseforetakene er gitt et særskilt finansieringsansvar for enkelte kostbare legemidler. Dette gjelder blant annet immunmodulerende legemidler til behandling av revmatiske lidelser (TNFα-hemmere), multippel sklerose og kreft. Kun legemidler ekspedert på resept til individer er tatt med i tabellen.

Reimbursement according to § 4

Drugs used for communicable diseases are reimbursed according to § 4 according to a specified disease list. The reimbursement is granted for anti-infectives, immunostimulants and vaccines. This support is provided to all who live in Norway, regardless of citizenship. The physician may self-prescribe these drugs in order to preserve patient anonymity; such prescriptions will not be available on an individual level in the NorPD.

Health trust prescriptions

The regional health trusts provide dedicated funding for certain expensive drugs. These include immune-modulating drugs for the treatment of rheumatic disorders (TNFα inhibitors), multiple sclerosis and cancer. Only drugs that are dispensed by prescription to individuals are included in the table.

Table 3.2.a Sales of drugs by prescription categories, overview 2014

	Number of individuals	Proportion (%) of the population	Number of DDDs	Sales in 1000 NOK
Non-reimbursable prescriptions	3 035 752	59,1	604 382 196	2 844 539
Reimbursement prescriptions	2 271 927	44,2	1 680 608 196	9 869 838
Health Trust prescriptions	22 171	0,4	8 985 734	2 043 261

Table 3.2.b: Sales of reimbursed drugs (§§ 2, 3a, 3b, 4, 5) by ATC main groups 2014

ATC main groups		Number of individuals	Proportion (%) of the population	Number of DDDs	Sales in 1000 NOK
A	Alimentary tract and metabolism	480 061	0,1	189 592 657	1 357 339
B	Blood and blood forming organs	300 582	0,1	99 131 993	1 034 320
C	Cardiovascular system	989 373	0,2	735 401 653	1 474 092
D	Dermatologicals	264 032	0,1	898 202	128 714
G	Genito urinary system and sex hormones	166 980	0,0	44 586 989	301 123
H	Systemic hormonal preparations, excl. sex hormones and insulins	343 805	0,1	64 870 246	430 719
J	Antiinfectives for systemic use	113 813	0,0	10 839 338	801 013
L	Antineoplastic and immunomodulating agents	79 787	0,0	22 710 362	1 128 072
M	Musculo-skeletal system	275 265	0,1	53 326 176	200 239
N	Nervous system	620 200	0,1	192 479 746	1 743 110
P	Antiparasitic products, insecticides and repellents	6 591	0,0	773 365	4 439
R	Respiratory system	815 948	0,2	238 267 489	1 298 847
S	Sensory organs	294 503	0,1	33 614 162	240 276
V	Various	16 573	0,0	293 265	102 471

Table 3.2.c: Reimbursed drugs (§§ 2, 3a, 3b, 4, 5) with the highest number of users 2014

	ATC code	Active ingredient	Use	Number of individuals	Proportion (%) of the population	Number of DDDs	Sales in 1000 NOK
1	C07AB02	metoprolol	Antihypertensive/ cardiac disease	271 616	5,3	43 904 469	135 168 544
2	C10AA01	simvastatin	Lipid modifying	269 524	5,2	85 854 053	83 072 779
3	R06AE07	cetirizine	Anti-allergic	250 633	4,9	50 241 291	58 968 947
4	C10AA05	atorvastatin	Lipid modifying	210 802	4,1	115 733 355	129 541 649
5	H03AA01	levothyroxine sodium	Thyroxine supplement	195 657	3,8	41 978 420	59 395 020
6	R03AC02	salbutamol	Asthma/COPD	193 287	3,8	18 854 856	71 996 907
7	R06AX27	desloratadine	Anti-allergic	149 886	2,9	24 717 473	39 788 354
8	N02BE01	paracetamol	Analgesic	143 626	2,8	16 091 242	42 457 087
9	C08CA01	amlodipine	Antihypertensive/ cardiac disease	128 836	2,5	58 110 486	51 357 322
10	R01AD09	mometasone	Anti-allergic, nose spray	120 515	2,3	14 303 755	34 427 019
11	A02BC02	pantoprazole	Reflux oesofagitis	117 899	2,3	25 211 590	66 770 972
12	N06AB10	escitalopram	Antidepressant	109 015	2,1	35 528 931	69 459 851
13	A10BA02	metformin	Diabetes	105 564	2,1	25 860 907	52 246 012
14	A02BC05	esomeprazole	Reflux oesofagitis	102 513	2,0	31 632 582	138 997 468
15	H02AB06	prednisolone	Antiinflammatory/ corticosteroid	98 445	1,9	14 889 650	24 168 903
16	C09CA06	candesartan	Antihypertensive/ cardiac disease	91 267	1,8	43 878 077	56 142 850
17	R03AK06	salmeterol and fluticasone	Asthma/COPD	90 487	1,8	20 130 448	284 901 804
18	S01GX02	levocabastine	Anti-allergic, eye drops	85 016	1,7	NULL*	21 236 533
19	R03AK07	formoterol and budeso-nide	Asthma/COPD	81 391	1,6	15 582 252	238 435 735
20	C03CA01	furosemide	Antihypertensive/ cardiac disease /oedema	80 630	1,6	20 649 581	19 691 184
21	B01AA03	warfarin	Antitrombotic	77 447	1,5	16 582 406	65 127 550
22	R01AD12	fluticasone furoate	Anti-allergic, nose spray	77 279	1,5	5 757 810	16 799 979
23	C09DA01	losartan and diuretics	Antihypertensive/ cardiac disease	66 106	1,3	21 812 361	41 282 288
24	C09AA05	ramipril	Antihypertensive/ cardiac disease	63 983	1,2	51 251 207	29 922 859
25	C09CA01	losartan	Antihypertensive/cardiac disease	63 702	1,2	24 847 118	35 478 431
26	D07AC13	mometasone	Inflammatory skin disorders / eczema/psoriasis	60 628	1,2	*	14 892 782
27	B03BA03	hydroxocobalamin	Vitamin B-12 supplement	59 636	1,2	18 756 000	12 262 816
28	R06AX13	loratadine	Anti-allergic	58 397	1,1	11 760 014	16 477 549
29	R03BA05	fluticasone	Asthma/COPD	57 510	1,1	4 734 873	39 294 173
30	C09DA06	candesartan and diuretics	Antihypertensive/ cardiac disease	56 642	1,1	18 353 312	42 621 380

* No DDD assigned for this ATC 5th level

Table 3.2.d: Reimbursed drugs (§§ 2, 3a, 3b, 4, 5) with highest sales in NOK 2014

	ATC code	Active ingredient	Use	Number of individuals	Proportion (%) of the population	Number of DDDs	Sales in 1000 NOK
1	R03AK06	salmeterol and fluticasone	Asthma/COPD	90 487	1,8	20 130 448	284 901 804
2	R03AK07	formoterol and budesonide	Asthma/COPD	81 391	1,6	15 582 252	238 435 735
3	B02BD02	coagulation factor VIII	Bleeding disorders	181	0,0	66 838	220 638 129
4	J05AX15	sofosbuvir	Hepatitis C infections	450	0,0	42 101	214 267 391
5	R03BB04	tiotropium bromide	COPD	40 468	0,8	11 229 840	157 105 391
6	N06BA04	methylphenidate	ADHD	30 590	0,6	12 760 226	148 078 467
7	A02BC05	esomeprazole	Reflux oesofagitis	102 513	2,0	31 632 582	138 997 468
8	H01AC01	somatropin	Growth hormone deficiency	1 934	0,0	827 903	135 621 517
9	C07AB02	metoprolol	Antihypertensive/ cardiac disease	271 616	5,3	43 904 469	135 168 544
10	C10AA05	atorvastatin	Lipid modifying	210 802	4,1	115 733 355	129 541 649
11	B01AF01	rivaroxaban	Antitrombotic	20 565	0,4	10 297 613	123 029 146
12	L01XE01	imatinib	Cancer	495	0,0	55 211	105 182 292
13	A10AC01	insulin (human)	Diabetes	33 036	0,6	11 814 116	99 567 251
14	B01AE07	dabigatran etexilate	Antitrombotic	15 241	0,3	4 912 338	98 290 563
15	L03AA13	pegfilgrastim	Multiple sclerosis	2 718	0,1	199 560	92 418 261
16	A10AB05	insulin aspart	Diabetes	29 192	0,6	9 488 785	91 901 224
17	N03AX09	lamotrigine	Epilepsy/bipolar disorders	27 320	0,5	7 225 371	88 210 002
18	A07EC02	mesalazine	Ulcerative colitis / Crohn's disease	16 664	0,3	6 594 632	87 718 246
19	C10AA01	simvastatin	Lipid modifying	269 524	5,2	85 854 053	83 072 779
20	N03AX16	pregabalin	Neuropatic pain /epilepsy	9 807	0,2	3 673 049	81 593 984
21	N02CC01	sumatriptan	Migraine	48 359	0,9	2 846 346	79 095 900
22	C10AX09	ezetimibe	Cholesterol lowering	22 530	0,4	6 647 820	79 060 477
23	A10BX07	liraglutide	Diabetes	6 598	0,1	2 380 545	75 954 998
24	J05AR03	tenofovir disoproxil and emtricitabine	HIV infections	1 580	0,0	426 420	74 527 935
25	R03AC02	salbutamol	Asthma/COPD	193 287	3,8	18 854 856	71 996 907
26	L04AX04	lenalidomide	Myelopathosis	306	0,0	48 867	71 618 056
27	N05AH04	quetiapine	Schizophrenia/psychosis/ bipolar disorders	30 398	0,6	3 644 305	70 814 759
28	N06AB10	escitalopram	Antidepressant	109 015	2,1	35 528 931	69 459 851
29	A02BC02	pantoprazole	Reflux oesofagitis	117 899	2,3	25 211 590	66 770 972
30	B01AA03	warfarin	Antitrombotic	77 447	1,5	16 582 406	65 127 550

* No DDD assigned for this ATC 5th level

3.3 Beskrivelse av hovedtabellene

Tabellene i del 3 i denne boken gir en oversikt over antall individer som har fått utlevert legemidler etter resept fra apotekene i Norge. Alle som har hentet ut minst ett legemiddel er inkludert og opplysningene er fordelt på enkeltlegemidler og legemiddelgrupper. Selv om et individ har fått utlevert samme legemiddel flere ganger, telles vedkommende som bruker bare én gang. Det er kun utleveringer til individer med fullt fødselsnummer som er inkludert i tabellene i boken. I Reseptregisteret er 0,36 % av utleveringene til individer hvor fullstendig fødselsnummer ikke er angitt i 2014.

Tabellene inneholder tall for perioden 2010–2014. I tillegg er følgende opplysninger for 2014 inkludert:

- Andel kvinner (%) av totalt antall individer som har hentet ut minst én resept
- Antall individer som har hentet ut minst ett legemiddel etter resept fordelt på følgende aldersgrupper: <15, 15–44, 45–69, ≥70
- Salg i kroner fra apotek for utvalget i tabellen, dvs. til individer med fullt fødselsnummer. Kronebeløpet tilsvarer reell utsalgspris fra apotek.

Tabellene er sortert i henhold til ATC-systemet (se nærmere beskrivelse på s. 35). De aller fleste ATC-grupper med legemidler på det norske markedet er inkludert. Legemidler til pasienter i sykehus eller sykehjem er ikke tilgjengelig på individnivå i Reseptregisteret. Det totale antall legemiddelbrukere vil derfor være høyere enn det som fremgår av tabellene for en del legemidler, og spesielt for legemidler som brukes mye i sykehus. Vi har valgt å utelate noen ATC-grupper. Dette er legemidler som hovedsaklig brukes i sykehus eller institusjoner. Følgende ATC-grupper er utelatt:

B05	Blodsubstitutter og infusjonsoppløsninger
J06	Immunsera og immunglobuliner
J07	Vaksiner
L01	Antineoplastiske midler
M03A	Perifert virkende muskelrelakserende midler
N01	Anestetika
S01H	Lokalanestetika
S01J	Diagnostika
S01L	Midler ved okulær vaskulær sykdom
V	Varia (kun ATC-gruppe V01 *Allergener* er inkludert i tabellen)

Reseptfrie legemidler skrives i noen tilfeller også ut på resept, men i hovedsak vil salg av reseptfrie legemidler ikke være inkludert i denne boken. Salg av reseptfrie

3.3 Description of the main tables

The tables in section 3 of this book provide an overview of the number of individuals who have had prescriptions dispensed from pharmacies in Norway. Anyone who has had at least one prescription dispensed is included and the data are given for each medicinal substance and for groups of medicines. Even if an individual has been given the same medicine several times, he or she is counted as a user only once. Only dispensing data to individuals with a personal identification number are included in the tables. In NorPD the complete personal identification number is missing for 0.36% of the dispensed medicines to individuals in 2014.

The tables contain figures for the period 2010–2014. In addition, the following information for 2014 includes:

- Share of women (%) of the total number of individuals who have had at least one prescription dispensed
- The number of individuals who have had at least one prescription dispensed in the following age groups: <15, 15–44, 45–69, ≥ 70
- Sales in million Norwegian kroner (mNOK), i.e. for prescriptions dispensed to individuals with a personal identification number. The amount in NOK corresponds to the actual retail price from the pharmacy.

The tables are arranged according to the ATC system (see further description in p. 35). The majority of ATC groups containing drugs on the Norwegian market are included. Medicine use by individuals in hospitals and nursing homes is not included at the individual level in the Norwegian Prescription Database. The total number of medicine users will therefore be higher than the figures in the tables for a number of drugs, particularly for drugs that are frequently used in hospitals or institutions. We have chosen to exclude some ATC groups in this book that are mainly used in hospitals or institutions. The following ATC groups have been omitted:

B05	Blood substitutes and perfusion solutions
J06	Immune sera and immunoglobulins
J07	Vaccines
L01	Antineoplastic agents
M03A	Muscle relaxants, peripherally acting agents
N01	Anesthetics
S01H	Local anesthetics
S01J	Diagnostic agents
S01L	Ocular vascular disorder agents
V	Various (ATC group V01 Allergens is included in the table)

Figure 3.2: The report generator at www.reseptregisteret.no (English version at www.norpd.no)

legemidler, både i og utenom apotek, er med i den grossistbaserte legemiddelstatistikken, hvor tallmaterialet blir publisert i publikasjonen Legemiddelforbruket i Norge (se også s. 35). I tabellene i del 3 i denne boken er det tatt med en fotnote tilknyttet de ulike ATC-kodene hvor det i tillegg også selges reseptfrie pakninger. I 2014 utgjorde reseptfrie legemidler en andel på 14 % av totalt antall solgte doser (DDD). Disse andelene har holdt seg relativt konstant over tid.

De fleste legemidler som forskrives på resept, har godkjent markedsføringstillatelse i Norge. Leger har imidlertid anledning til å forskrive legemidler uten markedsføringstillatelse. Det må da søkes om spesielt godkjenningsfritak fra Statens legemiddelverk. Det finnes også enkelte legemidler som inngår i en såkalt negativliste, og som bare kan utleveres etter spesiell tillatelse fra Legemiddelverket. Legemidler som er forskrevet på resept etter søknad om godkjenningsfritak eller etter spesiell tillatelse fra Legemiddelverket, er inkludert i tabellene i boken. Antall individer som behandles med disse legemidlene vil ofte være lavt. Dersom antall individer er lavere enn fem, angis < 5 i tabellene.

Mange individer bruker flere legemidler. Vær derfor oppmerksom på at man ikke kan summere antall brukere av ulike legemidler, eller legemiddelgrupper i tabellene, for å finne totalt antall brukere av to eller flere legemidler. Statistikk på aggregert nivå i tabel-

Non-prescription medicines are sometimes prescribed, but the majority of the OTC medicine sales will not be included in the tables in this book. Sales of OTC medicines are, however, included in the Norwegian Drug Wholesales Statistics database and the figures are published in "Drug Consumption in Norway" (see also p. 35). A footnote is used in the tables in part 3 of this book in the various ATC codes where OTC medicines are available in Norway. In 2014, OTC medicines had a share of 14% of total sales measured in DDDs. These shares have remained almost unchanged over time.

Most prescribed medicines have an approved marketing authorisation in Norway. However, physicians can prescribe drugs without marketing authorisation. They must then apply for a licence from the Norwegian Medicines Agency. There are also some medicines that are part of a so-called "negative list" which can only be prescribed by special permission from the Medicines Agency. Drugs that are prescribed on licence or by special permission are included in the tables in the book. The number of individuals who are prescribed these medicines is often low. If the number of individuals is less than five, <5 is used in the tables.

Many individuals use more than one medicine. Please be aware that it is not possible to add together the number of users of various drugs or drug groups in the tables to find the total number of users of two or more drugs. Statistics on the aggregate level in the

lene vil imidlertid inneholde brukere av minst ett av legemidlene i undernivåene. For eksempel viser tallene at totalt antall brukere av sovemidler (ATC-gruppe N05C) er lavere enn summen av antall brukere av de enkelte legemidlene som er klassifisert i N05C. Det betyr at noen individer har fått utlevert mer enn en type sovemiddel i løpet av et år, enten ved bruk av flere sovemidler samtidig eller ved bytte fra ett middel til et annet.

Reseptregisterets nettsider: www.reseptregisteret.no
Reseptregisteret har eget nettsted som kan brukes sammen med tabellene i denne rapporten for å få kompletterende informasjon. På søkesidene (figur 3.2) kan man selv lage rapporter over antall brukere av et bestemt legemiddel eller en legemiddelgruppe. Dette kan gjøres ved søk på forhåndsdefinerte legemiddelgrupper, via ATC-systemet eller ved søk på virkestoff eller produktnavn.

Følgende data om legemiddelbruk kan hentes ut fra nettstedet:

- Antall brukere, eventuelt fordelt på kjønn, 5 års aldersgrupper, fylke eller helseregion
- Antall brukere per 1 000 innbyggere (prevalens per 1 000)
- Omsetning i kroner
- Omsetning i doser (DDD – definerte døgndoser)
- Befolkningsgrunnlag i statistikken, eventuelt fordelt på kjønn, alder, fylke eller helseregion

Data er tilgjengelige fra 2004, og nettstedet oppdateres årlig med foregående års tall.

Tallene i denne rapporten kan avvike noe fra tallene som finnes på nettstedet. Årsaken er at uttrekket av data til boken er gjort på et noe senere tidspunkt enn datagrunnlaget for nettsiden. Rapporteringen av data fra apotek til Reseptregisteret er for en liten andel av reseptutleveringene forsinket. Forsinkelsen kan være på noen måneder, og dette innebærer at noen data fra foregående år blir rapportert på etterskudd. I tillegg er individer uten kjent bostedsadresse utelatt fra nettsiden, men inkludert i tabellene i denne rapporten. Nettstedet finnes også i engelsk versjon (www.norpd.no).

Utlevering av data fra Reseptregisteret
Det er mulig å søke om data fra Reseptregisteret til forskning eller til andre formål som er i henhold til formålet for Reseptregisteret. Søknadsskjema er tilgjengelige på nettstedet til FHI (www.fhi.no), og alle søknader om tilgang til data fra FHI skal sendes til datatilgang@fhi.no. Dataene er gratis, men kostnader i forbindelse med administrativ håndtering og filbehandling må påregnes.

tables will, however, include the use of at least one of the drugs in the included drug groups. For example, the figures in the tables show that the total number of users of sleeping pills (ATC group N05C) is lower than the sum of the number of users of the individual medicines that are classified in N05C. This means that some individuals have been given more than one type of sleeping pill during a year, either through the use of more than one simultaneously or by switching from one agent to another.

The NorPD website: www.norpd.no
The Norwegian Prescription Database has its own website which can be used together with the tables in this report for complementary information. On the website (figure 3.2), one can create reports on the number of users of a particular drug or drug group. This can be done by searching for pre-defined drug groups, through the ATC system or by searching the active substance or product name.

The following data on drug use can be extracted from the website:

- Number of users, split by gender, 5-year age groups, county or health region
- Number of users per 1 000 population (prevalence per 1 000)
- Turnover in NOK (pharmacy retail price)
- Turnover in doses (DDD – defined daily doses)
- Population base for the statistics, split by gender, age, county or health region

Data are available from 2004 with an annual update for the preceding year.

The figures in this book may differ slightly from the numbers found on the website. This is because the data extraction for the book was made at another date than the data on the website. Reporting of data from the pharmacy to NorPD is delayed for a minor number of prescriptions. The delay may be a few months, meaning that reports of data from a year can arrive the following year. Besides, individuals without known address are included in the tables in this book but not on the website.

Access to data from NorPD
It is possible to apply for data from the Norwegian Prescription Database for research or for other purposes which are according to the objectives of NorPD. Application forms are available on the website of NIPH (www.fhi.no) and all applications for access to data from NIPH should be sent to datatilgang@fhi.no. The data is free of charge, but fees for administration and file processing will be required.

Beregning av prevalens per 1000 innbyggere
Prevalens er ofte definert som antall individer som har fått utlevert ett legemiddel per 1000 innbyggere. Antall individer oppgitt i tabellene kan benyttes til å beregne prevalens av legemiddelbruken i befolkningen. Hvordan dette kan gjøres er vist i eksemplet nedenfor.

Antall individer som fikk minst ett hjerte-/karmiddel (ATC-gruppe C) i Norge i 2014: 1 060 258

Antall innbyggere i Norge per 1. juli 2014: 5 137 321

Beregning av prevalens (per 1000) for brukere av hjerte-/karmidler i Norge i 2014:

$$\frac{\textit{Antall individer x 1000}}{\textit{Antall innbyggere}} = \frac{\textit{1 060 258 x 1000}}{\textit{5 137 321}} = \textit{206,4 individer per 1000 innbyggere}$$

På s. 123 finnes tabeller over befolkningstallet i Norge for årene 2010–2014. Befolkningstallet for de fire aldersgruppene i tabellene er også angitt. Det brukes middelfolkemengden for hvert
år, dvs folketallet per 1. juli, beregnet ut fra Statistisk Sentralbyrås folketall 1.1 og 31.12. Alder er definert som den alder individet har ved slutten av året (utleveringsår minus fødselsår).

Calculation of prevalence per 1000 inhabitants
Prevalence is often defined as the number of individuals per 1000 inhabitants who have had at least one prescription dispensed in a pharmacy during a specific time period. The number of individuals listed in the tables can be used to calculate the prevalence of drug users in the population. Please read the following example:

The number of individuals who had at least one cardiovascular drug dispensed (ATC group C) in Norway in 2014: 1 060 258

The number of inhabitants in Norway as of 1st July 2014: 5 137 321

Calculation of the prevalence (per 1000) of users of cardiovascular drugs in Norway in 2014:

$$\frac{\textit{The number of individuals x 1000}}{\textit{The number of inhabitants}} = \frac{\textit{1 060 258 x 1000}}{\textit{5 137 321}} = \textit{206.4 individuals per 1000 inhabitants}$$

The population in Norway for the years 2010–2014 is shown on p. 123. The population of the four age groups in the tables is also provided. The population as of 1st July each year is used, calculated from the population figures by Statistics Norway from 1st January and 31st December. Age is defined as the age of the individual at the end of the year (year of dispensing minus birth year).

3.4 ATC main groups

ATC level		2010	2011	2012	2013	2014		2014				2014
		Number of individuals					Share of women (%)	Number of individuals per age group				Sales in 1000 NOK
								<15	15–44	45–69	≥70	
A	ALIMENTARY TRACT AND METABOLISM	702 509	742 204	791 540	832 965	883 617	57	29 396	208 003	390 463	255 755	1 668 691
B	BLOOD AND BLOOD FORMING ORGANS	581 349	597 921	617 386	629 097	640 752	50	3 326	63 594	273 287	300 545	1 197 426
C	CARDIOVASCULAR SYSTEM	975 141	998 461	1 019 237	1 040 279	1 060 258	51	7 467	101 635	546 403	404 753	1 515 865
D	DERMATOLOGICALS	611 440	624 493	632 677	645 681	673 447	55	83 923	257 149	225 358	107 017	260 975
G	GENITO URINARY SYSTEM AND SEX HORMONES	721 846	745 367	761 600	785 598	814 856	80	3 334	438 593	255 917	117 012	943 065
H	SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS	387 821	402 923	414 206	422 527	436 286	67	17 185	114 283	188 151	116 667	474 158
J	ANTIINFECTIVES FOR SYSTEMIC USE	1 252 392	1 326 405	1 336 787	1 288 914	1 250 326	60	145 461	500 319	409 350	195 196	1 083 499
L	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	76 656	81 612	86 336	90 729	95 223	54	1 348	20 633	45 350	27 892	3 077 838
M	MUSCULO-SKELETAL SYSTEM	901 910	927 355	937 937	925 319	928 041	57	14 840	324 466	430 134	158 601	366 238
N	NERVOUS SYSTEM	1 248 505	1 279 676	1 304 345	1 327 510	1 352 454	59	29 691	428 315	590 539	303 909	2 824 945
P	ANTIPARASITIC PRODUCTS, INSECTICIDES AND REPELLENTS	88 743	92 296	95 141	96 547	97 439	62	3 922	43 819	38 212	11 486	29 812
R	RESPIRATORY SYSTEM	1 183 735	1 223 490	1 239 078	1 220 116	1 258 951	56	166 570	461 617	455 301	175 463	1 456 546
S	SENSORY ORGANS	609 467	617 742	618 314	612 715	652 081	57	117 478	191 918	204 888	137 797	334 902
V	VARIOUS	15 898	18 601	21 869	23 890	27 402	51	3 455	8 839	9 572	5 536	108 419

3.5 ATC group A – Alimentary tract and metabolism

ATC level		2010	2011	2012	2013	2014		2014				2014
		Number of individuals					Share of women (%)	Number of individuals per age group				Sales in 1000 NOK
								<15	15–44	45–69	≥70	
A	**ALIMENTARY TRACT AND METABOLISM**	**702 509**	**742 204**	**791 540**	**832 965**	**883 617**	**57**	**29 396**	**208 003**	**390 463**	**255 755**	**1 668 691**
A01	**STOMATOLOGICAL PREPARATIONS**	**6 463**	**9 154**	**15 109**	**18 958**	**24 007**	**57**	**575**	**9 565**	**7 943**	**5 924**	**4 628**
A01A	**STOMATOLOGICAL PREPARATIONS**	**6 463**	**9 154**	**15 109**	**18 958**	**24 007**	**57**	**575**	**9 565**	**7 943**	**5 924**	**4 628**
A01AA	**Caries prophylactic agents**	**776**	**4 792**	**10 862**	**14 642**	**18 877**	**57**	**193**	**7 290**	**6 219**	**5 175**	**3 603**
A01AA01	sodium fluoride[1)]	776	4 792	10 862	14 642	18 877	57	193	7 290	6 219	5 175	3 603
A01AB	**Antiinfectives and antiseptics for local oral treatment**	**4 088**	**2 552**	**2 415**	**2 440**	**2 858**	**54**	**224**	**1 270**	**912**	**452**	**320**
A01AB02	hydrogen peroxide[1)]	<5	0	0	0	0	–	0	0	0	0	0
A01AB03	chlorhexidine[1)]	2 540	2 482	2 360	2 390	2 796	53	222	1 255	882	437	270
A01AB04	amphotericin B	1 529	52	36	25	29	66	0	7	17	5	28
A01AB09	miconazole	<5	5	8	10	7	86	0	<5	<5	<5	8
A01AB11	various[1)]	26	14	11	16	27	70	<5	5	12	8	15
A01AC	**Corticosteroids for local oral treatment**	**1 155**	**1 379**	**1 409**	**1 465**	**1 646**	**63**	**115**	**576**	**673**	**282**	**465**
A01AC01	triamcinolone	1 155	1 379	1 398	1 435	1 592	63	115	568	639	270	390
A01AC03	hydrocortisone	0	0	0	<5	<5	0	0	0	<5	0	6
A01AD	**Other agents for local oral treatment**	**508**	**516**	**532**	**519**	**762**	**60**	**44**	**473**	**184**	**61**	**241**
A01AD01	epinephrine	9	10	10	14	8	25	0	<5	6	0	9
A01AD02	benzydamine	475	494	496	477	730	60	32	465	173	60	228
A01AD11	various	24	12	26	28	24	63	12	6	5	<5	4
A02	**DRUGS FOR ACID RELATED DISORDERS**	**338 746**	**366 465**	**393 798**	**417 708**	**441 252**	**54**	**8 143**	**96 698**	**209 964**	**126 447**	**337 194**
A02A	**ANTACIDS**	**4 691**	**4 772**	**4 442**	**4 719**	**5 492**	**45**	**122**	**1 231**	**1 883**	**2 256**	**7 058**
A02AA	**Magnesium compounds**	**0**	**0**	**<5**	**12**	**19**	**63**	**<5**	**<5**	**6**	**9**	**9**
A02AA04	magnesium hydroxide	0	0	<5	12	19	63	<5	<5	6	9	9
A02AC	**Calcium compounds**	**1 229**	**1 085**	**1 009**	**928**	**812**	**41**	**13**	**154**	**274**	**371**	**531**
A02AC01	calcium carbonate[1)]	1 229	1 085	1 009	928	812	41	13	154	274	371	531
A02AD	**Combinations and complexes of aluminium, calcium and magnesium compounds**	**1 485**	**1 526**	**1 039**	**1 179**	**1 613**	**62**	**37**	**773**	**535**	**268**	**241**
A02AD01	ordinary salt combinations[1)]	1 485	1 526	1 039	1 179	1 613	62	37	773	535	268	241
A02AH	**Antacids with sodium bicarbonate**	**2 341**	**2 471**	**2 684**	**2 837**	**3 256**	**36**	**47**	**318**	**1 170**	**1 721**	**6 064**
A02B	**DRUGS FOR PEPTIC ULCER AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD)**	**336 339**	**364 176**	**391 644**	**415 383**	**438 774**	**55**	**8 061**	**96 241**	**209 209**	**125 263**	**330 136**
A02BA	**H_2-receptor antagonists**	**57 804**	**57 052**	**55 116**	**53 694**	**53 138**	**60**	**1 326**	**14 460**	**24 438**	**12 914**	**16 864**

[1)] The ATC level comprises OTC medicinal products. The number of individuals is registered for prescription sales only.

ATC level		2010	2011	2012	2013	2014		2014				2014
		Number of individuals					Share of women (%)	Number of individuals per age group				Sales in 1000 NOK
								<15	15–44	45–69	≥70	
A02BA01	cimetidine	46	34	28	23	26	50	0	6	14	6	23
A02BA02	ranitidine[1)]	54 984	54 650	53 485	52 431	52 108	60	1 319	14 344	23 946	12 499	15 878
A02BA03	famotidine[1)]	2 547	2 313	1 618	1 312	1 101	54	8	125	522	446	962
A02BA53	famotidine, combinations[1)]	367	221	127	0	0	–	0	0	0	0	0
A02BB	**Prostaglandins**	**259**	**255**	**360**	**346**	**376**	**86**	**<5**	**259**	**69**	**47**	**169**
A02BB01	misoprostol	259	255	360	346	376	86	<5	259	69	47	169
A02BC	**Proton pump inhibitors**	**292 835**	**321 967**	**352 025**	**377 400**	**402 261**	**54**	**6 914**	**86 212**	**193 089**	**116 046**	**312 260**
A02BC01	omeprazole	47 082	48 114	47 472	45 183	44 183	55	3 337	9 003	19 077	12 766	41 235
A02BC02	pantoprazole[1)]	102 237	125 091	148 733	171 451	193 341	54	783	44 244	91 216	57 098	86 836
A02BC03	lansoprazole	48 809	47 348	46 359	43 483	40 462	50	388	6 641	20 737	12 696	26 619
A02BC05	esomeprazole	117 963	125 642	135 124	142 299	148 787	56	2 916	33 062	73 634	39 175	157 569
A02BX	**Other drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD)**	**1 909**	**2 143**	**2 375**	**2 724**	**3 208**	**63**	**273**	**1 119**	**1 136**	**680**	**843**
A02BX02	sucralfate	366	419	440	470	488	61	<5	131	203	150	287
A02BX13	alginic acid[1)]	1 549	1 739	1 945	2 239	2 703	63	268	977	922	536	526
A03	**DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS**	**62 554**	**65 509**	**69 717**	**72 136**	**66 873**	**71**	**1 098**	**22 054**	**26 171**	**17 550**	**13 800**
A03A	**DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS**	**3 623**	**3 150**	**3 568**	**4 373**	**4 596**	**56**	**202**	**990**	**1 636**	**1 768**	**1 974**
A03AA	**Synthetic anticholinergics, esters with tertiary amino group**	**29**	**26**	**27**	**30**	**35**	**66**	**0**	**15**	**15**	**5**	**30**
A03AA04	mebeverine	29	26	27	30	34	65	0	14	15	5	30
A03AA07	dicycloverine	0	0	0	0	<5	100	0	<5	0	0	0
A03AB	**Synthetic anticholinergics, quaternary ammonium compounds**	**132**	**160**	**214**	**497**	**666**	**46**	**<5**	**28**	**237**	**399**	**397**
A03AB02	glycopyrronium bromide	128	155	206	491	662	46	<5	28	233	399	393
A03AB05	propantheline	<5	5	8	6	<5	25	0	0	<5	0	4
A03AD	**Papaverine and derivatives**	**59**	**47**	**62**	**39**	**40**	**38**	**0**	**9**	**21**	**10**	**64**
A03AD01	papaverine	59	47	62	39	40	38	0	9	21	10	64
A03AX	**Other drugs for functional gastrointestinal disorders**	**3 405**	**2 924**	**3 271**	**3 815**	**3 871**	**57**	**200**	**939**	**1 371**	**1 361**	**1 483**
A03AX13	silicones[1)]	3 405	2 924	3 271	3 815	3 871	57	200	939	1 371	1 361	1 483
A03B	**BELLADONNA AND DERIVATIVES, PLAIN**	**1 617**	**1 910**	**2 134**	**2 390**	**2 475**	**60**	**10**	**1 062**	**1 001**	**402**	**1 090**
A03BA	**Belladonna alkaloids, tertiary amines**	**1 297**	**1 510**	**1 670**	**1 825**	**1 876**	**58**	**6**	**821**	**728**	**321**	**715**
A03BA01	atropine	22	23	29	38	49	59	0	26	18	5	37

[1)] The ATC level comprises OTC medicinal products. The number of individuals is registered for prescription sales only.

ATC group A

ATC level		2010	2011	2012	2013	2014		2014				2014
		Number of individuals					Share of women (%)	Number of individuals per age group				Sales in 1000 NOK
								<15	15–44	45–69	≥70	
A03BA03	hyoscyamine	1 276	1 487	1 641	1 787	1 827	58	6	795	710	316	678
A03BB	**Belladonna alkaloids, semisynthetic, quaternary ammonium compounds**	**321**	**406**	**471**	**578**	**609**	**64**	**<5**	**245**	**278**	**82**	**375**
A03BB01	butylscopolamine	300	386	458	564	596	64	<5	241	274	77	367
A03BB03	methylscopolamine	23	21	13	14	14	50	0	<5	<5	6	9
A03C	**ANTISPASMODICS IN COMBINATION WITH PSYCHOLEPTICS**	**19**	**20**	**16**	**14**	**17**	**53**	**0**	**<5**	**9**	**6**	**28**
A03CA	**Synthetic anticholinergic agents in combination with psycholeptics**	**19**	**20**	**16**	**14**	**17**	**53**	**0**	**<5**	**9**	**6**	**28**
A03CA02	clidinium and psycholeptics	19	20	16	14	17	53	0	<5	9	6	28
A03F	**PROPULSIVES**	**58 104**	**61 221**	**64 906**	**66 521**	**60 905**	**72**	**893**	**20 231**	**24 019**	**15 762**	**10 707**
A03FA	**Propulsives**	**58 104**	**61 221**	**64 906**	**66 521**	**60 905**	**72**	**893**	**20 231**	**24 019**	**15 762**	**10 707**
A03FA01	metoclopramide	57 999	61 099	64 774	66 391	60 805	72	881	20 201	23 983	15 740	10 520
A03FA02	cisapride	83	79	83	59	14	50	<5	5	<5	<5	16
A03FA03	domperidone	55	71	62	80	94	71	12	21	37	24	150
A03FA05	alizapride	0	0	11	9	13	62	<5	10	<5	0	21
A04	**ANTIEMETICS AND ANTINAUSEANTS**	**13 797**	**14 669**	**15 274**	**16 026**	**17 283**	**61**	**366**	**3 225**	**9 060**	**4 632**	**37 588**
A04A	**ANTIEMETICS AND ANTINAUSEANTS**	**13 797**	**14 669**	**15 274**	**16 026**	**17 283**	**61**	**366**	**3 225**	**9 060**	**4 632**	**37 588**
A04AA	**Serotonin ($5HT_3$) antagonists**	**11 434**	**11 986**	**12 407**	**12 856**	**14 005**	**60**	**294**	**2 202**	**7 385**	**4 124**	**27 405**
A04AA01	ondansetron	11 150	11 784	12 278	12 840	13 984	60	292	2 199	7 372	4 121	26 916
A04AA02	granisetron	0	<5	<5	<5	13	38	5	<5	<5	<5	117
A04AA03	tropisetron	440	324	210	26	<5	100	0	<5	<5	0	3
A04AA05	palonosetron	5	<5	7	16	51	86	0	10	33	8	369
A04AD	**Other antiemetics**	**3 887**	**4 658**	**5 185**	**5 735**	**6 100**	**69**	**74**	**1 510**	**3 576**	**940**	**10 183**
A04AD01	scopolamine	2 135	2 400	2 318	2 424	2 393	58	72	881	1 042	398	932
A04AD10	dronabinol	<5	5	5	0	0	–	0	0	0	0	0
A04AD12	aprepitant	1 761	2 269	2 873	3 323	3 724	77	<5	632	2 547	543	9 251
A05	**BILE AND LIVER THERAPY**	**2 015**	**2 303**	**2 600**	**2 728**	**2 891**	**75**	**90**	**896**	**1 380**	**525**	**8 929**
A05A	**BILE THERAPY**	**2 015**	**2 303**	**2 600**	**2 728**	**2 891**	**75**	**90**	**896**	**1 380**	**525**	**8 929**
A05AA	**Bile acid preparations**	**2 015**	**2 303**	**2 600**	**2 728**	**2 891**	**75**	**90**	**896**	**1 380**	**525**	**8 929**
A05AA02	ursodeoxycholic acid	2 015	2 303	2 600	2 728	2 891	75	90	896	1 380	525	8 929
A06	**DRUGS FOR CONSTIPATION**	**44 230**	**50 571**	**49 919**	**55 321**	**65 396**	**57**	**9 761**	**10 428**	**21 664**	**23 543**	**38 949**
A06A	**DRUGS FOR CONSTIPATION**	**44 230**	**50 571**	**49 919**	**55 321**	**65 396**	**57**	**9 761**	**10 428**	**21 664**	**23 543**	**38 949**
A06AA	**Softeners, emollients**	**112**	**208**	**368**	**743**	**1 113**	**53**	**121**	**157**	**355**	**480**	**744**

ATC level		2010	2011	2012	2013	2014		2014				2014
		Number of individuals					Share of women (%)	Number of individuals per age group				Sales in 1000 NOK
								<15	15–44	45–69	≥70	
A06AA01	liquid paraffin[1)]	112	194	354	699	1 058	54	111	149	336	462	468
A06AB	**Contact laxatives**	**15 058**	**21 757**	**22 562**	**24 463**	**27 547**	**58**	**374**	**3 392**	**11 742**	**12 039**	**8 520**
A06AB02	bisacodyl[1)]	4 056	6 514	6 040	5 666	5 695	60	85	758	1 905	2 947	2 019
A06AB06	senna glycosides[1)]	2 120	4 322	2 820	2 216	1 758	64	10	164	436	1 148	1 049
A06AB08	sodium picosulfate[1)]	10 082	10 948	11 687	12 659	14 068	55	271	1 736	5 381	6 680	3 090
A06AB20	contact laxatives in combination[1)]	6	8	<5	<5	27	81	0	<5	11	15	14
A06AB53	dantron, combinations	<5	0	0	0	0	–	0	0	0	0	0
A06AB56	senna glycosides, combinations[1)]	10	12	11	8	36	72	0	9	11	16	8
A06AB58	sodium picosulfate, combinations[1)]	31	1 581	3 535	5 410	7 598	59	11	877	4 623	2 087	2 339
A06AC	**Bulk-forming laxatives**	**1 996**	**2 054**	**2 084**	**2 266**	**2 512**	**61**	**64**	**725**	**934**	**789**	**745**
A06AC01	ispaghula (psylla seeds)[1)]	1 996	2 054	2 084	2 266	2 511	61	64	725	933	789	745
A06AC51	ispaghula, combinations[1)]	0	0	0	0	<5	0	0	0	<5	0	0
A06AD	**Osmotically acting laxatives**	**30 442**	**30 643**	**29 326**	**32 340**	**39 348**	**55**	**9 215**	**5 918**	**10 929**	**13 286**	**17 050**
A06AD11	lactulose[1)]	14 464	14 513	14 603	14 837	16 205	51	723	2 207	6 126	7 149	4 430
A06AD12	lactitol	59	58	51	39	34	50	19	9	<5	<5	36
A06AD15	macrogol	45	79	135	221	265	56	242	22	<5	0	233
A06AD17	sodium phosphate	9 665	7 334	2 813	2 015	1 686	56	0	324	913	449	354
A06AD65	macrogol, combinations[1)]	7 273	9 943	12 962	16 618	22 887	57	8 415	3 565	4 548	6 359	11 997
A06AG	**Enemas**	**4 892**	**5 458**	**5 325**	**5 466**	**6 066**	**49**	**597**	**1 423**	**2 070**	**1 976**	**8 874**
A06AG02	bisacodyl[1)]	1 410	1 680	1 676	1 699	1 807	47	62	518	713	514	773
A06AG04	glycerol[1)]	827	905	861	763	832	48	171	238	231	192	4 326
A06AG10	docusate sodium, incl. combinations	1 394	1 484	1 369	1 412	1 619	49	92	352	609	566	1 922
A06AG11	laurilsulfate, incl. combinations[1)]	1 647	1 826	1 786	1 920	2 192	50	284	385	690	833	1 854
A06AH	**Peripheral opioid receptor antagonists**	**197**	**195**	**181**	**177**	**173**	**47**	**0**	**15**	**97**	**61**	**929**
A06AH01	methylnaltrexone bromide	197	195	181	177	173	47	0	15	97	61	929
A06AX	**Other drugs for constipation**	**0**	**0**	**9**	**474**	**1 173**	**81**	**<5**	**478**	**494**	**197**	**2 087**
A06AX04	linaclotide	0	0	0	216	768	75	<5	329	323	114	968
A06AX05	prucalopride	0	0	9	271	452	91	<5	174	190	86	1 119
A07	**ANTIDIARRHEALS, INTESTINAL ANTIINFLAMMATORY/ANTIINFECTIVE AGENTS**	**69 807**	**72 492**	**73 982**	**77 004**	**80 519**	**58**	**7 703**	**21 811**	**32 898**	**18 107**	**141 264**

[1)] The ATC level comprises OTC medicinal products. The number of individuals is registered for prescription sales only.

ATC group A

ATC level		2010	2011	2012	2013	2014	Share of women (%)	2014 Number of individuals per age group				2014 Sales in 1000 NOK
		Number of individuals						<15	15–44	45–69	≥70	
A07A	**INTESTINAL ANTIINFECTIVES**	**31 199**	**32 204**	**32 358**	**33 905**	**35 179**	**64**	**7 103**	**8 985**	**11 755**	**7 336**	**14 709**
A07AA	**Antibiotics**	**31 199**	**32 204**	**32 358**	**33 905**	**35 179**	**64**	**7 103**	**8 985**	**11 755**	**7 336**	**14 709**
A07AA01	neomycin	0	0	0	37	28	82	0	13	14	<5	16
A07AA02	nystatin	30 730	31 544	31 731	33 307	34 639	64	7 075	8 790	11 552	7 222	12 400
A07AA06	paromomycin	154	316	257	322	344	69	36	171	129	8	302
A07AA09	vancomycin	182	200	234	238	239	69	<5	46	84	107	831
A07AA11	rifaximin	184	211	189	230	173	65	0	81	81	11	1 037
A07AA12	fidaxomicin	0	0	<5	7	6	67	0	<5	<5	<5	124
A07B	**INTESTINAL ADSORBENTS**	**80**	**84**	**102**	**103**	**127**	**55**	**15**	**41**	**47**	**24**	**28**
A07BA	**Charcoal preparations**	**80**	**84**	**96**	**88**	**87**	**55**	**15**	**24**	**33**	**15**	**11**
A07BA01	medicinal charcoal[1)]	80	84	96	88	87	55	15	24	33	15	11
A07BB	**Bismuth preparations**	**0**	**0**	**6**	**15**	**40**	**55**	**0**	**17**	**14**	**9**	**17**
A07C	**ELECTROLYTES WITH CARBOHYDRATES**	**259**	**279**	**364**	**449**	**485**	**49**	**197**	**137**	**104**	**47**	**1 215**
A07CA	**Oral rehydration salt formulations[1)]**	**259**	**279**	**364**	**442**	**477**	**49**	**189**	**137**	**104**	**47**	**301**
A07D	**ANTIPROPULSIVES**	**16 710**	**17 200**	**18 029**	**18 647**	**19 766**	**56**	**130**	**3 719**	**8 939**	**6 978**	**9 205**
A07DA	**Antipropulsives**	**16 710**	**17 200**	**18 029**	**18 647**	**19 766**	**56**	**130**	**3 719**	**8 939**	**6 978**	**9 205**
A07DA01	diphenoxylate	<5	<5	<5	<5	<5	50	0	<5	<5	0	7
A07DA02	opium	79	86	80	143	222	54	0	20	118	84	633
A07DA03	loperamide[1)]	16 464	16 933	17 714	18 322	19 563	56	129	3 660	8 865	6 909	8 506
A07DA53	loperamide, combinations[1)]	294	283	359	361	197	57	<5	64	76	56	59
A07E	**INTESTINAL ANTIINFLAMMATORY AGENTS**	**22 753**	**23 690**	**24 490**	**25 613**	**26 772**	**52**	**239**	**9 114**	**13 016**	**4 403**	**114 046**
A07EA	**Corticosteroids acting locally**	**5 212**	**5 155**	**5 208**	**5 549**	**5 833**	**61**	**69**	**1 841**	**2 713**	**1 210**	**15 334**
A07EA01	prednisolone	1 175	1 292	1 222	1 175	1 144	50	23	470	515	136	1 100
A07EA02	hydrocortisone	1 154	408	356	327	324	68	<5	85	181	57	595
A07EA06	budesonide	3 190	3 583	3 766	4 153	4 476	63	47	1 336	2 062	1 031	13 639
A07EB	**Antiallergic agents, excl. corticosteroids**	**53**	**64**	**50**	**35**	**43**	**81**	**7**	**11**	**21**	**<5**	**523**
A07EB01	cromoglicic acid	53	64	50	35	43	81	7	11	21	<5	523
A07EC	**Aminosalicylic acid and similar agents**	**19 918**	**20 669**	**21 351**	**22 091**	**23 001**	**50**	**187**	**8 149**	**11 227**	**3 438**	**98 188**
A07EC01	sulfasalazine	6 104	5 966	5 803	5 666	5 730	56	5	1 315	3 251	1 159	6 838
A07EC02	mesalazine	13 330	14 229	15 091	16 050	16 914	48	181	6 740	7 794	2 199	88 100
A07EC03	olsalazine	494	452	406	381	346	45	<5	77	201	67	1 213
A07EC04	balsalazide	750	687	613	589	555	44	0	170	293	92	2 038

[1)] The ATC level comprises OTC medicinal products. The number of individuals is registered for prescription sales only.

ATC level		2010	2011	2012	2013	2014		2014				2014
		Number of individuals					Share of women (%)	Number of individuals per age group				Sales in 1000 NOK
								<15	15–44	45–69	≥70	
A07F	**ANTIDIARRHEAL MICROORGANISMS**	**1 252**	**1 507**	**1 244**	**1 228**	**1 241**	**72**	**39**	**601**	**494**	**107**	**1 948**
A07FA	**Antidiarrheal microorganisms**	**1 252**	**1 507**	**1 244**	**1 228**	**1 241**	**72**	**39**	**601**	**494**	**107**	**1 948**
A07FA01	lactic acid producing organisms	918	912	768	806	769	74	20	393	324	32	1 532
A07FA02	saccharomyces boulardii	283	381	431	505	556	67	28	240	212	76	341
A07FA51	lactic acid producing organisms, combinations	0	0	16	14	13	77	<5	10	<5	0	29
A07X	**OTHER ANTIDIARRHEALS**	**99**	**117**	**64**	**43**	**28**	**46**	**15**	**5**	**5**	**<5**	**10**
A07XA	**Other antidiarrheals**	**99**	**117**	**64**	**43**	**28**	**46**	**15**	**5**	**5**	**<5**	**10**
A07XA04	racecadotril	0	0	0	0	18	39	15	<5	<5	0	5
A08	**ANTIOBESITY PREPARATIONS, EXCL. DIET PRODUCTS**	**19 168**	**10 373**	**7 674**	**7 245**	**6 718**	**77**	**<5**	**2 399**	**3 707**	**611**	**11 605**
A08A	**ANTIOBESITY PREPARATIONS, EXCL. DIET PRODUCTS**	**19 168**	**10 373**	**7 674**	**7 245**	**6 718**	**77**	**<5**	**2 399**	**3 707**	**611**	**11 605**
A08AA	**Centrally acting antiobesity products**	**5 782**	**0**	**0**	**0**	**0**	**–**	**0**	**0**	**0**	**0**	**0**
A08AA10	sibutramine	5 782	0	0	0	0	–	0	0	0	0	0
A08AB	**Peripherally acting antiobesity products**	**14 575**	**10 373**	**7 674**	**7 245**	**6 718**	**77**	**<5**	**2 399**	**3 707**	**611**	**11 605**
A08AB01	orlistat	14 575	10 373	7 674	7 245	6 718	77	<5	2 399	3 707	611	11 605
A08AX	**Other antiobesity drugs**	**<5**	**0**	**0**	**0**	**0**	**–**	**0**	**0**	**0**	**0**	**0**
A08AX01	rimonabant	<5	0	0	0	0	–	0	0	0	0	0
A09	**DIGESTIVES, INCL. ENZYMES**	**5 479**	**5 758**	**5 740**	**5 720**	**5 755**	**55**	**105**	**819**	**2 734**	**2 097**	**15 875**
A09A	**DIGESTIVES, INCL. ENZYMES**	**5 479**	**5 758**	**5 740**	**5 720**	**5 755**	**55**	**105**	**819**	**2 734**	**2 097**	**15 875**
A09AA	**Enzyme preparations**	**5 441**	**5 699**	**5 692**	**5 637**	**5 682**	**55**	**105**	**789**	**2 711**	**2 077**	**15 792**
A09AA02	multienzymes (lipase, protease etc.)[1)]	5 441	5 699	5 687	5 628	5 675	55	105	786	2 707	2 077	15 763
A09AB	**Acid preparations**	**50**	**61**	**52**	**63**	**62**	**82**	**0**	**18**	**20**	**24**	**42**
A09AB01	glutamic acid hydrochloride[1)]	44	54	39	45	33	70	0	5	8	20	26
A09AB02	betaine hydrochloride	0	<5	<5	10	22	95	0	9	11	<5	15
A09AB03	hydrochloric acid[1)]	6	6	10	8	7	100	0	<5	<5	<5	1
A09AC	**Enzyme and acid preparations, combinations**	**15**	**17**	**9**	**33**	**23**	**78**	**0**	**16**	**7**	**0**	**41**
A09AC02	multienzymes and acid preparations	15	17	9	33	23	78	0	16	7	0	41
A10	**DRUGS USED IN DIABETES**	**152 065**	**156 542**	**161 132**	**165 315**	**170 510**	**43**	**1 842**	**23 696**	**87 446**	**57 526**	**665 588**
A10A	**INSULINS AND ANALOGUES**	**54 014**	**54 994**	**56 508**	**58 187**	**59 814**	**43**	**1 825**	**14 457**	**26 825**	**16 707**	**346 893**

[1)] The ATC level comprises OTC medicinal products. The number of individuals is registered for prescription sales only.

ATC group A

ATC level		2010	2011	2012	2013	2014		2014				2014
		Number of individuals					Share of women (%)	Number of individuals per age group				Sales in 1000 NOK
								<15	15–44	45–69	≥70	
A10AB	**Insulins and analogues for injection, fast-acting**	**34 874**	**35 659**	**36 959**	**38 386**	**39 569**	**43**	**1 816**	**13 206**	**17 212**	**7 335**	**130 211**
A10AB01	insulin (human)	1 604	1 403	1 294	1 144	1 024	41	7	142	557	318	2 094
A10AB04	insulin lispro	8 835	9 021	9 118	9 462	9 808	42	230	3 937	4 365	1 276	34 826
A10AB05	insulin aspart	25 159	25 860	27 075	28 325	29 240	43	1 648	9 351	12 458	5 783	91 988
A10AB06	insulin glulisine	375	404	379	408	418	48	<5	138	228	50	1 304
A10AC	**Insulins and analogues for injection, intermediate-acting**	**32 520**	**31 916**	**32 046**	**32 559**	**33 085**	**41**	**556**	**5 027**	**15 754**	**11 748**	**99 649**
A10AC01	insulin (human)	32 520	31 916	32 046	32 559	33 085	41	556	5 027	15 754	11 748	99 649
A10AD	**Insulins and analogues for injection, intermediate- or long-acting combined with fast-acting**	**9 112**	**8 304**	**7 706**	**7 154**	**6 561**	**42**	**<5**	**421**	**2 883**	**3 253**	**28 931**
A10AD01	insulin (human)	<5	<5	<5	0	0	–	0	0	0	0	0
A10AD03	insulin (pork)	0	<5	0	0	<5	0	0	0	<5	0	0
A10AD04	insulin lispro	647	643	609	645	616	42	<5	105	290	219	2 461
A10AD05	insulin aspart	8 476	7 672	7 111	6 522	5 957	42	<5	317	2 598	3 040	26 471
A10AE	**Insulins and analogues for injection, long-acting**	**13 695**	**15 222**	**16 426**	**17 686**	**18 621**	**44**	**750**	**7 198**	**8 183**	**2 490**	**88 101**
A10AE02	insulin (beef)	<5	<5	<5	<5	<5	0	0	0	<5	0	16
A10AE04	insulin glargine	8 433	9 559	10 629	11 727	12 573	44	228	4 909	5 689	1 747	55 710
A10AE05	insulin detemir	5 526	5 927	6 023	6 207	6 258	45	533	2 388	2 573	764	32 363
A10AE06	insulin degludec	0	0	0	0	5	60	0	<5	<5	0	12
A10B	**BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS**	**117 293**	**121 207**	**125 155**	**128 629**	**133 291**	**43**	**19**	**10 869**	**73 477**	**48 926**	**318 695**
A10BA	**Biguanides**	**101 637**	**103 523**	**105 196**	**106 357**	**108 023**	**44**	**14**	**9 496**	**60 703**	**37 810**	**52 928**
A10BA02	metformin	101 637	103 523	105 196	106 357	108 023	44	14	9 496	60 703	37 810	52 928
A10BB	**Sulfonylureas**	**46 112**	**43 116**	**40 676**	**38 381**	**36 011**	**40**	**5**	**1 457**	**18 472**	**16 077**	**16 393**
A10BB01	glibenclamide	1 539	1 343	1 190	1 098	981	42	<5	38	443	496	516
A10BB02	chlorpropamide	<5	<5	<5	0	0	–	0	0	0	0	0
A10BB07	glipizide	4 807	4 281	3 860	3 413	3 055	40	0	71	1 257	1 727	1 815
A10BB12	glimepiride	40 028	37 733	35 800	34 007	32 090	40	<5	1 351	16 820	13 918	14 062
A10BD	**Combinations of oral blood glucose lowering drugs**	**8 219**	**10 974**	**13 316**	**15 765**	**18 386**	**36**	**0**	**1 155**	**12 069**	**5 162**	**73 382**
A10BD03	metformin and rosiglitazone	2 284	0	0	0	0	–	0	0	0	0	0
A10BD05	metformin and pioglitazone	32	35	26	30	34	44	0	<5	22	9	135
A10BD07	metformin and sitagliptin	2 187	4 053	5 228	6 295	7 751	36	0	496	5 031	2 224	30 315
A10BD08	metformin and vildagliptin	4 791	7 030	8 175	9 360	10 120	36	0	616	6 673	2 831	41 015
A10BD10	metformin and saxagliptin	0	0	0	43	81	30	0	8	58	15	318

ATC level		2010	2011	2012	2013	2014		2014				2014
		Number of individuals					Share of women (%)	Number of individuals per age group				Sales in 1000 NOK
								<15	15–44	45–69	≥70	
A10BD11	metformin and linagliptin	0	0	0	166	369	33	0	26	248	95	1 256
A10BD15	metformin and dapagliflozin	0	0	0	0	165	41	0	17	129	19	345
A10BF	**Alpha glucosidase inhibitors**	**813**	**701**	**640**	**597**	**519**	**44**	**0**	**37**	**241**	**241**	**728**
A10BF01	acarbose	813	701	640	597	519	44	0	37	241	241	728
A10BG	**Thiazolidinediones**	**4 672**	**1 912**	**1 642**	**1 579**	**1 553**	**40**	**0**	**58**	**982**	**513**	**3 452**
A10BG02	rosiglitazone	3 104	20	<5	0	0	–	0	0	0	0	0
A10BG03	pioglitazone	1 779	1 894	1 641	1 579	1 553	40	0	58	982	513	3 452
A10BH	**Dipeptidyl peptidase 4 (DPP-4) inhibitors**	**6 478**	**9 436**	**11 112**	**13 439**	**16 324**	**41**	**<5**	**828**	**8 918**	**6 577**	**63 011**
A10BH01	sitagliptin	4 799	6 711	7 209	7 621	8 852	42	<5	494	5 160	3 197	35 038
A10BH02	vildagliptin	935	1 274	1 755	2 289	2 520	45	0	123	1 318	1 079	8 095
A10BH03	saxagliptin	854	1 616	1 767	1 684	1 547	39	0	92	922	533	6 649
A10BH05	linagliptin	0	0	609	2 145	3 715	40	0	133	1 676	1 906	13 228
A10BX	**Other blood glucose lowering drugs, excl. insulins**	**1 335**	**3 523**	**5 430**	**7 805**	**12 938**	**44**	**0**	**1 408**	**9 212**	**2 318**	**108 801**
A10BX02	repaglinide	283	252	237	213	208	38	0	5	111	92	387
A10BX03	nateglinide	11	9	10	0	0	–	0	0	0	0	0
A10BX04	exenatide	554	795	874	972	1 067	44	0	132	776	159	8 622
A10BX07	liraglutide	535	2 605	4 433	5 666	6 716	45	0	801	4 866	1 049	76 783
A10BX09	dapagliflozin	0	0	0	1 311	5 717	42	0	533	4 077	1 107	21 184
A10BX10	lixisenatide	0	0	0	73	488	44	0	51	366	71	1 825
A11	**VITAMINS**	**93 046**	**102 139**	**119 090**	**128 838**	**156 142**	**60**	**1 725**	**44 372**	**59 696**	**50 349**	**89 115**
A11A	**MULTIVITAMINS, COMBINATIONS**	**0**	**28**	**96**	**138**	**163**	**45**	**79**	**78**	**6**	**0**	**577**
A11AA	**Multivitamins with minerals**	**0**	**28**	**96**	**138**	**163**	**45**	**79**	**78**	**6**	**0**	**577**
A11AA03	multivitamins and other minerals, incl. combinations	0	28	96	138	163	45	79	78	6	0	577
A11B	**MULTIVITAMINS, PLAIN**	**100**	**74**	**69**	**44**	**49**	**69**	**40**	**8**	**<5**	**0**	**50**
A11BA	**Multivitamins, plain**	**100**	**74**	**69**	**44**	**49**	**69**	**40**	**8**	**<5**	**0**	**50**
A11C	**VITAMIN A AND D, INCL. COMBINATIONS OF THE TWO**	**11 360**	**17 026**	**25 182**	**34 758**	**59 107**	**60**	**1 146**	**24 770**	**22 099**	**11 092**	**28 969**
A11CA	**Vitamin A, plain**	**30**	**42**	**58**	**51**	**76**	**64**	**8**	**23**	**38**	**7**	**178**
A11CA01	retinol (vit A)	14	20	37	35	57	63	5	15	32	5	73
A11CA02	betacarotene	16	22	21	16	19	68	<5	8	6	<5	105
A11CC	**Vitamin D and analogues**	**11 337**	**16 992**	**25 144**	**34 722**	**59 054**	**60**	**1 139**	**24 753**	**22 076**	**11 086**	**28 791**
A11CC01	ergocalciferol	4 250	8 654	13 289	49	26	42	0	9	14	<5	10
A11CC03	alfacalcidol	3 884	4 123	4 861	4 730	4 732	47	130	699	1 868	2 035	6 981

ATC group A

ATC level		2010	2011	2012	2013	2014		2014				2014
		Number of individuals					Share of women (%)	Number of individuals per age group				Sales in 1000 NOK
								<15	15–44	45–69	≥70	
A11CC04	calcitriol	2 396	2 632	2 947	3 068	2 971	44	<5	446	1 243	1 280	3 664
A11CC05	colecalciferol	939	1 733	4 421	27 121	51 625	62	1 009	23 664	19 092	7 860	18 136
A11D	**VITAMIN B1, PLAIN AND IN COMBINATION WITH VITAMIN B6 AND B12**	**790**	**749**	**800**	**784**	**897**	**34**	**16**	**128**	**540**	**213**	**798**
A11DA	**Vitamin B1, plain**	**782**	**739**	**788**	**774**	**887**	**34**	**16**	**126**	**535**	**210**	**792**
A11DA01	thiamine (vit B1)[1)]	782	739	788	774	887	34	16	126	535	210	792
A11DB	**Vitamin B1 in combination with vitamin B6 and/or vitamin B12**	**8**	**10**	**12**	**10**	**10**	**60**	**0**	**<5**	**5**	**<5**	**6**
A11E	**VITAMIN B-COMPLEX, INCL. COMBINATIONS**	**78 352**	**82 349**	**92 535**	**93 711**	**99 994**	**60**	**297**	**20 670**	**39 318**	**39 709**	**55 628**
A11EA	**Vitamin B-complex, plain[1)]**	**77 144**	**80 810**	**91 094**	**92 410**	**98 567**	**60**	**252**	**20 357**	**38 777**	**39 181**	**54 370**
A11EB	**Vitamin B-complex with vitamin C[1)]**	**92**	**155**	**231**	**270**	**593**	**58**	**6**	**228**	**234**	**125**	**140**
A11EX	**Vitamin B-complex, other combinations**	**1 155**	**1 443**	**1 278**	**1 083**	**946**	**39**	**39**	**105**	**356**	**446**	**1 119**
A11G	**ASCORBIC ACID (VITAMIN C), INCL. COMBINATIONS**	**3 677**	**3 759**	**3 674**	**3 502**	**3 424**	**66**	**8**	**429**	**781**	**2 206**	**1 131**
A11GA	**Ascorbic acid (vitamin C), plain**	**3 677**	**3 759**	**3 674**	**3 502**	**3 424**	**66**	**8**	**429**	**781**	**2 206**	**1 131**
A11GA01	ascorbic acid (vit C)[1)]	3 677	3 759	3 674	3 502	3 424	66	8	429	781	2 206	1 131
A11H	**OTHER PLAIN VITAMIN PREPARATIONS**	**1 604**	**1 730**	**1 589**	**1 757**	**1 742**	**61**	**222**	**929**	**431**	**160**	**1 510**
A11HA	**Other plain vitamin preparations**	**1 604**	**1 730**	**1 589**	**1 757**	**1 742**	**61**	**222**	**929**	**431**	**160**	**1 510**
A11HA01	nicotinamide[1)]	13	11	19	11	20	50	0	7	9	<5	14
A11HA02	pyridoxine (vit B6)[1)]	1 072	1 134	1 109	1 374	1 398	62	144	821	329	104	664
A11HA03	tocopherol (vit E)[1)]	442	412	320	289	261	53	66	69	78	48	571
A11HA04	riboflavin (vit B2)	12	11	9	21	20	80	<5	10	5	<5	8
A11HA05	biotin	0	0	0	<5	8	63	<5	<5	0	0	170
A11HA06	pyridoxal phosphate	66	161	131	56	35	83	<5	20	11	<5	17
A11HA08	tocofersolan	0	<5	<5	<5	<5	67	<5	0	0	0	66
A11J	**OTHER VITAMIN PRODUCTS, COMBINATIONS**	**61**	**91**	**94**	**79**	**70**	**49**	**49**	**12**	**6**	**<5**	**318**
A11JA	**Combinations of vitamins**	**48**	**53**	**55**	**62**	**63**	**43**	**49**	**9**	**<5**	**<5**	**314**
A11JB	**Vitamins with minerals**	**13**	**38**	**39**	**17**	**7**	**100**	**0**	**<5**	**<5**	**0**	**4**
A12	**MINERAL SUPPLEMENTS**	**100 943**	**111 514**	**125 551**	**134 766**	**141 438**	**78**	**443**	**11 549**	**57 754**	**71 692**	**107 316**
A12A	**CALCIUM**	**80 569**	**91 211**	**104 462**	**113 047**	**120 033**	**81**	**238**	**10 148**	**50 473**	**59 174**	**85 055**
A12AA	**Calcium**	**1 417**	**1 137**	**1 071**	**1 005**	**1 089**	**66**	**77**	**190**	**430**	**392**	**1 226**
A12AA02	calcium glubionate	7	<5	6	<5	<5	33	<5	0	<5	0	22

[1)] The ATC level comprises OTC medicinal products. The number of individuals is registered for prescription sales only.

ATC level		2010	2011	2012	2013	2014		2014				2014
		Number of individuals					Share of women (%)	Number of individuals per age group				Sales in 1000 NOK
								<15	15–44	45–69	≥70	
A12AA04	calcium carbonate[1)]	412	188	<5	0	0	–	0	0	0	0	0
A12AA06	calcium lactate gluconate[1)]	984	928	1 034	984	1 084	66	75	188	429	392	1 201
A12AA12	calcium acetate anhydrous	28	24	32	18	0	–	0	0	0	0	0
A12AX	**Calcium, combinations with vitamin D and/or other drugs[1)]**	**79 351**	**90 245**	**103 588**	**112 275**	**119 215**	**81**	**167**	**10 007**	**50 147**	**58 894**	**83 829**
A12B	**POTASSIUM**	**20 544**	**20 029**	**20 998**	**21 980**	**21 246**	**64**	**96**	**1 110**	**6 986**	**13 054**	**16 334**
A12BA	**Potassium**	**20 544**	**20 029**	**20 998**	**21 980**	**21 246**	**64**	**96**	**1 110**	**6 986**	**13 054**	**16 334**
A12BA01	potassium chloride[1)]	18 800	18 295	19 060	19 870	19 251	64	17	928	6 301	12 005	12 713
A12BA02	potassium citrate[1)]	2 055	2 034	2 268	2 446	2 347	62	81	215	817	1 234	3 595
A12BA30	combinations	<5	<5	<5	5	<5	50	0	<5	<5	<5	26
A12C	**OTHER MINERAL SUPPLEMENTS**	**4 004**	**4 809**	**5 401**	**5 736**	**6 704**	**59**	**120**	**607**	**2 370**	**3 607**	**5 586**
A12CA	**Sodium**	**715**	**878**	**983**	**1 182**	**1 440**	**66**	**7**	**67**	**430**	**936**	**929**
A12CA01	sodium chloride[1)]	715	878	983	1 182	1 440	66	7	67	430	936	929
A12CB	**Zinc**	**767**	**697**	**769**	**714**	**711**	**68**	**46**	**145**	**236**	**284**	**474**
A12CB01	zinc sulfate	767	697	769	714	711	68	46	145	236	284	474
A12CC	**Magnesium**	**2 591**	**3 300**	**3 717**	**3 941**	**4 684**	**56**	**67**	**401**	**1 764**	**2 452**	**4 119**
A12CC10	magnesium oxide	18	103	174	164	158	54	6	15	58	79	179
A12CC30	magnesium (different salts in combination)[1)]	2 573	3 212	3 563	3 792	4 549	56	50	386	1 722	2 391	3 530
A12CX	**Other mineral products**	**0**	**0**	**0**	**<5**	**7**	**57**	**<5**	**<5**	**<5**	**<5**	**63**
A14	**ANABOLIC AGENTS FOR SYSTEMIC USE**	**847**	**866**	**885**	**1 008**	**1 229**	**86**	**<5**	**309**	**803**	**115**	**876**
A14A	**ANABOLIC STEROIDS**	**847**	**866**	**885**	**1 008**	**1 229**	**86**	**<5**	**309**	**803**	**115**	**876**
A14AA	**Androstan derivatives**	**827**	**841**	**847**	**963**	**1 187**	**87**	**<5**	**290**	**781**	**114**	**611**
A14AA07	prasterone	827	841	847	963	1 187	87	<5	290	781	114	611
A14AB	**Estren derivatives**	**21**	**25**	**24**	**26**	**29**	**10**	**0**	**15**	**14**	**0**	**92**
A14AB01	nandrolone	21	25	24	26	29	10	0	15	14	0	92
A16	**OTHER ALIMENTARY TRACT AND METABOLISM PRODUCTS**	**548**	**663**	**604**	**507**	**402**	**55**	**119**	**150**	**105**	**28**	**195 860**
A16A	**OTHER ALIMENTARY TRACT AND METABOLISM PRODUCTS**	**317**	**335**	**379**	**396**	**377**	**54**	**118**	**135**	**97**	**27**	**195 835**
A16AA	**Amino acids and derivatives**	**123**	**131**	**157**	**164**	**184**	**57**	**91**	**53**	**26**	**14**	**4 233**
A16AA01	levocarnitine	87	79	86	99	128	51	83	30	5	10	2 343
A16AA03	glutamine	12	19	11	17	13	92	0	6	<5	<5	16
A16AA04	mercaptamine	10	8	8	8	9	44	<5	5	0	0	740
A16AA06	betaine	16	20	22	23	23	52	7	12	<5	0	1 124

[1)] The ATC level comprises OTC medicinal products. The number of individuals is registered for prescription sales only.

ATC group A

ATC level		2010	2011	2012	2013	2014		2014				2014
		Number of individuals					Share of women (%)	Number of individuals per age group				Sales in 1000 NOK
								<15	15–44	45–69	≥70	
A16AB	**Enzymes**	**50**	**56**	**59**	**65**	**69**	**38**	**6**	**27**	**30**	**6**	**154 652**
A16AB02	imiglucerase	7	7	<5	7	8	50	0	<5	<5	<5	18 711
A16AB03	agalsidase alfa	32	33	34	24	22	36	0	8	9	5	39 534
A16AB04	agalsidase beta	18	7	14	23	30	33	<5	16	13	0	47 102
A16AB05	laronidase	<5	<5	0	<5	<5	0	0	0	<5	0	6
A16AB07	alglucosidase alfa	<5	<5	<5	<5	<5	0	0	0	<5	0	11 613
A16AB08	galsulfase	0	0	<5	<5	<5	100	<5	0	0	0	20 744
A16AB09	idursulfase	<5	<5	<5	<5	<5	0	<5	<5	0	0	8 864
A16AB10	velaglucerase alfa	0	6	5	5	<5	0	0	<5	<5	0	8 078
A16AX	**Various alimentary tract and metabolism products**	**149**	**151**	**166**	**170**	**129**	**59**	**22**	**56**	**44**	**7**	**36 949**
A16AX01	thioctic acid	121	109	113	118	67	64	0	21	39	7	71
A16AX03	sodium phenylbutyrate	<5	<5	<5	<5	<5	0	<5	0	0	0	56
A16AX04	nitisinone	13	14	14	16	17	35	12	5	0	0	13 825
A16AX05	zinc acetate	7	8	11	11	16	50	<5	9	<5	0	147
A16AX06	miglustat	<5	<5	<5	<5	5	60	<5	<5	0	0	3 555
A16AX07	sapropterin	5	15	22	20	23	70	<5	20	<5	0	19 296

3.6 ATC group B – Blood and bloodforming organs

ATC level		2010	2011	2012	2013	2014		2014				2014
		Number of individuals					Share of women (%)	Number of individuals per age group				Sales in 1000 NOK
								<15	15–44	45–69	≥70	
B	**BLOOD AND BLOOD FORMING ORGANS**	**581 349**	**597 921**	**617 386**	**629 097**	**640 752**	**50**	**3 326**	**63 594**	**273 287**	**300 545**	**1 197 426**
B01	**ANTITHROMBOTIC AGENTS**	**485 783**	**497 174**	**509 369**	**519 085**	**525 382**	**44**	**459**	**23 311**	**223 701**	**277 911**	**697 341**
B01A	**ANTITHROMBOTIC AGENTS**	**485 783**	**497 174**	**509 369**	**519 085**	**525 382**	**44**	**459**	**23 311**	**223 701**	**277 911**	**697 341**
B01AA	**Vitamin K antagonists**	**88 730**	**92 222**	**94 810**	**88 089**	**77 829**	**40**	**50**	**2 470**	**21 663**	**53 646**	**65 823**
B01AA01	dicoumarol	90	93	81	70	63	54	0	7	24	32	293
B01AA02	phenindione	24	15	<5	<5	<5	100	0	0	<5	0	29
B01AA03	warfarin	88 631	92 133	94 729	88 017	77 768	40	50	2 464	21 639	53 615	65 501
B01AB	**Heparin group**	**36 949**	**42 027**	**46 978**	**49 253**	**50 686**	**59**	**213**	**11 326**	**22 811**	**16 336**	**116 291**
B01AB01	heparin	926	943	1 056	1 141	1 208	55	147	197	546	318	2 082
B01AB02	antithrombin III	<5	0	0	0	0	–	0	0	0	0	0
B01AB04	dalteparin	21 249	25 588	28 632	28 495	27 593	60	52	6 019	12 817	8 705	63 271
B01AB05	enoxaparin	15 363	16 078	17 952	20 454	22 723	59	17	5 270	9 854	7 582	50 933
B01AB10	tinzaparin	0	6	7	10	<5	50	0	<5	0	<5	5
B01AC	**Platelet aggregation inhibitors excl. heparin**	**390 081**	**394 911**	**399 674**	**400 083**	**397 630**	**43**	**210**	**9 863**	**179 421**	**208 136**	**255 955**
B01AC04	clopidogrel	28 372	29 470	28 352	25 620	25 595	37	<5	565	11 323	13 705	25 286
B01AC05	ticlopidine	327	273	229	187	180	48	0	<5	57	121	500
B01AC06	acetylsalicylic acid	376 011	377 738	379 980	378 066	373 993	43	209	9 354	169 700	194 730	104 429
B01AC07	dipyridamole	19 310	19 501	19 782	19 830	19 569	43	0	286	7 351	11 932	23 362
B01AC09	epoprostenol	<5	<5	<5	<5	<5	100	0	0	<5	0	1 204
B01AC11	iloprost	<5	6	10	9	8	75	0	<5	5	<5	1 455
B01AC21	treprostinil	9	8	9	15	16	63	<5	10	5	0	29 876
B01AC22	prasugrel	214	487	1 130	1 711	1 748	19	0	111	1 352	285	7 304
B01AC24	ticagrelor	0	26	2 341	6 773	8 737	25	0	386	5 688	2 663	45 098
B01AC30	combinations	8 788	11 324	13 223	14 622	15 576	43	0	322	6 411	8 843	17 442
B01AC56	acetylsalicylic acid, combinations with proton pump inhibitors	0	0	80	312	0	–	0	0	0	0	0
B01AD	**Enzymes**	**<5**	**<5**	**<5**	**<5**	**<5**	**100**	**<5**	**0**	**<5**	**0**	**428**
B01AD02	alteplase	<5	<5	<5	<5	<5	100	<5	0	<5	0	428
B01AE	**Direct thrombin inhibitors**	**187**	**1 168**	**4 102**	**13 879**	**15 363**	**39**	**<5**	**209**	**5 233**	**9 920**	**98 918**
B01AE07	dabigatran etexilate	187	1 168	4 102	13 879	15 363	39	<5	209	5 233	9 920	98 918
B01AF	**Direct factor Xa inhibitors**	**191**	**899**	**1 666**	**15 590**	**28 933**	**45**	**0**	**1 270**	**9 923**	**17 740**	**159 893**
B01AF01	rivaroxaban	191	899	1 332	13 426	20 801	44	0	1 160	7 277	12 364	123 729
B01AF02	apixaban	0	0	335	2 261	8 647	47	0	121	2 799	5 727	36 164
B01AX	**Other antithrombotic agents**	**17**	**8**	**5**	**6**	**10**	**80**	**0**	**<5**	**5**	**<5**	**32**
B01AX05	fondaparinux	17	8	5	6	10	80	0	<5	5	<5	32
B02	**ANTIHEMORRHAGICS**	**12 210**	**12 954**	**13 337**	**13 981**	**13 806**	**92**	**281**	**6 816**	**6 056**	**653**	**301 356**

ATC group B

ATC level		2010	2011	2012	2013	2014		2014				2014
		Number of individuals					Share of women (%)	Number of individuals per age group				Sales in 1000 NOK
								<15	15–44	45–69	≥70	
B02A	**ANTIFIBRINOLYTICS**	**11 846**	**12 577**	**12 908**	**13 492**	**13 307**	**94**	**170**	**6 634**	**5 949**	**554**	**6 251**
B02AA	**Amino acids**	**11 845**	**12 575**	**12 906**	**13 490**	**13 305**	**94**	**170**	**6 632**	**5 949**	**554**	**4 960**
B02AA02	tranexamic acid	11 845	12 575	12 906	13 490	13 305	94	170	6 632	5 949	554	4 960
B02AB	**Proteinase inhibitors**	**<5**	**<5**	**<5**	**<5**	**<5**	**50**	**0**	**<5**	**0**	**0**	**1 291**
B02AB02	alfa1 antitrypsin	<5	<5	<5	<5	<5	50	0	<5	0	0	1 291
B02B	**VITAMIN K AND OTHER HEMOSTATICS**	**419**	**427**	**507**	**564**	**585**	**34**	**128**	**215**	**134**	**108**	**295 105**
B02BA	**Vitamin K**	**212**	**208**	**224**	**246**	**255**	**55**	**54**	**85**	**40**	**76**	**130**
B02BA01	phytomenadione	212	208	224	246	255	55	54	85	40	76	130
B02BB	**Fibrinogen**	**0**	**<5**	**<5**	**<5**	**<5**	**50**	**0**	**<5**	**<5**	**0**	**254**
B02BB01	fibrinogen, human	0	<5	<5	<5	<5	50	0	<5	<5	0	254
B02BC	**Local hemostatics**	**0**	**0**	**0**	**0**	**<5**	**0**	**0**	**0**	**<5**	**0**	**1**
B02BC30	combinations	0	0	0	0	<5	0	0	0	<5	0	1
B02BD	**Blood coagulation factors**	**189**	**190**	**241**	**258**	**255**	**7**	**74**	**113**	**62**	**6**	**281 126**
B02BD01	coagulation factor IX, II, VII and X in combination	<5	<5	<5	<5	<5	100	0	<5	0	0	484
B02BD02	coagulation factor VIII	134	132	169	176	181	1	58	78	44	<5	220 638
B02BD03	factor VIII inhibitor bypassing activity	6	7	6	9	9	0	<5	<5	<5	<5	20 419
B02BD04	coagulation factor IX	28	30	37	42	34	0	9	18	5	<5	13 444
B02BD06	von Willebrand factor and coagulation factor VIII in combination	12	9	14	15	15	53	<5	5	5	<5	6 969
B02BD07	coagulation factor XIII	0	0	<5	<5	<5	100	0	0	<5	0	116
B02BD08	eptacog alfa (activated)	7	7	10	12	11	36	5	<5	<5	0	6 205
B02BD09	nonacog alfa	<5	<5	<5	<5	<5	0	0	<5	<5	0	2 562
B02BD10	von Willebrand factor	<5	<5	<5	<5	<5	67	<5	<5	0	0	10 289
B02BX	**Other systemic hemostatics**	**18**	**28**	**41**	**59**	**72**	**58**	**0**	**16**	**30**	**26**	**13 594**
B02BX04	romiplostim	14	15	17	20	17	53	0	<5	9	5	5 969
B02BX05	eltrombopag	<5	15	25	39	59	58	0	15	22	22	7 624
B03	**ANTIANEMIC PREPARATIONS**	**129 328**	**135 640**	**144 891**	**146 457**	**153 275**	**66**	**2 416**	**36 100**	**58 691**	**56 068**	**121 816**
B03A	**IRON PREPARATIONS**	**24 019**	**25 072**	**25 887**	**27 377**	**30 345**	**69**	**1 494**	**9 464**	**6 656**	**12 731**	**10 438**
B03AA	**Iron bivalent, oral preparations**	**22 588**	**23 597**	**24 308**	**25 635**	**28 787**	**68**	**1 491**	**8 650**	**6 156**	**12 490**	**8 546**
B03AA01	ferrous glycine sulfate[1)]	3 574	4 189	4 998	6 968	8 738	72	144	3 209	2 095	3 290	4 371
B03AA02	ferrous fumarate[1)]	1 320	1 324	1 361	1 466	1 653	52	1 106	291	81	175	286
B03AA03	ferrous gluconate	101	52	0	0	0	–	0	0	0	0	0
B03AA07	ferrous sulfate[1)]	17 767	18 255	18 290	17 470	18 750	68	255	5 241	4 033	9 221	3 889

[1)] The ATC level comprises OTC medicinal products. The number of individuals is registered for prescription sales only.

ATC level		2010	2011	2012	2013	2014		2014				2014
		Number of individuals					Share of women (%)	Number of individuals per age group				Sales in 1000 NOK
								<15	15–44	45–69	≥70	
B03AC	**Iron, parenteral preparations**	**1 524**	**1 577**	**1 699**	**1 869**	**1 667**	**87**	**<5**	**865**	**525**	**274**	**1 892**
B03B	**VITAMIN B12 AND FOLIC ACID**	**107 727**	**113 339**	**122 260**	**122 663**	**126 638**	**65**	**1 003**	**28 075**	**52 738**	**44 822**	**35 951**
B03BA	**Vitamin B12 (cyanocobalamin and analogues)**	**76 095**	**79 008**	**85 534**	**83 417**	**86 841**	**68**	**215**	**20 258**	**33 916**	**32 452**	**19 315**
B03BA01	cyanocobalamin	7 389	7 469	8 514	8 210	12 835	69	37	3 966	5 020	3 812	2 546
B03BA02	cyanocobalamin tannin complex	39 772	40 827	44 239	43 570	9 831	68	16	2 339	3 790	3 686	1 872
B03BA03	hydroxocobalamin	31 131	32 969	35 304	33 807	68 906	68	165	15 130	26 979	26 632	14 594
B03BA05	mecobalamin	38	91	125	211	253	68	<5	125	103	23	299
B03BB	**Folic acid and derivatives**	**36 321**	**39 074**	**41 739**	**44 258**	**44 288**	**60**	**800**	**8 517**	**20 382**	**14 589**	**16 636**
B03BB01	folic acid[1)]	36 321	39 074	41 739	44 258	44 288	60	800	8 517	20 382	14 589	16 636
B03X	**OTHER ANTIANEMIC PREPARATIONS**	**3 485**	**3 456**	**3 440**	**3 287**	**3 391**	**39**	**25**	**336**	**1 144**	**1 886**	**75 427**
B03XA	**Other antianemic preparations**	**3 485**	**3 456**	**3 440**	**3 287**	**3 391**	**39**	**25**	**336**	**1 144**	**1 886**	**75 427**
B03XA01	erythropoietin	334	279	280	255	267	42	<5	30	98	137	6 919
B03XA02	darbepoetin alfa	2 714	2 704	2 871	2 778	2 897	39	24	283	975	1 615	62 939
B03XA03	methoxy polyethylene glycol-epoetin beta	475	516	446	291	261	37	0	26	84	151	5 569
B06	**OTHER HEMATOLOGICAL AGENTS**	**54**	**52**	**81**	**84**	**95**	**64**	**<5**	**52**	**35**	**5**	**47 990**
B06A	**OTHER HEMATOLOGICAL AGENTS**	**54**	**52**	**81**	**84**	**95**	**64**	**<5**	**52**	**35**	**5**	**47 990**
B06AA	**Enzymes**	**7**	**5**	**<5**	**<5**	**10**	**90**	**0**	**6**	**<5**	**0**	**11**
B06AA03	hyaluronidase	<5	<5	<5	<5	10	90	0	6	<5	0	11
B06AA55	streptokinase, combinations	5	<5	0	0	0	–	0	0	0	0	0
B06AB	**Other hem products**	**0**	**<5**	**<5**	**<5**	**0**	**–**	**0**	**0**	**0**	**0**	**0**
B06AC	**Drugs used in hereditary angioedema**	**47**	**46**	**76**	**80**	**85**	**61**	**<5**	**46**	**31**	**5**	**47 979**
B06AC01	c1-inhibitor, plasma derived	37	29	44	55	58	64	<5	33	18	<5	33 094
B06AC02	icatibant	14	23	53	57	58	59	<5	31	24	<5	14 657
B06AC04	conestat alfa	0	0	<5	<5	<5	100	0	<5	0	0	229

[1)] The ATC level comprises OTC medicinal products. The number of individuals is registered for prescription sales only.

3.7 ATC group C – Cardiovascular system

ATC level		2010	2011	2012	2013	2014		2014				2014
		Number of individuals					Share of women (%)	Number of individuals per age group				Sales in 1000 NOK
								<15	15–44	45–69	≥70	
C	**CARDIOVASCULAR SYSTEM**	**975 141**	**998 461**	**1 019 237**	**1 040 279**	**1 060 258**	**51**	**7 467**	**101 635**	**546 403**	**404 753**	**1 515 865**
C01	**CARDIAC THERAPY**	**122 995**	**120 544**	**119 110**	**113 974**	**113 020**	**48**	**5 484**	**9 394**	**38 502**	**59 640**	**86 757**
C01A	**CARDIAC GLYCOSIDES**	**24 749**	**23 214**	**20 106**	**16 077**	**14 059**	**49**	**40**	**96**	**2 557**	**11 366**	**4 798**
C01AA	**Digitalis glycosides**	**24 749**	**23 214**	**20 106**	**16 077**	**14 059**	**49**	**40**	**96**	**2 557**	**11 366**	**4 798**
C01AA04	digitoxin	23 709	22 197	14 057	3 070	932	50	0	5	121	806	277
C01AA05	digoxin	1 068	1 084	10 662	14 333	13 213	49	40	92	2 451	10 630	4 521
C01B	**ANTIARRHYTHMICS, CLASS I AND III**	**11 688**	**12 400**	**13 122**	**13 951**	**14 593**	**36**	**86**	**594**	**7 331**	**6 582**	**30 613**
C01BA	**Antiarrhythmics, class Ia**	**159**	**131**	**121**	**114**	**103**	**54**	**0**	**8**	**35**	**60**	**240**
C01BA01	quinidine	<5	5	<5	<5	<5	100	0	0	<5	<5	3
C01BA03	disopyramide	156	126	117	112	101	53	0	8	34	59	237
C01BB	**Antiarrhythmics, class Ib**	**17**	**17**	**18**	**17**	**26**	**46**	**0**	**7**	**15**	**<5**	**284**
C01BB01	lidocaine	0	0	<5	0	0	–	0	0	0	0	0
C01BB02	mexiletine	17	17	17	17	26	46	0	7	15	<5	284
C01BC	**Antiarrhythmics, class Ic**	**6 393**	**6 735**	**7 036**	**7 373**	**7 599**	**41**	**83**	**437**	**4 479**	**2 600**	**15 267**
C01BC03	propafenone	<5	5	<5	<5	6	83	0	<5	<5	<5	11
C01BC04	flecainide	6 390	6 730	7 033	7 371	7 593	41	83	436	4 476	2 598	15 256
C01BD	**Antiarrhythmics, class III**	**5 432**	**5 809**	**6 269**	**6 750**	**7 168**	**32**	**<5**	**161**	**2 992**	**4 012**	**14 821**
C01BD01	amiodarone	4 853	4 912	5 236	5 593	5 785	30	<5	120	2 286	3 376	4 194
C01BD07	dronedarone	767	1 034	1 166	1 269	1 526	39	0	44	787	695	10 627
C01C	**CARDIAC STIMULANTS EXCL. CARDIAC GLYCOSIDES**	**14 121**	**15 618**	**18 389**	**19 662**	**22 877**	**58**	**5 359**	**7 784**	**7 832**	**1 902**	**15 765**
C01CA	**Adrenergic and dopaminergic agents**	**14 121**	**15 618**	**18 389**	**19 662**	**22 877**	**58**	**5 359**	**7 784**	**7 832**	**1 902**	**15 765**
C01CA01	etilefrine	95	112	110	100	102	57	<5	33	38	30	194
C01CA02	isoprenaline	0	0	<5	0	0	–	0	0	0	0	0
C01CA06	phenylephrine	0	0	0	<5	<5	0	0	0	<5	0	1
C01CA17	midodrine	16	20	20	28	29	48	<5	13	7	8	261
C01CA24	epinephrine	14 006	15 480	18 251	19 530	22 741	58	5 357	7 738	7 783	1 863	15 298
C01CA26	ephedrine	6	8	8	6	8	13	0	<5	5	<5	11
C01D	**VASODILATORS USED IN CARDIAC DISEASES**	**79 479**	**75 844**	**73 279**	**69 136**	**65 803**	**46**	**0**	**962**	**21 816**	**43 025**	**35 085**
C01DA	**Organic nitrates**	**79 479**	**75 844**	**73 279**	**69 136**	**65 802**	**46**	**0**	**962**	**21 815**	**43 025**	**35 084**
C01DA02	glyceryl trinitrate	60 717	58 282	56 629	53 076	50 736	45	0	919	19 043	30 774	11 713
C01DA08	isosorbide dinitrate	2 311	1 950	1 705	1 377	1 154	52	0	9	153	992	926
C01DA14	isosorbide mononitrate	34 145	31 873	30 300	28 711	27 090	50	0	100	5 549	21 441	22 445
C01DX	**Other vasodilators used in cardiac diseases**	**0**	**0**	**0**	**0**	**<5**	**0**	**0**	**0**	**<5**	**<5**	**1**
C01DX12	molsidomine	0	0	0	0	<5	0	0	0	<5	<5	1

ATC level		2010	2011	2012	2013	2014		2014				2014
		Number of individuals					Share of women (%)	Number of individuals per age group				Sales in 1000 NOK
								<15	15–44	45–69	≥70	
C01E	**OTHER CARDIAC PREPARATIONS**	**138**	**67**	**11**	**29**	**62**	**50**	**0**	**17**	**25**	**20**	**497**
C01EB	**Other cardiac preparations**	**138**	**67**	**11**	**29**	**62**	**50**	**0**	**17**	**25**	**20**	**497**
C01EB09	ubidecarenone	126	59	0	0	0	–	0	0	0	0	0
C01EB15	trimetazidine	10	6	7	8	5	80	0	0	5	0	6
C01EB17	ivabradine	0	0	<5	15	42	62	0	17	14	11	356
C01EB18	ranolazine	0	0	0	6	15	7	0	0	6	9	135
C02	**ANTIHYPERTENSIVES**	**17 442**	**17 597**	**17 548**	**17 267**	**16 927**	**28**	**19**	**711**	**7 709**	**8 488**	**73 486**
C02A	**ANTIADRENERGIC AGENTS, CENTRALLY ACTING**	**6 469**	**6 521**	**6 520**	**6 532**	**6 476**	**39**	**<5**	**307**	**3 415**	**2 753**	**6 260**
C02AB	**Methyldopa**	**141**	**107**	**88**	**65**	**60**	**75**	**0**	**29**	**20**	**11**	**158**
C02AB01	methyldopa (levorotatory)	141	107	88	65	60	75	0	29	20	11	158
C02AC	**Imidazoline receptor agonists**	**6 340**	**6 427**	**6 440**	**6 476**	**6 426**	**39**	**<5**	**280**	**3 402**	**2 743**	**6 101**
C02AC01	clonidine	64	85	80	92	100	51	<5	29	57	13	236
C02AC05	moxonidine	6 276	6 342	6 361	6 385	6 327	39	0	251	3 346	2 730	5 865
C02C	**ANTIADRENERGIC AGENTS, PERIPHERALLY ACTING**	**11 221**	**11 285**	**11 263**	**10 952**	**10 636**	**19**	**0**	**380**	**4 452**	**5 804**	**13 682**
C02CA	**Alpha-adrenoreceptor antagonists**	**11 221**	**11 285**	**11 263**	**10 952**	**10 636**	**19**	**0**	**380**	**4 452**	**5 804**	**13 682**
C02CA01	prazosin	0	0	0	35	62	61	0	42	18	<5	84
C02CA04	doxazosin	11 221	11 285	11 263	10 920	10 574	19	0	338	4 434	5 802	13 598
C02D	**ARTERIOLAR SMOOTH MUSCLE, AGENTS ACTING ON**	**301**	**317**	**318**	**335**	**337**	**30**	**<5**	**15**	**133**	**185**	**369**
C02DB	**Hydrazinophthalazine derivatives**	**270**	**288**	**294**	**316**	**306**	**30**	**<5**	**8**	**116**	**178**	**220**
C02DB02	hydralazine	270	288	294	316	306	30	<5	8	116	178	220
C02DC	**Pyrimidine derivatives**	**32**	**29**	**23**	**20**	**31**	**29**	**0**	**7**	**17**	**7**	**149**
C02DC01	minoxidil	32	29	23	20	31	29	0	7	17	7	149
C02DD	**Nitroferricyanide derivatives**	**0**	**0**	**<5**	**0**	**0**	**–**	**0**	**0**	**0**	**0**	**0**
C02DD01	nitroprusside	0	0	<5	0	0	–	0	0	0	0	0
C02K	**OTHER ANTIHYPERTENSIVES**	**142**	**161**	**178**	**193**	**230**	**69**	**14**	**64**	**111**	**41**	**53 175**
C02KD	**Serotonin antagonists**	**19**	**20**	**14**	**13**	**12**	**92**	**0**	**<5**	**6**	**<5**	**416**
C02KD01	ketanserin	19	20	14	13	12	92	0	<5	6	<5	416
C02KX	**Antihypertensives for pulmonary arterial hypertension**	**124**	**142**	**166**	**182**	**219**	**68**	**14**	**62**	**106**	**37**	**52 758**
C02KX01	bosentan	103	114	124	132	133	68	14	42	55	22	30 711
C02KX02	ambrisentan	19	33	46	50	56	70	0	13	35	8	15 301
C02KX03	sitaxentan	<5	0	0	0	0	0	0	0	0	0	0

ATC group C

ATC level		2010	2011	2012	2013	2014	Share of women (%)	2014				2014
		Number of individuals						Number of individuals per age group				Sales in 1000 NOK
								<15	15–44	45–69	≥70	
C02KX04	macitentan	0	0	0	0	38	74	0	9	24	5	6 234
C02KX05	riociguat	0	0	0	0	7	29	0	<5	<5	5	512
C03	**DIURETICS**	**223 842**	**208 905**	**201 895**	**194 790**	**187 627**	**60**	**231**	**7 578**	**69 281**	**110 537**	**92 573**
C03A	**LOW-CEILING DIURETICS, THIAZIDES**	**66 001**	**53 889**	**49 049**	**44 778**	**40 867**	**61**	**10**	**1 523**	**20 140**	**19 194**	**18 831**
C03AA	**Thiazides, plain**	**36 364**	**16 033**	**14 935**	**14 014**	**13 431**	**58**	**7**	**594**	**6 644**	**6 186**	**3 976**
C03AA01	bendroflumethiazide	22 807	<5	0	0	0	–	0	0	0	0	0
C03AA03	hydrochlorothiazide	16 731	16 032	14 935	14 014	13 431	58	7	594	6 644	6 186	3 976
C03AB	**Thiazides and potassium in combination**	**41 642**	**38 130**	**34 269**	**30 853**	**27 545**	**63**	**<5**	**942**	**13 540**	**13 060**	**14 855**
C03AB01	bendroflumethiazide and potassium	41 642	38 130	34 269	30 853	27 545	63	<5	942	13 540	13 060	14 855
C03B	**LOW-CEILING DIURETICS, EXCL. THIAZIDES**	**5**	**6**	**8**	**9**	**17**	**47**	**0**	**<5**	**<5**	**13**	**59**
C03BA	**Sulfonamides, plain**	**5**	**6**	**8**	**9**	**17**	**47**	**0**	**<5**	**<5**	**13**	**59**
C03BA04	chlortalidone	5	6	6	7	10	30	0	<5	<5	6	22
C03BA08	metolazone	0	0	<5	<5	7	71	0	0	0	7	37
C03C	**HIGH-CEILING DIURETICS**	**127 391**	**125 517**	**125 342**	**124 184**	**122 402**	**59**	**204**	**4 891**	**37 470**	**79 837**	**49 685**
C03CA	**Sulfonamides, plain**	**127 391**	**125 517**	**125 342**	**124 184**	**122 402**	**59**	**204**	**4 891**	**37 470**	**79 837**	**49 685**
C03CA01	furosemide	99 010	95 661	93 558	90 249	86 827	62	200	4 016	28 251	54 360	20 545
C03CA02	bumetanide	33 444	34 790	36 795	38 766	40 285	53	<5	996	10 281	29 004	29 136
C03CA04	torasemide	<5	<5	<5	<5	<5	50	0	<5	<5	0	4
C03D	**POTASSIUM-SPARING AGENTS**	**17 636**	**17 868**	**18 231**	**19 007**	**19 322**	**46**	**38**	**1 043**	**7 535**	**10 706**	**14 531**
C03DA	**Aldosterone antagonists**	**17 623**	**17 851**	**18 216**	**18 990**	**19 303**	**46**	**37**	**1 037**	**7 530**	**10 699**	**14 396**
C03DA01	spironolactone	17 038	17 160	17 438	18 084	18 244	48	37	978	6 923	10 306	7 383
C03DA02	potassium canrenoate	<5	<5	0	<5	0	–	0	0	0	0	0
C03DA04	eplerenone	678	798	912	1 030	1 208	15	0	68	690	450	7 014
C03DB	**Other potassium-sparing agents**	**18**	**22**	**16**	**19**	**21**	**38**	**<5**	**7**	**6**	**7**	**135**
C03DB01	amiloride	18	22	16	19	21	38	<5	7	6	7	135
C03E	**DIURETICS AND POTASSIUM-SPARING AGENTS IN COMBINATION**	**31 692**	**28 452**	**25 731**	**23 234**	**20 874**	**67**	**10**	**494**	**9 136**	**11 234**	**4 010**
C03EA	**Low-ceiling diuretics and potassium-sparing agents**	**31 692**	**28 452**	**25 731**	**23 234**	**20 874**	**67**	**10**	**494**	**9 136**	**11 234**	**4 010**
C03EA01	hydrochlorothiazide and potassium-sparing agents	31 692	28 452	25 731	23 234	20 874	67	10	494	9 136	11 234	4 010
C03X	**OTHER DIURETICS**	**<5**	**<5**	**17**	**35**	**61**	**54**	**0**	**<5**	**31**	**27**	**5 458**
C03XA	**Vasopressin antagonists**	**<5**	**<5**	**17**	**35**	**61**	**54**	**0**	**<5**	**31**	**27**	**5 458**
C03XA01	tolvaptan	<5	<5	17	35	61	54	0	<5	31	27	5 458

ATC level		2010	2011	2012	2013	2014		2014				2014
		Number of individuals					Share of women (%)	Number of individuals per age group				Sales in 1000 NOK
								<15	15–44	45–69	≥70	
C04	**PERIPHERAL VASODILATORS**	**1 165**	**1 019**	**928**	**810**	**739**	**45**	**<5**	**14**	**210**	**514**	**769**
C04A	**PERIPHERAL VASODILATORS**	**1 165**	**1 019**	**928**	**810**	**739**	**45**	**<5**	**14**	**210**	**514**	**769**
C04AB	**Imidazoline derivatives**	**0**	**0**	**0**	**<5**	**0**	**–**	**0**	**0**	**0**	**0**	**0**
C04AB01	phentolamine	0	0	0	<5	0	–	0	0	0	0	0
C04AD	**Purine derivatives**	**1 160**	**1 018**	**927**	**808**	**737**	**45**	**<5**	**14**	**208**	**514**	**754**
C04AD03	pentoxifylline	1 160	1 018	927	808	737	45	<5	14	208	514	754
C04AX	**Other peripheral vasodilators**	**5**	**<5**	**<5**	**0**	**<5**	**50**	**0**	**0**	**<5**	**0**	**14**
C04AX02	phenoxybenzamine	5	<5	<5	0	<5	50	0	0	<5	0	14
C05	**VASOPROTECTIVES**	**59 372**	**62 337**	**61 786**	**66 461**	**72 159**	**57**	**851**	**29 876**	**28 850**	**12 582**	**14 595**
C05A	**AGENTS FOR TREATMENT OF HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE**	**54 315**	**56 902**	**56 316**	**60 385**	**65 982**	**56**	**808**	**28 731**	**26 228**	**10 215**	**12 316**
C05AA	**Corticosteroids**	**52 387**	**54 740**	**53 845**	**57 822**	**63 517**	**56**	**779**	**27 477**	**25 257**	**10 004**	**9 221**
C05AA01	hydrocortisone[1)]	9 749	9 666	11 151	6 121	4 102	54	78	1 608	1 723	693	666
C05AA04	prednisolone[1)]	44 303	46 731	45 327	53 098	60 660	56	712	26 419	24 029	9 500	8 555
C05AE	**Muscle relaxants**	**2 732**	**2 893**	**3 174**	**3 568**	**4 035**	**52**	**30**	**2 060**	**1 620**	**325**	**3 046**
C05AE01	glyceryl trinitrate	2 732	2 893	3 174	3 568	4 035	52	30	2 060	1 620	325	3 046
C05AX	**Other agents for treatment of hemorrhoids and anal fissures for topical use**	**826**	**852**	**1 139**	**841**	**159**	**52**	**8**	**65**	**53**	**33**	**49**
C05AX03	other preparations, combinations	807	832	1 117	819	147	52	8	58	49	32	21
C05B	**ANTIVARICOSE THERAPY**	**5 250**	**5 664**	**5 663**	**6 294**	**6 430**	**68**	**43**	**1 197**	**2 726**	**2 464**	**2 263**
C05BA	**Heparins or heparinoids for topical use**	**5 245**	**5 654**	**5 658**	**6 288**	**6 419**	**68**	**43**	**1 193**	**2 720**	**2 463**	**2 258**
C05BA01	organo-heparinoid[1)]	5 211	5 627	5 627	6 249	6 382	67	43	1 185	2 703	2 451	889
C05BA04	pentosan polysulfate sodium	34	27	31	40	37	84	0	8	17	12	1 370
C05BB	**Sclerosing agents for local injection**	**5**	**10**	**5**	**6**	**11**	**64**	**0**	**<5**	**6**	**<5**	**4**
C05BB02	polidocanol	5	10	5	6	11	64	0	<5	6	<5	4
C05C	**CAPILLARY STABILIZING AGENTS**	**0**	**0**	**19**	**8**	**7**	**86**	**0**	**<5**	**<5**	**<5**	**17**
C05CA	**Bioflavonoids**	**0**	**0**	**<5**	**8**	**7**	**86**	**0**	**<5**	**<5**	**<5**	**17**
C05CA01	rutoside	0	0	<5	8	7	86	0	<5	<5	<5	17
C05CX	**Other capillary stabilizing agents**	**0**	**0**	**16**	**0**	**0**	**–**	**0**	**0**	**0**	**0**	**0**
C05CX03	Hippocastani semen	0	0	16	0	0	–	0	0	0	0	0
C07	**BETA BLOCKING AGENTS**	**361 077**	**364 247**	**368 506**	**371 823**	**372 432**	**49**	**509**	**21 076**	**162 165**	**188 682**	**190 556**

[1)] The ATC level comprises OTC medicinal products. The number of individuals is registered for prescription sales only.

ATC group C

ATC level		2010	2011	2012	2013	2014	Share of women (%)	2014 Number of individuals per age group <15	15–44	45–69	≥70	2014 Sales in 1000 NOK
		Number of individuals										
C07A	**BETA BLOCKING AGENTS**	**355 652**	**359 141**	**363 938**	**367 435**	**368 796**	**49**	**509**	**20 940**	**159 974**	**187 373**	**187 933**
C07AA	**Beta blocking agents, non-selective**	**24 967**	**24 720**	**24 341**	**24 423**	**22 870**	**59**	**213**	**4 981**	**9 778**	**7 898**	**10 243**
C07AA03	pindolol	28	26	20	12	11	64	0	<5	8	<5	21
C07AA05	propranolol	16 856	17 413	17 656	18 262	17 190	63	194	4 741	7 822	4 433	5 718
C07AA06	timolol	13	9	10	7	13	77	0	<5	7	<5	35
C07AA07	sotalol	8 082	7 269	6 706	6 098	5 601	47	5	180	1 936	3 480	3 540
C07AA12	nadolol	17	29	39	88	109	59	14	62	33	0	929
C07AB	**Beta blocking agents, selective**	**311 151**	**315 104**	**320 868**	**324 369**	**328 610**	**48**	**301**	**14 152**	**142 298**	**171 859**	**160 900**
C07AB02	metoprolol	256 754	261 252	266 875	270 550	274 761	48	280	11 925	119 855	142 701	136 307
C07AB03	atenolol	36 754	33 974	31 827	29 679	27 976	60	20	1 305	11 321	15 330	7 662
C07AB07	bisoprolol	21 004	23 115	25 416	27 355	29 014	46	<5	1 066	12 348	15 598	16 919
C07AB12	nebivolol	0	0	0	9	36	39	0	13	18	5	12
C07AG	**Alpha and beta blocking agents**	**23 887**	**23 378**	**22 899**	**22 479**	**22 101**	**45**	**11**	**2 316**	**9 996**	**9 778**	**16 790**
C07AG01	labetalol	2 392	2 447	2 475	2 442	2 467	83	<5	1 612	535	317	2 159
C07AG02	carvedilol	21 525	20 958	20 442	20 062	19 652	40	8	710	9 469	9 465	14 631
C07B	**BETA BLOCKING AGENTS AND THIAZIDES**	**5 815**	**5 485**	**5 214**	**4 816**	**4 029**	**55**	**0**	**147**	**2 392**	**1 490**	**2 623**
C07BB	**Beta blocking agents, selective, and thiazides**	**5 815**	**5 485**	**5 214**	**4 816**	**4 029**	**55**	**0**	**147**	**2 392**	**1 490**	**2 623**
C07BB07	bisoprolol and thiazides	5 815	5 485	5 214	4 816	4 027	55	0	146	2 391	1 490	2 622
C07BB12	nebivolol and thiazides	0	0	0	<5	<5	67	0	<5	<5	0	1
C08	**CALCIUM CHANNEL BLOCKERS**	**221 256**	**224 233**	**230 084**	**235 380**	**237 462**	**48**	**105**	**9 435**	**111 320**	**116 602**	**144 842**
C08C	**SELECTIVE CALCIUM CHANNEL BLOCKERS WITH MAINLY VASCULAR EFFECTS**	**200 625**	**205 165**	**212 139**	**218 463**	**221 490**	**48**	**91**	**8 654**	**105 450**	**107 295**	**128 722**
C08CA	**Dihydropyridine derivatives**	**200 625**	**205 165**	**212 139**	**218 463**	**221 490**	**48**	**91**	**8 654**	**105 450**	**107 295**	**128 722**
C08CA01	amlodipine	119 283	121 607	125 897	129 021	129 556	46	69	4 318	61 850	63 319	51 664
C08CA02	felodipine	16 309	16 008	15 423	14 850	14 310	50	0	330	5 970	8 010	10 589
C08CA03	isradipine	620	568	518	493	458	56	<5	7	172	278	843
C08CA05	nifedipine	31 649	32 708	34 567	36 991	38 803	49	22	2 823	18 477	17 481	43 512
C08CA06	nimodipine	44	51	56	39	37	62	0	8	26	<5	32
C08CA13	lercanidipine	36 038	37 460	39 048	40 491	41 544	50	0	1 324	20 449	19 771	22 082
C08D	**SELECTIVE CALCIUM CHANNEL BLOCKERS WITH DIRECT CARDIAC EFFECTS**	**21 851**	**20 196**	**19 116**	**18 080**	**17 061**	**56**	**14**	**800**	**6 286**	**9 961**	**16 119**
C08DA	**Phenylalkylamine derivatives**	**16 444**	**15 365**	**14 679**	**13 847**	**13 057**	**56**	**14**	**715**	**4 847**	**7 481**	**8 786**
C08DA01	verapamil	16 444	15 365	14 679	13 847	13 057	56	14	715	4 847	7 481	8 786

ATC level		2010	2011	2012	2013	2014	Share of women (%)	2014				2014
		Number of individuals						Number of individuals per age group				Sales in 1000 NOK
								<15	15–44	45–69	≥70	
C08DB	**Benzothiazepine derivatives**	**5 473**	**4 875**	**4 472**	**4 281**	**4 049**	**55**	**0**	**91**	**1 457**	**2 501**	**7 334**
C08DB01	diltiazem	5 473	4 875	4 472	4 281	4 049	55	0	91	1 457	2 501	7 334
C09	**AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM**	**498 501**	**517 053**	**535 479**	**552 012**	**565 363**	**47**	**455**	**29 286**	**303 638**	**231 984**	**499 197**
C09A	**ACE INHIBITORS, PLAIN**	**130 265**	**132 249**	**134 815**	**135 072**	**134 831**	**41**	**375**	**6 976**	**63 068**	**64 412**	**63 984**
C09AA	**ACE inhibitors, plain**	**130 265**	**132 249**	**134 815**	**135 072**	**134 831**	**41**	**375**	**6 976**	**63 068**	**64 412**	**63 984**
C09AA01	captopril	2 858	2 509	2 221	1 962	1 716	45	187	78	545	906	3 856
C09AA02	enalapril	45 453	45 871	46 498	46 508	45 948	46	191	2 919	22 392	20 446	19 180
C09AA03	lisinopril	26 749	26 060	25 506	24 380	23 391	47	<5	1 272	11 312	10 806	10 700
C09AA04	perindopril	0	0	0	0	14	14	0	<5	9	<5	6
C09AA05	ramipril	55 804	58 431	61 192	62 787	64 294	35	6	2 737	29 020	32 531	30 098
C09AA10	trandolapril	92	85	83	77	62	24	0	<5	29	29	144
C09AA15	zofenopril	0	0	0	0	<5	100	0	0	0	<5	1
C09B	**ACE INHIBITORS, COMBINATIONS**	**35 985**	**35 727**	**35 224**	**34 166**	**32 716**	**48**	**0**	**1 014**	**16 405**	**15 297**	**25 165**
C09BA	**ACE inhibitors and diuretics**	**35 193**	**34 459**	**33 721**	**32 644**	**31 146**	**48**	**0**	**939**	**15 484**	**14 723**	**23 119**
C09BA02	enalapril and diuretics	20 520	20 244	20 047	19 540	18 920	48	0	606	9 623	8 691	14 802
C09BA03	lisinopril and diuretics	14 697	14 237	13 715	13 133	12 245	48	0	334	5 868	6 043	8 317
C09BB	**ACE inhibitors and calcium channel blockers**	**820**	**1 307**	**1 536**	**1 546**	**1 593**	**43**	**0**	**76**	**932**	**585**	**2 046**
C09BB02	enalapril and lercanidipine	820	1 307	1 536	1 546	1 593	43	0	76	932	585	2 046
C09C	**ANGIOTENSIN II ANTAGONISTS, PLAIN**	**180 140**	**187 470**	**197 324**	**206 884**	**215 141**	**51**	**98**	**15 117**	**119 821**	**80 105**	**155 581**
C09CA	**Angiotensin II antagonists, plain**	**180 140**	**187 470**	**197 324**	**206 884**	**215 141**	**51**	**98**	**15 117**	**119 821**	**80 105**	**155 581**
C09CA01	losartan	51 872	57 364	61 615	63 676	64 085	51	37	3 564	35 135	25 349	35 723
C09CA02	eprosartan	2 063	1 785	1 601	1 443	1 285	51	0	32	568	685	2 564
C09CA03	valsartan	20 748	22 462	25 171	28 100	30 020	48	0	1 843	17 196	10 981	26 870
C09CA04	irbesartan	21 419	20 347	19 745	19 088	18 713	49	0	708	10 089	7 916	21 029
C09CA06	candesartan	78 234	79 742	83 562	88 885	95 252	53	61	8 678	53 487	33 026	57 979
C09CA07	telmisartan	5 988	5 977	5 838	5 822	5 704	44	0	288	3 227	2 189	8 281
C09CA08	olmesartan medoxomil	1 680	1 642	1 642	1 639	1 600	49	0	110	956	534	3 134
C09D	**ANGIOTENSIN II ANTAGONISTS, COMBINATIONS**	**195 551**	**202 970**	**210 395**	**217 369**	**221 095**	**48**	**<5**	**8 225**	**124 903**	**87 966**	**254 324**
C09DA	**Angiotensin II antagonists and diuretics**	**179 893**	**180 857**	**181 947**	**182 682**	**181 507**	**51**	**<5**	**5 933**	**100 326**	**75 247**	**161 079**
C09DA01	losartan and diuretics	66 088	66 981	67 519	67 346	66 308	52	<5	2 064	35 398	28 845	41 447
C09DA02	eprosartan and diuretics	1 924	1 774	1 661	1 552	1 394	48	0	34	720	640	3 037
C09DA03	valsartan and diuretics	25 643	25 522	25 941	26 635	26 790	50	0	910	15 085	10 795	30 476
C09DA04	irbesartan and diuretics	30 818	29 807	28 634	27 373	26 033	50	0	585	13 834	11 614	32 842

ATC group C

ATC level		2010	2011	2012	2013	2014	Share of women (%)	2014				2014
		Number of individuals						Number of individuals per age group				Sales in 1000 NOK
								<15	15–44	45–69	≥70	
C09DA06	candesartan and diuretics	51 649	52 876	54 286	55 802	56 928	50	0	2 215	32 900	21 813	42 888
C09DA07	telmisartan and diuretics	3 991	3 940	3 818	3 785	3 689	40	0	123	2 154	1 412	8 154
C09DA08	olmesartan medoxomil and diuretics	1 124	1 146	1 117	1 087	1 088	49	0	35	640	413	2 235
C09DB	**Angiotensin II antagonists and calcium channel blockers**	**16 484**	**18 665**	**21 178**	**23 699**	**25 207**	**41**	**0**	**1 550**	**15 506**	**8 151**	**47 123**
C09DB01	valsartan and amlodipine	16 483	18 494	20 903	23 407	24 909	41	0	1 528	15 315	8 066	46 381
C09DB02	olmesartan medoxomil and amlodipine	<5	185	280	297	304	36	0	22	194	88	742
C09DX	**Angiotensin II antagonists, other combinations**	**4 017**	**8 368**	**12 249**	**16 435**	**19 317**	**37**	**0**	**1 018**	**12 052**	**6 247**	**46 122**
C09DX01	valsartan, amlodipine and hydrochlorothiazide	4 017	8 368	12 249	16 435	19 317	37	0	1 018	12 052	6 247	46 122
C09X	**OTHER AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM**	**93**	**84**	**80**	**69**	**53**	**40**	**<5**	**<5**	**32**	**16**	**144**
C09XA	**Renin-inhibitors**	**93**	**84**	**80**	**69**	**53**	**40**	**<5**	**<5**	**32**	**16**	**144**
C09XA02	aliskiren	92	84	80	69	53	40	<5	<5	32	16	144
C09XA52	aliskiren and hydrochloro-thiazide	<5	0	0	0	0	–	0	0	0	0	0
C10	**LIPID MODIFYING AGENTS**	**478 362**	**495 451**	**504 104**	**509 945**	**518 511**	**46**	**150**	**19 415**	**277 869**	**221 077**	**413 091**
C10A	**LIPID MODIFYING AGENTS, PLAIN**	**477 639**	**494 337**	**501 719**	**506 662**	**514 655**	**46**	**150**	**19 256**	**275 416**	**219 833**	**396 412**
C10AA	**HMG CoA reductase inhibitors**	**472 860**	**488 704**	**495 110**	**499 107**	**506 351**	**45**	**133**	**18 439**	**270 787**	**216 992**	**278 900**
C10AA01	simvastatin	349 782	336 480	314 351	290 634	271 531	47	15	7 555	132 306	131 655	83 936
C10AA02	lovastatin	1 260	1 134	1 050	930	825	56	0	<5	298	524	1 330
C10AA03	pravastatin	21 340	20 827	20 330	19 842	19 188	50	13	444	8 841	9 890	16 569
C10AA04	fluvastatin	7 510	7 474	7 445	7 372	7 432	46	<5	497	4 164	2 770	12 245
C10AA05	atorvastatin	112 783	140 852	166 650	189 401	211 725	43	83	9 549	127 073	75 020	130 236
C10AA07	rosuvastatin	2 115	4 420	6 722	9 506	12 550	46	23	1 092	8 343	3 092	34 226
C10AA08	pitavastatin	0	0	0	6	24	50	0	<5	18	<5	359
C10AB	**Fibrates**	**331**	**317**	**314**	**314**	**311**	**28**	**<5**	**52**	**215**	**41**	**1 659**
C10AB02	bezafibrate	58	49	50	47	44	32	<5	<5	32	8	154
C10AB04	gemfibrozil	104	103	93	85	87	26	0	13	60	14	771
C10AB05	fenofibrate	170	167	173	184	181	28	<5	36	124	19	735
C10AC	**Bile acid sequestrants**	**2 238**	**2 413**	**2 439**	**2 530**	**2 555**	**54**	**12**	**505**	**1 392**	**646**	**8 751**
C10AC01	colestyramine	1 686	1 817	1 795	1 864	1 866	58	11	434	957	464	2 331
C10AC02	colestipol	292	273	280	287	268	43	<5	23	130	114	816
C10AC04	colesevelam	280	351	407	444	453	41	0	58	322	73	5 604
C10AD	**Nicotinic acid and derivatives**	**396**	**391**	**351**	**58**	**25**	**36**	**0**	**<5**	**16**	**7**	**597**

ATC level		2010	2011	2012	2013	2014		2014				2014
		Number of individuals					Share of women (%)	Number of individuals per age group				Sales in 1000 NOK
								<15	15–44	45–69	≥70	
C10AD02	nicotinic acid	153	107	30	29	18	33	0	<5	10	6	553
C10AD06	acipimox	12	9	9	6	7	43	0	0	6	<5	43
C10AD52	nicotinic acid, combinations	249	301	315	27	0	0	0	0	0	0	0
C10AX	**Other lipid modifying agents**	**16 505**	**19 315**	**22 165**	**24 366**	**26 228**	**43**	**5**	**1 721**	**16 989**	**7 513**	**106 506**
C10AX06	omega-3-triglycerides incl. other esters and acids	3 038	3 591	3 992	4 199	4 229	28	<5	569	3 035	624	27 359
C10AX09	ezetimibe	13 819	16 166	18 711	20 751	22 564	45	<5	1 197	14 395	6 968	79 147
C10B	**LIPID MODIFYING AGENTS, COMBINATIONS**	**81**	**1 370**	**2 661**	**3 215**	**3 664**	**40**	**0**	**169**	**2 366**	**1 129**	**13 821**
C10BA	**HMG CoA reductase inhibitors in combination with other lipid modifying agents**	**81**	**1 370**	**2 661**	**3 215**	**3 664**	**40**	**0**	**169**	**2 366**	**1 129**	**13 821**
C10BA02	simvastatin and ezetimibe	81	1 370	2 661	3 215	3 664	40	0	169	2 366	1 129	13 821

3.8 ATC group D – Dermatologicals

ATC level		2010	2011	2012	2013	2014		2014				2014
		Number of individuals					Share of women (%)	Number of individuals per age group				Sales in 1000 NOK
								<15	15–44	45–69	≥70	
D	**DERMATOLOGICALS**	**611 440**	**624 493**	**632 677**	**645 681**	**673 447**	**55**	**83 923**	**257 149**	**225 358**	**107 017**	**260 975**
D01	**ANTIFUNGALS FOR DERMATOLOGICAL USE**	**116 703**	**120 515**	**121 196**	**128 325**	**137 912**	**47**	**13 475**	**51 969**	**49 868**	**22 600**	**35 793**
D01A	**ANTIFUNGALS FOR TOPICAL USE**	**101 082**	**105 109**	**105 050**	**111 180**	**120 667**	**48**	**13 197**	**45 426**	**41 365**	**20 679**	**19 691**
D01AA	**Antibiotics**	**54**	**52**	**36**	**41**	**43**	**77**	**<5**	**28**	**7**	**<5**	**9**
D01AA01	nystatin	54	52	36	41	43	77	<5	28	7	<5	9
D01AC	**Imidazole and triazole derivatives**	**79 238**	**83 294**	**83 177**	**87 831**	**95 383**	**48**	**10 826**	**35 335**	**32 041**	**17 181**	**12 667**
D01AC01	clotrimazole[1)]	9 516	8 746	8 018	8 572	9 339	52	1 243	3 491	2 499	2 106	1 417
D01AC02	miconazole[1)]	2 121	2 193	1 928	2 157	2 420	45	390	877	756	397	423
D01AC03	econazole[1)]	1 119	588	694	732	836	58	40	173	295	328	118
D01AC08	ketoconazole[1)]	15 121	16 258	16 243	16 928	18 350	41	1 208	8 714	6 182	2 246	3 362
D01AC20	combinations[1)]	55 208	59 481	59 953	63 529	69 233	49	8 384	23 936	23 882	13 031	7 347
D01AE	**Other antifungals for topical use**	**24 671**	**24 755**	**24 872**	**26 681**	**28 844**	**46**	**2 711**	**11 461**	**10 580**	**4 092**	**7 015**
D01AE02	methylrosaniline[1)]	694	751	698	736	843	53	244	214	233	152	98
D01AE14	ciclopirox[1)]	<5	13	48	841	2 765	54	80	874	1 394	417	1 137
D01AE15	terbinafine[1)]	17 514	17 812	18 224	19 247	19 929	43	2 200	8 765	6 355	2 609	3 423
D01AE16	amorolfine	6 829	6 520	6 232	6 333	5 821	55	216	1 789	2 826	990	2 356
D01B	**ANTIFUNGALS FOR SYSTEMIC USE**	**19 232**	**19 020**	**19 762**	**21 092**	**21 527**	**39**	**443**	**8 431**	**10 283**	**2 370**	**16 102**
D01BA	**Antifungals for systemic use**	**19 232**	**19 020**	**19 762**	**21 092**	**21 527**	**39**	**443**	**8 431**	**10 283**	**2 370**	**16 102**
D01BA01	griseofulvin	15	19	21	38	29	48	25	<5	<5	0	18
D01BA02	terbinafine	19 222	19 009	19 744	21 060	21 503	39	422	8 429	10 282	2 370	16 083
D02	**EMOLLIENTS AND PROTECTIVES**	**2 223**	**2 338**	**2 528**	**2 548**	**3 122**	**54**	**533**	**994**	**1 040**	**555**	**1 128**
D02A	**EMOLLIENTS AND PROTECTIVES**	**2 223**	**2 338**	**2 528**	**2 548**	**3 122**	**54**	**533**	**994**	**1 040**	**555**	**1 128**
D02AB	**Zinc products[1)]**	**10**	**15**	**6**	**9**	**6**	**67**	**<5**	**<5**	**<5**	**<5**	**1**
D02AE	**Carbamide products**	**859**	**971**	**1 178**	**1 153**	**1 412**	**54**	**201**	**500**	**426**	**285**	**694**
D02AE01	carbamide[1)]	859	971	1 178	1 153	1 412	54	201	500	426	285	694
D02AF	**Salicylic acid preparations**	**1 229**	**1 206**	**1 167**	**1 179**	**1 382**	**54**	**164**	**422**	**558**	**238**	**264**
D02AX	**Other emollients and protectives**	**148**	**168**	**228**	**244**	**351**	**54**	**180**	**76**	**59**	**36**	**169**
D03	**PREPARATIONS FOR TREATMENT OF WOUNDS AND ULCERS**	**60**	**68**	**80**	**85**	**56**	**45**	**<5**	**<5**	**31**	**21**	**17**
D03A	**CICATRIZANTS**	**60**	**68**	**80**	**85**	**56**	**45**	**<5**	**<5**	**31**	**21**	**17**
D03AX	**Other cicatrizants**	**60**	**68**	**80**	**85**	**56**	**45**	**<5**	**<5**	**31**	**21**	**17**

[1)] The ATC level comprises OTC medicinal products. The number of individuals is registered for prescription sales only.

ATC level		2010	2011	2012	2013	2014		2014				2014
		Number of individuals					Share of women (%)	Number of individuals per age group				Sales in 1000 NOK
								<15	15–44	45–69	≥70	
D03AX03	dexpanthenol	60	68	80	85	56	45	<5	<5	31	21	17
D04	**ANTIPRURITICS, INCL. ANTIHISTAMINES, ANESTHETICS, ETC.**	**3 871**	**4 259**	**4 328**	**6 698**	**8 032**	**66**	**1 005**	**3 317**	**2 197**	**1 513**	**1 211**
D04A	**ANTIPRURITICS, INCL. ANTIHISTAMINES, ANESTHETICS, ETC.**	**3 871**	**4 259**	**4 328**	**6 698**	**8 032**	**66**	**1 005**	**3 317**	**2 197**	**1 513**	**1 211**
D04AA	**Antihistamines for topical use**	**0**	**<5**	**8**	**8**	**<5**	**67**	**0**	**0**	**<5**	**<5**	**1**
D04AA13	dimetindene	0	<5	8	8	<5	67	0	0	<5	<5	1
D04AB	**Anesthetics for topical use**	**2 798**	**3 097**	**3 669**	**5 405**	**6 532**	**68**	**727**	**2 888**	**1 855**	**1 062**	**1 022**
D04AB01	lidocaine[1)]	2 798	3 097	3 669	5 405	6 532	68	727	2 888	1 855	1 062	1 022
D04AX	**Other antipruritics**	**1 093**	**1 169**	**674**	**1 307**	**1 522**	**58**	**282**	**435**	**346**	**459**	**189**
D05	**ANTIPSORIATICS**	**29 930**	**31 269**	**31 759**	**30 335**	**29 409**	**44**	**481**	**8 610**	**15 171**	**5 147**	**37 363**
D05A	**ANTIPSORIATICS FOR TOPICAL USE**	**28 654**	**29 921**	**30 308**	**28 872**	**27 844**	**44**	**475**	**8 315**	**14 178**	**4 876**	**29 604**
D05AA	**Tars[1)]**	**1 044**	**1 017**	**905**	**960**	**1 100**	**60**	**102**	**318**	**381**	**299**	**272**
D05AC	**Antracen derivatives**	**9**	**7**	**<5**	**10**	**11**	**73**	**0**	**9**	**0**	**<5**	**4**
D05AC01	dithranol	9	7	<5	10	11	73	0	9	0	<5	4
D05AD	**Psoralens for topical use**	**<5**	**0**	**0**	**0**	**0**	**–**	**0**	**0**	**0**	**0**	**0**
D05AD01	trioxysalen	<5	0	0	0	0	–	0	0	0	0	0
D05AX	**Other antipsoriatics for topical use**	**27 804**	**29 076**	**29 573**	**28 055**	**26 890**	**43**	**375**	**8 038**	**13 872**	**4 605**	**29 319**
D05AX02	calcipotriol	8 029	5 640	2 226	1 559	902	37	9	191	502	200	345
D05AX03	calcitriol	1 127	1 092	1 174	1 170	1 438	47	37	371	786	244	970
D05AX52	calcipotriol, combinations	22 343	25 237	27 797	26 578	25 692	43	349	7 769	13 192	4 382	28 005
D05B	**ANTIPSORIATICS FOR SYSTEMIC USE**	**1 880**	**1 943**	**2 106**	**2 106**	**2 118**	**43**	**6**	**426**	**1 343**	**343**	**7 760**
D05BA	**Psoralens for systemic use**	**40**	**32**	**26**	**20**	**14**	**21**	**0**	**<5**	**5**	**5**	**10**
D05BA02	methoxsalen	35	29	26	20	14	21	0	<5	5	5	10
D05BA03	bergapten	5	<5	0	0	0	0	0	0	0	0	0
D05BB	**Retinoids for treatment of psoriasis**	**1 808**	**1 866**	**2 019**	**2 026**	**2 048**	**43**	**6**	**403**	**1 309**	**330**	**5 618**
D05BB02	acitretin	1 808	1 866	2 019	2 026	2 048	43	6	403	1 309	330	5 618
D05BX	**Other antipsoriatics for systemic use**	**42**	**50**	**71**	**63**	**60**	**40**	**0**	**22**	**30**	**8**	**2 131**
D05BX51	fumaric acid derivatives, combinations	42	50	71	63	60	40	0	22	30	8	2 131
D06	**ANTIBIOTICS AND CHEMO-THERAPEUTICS FOR DERMATOLOGICAL USE**	**111 213**	**113 829**	**110 679**	**110 706**	**114 445**	**58**	**12 981**	**45 442**	**37 159**	**18 863**	**27 828**

[1)] The ATC level comprises OTC medicinal products. The number of individuals is registered for prescription sales only.

ATC group D

ATC level		2010	2011	2012	2013	2014		2014				2014
		Number of individuals					Share of women (%)	Number of individuals per age group				Sales in 1000 NOK
								<15	15–44	45–69	≥70	
D06A	**ANTIBIOTICS FOR TOPICAL USE**	**58 829**	**61 008**	**58 567**	**57 381**	**58 240**	**55**	**10 920**	**18 504**	**18 440**	**10 376**	**5 480**
D06AA	**Tetracycline and derivatives**	**2 729**	**2 878**	**2 922**	**3 260**	**3 251**	**54**	**359**	**939**	**1 277**	**676**	**427**
D06AA02	chlortetracycline	19	28	27	27	25	60	<5	10	6	8	5
D06AA03	oxytetracycline	2 710	2 850	2 897	3 234	3 228	54	358	929	1 271	670	422
D06AX	**Other antibiotics for topical use**	**56 239**	**58 299**	**55 806**	**54 292**	**55 167**	**56**	**10 577**	**17 623**	**17 222**	**9 745**	**5 053**
D06AX01	fusidic acid	53 684	55 137	53 101	51 166	51 824	56	9 353	16 570	16 540	9 361	4 563
D06AX05	bacitracin	1 739	2 378	1 986	2 231	2 111	50	641	697	448	325	245
D06AX09	mupirocin	14	31	41	90	89	55	10	35	38	6	22
D06AX13	retapamulin	1 008	1 005	875	1 046	1 384	54	645	399	242	98	222
D06B	**CHEMOTHERAPEUTICS FOR TOPICAL USE**	**54 414**	**54 942**	**54 044**	**55 283**	**58 212**	**60**	**2 177**	**27 687**	**19 423**	**8 925**	**22 348**
D06BA	**Sulfonamides**	**3 373**	**3 410**	**3 569**	**3 482**	**3 425**	**54**	**575**	**1 152**	**1 051**	**647**	**523**
D06BA01	silver sulfadiazine	3 373	3 410	3 569	3 482	3 425	54	575	1 152	1 051	647	523
D06BB	**Antivirals**	**41 885**	**40 813**	**39 042**	**38 980**	**38 259**	**59**	**1 432**	**21 285**	**10 751**	**4 791**	**14 813**
D06BB03	aciclovir[1)]	19 696	18 274	16 784	16 801	16 331	72	940	7 425	6 272	1 694	2 794
D06BB04	podophyllotoxin	13 567	13 738	12 944	13 095	13 271	44	131	11 654	1 409	77	2 937
D06BB06	penciclovir[1)]	3 349	2 738	1 886	1 560	1 382	69	57	566	558	201	278
D06BB10	imiquimod	6 196	7 040	8 413	8 386	8 081	54	305	2 306	2 617	2 853	8 740
D06BB12	sinecatechins	0	0	0	0	102	48	<5	78	18	<5	65
D06BX	**Other chemotherapeutics**	**9 426**	**11 017**	**11 737**	**13 197**	**17 168**	**65**	**171**	**5 404**	**7 866**	**3 727**	**7 012**
D06BX01	metronidazole	9 426	11 017	11 737	12 942	14 084	68	171	5 356	6 512	2 045	2 760
D06BX02	ingenol mebutate	0	0	0	259	3 131	50	0	49	1 383	1 699	4 252
D07	**CORTICOSTEROIDS, DERMATOLOGICAL PREPARATIONS**	**359 113**	**361 203**	**366 001**	**368 248**	**383 391**	**54**	**55 204**	**118 378**	**138 688**	**71 121**	**86 732**
D07A	**CORTICOSTEROIDS, PLAIN**	**299 004**	**300 645**	**311 219**	**314 150**	**326 417**	**55**	**49 224**	**100 442**	**116 686**	**60 065**	**66 913**
D07AA	**Corticosteroids, weak (group I)**	**28 352**	**28 849**	**30 901**	**29 941**	**31 054**	**55**	**14 433**	**8 237**	**5 266**	**3 118**	**3 715**
D07AA02	hydrocortisone[1)]	28 352	28 849	30 901	29 931	31 043	55	14 432	8 236	5 259	3 116	3 698
D07AB	**Corticosteroids, moderately potent (group II)**	**102 087**	**102 552**	**102 396**	**105 292**	**108 731**	**55**	**26 356**	**32 968**	**31 768**	**17 639**	**15 189**
D07AB02	hydrocortisone butyrate	67 907	70 580	97 892	85 367	86 629	55	22 014	26 357	24 461	13 797	12 073
D07AB08	desonide	35 702	33 950	5 881	21 365	23 431	55	4 772	6 919	7 681	4 059	3 116
D07AC	**Corticosteroids, potent (group III)**	**158 099**	**157 096**	**164 821**	**163 406**	**169 221**	**54**	**16 964**	**54 896**	**63 756**	**33 605**	**34 902**
D07AC01	betamethasone	52 441	54 076	58 253	58 313	61 394	54	3 894	19 760	24 684	13 056	8 147
D07AC03	desoximetasone	13 701	12 998	12 664	11 671	11 616	53	466	3 011	5 262	2 877	4 550

[1)] The ATC level comprises OTC medicinal products. The number of individuals is registered for prescription sales only.

ATC level		2010	2011	2012	2013	2014	Share of women (%)	2014				2014
		Number of individuals						Number of individuals per age group				Sales in 1000 NOK
								<15	15–44	45–69	≥70	
D07AC04	fluocinolone acetonide	6 500	6 008	5 854	5 421	5 242	55	137	1 024	2 450	1 631	969
D07AC08	fluocinonide	724	670	602	541	499	51	8	74	267	150	93
D07AC13	mometasone	78 920	78 528	82 943	83 267	86 611	54	11 163	29 571	30 266	15 611	18 367
D07AC17	fluticasone	13 078	11 896	12 072	11 613	11 447	55	1 919	3 886	3 646	1 996	2 774
D07AD	**Corticosteroids, very potent (group IV)**	**52 825**	**54 584**	**57 408**	**60 150**	**64 278**	**57**	**1 972**	**19 241**	**30 337**	**12 728**	**13 107**
D07AD01	clobetasol	52 825	54 584	57 408	60 150	64 278	57	1 972	19 241	30 337	12 728	13 107
D07B	**CORTICOSTEROIDS, COMBINATIONS WITH ANTISEPTICS**	**36 056**	**37 823**	**29 417**	**29 528**	**32 128**	**49**	**4 023**	**9 544**	**11 924**	**6 637**	**3 743**
D07BB	**Corticosteroids, moderately potent, combinations with antiseptics**	**15 445**	**15 218**	**194**	**1 955**	**6 060**	**49**	**1 277**	**1 680**	**2 033**	**1 070**	**907**
D07BB02	desonide and antiseptics	15 445	15 217	194	1 955	6 060	49	1 277	1 680	2 033	1 070	907
D07BB03	triamcinolone and antiseptics	0	<5	0	0	0	–	0	0	0	0	0
D07BC	**Corticosteroids, potent, combinations with antiseptics**	**21 373**	**23 508**	**29 251**	**27 796**	**26 504**	**49**	**2 849**	**8 000**	**10 017**	**5 638**	**2 836**
D07BC01	betamethasone and antiseptics	18 864	21 243	26 888	25 387	23 808	49	2 643	7 267	8 842	5 056	2 514
D07BC02	fluocinolone acetonide and antiseptics	2 601	2 358	2 471	2 540	3 029	48	240	817	1 286	686	322
D07C	**CORTICOSTEROIDS, COMBINATIONS WITH ANTIBIOTICS**	**26 769**	**26 158**	**26 354**	**25 078**	**25 819**	**54**	**5 064**	**7 683**	**8 424**	**4 648**	**3 298**
D07CA	**Corticosteroids, weak, combinations with antibiotics**	**26 768**	**26 158**	**26 350**	**25 072**	**25 812**	**54**	**5 064**	**7 681**	**8 419**	**4 648**	**3 295**
D07CA01	hydrocortisone and antibiotics	26 768	26 158	26 350	25 072	25 812	54	5 064	7 681	8 419	4 648	3 295
D07CB	**Corticosteroids, moderately potent, combinations with antibiotics**	**0**	**0**	**0**	**<5**	**<5**	**0**	**0**	**0**	**<5**	**0**	**0**
D07CB01	triamcinolone and antibiotics	0	0	0	<5	<5	0	0	0	<5	0	0
D07CC	**Corticosteroids, potent, combinations with antibiotics**	**<5**	**0**	**5**	**<5**	**6**	**33**	**0**	**<5**	**<5**	**0**	**2**
D07CC01	betamethasone and antibiotics	<5	0	<5	<5	5	20	0	<5	<5	0	1
D07CC05	fluocinonide and antibiotics	0	0	<5	<5	<5	100	0	<5	0	0	2
D07X	**CORTICOSTEROIDS, OTHER COMBINATIONS**	**26 439**	**25 912**	**26 280**	**26 715**	**28 020**	**51**	**924**	**9 487**	**12 203**	**5 406**	**12 778**
D07XC	**Corticosteroids, potent, other combinations**	**26 439**	**25 912**	**26 280**	**26 715**	**28 020**	**51**	**924**	**9 487**	**12 203**	**5 406**	**12 778**
D07XC01	betamethasone	26 439	25 912	26 280	26 715	28 020	51	924	9 487	12 203	5 406	12 778

ATC group D

ATC level		2010	2011	2012	2013	2014		2014				2014
		Number of individuals					Share of women (%)	Number of individuals per age group				Sales in 1000 NOK
								<15	15–44	45–69	≥70	
D08	**ANTISEPTICS AND DISINFECTANTS**	**19 280**	**19 088**	**19 212**	**20 441**	**20 754**	**60**	**3 497**	**8 598**	**6 147**	**2 512**	**3 314**
D08A	**ANTISEPTICS AND DISINFECTANTS[1)]**	**19 280**	**19 088**	**19 212**	**20 441**	**20 754**	**60**	**3 497**	**8 598**	**6 147**	**2 512**	**3 314**
D08AB	**Aluminium agents**	**278**	**338**	**416**	**429**	**457**	**54**	**166**	**118**	**115**	**58**	**77**
D08AC	**Biguanides and amidines**	**15 910**	**15 689**	**15 791**	**17 326**	**17 501**	**61**	**2 625**	**7 663**	**5 275**	**1 938**	**2 694**
D08AC01	dibrompropamidine[1)]	5 282	3 802	4 729	5 561	6 315	51	2 015	2 082	1 300	918	852
D08AC02	chlorhexidine[1)]	10 883	12 095	11 282	12 076	11 580	66	750	5 742	4 040	1 048	1 842
D08AG	**Iodine products**	**74**	**62**	**85**	**79**	**108**	**59**	**14**	**14**	**31**	**49**	**30**
D08AG01	iodine/octylphenoxy-polyglycolether[1)]	<5	0	0	0	0	–	0	0	0	0	0
D08AG02	povidone-iodine	31	26	56	50	78	60	<5	10	20	44	22
D08AG03	iodine[1)]	42	36	29	29	30	57	10	<5	11	5	8
D08AJ	**Quaternary ammonium compounds**	**151**	**173**	**134**	**124**	**156**	**61**	**23**	**53**	**39**	**41**	**75**
D08AJ03	cetylpyridinium[1)]	151	173	134	124	156	61	23	53	39	41	75
D08AL	**Silver compounds**	**<5**	**<5**	**<5**	**10**	**26**	**31**	**<5**	**10**	**12**	**<5**	**16**
D08AL01	silver nitrate	<5	<5	<5	10	26	31	<5	10	12	<5	16
D08AX	**Other antiseptics and disinfectants**	**3 022**	**2 971**	**2 922**	**2 618**	**2 681**	**52**	**729**	**795**	**707**	**450**	**422**
D08AX01	hydrogen peroxide[1)]	1 829	1 741	1 669	1 526	1 443	56	397	441	347	258	167
D08AX06	potassium permanganate[1)]	1 207	1 240	1 264	1 103	1 258	47	338	365	361	194	254
D09	**MEDICATED DRESSINGS**	**1 913**	**1 848**	**1 767**	**1 718**	**1 669**	**57**	**126**	**344**	**541**	**658**	**565**
D09A	**MEDICATED DRESSINGS**	**1 913**	**1 848**	**1 767**	**1 718**	**1 669**	**57**	**126**	**344**	**541**	**658**	**565**
D09AA	**Medicated dressings with antiinfectives**	**1 913**	**1 848**	**1 684**	**1 607**	**1 538**	**57**	**122**	**333**	**496**	**587**	**224**
D09AA02	fusidic acid	1 913	1 848	1 684	1 607	1 538	57	122	333	496	587	224
D09AB	**Zinc bandages**	**0**	**0**	**84**	**112**	**135**	**51**	**<5**	**11**	**46**	**74**	**341**
D09AB01	zinc bandage without supplements	0	0	84	112	135	51	<5	11	46	74	341
D10	**ANTI-ACNE PREPARATIONS**	**54 317**	**60 886**	**66 816**	**70 355**	**73 055**	**65**	**4 578**	**55 998**	**10 088**	**2 391**	**45 794**
D10A	**ANTI-ACNE PREPARATIONS FOR TOPICAL USE**	**50 390**	**56 374**	**61 689**	**64 217**	**66 001**	**67**	**4 471**	**49 435**	**9 724**	**2 371**	**24 718**
D10AD	**Retinoids for topical use in acne**	**27 056**	**32 174**	**36 043**	**37 161**	**38 217**	**66**	**3 095**	**31 599**	**2 682**	**841**	**16 982**
D10AD01	tretinoin	10 547	10 221	10 977	6 861	2 723	85	40	1 092	1 149	442	825
D10AD02	retinol	170	176	185	63	0	–	0	0	0	0	0
D10AD03	adapalene	7 113	6 598	5 960	6 750	8 020	68	600	6 258	811	351	1 713
D10AD51	tretinoin, combinations	0	0	0	<5	740	74	74	611	46	9	181
D10AD53	adapalene, combinations	10 280	16 392	20 141	24 781	27 891	64	2 503	24 621	721	46	14 263

[1)] The ATC level comprises OTC medicinal products. The number of individuals is registered for prescription sales only.

ATC level		2010	2011	2012	2013	2014		2014				2014
		Number of individuals					Share of women (%)	Number of individuals per age group				Sales in 1000 NOK
								<15	15–44	45–69	≥70	
D10AE	**Peroxides**	**2 267**	**2 354**	**2 633**	**2 995**	**2 878**	**56**	**335**	**2 391**	**130**	**22**	**583**
D10AE01	benzoyl peroxide[1)]	2 267	2 354	2 633	2 995	2 878	56	335	2 391	130	22	583
D10AF	**Antiinfectives for treatment of acne**	**16 076**	**16 714**	**17 068**	**17 498**	**17 296**	**66**	**1 245**	**12 637**	**2 944**	**470**	**3 448**
D10AF01	clindamycin	16 054	16 677	17 029	17 450	17 260	66	1 242	12 611	2 938	469	3 431
D10AF02	erythromycin	24	38	41	50	38	71	<5	27	7	<5	17
D10AX	**Other anti-acne preparations for topical use**	**13 285**	**13 815**	**14 942**	**15 685**	**16 590**	**71**	**689**	**10 427**	**4 399**	**1 075**	**3 706**
D10AX03	azelaic acid	13 276	13 810	14 935	15 673	16 583	71	689	10 424	4 397	1 073	3 704
D10AX30	various combinations	11	5	7	12	7	71	0	<5	<5	<5	1
D10B	**ANTI-ACNE PREPARATIONS FOR SYSTEMIC USE**	**5 748**	**6 609**	**7 853**	**9 255**	**10 678**	**51**	**247**	**9 946**	**458**	**27**	**21 076**
D10BA	**Retinoids for treatment of acne**	**5 748**	**6 609**	**7 853**	**9 255**	**10 678**	**51**	**247**	**9 946**	**458**	**27**	**21 076**
D10BA01	isotretinoin	5 748	6 609	7 853	9 255	10 678	51	247	9 946	458	27	21 076
D11	**OTHER DERMATOLOGICAL PREPARATIONS**	**16 780**	**18 059**	**18 430**	**19 627**	**23 322**	**59**	**3 270**	**10 880**	**7 223**	**1 949**	**21 110**
D11A	**OTHER DERMATOLOGICAL PREPARATIONS**	**16 780**	**18 059**	**18 430**	**19 627**	**23 322**	**59**	**3 270**	**10 880**	**7 223**	**1 949**	**21 110**
D11AC	**Medicated shampoos**	**1 059**	**1 205**	**1 220**	**1 449**	**1 714**	**51**	**147**	**1 108**	**350**	**109**	**244**
D11AC03	selenium compounds[1)]	1 059	1 205	1 220	1 449	1 714	51	147	1 108	350	109	244
D11AF	**Wart and anti-corn preparations[1)]**	**1 926**	**2 068**	**1 972**	**2 333**	**2 675**	**50**	**1 196**	**975**	**389**	**115**	**516**
D11AH	**Agents for dermatitis, excluding corticosteroids**	**10 818**	**12 174**	**12 661**	**13 169**	**14 357**	**58**	**1 915**	**6 531**	**4 772**	**1 139**	**15 011**
D11AH01	tacrolimus	7 498	8 318	8 696	8 887	9 658	58	1 283	4 431	3 180	764	4 355
D11AH02	pimecrolimus	3 534	3 996	3 952	4 224	4 570	59	661	2 095	1 445	369	2 164
D11AH04	alitretinoin	0	80	221	317	364	53	0	123	223	18	8 493
D11AX	**Other dermatologicals**	**3 036**	**2 677**	**2 634**	**2 757**	**4 732**	**70**	**21**	**2 342**	**1 769**	**600**	**5 340**
D11AX01	minoxidil	202	161	199	292	325	69	<5	199	81	42	189
D11AX10	finasteride	742	673	625	583	566	1	0	426	133	7	2 874
D11AX16	eflornithine	<5	126	295	380	559	98	8	341	171	39	418
D11AX18	diclofenac	1 604	1 132	709	465	339	45	0	10	109	220	369
D11AX21	brimonidine	0	0	0	0	1 571	72	<5	587	805	175	984

[1)] The ATC level comprises OTC medicinal products. The number of individuals is registered for prescription sales only.

3.9 ATC group G – Genito urinary system and sex hormones

ATC level		2010	2011	2012	2013	2014	Share of women (%)	2014 Number of individuals per age group				2014 Sales in 1000 NOK
		Number of individuals						<15	15–44	45–69	≥70	
G	**GENITO URINARY SYSTEM AND SEX HORMONES**	**721 846**	**745 367**	**761 600**	**785 598**	**814 856**	**80**	**3 334**	**438 593**	**255 917**	**117 012**	**943 065**
G01	**GYNECOLOGICAL ANTIINFECTIVES AND ANTISEPTICS**	**32 068**	**33 034**	**33 653**	**35 989**	**37 651**	**99**	**103**	**27 079**	**8 724**	**1 745**	**8 306**
G01A	**ANTIINFECTIVES AND ANTISEPTICS, EXCL. COMBINATIONS WITH CORTICOSTEROIDS**	**32 068**	**33 034**	**33 653**	**35 989**	**37 651**	**99**	**103**	**27 079**	**8 724**	**1 745**	**8 306**
G01AA	**Antibiotics**	**20 707**	**20 475**	**20 926**	**22 040**	**22 774**	**100**	**48**	**16 505**	**5 445**	**776**	**5 406**
G01AA10	clindamycin	20 707	20 475	20 926	22 040	22 774	100	48	16 505	5 445	776	5 406
G01AD	**Organic acids**	**0**	**0**	**<5**	**7**	**11**	**73**	**0**	**<5**	**<5**	**6**	**8**
G01AD02	acetic acid	0	0	<5	7	11	73	0	<5	<5	6	8
G01AF	**Imidazole derivatives**	**12 788**	**13 896**	**14 039**	**15 467**	**16 452**	**99**	**57**	**11 810**	**3 576**	**1 009**	**2 871**
G01AF01	metronidazole	5 467	6 546	7 327	7 569	7 540	99	6	5 509	1 772	253	1 038
G01AF02	clotrimazole[1)]	5 614	5 949	5 667	6 873	7 945	99	44	5 647	1 588	666	1 598
G01AF04	miconazole[1)]	634	64	0	0	0	–	0	0	0	0	0
G01AF05	econazole[1)]	1 335	1 621	1 328	1 322	1 269	97	9	878	275	107	236
G01AX	**Other antiinfectives and antiseptics**	**<5**	**5**	**8**	**9**	**8**	**50**	**0**	**<5**	**5**	**<5**	**15**
G01AX03	policresulen	<5	5	8	9	8	50	0	<5	5	<5	15
G02	**OTHER GYNECOLOGICALS**	**45 250**	**46 752**	**47 284**	**47 703**	**48 763**	**99**	**9**	**42 098**	**6 449**	**207**	**52 129**
G02A	**UTEROTONICS**	**15**	**11**	**7**	**6**	**9**	**100**	**0**	**9**	**0**	**0**	**1**
G02AB	**Ergot alkaloids**	**15**	**11**	**7**	**5**	**9**	**100**	**0**	**9**	**0**	**0**	**1**
G02AB01	methylergometrine	15	11	7	5	9	100	0	9	0	0	1
G02AD	**Prostaglandins**	**0**	**0**	**0**	**<5**	**0**	**–**	**0**	**0**	**0**	**0**	**0**
G02AD02	dinoprostone	0	0	0	<5	0	–	0	0	0	0	0
G02B	**CONTRACEPTIVES FOR TOPICAL USE**	**42 960**	**44 425**	**45 106**	**45 532**	**46 536**	**100**	**<5**	**40 796**	**5 730**	**6**	**49 161**
G02BA	**Intrauterine contraceptives**	**24 858**	**25 084**	**25 507**	**25 540**	**27 849**	**100**	**<5**	**22 651**	**5 188**	**6**	**32 128**
G02BA03	plastic IUD with progestogen	24 858	25 084	25 507	25 540	27 849	100	<5	22 651	5 188	6	32 128
G02BB	**Intravaginal contraceptives**	**18 263**	**19 552**	**19 825**	**20 195**	**18 993**	**100**	**0**	**18 439**	**554**	**0**	**17 033**
G02BB01	vaginal ring with progestogen and estrogen	18 263	19 552	19 825	20 195	18 993	100	0	18 439	554	0	17 033
G02C	**OTHER GYNECOLOGICALS**	**2 367**	**2 414**	**2 267**	**2 270**	**2 310**	**74**	**5**	**1 383**	**721**	**201**	**2 967**
G02CB	**Prolactine inhibitors**	**2 367**	**2 414**	**2 267**	**2 270**	**2 310**	**74**	**5**	**1 383**	**721**	**201**	**2 967**
G02CB01	bromocriptine	1 226	1 248	1 057	998	935	89	<5	687	191	55	595
G02CB03	cabergoline	921	948	1 004	1 104	1 197	63	<5	626	439	129	1 630
G02CB04	quinagolide	284	260	245	224	215	73	0	94	102	19	742

[1)] The ATC level comprises OTC medicinal products. The number of individuals is registered for prescription sales only.

ATC level		2010	2011	2012	2013	2014		2014				2014
		Number of individuals					Share of women (%)	Number of individuals per age group				Sales in 1000 NOK
								<15	15–44	45–69	≥70	
G03	**SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM**	**525 683**	**538 164**	**545 211**	**558 156**	**574 970**	**98**	**2 520**	**375 694**	**153 780**	**42 976**	**436 934**
G03A	**HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE**	**315 379**	**321 843**	**326 979**	**336 365**	**344 780**	**100**	**1 170**	**328 293**	**15 310**	**7**	**188 720**
G03AA	**Progestogens and estrogens, fixed combinations**	**221 431**	**225 448**	**228 299**	**233 755**	**237 257**	**100**	**948**	**230 895**	**5 412**	**<5**	**137 358**
G03AA07	levonorgestrel and ethinylestradiol	90 257	97 290	113 359	125 595	138 446	100	728	135 286	2 430	<5	66 649
G03AA09	desogestrel and ethinylestradiol	61 035	63 104	56 448	51 914	45 947	100	122	44 605	1 220	0	18 315
G03AA12	drospirenone and ethinylestradiol	72 600	68 101	59 748	56 408	51 722	100	127	50 113	1 482	0	44 508
G03AA13	norelgestromin and ethinylestradiol	8 982	9 054	8 962	8 904	9 068	100	7	8 773	288	0	6 844
G03AA14	nomegestrol and estradiol	0	0	972	1 194	1 136	100	7	1 091	38	0	1 042
G03AB	**Progestogens and estrogens, sequential preparations**	**17 640**	**16 199**	**14 793**	**13 478**	**12 595**	**100**	**27**	**11 770**	**797**	**<5**	**5 380**
G03AB03	levonorgestrel and ethinylestradiol	0	<5	0	0	0	–	0	0	0	0	0
G03AB04	norethisterone and ethinylestradiol	16 059	14 345	12 782	11 584	10 756	100	21	10 065	669	<5	3 495
G03AB08	dienogest and estradiol	1 624	1 895	2 050	1 921	1 860	100	6	1 726	128	0	1 885
G03AC	**Progestogens**	**92 562**	**96 460**	**100 424**	**105 909**	**112 335**	**100**	**243**	**102 782**	**9 306**	**<5**	**45 669**
G03AC01	norethisterone	7 402	6 657	6 120	5 776	5 330	100	8	4 502	820	0	1 275
G03AC03	levonorgestrel	115	<5	0	0	0	–	0	0	0	0	0
G03AC06	medroxyprogesterone	19 607	19 338	18 871	18 870	18 611	100	29	14 817	3 762	<5	4 640
G03AC08	etonogestrel	3 298	4 147	5 381	6 642	8 049	100	29	7 803	216	<5	9 229
G03AC09	desogestrel	64 136	68 331	72 227	77 052	83 057	100	187	78 299	4 571	0	30 525
G03AD	**Emergency contraceptives**	**159**	**165**	**134**	**241**	**1 090**	**100**	**7**	**1 040**	**43**	**0**	**314**
G03AD01	levonorgestrel[1)]	79	87	82	113	131	98	0	122	9	0	30
G03AD02	ulipristal	80	78	53	129	961	100	7	920	34	0	284
G03B	**ANDROGENS**	**5 552**	**6 300**	**7 262**	**8 752**	**10 764**	**12**	**37**	**2 656**	**6 607**	**1 464**	**32 986**
G03BA	**3-oxoandrosten (4) derivatives**	**5 550**	**6 282**	**7 254**	**8 741**	**10 756**	**12**	**37**	**2 650**	**6 605**	**1 464**	**32 971**
G03BA03	testosterone	5 550	6 282	7 254	8 741	10 756	12	37	2 650	6 605	1 464	32 971
G03BB	**5-androstanon (3) derivatives**	**<5**	**22**	**8**	**11**	**11**	**0**	**0**	**8**	**<5**	**0**	**15**
G03BB01	mesterolone	<5	22	8	11	11	0	0	8	<5	0	15
G03C	**ESTROGENS**	**116 574**	**121 775**	**123 293**	**126 359**	**134 148**	**100**	**178**	**5 585**	**90 640**	**37 745**	**87 347**
G03CA	**Natural and semisynthetic estrogens, plain**	**108 549**	**114 351**	**116 345**	**119 654**	**127 231**	**100**	**178**	**5 373**	**84 718**	**36 962**	**77 396**

[1)] The ATC level comprises OTC medicinal products. The number of individuals is registered for prescription sales only.

ATC group G

ATC level		2010	2011	2012	2013	2014		2014				2014
		Number of individuals					Share of women (%)	Number of individuals per age group				Sales in 1000 NOK
								<15	15–44	45–69	≥70	
G03CA01	ethinylestradiol	127	112	71	48	35	97	11	15	7	<5	227
G03CA03	estradiol	95 212	102 308	105 497	109 820	118 075	100	42	5 113	81 978	30 942	72 668
G03CA04	estriol[1)]	14 807	13 574	12 313	11 302	10 653	100	125	284	3 441	6 803	4 498
G03CA57	conjugated estrogens	<5	<5	<5	<5	6	100	0	0	5	<5	3
G03CX	**Other estrogens**	**8 841**	**8 224**	**7 705**	**7 534**	**7 896**	**100**	**0**	**268**	**6 768**	**860**	**9 951**
G03CX01	tibolone	8 841	8 224	7 705	7 534	7 896	100	0	268	6 768	860	9 951
G03D	**PROGESTOGENS**	**38 788**	**39 101**	**40 073**	**41 850**	**40 199**	**100**	**1 130**	**29 018**	**9 835**	**216**	**21 162**
G03DA	**Pregnen (4) derivatives**	**12 990**	**13 134**	**13 808**	**14 386**	**14 965**	**100**	**34**	**10 726**	**4 008**	**197**	**18 379**
G03DA02	medroxyprogesterone	6 869	6 816	6 651	6 590	6 566	100	34	3 611	2 815	106	1 268
G03DA04	progesterone	6 240	6 465	7 294	7 929	8 561	100	0	7 259	1 211	91	17 111
G03DB	**Pregnadien derivatives**	**0**	**12**	**127**	**159**	**169**	**100**	**<5**	**146**	**22**	**0**	**456**
G03DB08	dienogest	0	12	127	159	169	100	<5	146	22	0	456
G03DC	**Estren derivatives**	**26 536**	**26 716**	**26 901**	**28 086**	**25 826**	**100**	**1 096**	**18 750**	**5 961**	**19**	**2 327**
G03DC02	norethisterone	26 536	26 716	26 901	28 086	25 826	100	1 096	18 750	5 961	19	2 327
G03F	**PROGESTOGENS AND ESTROGENS IN COMBINATION**	**44 082**	**43 373**	**41 804**	**41 341**	**43 977**	**100**	**0**	**2 769**	**37 589**	**3 619**	**34 345**
G03FA	**Progestogens and estrogens, fixed combinations**	**35 051**	**34 460**	**33 190**	**32 658**	**34 654**	**100**	**0**	**873**	**30 328**	**3 453**	**28 076**
G03FA01	norethisterone and estrogen	34 521	33 827	32 517	31 956	33 826	100	0	828	29 588	3 410	27 141
G03FA12	medroxyprogesterone and estrogen	715	764	795	801	954	100	0	52	854	48	935
G03FA15	dienogest and estrogen	<5	<5	0	0	0	–	0	0	0	0	0
G03FB	**Progestogens and estrogens, sequential preparations**	**10 322**	**10 082**	**9 652**	**9 671**	**10 428**	**100**	**0**	**1 994**	**8 256**	**178**	**6 269**
G03FB05	norethisterone and estrogen	10 322	10 082	9 652	9 671	10 428	100	0	1 994	8 256	178	6 269
G03G	**GONADOTROPINS AND OTHER OVULATION STIMULANTS**	**10 343**	**10 634**	**10 473**	**10 334**	**10 402**	**94**	**<5**	**10 104**	**287**	**7**	**62 933**
G03GA	**Gonadotropins**	**6 137**	**6 273**	**6 248**	**6 317**	**6 466**	**96**	**<5**	**6 332**	**131**	**0**	**61 405**
G03GA01	chorionic gonadotrophin	1 476	1 660	1 317	1 143	988	76	<5	927	58	0	433
G03GA02	human menopausal gonadotrophin	1 540	1 842	2 064	2 101	2 215	100	0	2 178	37	0	18 201
G03GA04	urofollitropin	85	154	200	268	460	100	0	455	5	0	3 567
G03GA05	follitropin alfa	1 743	1 799	1 941	1 926	2 003	99	0	1 968	35	0	17 594
G03GA06	follitropin beta	3 016	2 824	2 408	2 335	2 038	100	0	2 022	16	0	15 654
G03GA07	lutropin alfa	26	21	17	9	8	88	0	7	<5	0	25
G03GA08	choriogonadotropin alfa	4 538	4 600	4 820	5 007	5 297	100	0	5 235	62	0	3 254
G03GA09	corifollitropin alfa	132	316	283	323	287	100	0	286	<5	0	2 307

[1)] The ATC level comprises OTC medicinal products. The number of individuals is registered for prescription sales only.

ATC level		2010	2011	2012	2013	2014		2014				2014
		Number of individuals					Share of women (%)	Number of individuals per age group				Sales in 1000 NOK
								<15	15–44	45–69	≥70	
G03GA30	combinations	<5	<5	16	8	28	100	0	27	<5	0	368
G03GB	**Ovulation stimulants, synthetic**	**5 387**	**5 646**	**5 315**	**5 048**	**4 884**	**90**	**<5**	**4 690**	**186**	**7**	**1 528**
G03GB02	clomifene	5 387	5 646	5 315	5 048	4 884	90	<5	4 690	186	7	1 528
G03H	**ANTIANDROGENS**	**16 764**	**17 326**	**18 067**	**17 481**	**15 966**	**99**	**94**	**15 403**	**386**	**83**	**6 889**
G03HA	**Antiandrogens, plain**	**205**	**199**	**178**	**175**	**175**	**4**	**0**	**42**	**51**	**82**	**505**
G03HA01	cyproterone	205	199	178	175	175	4	0	42	51	82	505
G03HB	**Antiandrogens and estrogens**	**16 565**	**17 130**	**17 895**	**17 309**	**15 792**	**100**	**94**	**15 362**	**335**	**<5**	**6 384**
G03HB01	cyproterone and estrogen	16 565	17 130	17 895	17 309	15 792	100	94	15 362	335	<5	6 384
G03X	**OTHER SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM**	**1 142**	**979**	**867**	**767**	**838**	**95**	**0**	**158**	**305**	**375**	**2 551**
G03XA	**Antigonadotropins and similar agents**	**49**	**50**	**51**	**53**	**57**	**26**	**0**	**23**	**23**	**11**	**204**
G03XA01	danazol	49	50	51	53	57	26	0	23	23	11	204
G03XB	**Progesterone receptor modulators**	**<5**	**<5**	**6**	**15**	**255**	**100**	**0**	**131**	**124**	**0**	**1 099**
G03XB01	mifepristone	<5	<5	6	0	0	–	0	0	0	0	0
G03XB02	ulipristal	0	0	0	15	255	100	0	131	124	0	1 099
G03XC	**Selective estrogen receptor modulators**	**1 092**	**927**	**810**	**699**	**526**	**99**	**0**	**<5**	**158**	**364**	**1 247**
G03XC01	raloxifene	1 092	927	810	699	526	99	0	<5	158	364	1 247
G04	**UROLOGICALS**	**156 067**	**166 514**	**175 080**	**185 259**	**198 282**	**20**	**716**	**19 274**	**99 380**	**78 912**	**445 696**
G04B	**UROLOGICALS**	**113 502**	**119 124**	**123 051**	**128 784**	**136 848**	**28**	**715**	**16 458**	**76 251**	**43 424**	**360 247**
G04BA	**Acidifiers**	**0**	**0**	**0**	**0**	**<5**	**100**	**<5**	**0**	**<5**	**0**	**11**
G04BD	**Drugs for urinary frequency and incontinence**	**46 177**	**49 166**	**50 206**	**52 117**	**56 077**	**68**	**662**	**4 659**	**23 291**	**27 465**	**165 856**
G04BD04	oxybutynin	1 504	1 516	1 525	1 468	1 585	61	158	606	450	371	10 215
G04BD07	tolterodine	15 679	14 238	12 763	11 304	9 818	72	414	535	3 471	5 398	21 529
G04BD08	solifenacin	19 877	21 934	22 341	20 910	18 607	69	92	1 360	7 754	9 401	56 115
G04BD10	darifenacin	5 126	4 566	4 059	3 475	2 863	74	0	138	1 129	1 596	8 388
G04BD11	fesoterodine	7 639	10 610	12 962	13 441	11 252	67	7	860	4 822	5 563	32 923
G04BD12	mirabegron	0	0	0	6 735	17 825	65	20	1 611	8 118	8 076	36 687
G04BE	**Drugs used in erectile dysfunction**	**68 779**	**71 519**	**74 530**	**78 488**	**82 780**	**0**	**49**	**11 900**	**54 116**	**16 715**	**194 340**
G04BE01	alprostadil	2 543	2 525	2 809	2 893	3 165	0	0	135	1 990	1 040	5 378
G04BE03	sildenafil	34 385	34 578	34 385	35 222	36 588	1	49	5 089	23 344	8 106	73 282
G04BE04	yohimbine	15	10	7	11	11	27	0	<5	6	<5	5
G04BE08	tadalafil	29 887	32 997	36 673	40 063	43 271	0	0	6 852	28 987	7 432	100 696

ATC group G

ATC level		2010	2011	2012	2013	2014		2014				2014
		Number of individuals					Share of women (%)	Number of individuals per age group				Sales in 1000 NOK
								<15	15–44	45–69	≥70	
G04BE09	vardenafil	9 934	9 427	9 073	8 785	8 323	0	0	994	5 570	1 759	14 273
G04BE30	combinations	495	539	347	293	321	0	0	17	220	84	707
G04BX	**Other urologicals**	**11**	**11**	**13**	**19**	**33**	**27**	**<5**	**17**	**10**	**<5**	**40**
G04BX01	magnesium hydroxide	11	11	13	19	20	45	<5	6	8	<5	33
G04BX14	dapoxetine	0	0	0	0	13	0	0	11	<5	0	8
G04C	**DRUGS USED IN BENIGN PROSTATIC HYPERTROPHY**	**49 918**	**55 531**	**61 004**	**66 317**	**72 748**	**1**	**<5**	**3 064**	**28 410**	**41 273**	**85 449**
G04CA	**Alpha-adrenoreceptor antagonists**	**38 363**	**43 210**	**48 624**	**53 898**	**60 224**	**2**	**<5**	**1 840**	**25 341**	**33 042**	**64 984**
G04CA01	alfuzosin	498	451	398	48	16	0	0	0	7	9	25
G04CA02	tamsulosin	37 383	41 362	43 587	45 144	47 798	2	<5	1 756	20 562	25 479	37 186
G04CA03	terazosin	649	598	599	601	547	2	0	74	220	253	469
G04CA52	tamsulosin and dutasteride	<5	1 628	6 169	10 799	14 946	0	0	24	5 881	9 041	27 304
G04CB	**Testosterone-5-alpha reductase inhibitors**	**16 984**	**18 676**	**18 628**	**18 209**	**17 831**	**0**	**0**	**1 232**	**4 711**	**11 888**	**20 465**
G04CB01	finasteride	15 194	17 122	17 271	17 016	16 789	0	0	1 206	4 475	11 108	17 493
G04CB02	dutasteride	1 939	1 661	1 421	1 258	1 099	0	0	33	249	817	2 972

3.10 ATC group H – Systemic hormonal preparations, excl. sex hormones and insulins

ATC level		2010	2011	2012	2013	2014		2014				2014
		Number of individuals					Share of women (%)	Number of individuals per age group				Sales in 1000 NOK
								<15	15–44	45–69	≥70	
H	**SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS**	**387 821**	**402 923**	**414 206**	**422 527**	**436 286**	**67**	**17 185**	**114 283**	**188 151**	**116 667**	**474 158**
H01	**PITUITARY AND HYPO-THALAMIC HORMONES AND ANALOGUES**	**24 833**	**24 910**	**24 985**	**25 586**	**26 197**	**65**	**9 695**	**13 319**	**1 961**	**1 222**	**296 983**
H01A	**ANTERIOR PITUITARY LOBE HORMONES AND ANALOGUES**	**1 658**	**1 767**	**1 866**	**1 975**	**2 027**	**43**	**1 090**	**573**	**318**	**46**	**145 957**
H01AA	**ACTH**	**<5**	**<5**	**0**	**<5**	**0**	**–**	**0**	**0**	**0**	**0**	**0**
H01AA02	tetracosactide	<5	<5	0	<5	0	–	0	0	0	0	0
H01AB	**Thyrotropin**	**<5**	**7**	**10**	**16**	**0**	**–**	**0**	**0**	**0**	**0**	**0**
H01AB01	thyrotropin alfa	<5	7	10	16	0	–	0	0	0	0	0
H01AC	**Somatropin and somatropin agonists**	**1 631**	**1 735**	**1 825**	**1 928**	**1 995**	**43**	**1 090**	**563**	**299**	**43**	**136 728**
H01AC01	somatropin	1 631	1 735	1 825	1 928	1 995	43	1 090	563	299	43	136 728
H01AX	**Other anterior pituitary lobe hormones and analogues**	**24**	**24**	**31**	**30**	**32**	**34**	**0**	**10**	**19**	**<5**	**9 229**
H01AX01	pegvisomant	24	24	31	30	32	34	0	10	19	<5	9 229
H01B	**POSTERIOR PITUITARY LOBE HORMONES**	**18 982**	**19 167**	**18 728**	**19 133**	**18 829**	**60**	**8 635**	**8 077**	**1 235**	**882**	**40 129**
H01BA	**Vasopressin and analogues**	**11 248**	**11 388**	**11 209**	**11 257**	**11 727**	**36**	**8 577**	**1 101**	**1 170**	**879**	**38 254**
H01BA02	desmopressin	11 248	11 387	11 209	11 257	11 727	36	8 577	1 101	1 170	879	38 254
H01BA04	terlipressin	0	<5	0	0	0	–	0	0	0	0	0
H01BB	**Oxytocin and analogues**	**7 736**	**7 781**	**7 522**	**7 878**	**7 107**	**99**	**58**	**6 980**	**66**	**<5**	**1 875**
H01BB02	oxytocin	7 736	7 781	7 522	7 878	7 107	99	58	6 980	66	<5	1 875
H01C	**HYPOTHALAMIC HORMONES**	**4 430**	**4 218**	**4 643**	**4 737**	**5 600**	**92**	**8**	**4 801**	**488**	**303**	**110 898**
H01CA	**Gonadotropin-releasing hormones**	**2 314**	**2 076**	**2 362**	**2 337**	**2 829**	**100**	**0**	**2 812**	**17**	**0**	**6 604**
H01CA02	nafarelin	2 314	2 076	2 362	2 337	2 829	100	0	2 812	17	0	6 604
H01CB	**Somatostatin and analogues**	**593**	**630**	**726**	**751**	**830**	**47**	**8**	**85**	**434**	**303**	**97 829**
H01CB02	octreotide	472	497	569	569	603	48	5	67	311	220	65 310
H01CB03	lanreotide	137	148	184	204	248	46	6	20	132	90	31 907
H01CB05	pasireotide	0	0	0	<5	<5	25	0	<5	<5	<5	613
H01CC	**Anti-gonadotropin-releasing hormones**	**1 887**	**1 774**	**1 814**	**1 934**	**2 298**	**100**	**0**	**2 260**	**38**	**0**	**6 464**
H01CC01	ganirelix	1 513	1 397	1 429	1 504	2 069	100	0	2 039	30	0	5 642
H01CC02	cetrorelix	481	413	406	451	286	100	0	277	9	0	822
H02	**CORTICOSTEROIDS FOR SYSTEMIC USE**	**197 259**	**208 089**	**214 495**	**216 727**	**226 262**	**56**	**5 291**	**64 804**	**94 762**	**61 405**	**66 202**

ATC group H

ATC level		2010	2011	2012	2013	2014	Share of women (%)	2014				2014
		Number of individuals						Number of individuals per age group				Sales in 1000 NOK
								<15	15–44	45–69	≥70	
H02A	**CORTICOSTEROIDS FOR SYSTEMIC USE, PLAIN**	**197 075**	**207 853**	**214 275**	**216 487**	**226 029**	**56**	**5 291**	**64 772**	**94 616**	**61 350**	**66 122**
H02AA	**Mineralocorticoids**	**1 223**	**1 267**	**1 323**	**1 367**	**1 404**	**57**	**93**	**432**	**628**	**251**	**394**
H02AA02	fludrocortisone	1 223	1 267	1 323	1 367	1 404	57	93	432	628	251	394
H02AB	**Glucocorticoids**	**196 940**	**207 710**	**214 119**	**216 321**	**225 847**	**56**	**5 286**	**64 726**	**94 549**	**61 286**	**65 728**
H02AB01	betamethasone	1 637	1 528	1 495	1 988	2 286	43	1 383	362	455	86	649
H02AB02	dexamethasone	2 552	2 786	3 208	3 485	5 473	49	151	531	2 958	1 833	9 294
H02AB04	methylprednisolone	10 812	11 020	11 094	11 015	10 306	53	49	2 456	5 183	2 618	3 705
H02AB06	prednisolone	152 240	159 525	167 804	168 957	172 913	58	3 028	39 730	74 429	55 726	32 905
H02AB07	prednisone	82	246	267	347	329	69	<5	51	149	128	827
H02AB08	triamcinolone	32 179	35 711	33 528	34 019	38 506	50	570	22 469	13 320	2 147	6 339
H02AB09	hydrocortisone	481	549	597	637	683	65	74	244	325	40	5 378
H02AB10	cortisone	2 662	2 750	2 817	2 820	2 903	51	120	752	1 386	645	6 466
H02AB13	deflazacort	17	25	25	26	36	36	21	<5	6	5	166
H02B	**CORTICOSTEROIDS FOR SYSTEMIC USE, COMBINATIONS**	**372**	**415**	**409**	**386**	**416**	**67**	**0**	**51**	**241**	**124**	**80**
H02BX	**Corticosteroids for systemic use, combinations**	**372**	**415**	**409**	**386**	**416**	**67**	**0**	**51**	**241**	**124**	**80**
H02BX01	methylprednisolone, combinations	372	415	409	386	416	67	0	51	241	124	80
H03	**THYROID THERAPY**	**180 847**	**185 868**	**192 035**	**197 795**	**202 566**	**82**	**1 404**	**38 136**	**100 499**	**62 527**	**72 734**
H03A	**THYROID PREPARATIONS**	**177 261**	**182 151**	**187 897**	**193 254**	**197 826**	**82**	**1 377**	**36 718**	**98 426**	**61 305**	**66 688**
H03AA	**Thyroid hormones**	**177 261**	**182 151**	**187 897**	**193 254**	**197 826**	**82**	**1 377**	**36 718**	**98 426**	**61 305**	**66 688**
H03AA01	levothyroxine sodium	176 910	181 641	187 229	192 528	196 810	82	1 364	36 377	97 832	61 237	59 936
H03AA02	liothyronine sodium	4 142	4 538	4 698	4 750	5 364	90	21	1 602	3 251	490	3 682
H03AA03	combinations of levothyroxine and liothyronine	328	549	701	872	1 352	93	<5	507	779	62	2 082
H03AA05	thyroid gland preparations	182	187	265	353	484	90	<5	173	301	9	987
H03B	**ANTITHYROID PREPARATIONS**	**5 125**	**5 432**	**5 927**	**6 398**	**6 704**	**79**	**43**	**2 163**	**3 038**	**1 460**	**6 041**
H03BA	**Thiouracils**	**521**	**651**	**582**	**581**	**734**	**86**	**<5**	**364**	**285**	**84**	**725**
H03BA02	propylthiouracil	521	651	582	581	734	86	<5	364	285	84	725
H03BB	**Sulfur-containing imidazole derivatives**	**4 727**	**5 042**	**5 510**	**6 039**	**6 229**	**79**	**42**	**1 936**	**2 845**	**1 406**	**5 316**
H03BB01	carbimazole	4 727	5 042	5 510	6 039	6 229	79	42	1 936	2 845	1 406	5 316
H03C	**IODINE THERAPY**	**0**	**0**	**0**	**<5**	**6**	**83**	**0**	**<5**	**<5**	**0**	**5**
H03CA	**Iodine therapy**	**0**	**0**	**0**	**<5**	**6**	**83**	**0**	**<5**	**<5**	**0**	**5**
H04	**PANCREATIC HORMONES**	**5 490**	**5 591**	**5 586**	**5 688**	**5 490**	**46**	**1 133**	**2 541**	**1 457**	**359**	**2 359**
H04A	**GLYCOGENOLYTIC HORMONES**	**5 490**	**5 591**	**5 586**	**5 688**	**5 490**	**46**	**1 133**	**2 541**	**1 457**	**359**	**2 359**

ATC level		2010	2011	2012	2013	2014		2014				2014
		Number of individuals					Share of women (%)	Number of individuals per age group				Sales in 1000 NOK
								<15	15–44	45–69	≥70	
H04AA	**Glycogenolytic hormones**	**5 490**	**5 591**	**5 586**	**5 688**	**5 490**	**46**	**1 133**	**2 541**	**1 457**	**359**	**2 359**
H04AA01	glucagon	5 490	5 591	5 586	5 688	5 490	46	1 133	2 541	1 457	359	2 359
H05	**CALCIUM HOMEOSTASIS**	**803**	**916**	**1 090**	**1 224**	**1 375**	**62**	**0**	**147**	**671**	**557**	**35 881**
H05A	**PARATHYROID HORMONES AND ANALOGUES**	**263**	**294**	**377**	**468**	**608**	**83**	**0**	**67**	**340**	**201**	**17 544**
H05AA	**Parathyroid hormones and analogues**	**263**	**294**	**377**	**468**	**608**	**83**	**0**	**67**	**340**	**201**	**17 544**
H05AA02	teriparatide	253	281	367	467	608	83	0	67	340	201	17 544
H05AA03	parathyroid hormone	12	13	11	<5	0	–	0	0	0	0	0
H05B	**ANTI-PARATHYROID AGENTS**	**541**	**623**	**713**	**756**	**767**	**46**	**0**	**80**	**331**	**356**	**18 337**
H05BA	**Calcitonin preparations**	**80**	**83**	**69**	**21**	**16**	**81**	**0**	**<5**	**<5**	**11**	**95**
H05BA01	calcitonin (salmon synthetic)	80	83	69	21	16	81	0	<5	<5	11	95
H05BX	**Other anti-parathyroid agents**	**461**	**540**	**644**	**735**	**751**	**45**	**0**	**78**	**328**	**345**	**18 241**
H05BX01	cinacalcet	418	474	501	525	520	50	0	46	216	258	13 803
H05BX02	paricalcitol	59	87	188	284	289	34	0	42	140	107	4 438

3.11 ATC group J – Antiinfectives for systemic use

ATC level		2010	2011	2012	2013	2014		2014				2014
		Number of individuals					Share of women (%)	Number of individuals per age group				Sales in 1000 NOK
								<15	15–44	45–69	≥70	
J	**ANTIINFECTIVES FOR SYSTEMIC USE**	**1 252 392**	**1 326 405**	**1 336 787**	**1 288 914**	**1 250 326**	**60**	**145 461**	**500 319**	**409 350**	**195 196**	**1 083 499**
J01	**ANTIBACTERIALS FOR SYSTEMIC USE**	**1 180 410**	**1 250 480**	**1 261 271**	**1 195 320**	**1 169 503**	**59**	**140 787**	**458 841**	**382 491**	**187 384**	**305 089**
J01A	**TETRACYCLINES**	**167 058**	**188 189**	**206 426**	**187 918**	**179 769**	**57**	**2 141**	**86 686**	**64 461**	**26 481**	**35 736**
J01AA	**Tetracyclines**	**167 058**	**188 189**	**206 426**	**187 918**	**179 769**	**57**	**2 141**	**86 686**	**64 461**	**26 481**	**35 736**
J01AA02	doxycycline	129 848	148 596	164 753	145 943	138 194	57	830	56 787	55 746	24 831	20 997
J01AA04	lymecycline	14 771	19 412	22 520	23 686	24 937	59	793	18 308	4 943	893	9 718
J01AA06	oxytetracycline	5 164	2 625	<5	10	33	85	0	14	15	<5	11
J01AA07	tetracycline	19 710	21 378	22 166	20 959	19 692	58	565	13 695	4 499	933	4 870
J01AA08	minocycline	58	85	145	240	91	57	<5	38	44	7	108
J01AA12	tigecycline	<5	<5	<5	<5	<5	50	0	<5	<5	<5	31
J01B	**AMPHENICOLS**	**<5**	**0**	**0**	**0**	**0**	**–**	**0**	**0**	**0**	**0**	**0**
J01BA	**Amphenicols**	**<5**	**0**	**0**	**0**	**0**	**–**	**0**	**0**	**0**	**0**	**0**
J01BA01	chloramphenicol	<5	0	0	0	0	–	0	0	0	0	0
J01C	**BETA-LACTAM ANTI-BACTERIALS, PENICILLINS**	**776 398**	**797 519**	**801 997**	**774 820**	**771 971**	**61**	**106 106**	**293 883**	**244 093**	**127 889**	**137 628**
J01CA	**Penicillins with extended spectrum**	**301 349**	**309 246**	**318 249**	**321 225**	**322 639**	**75**	**33 687**	**103 543**	**106 898**	**78 511**	**62 002**
J01CA01	ampicillin	39	24	56	57	46	37	0	0	14	32	43
J01CA02	pivampicillin	0	<5	0	0	0	–	0	0	0	0	0
J01CA04	amoxicillin	127 541	131 915	137 759	134 844	132 716	55	29 257	30 767	44 593	28 099	20 050
J01CA08	pivmecillinam	186 059	189 598	193 934	200 464	203 619	88	4 787	75 934	67 063	55 835	41 886
J01CA11	mecillinam	<5	<5	10	8	11	82	0	<5	6	<5	22
J01CE	**Beta-lactamase sensitive penicillins**	**458 149**	**466 195**	**458 225**	**438 658**	**420 792**	**54**	**75 158**	**172 427**	**125 736**	**47 471**	**42 136**
J01CE01	benzylpenicillin	52	64	85	103	120	43	<5	12	35	69	130
J01CE02	phenoxymethylpenicillin	458 036	466 096	458 104	438 508	420 665	54	75 156	172 390	125 681	47 438	41 767
J01CE08	benzathine benzylpenicillin	99	83	81	112	81	26	0	37	39	5	240
J01CF	**Beta-lactamase resistant penicillins**	**92 702**	**100 307**	**104 992**	**87 628**	**102 620**	**48**	**5 548**	**43 891**	**35 354**	**17 827**	**32 647**
J01CF01	dicloxacillin	91 099	98 912	103 764	81 161	99 365	48	5 327	42 615	34 229	17 194	30 510
J01CF02	cloxacillin	1 929	1 714	1 520	8 105	3 935	48	230	1 526	1 384	795	2 097
J01CF05	flucloxacillin	22	17	21	28	22	55	18	<5	0	<5	40
J01CR	**Combinations of penicillins, incl. beta-lactamase inhibitors**	**135**	**114**	**188**	**434**	**646**	**58**	**361**	**67**	**106**	**112**	**843**
J01CR02	amoxicillin and enzyme inhibitor	118	94	151	381	593	59	360	56	87	90	545
J01CR05	piperacillin and enzyme inhibitor	17	20	37	53	53	49	<5	11	19	22	298

ATC level		2010	2011	2012	2013	2014		2014				2014
		Number of individuals					Share of women (%)	Number of individuals per age group				Sales in 1000 NOK
								<15	15–44	45–69	≥70	
J01D	**OTHER BETA-LACTAM ANTIBACTERIALS**	**23 566**	**23 142**	**21 542**	**22 070**	**19 380**	**59**	**2 734**	**6 630**	**6 430**	**3 586**	**7 508**
J01DB	**First-generation cephalosporins**	**23 116**	**22 707**	**20 726**	**20 949**	**18 004**	**59**	**2 679**	**6 279**	**5 953**	**3 093**	**2 755**
J01DB01	cefalexin	23 099	22 698	20 707	20 940	17 990	59	2 679	6 278	5 947	3 086	2 744
J01DB03	cefalotin	17	9	20	9	15	33	0	<5	7	7	11
J01DC	**Second-generation cephalosporins**	**71**	**72**	**103**	**98**	**75**	**41**	**<5**	**8**	**19**	**47**	**81**
J01DC02	cefuroxime	71	72	103	98	75	41	<5	8	19	47	81
J01DD	**Third-generation cephalosporins**	**388**	**362**	**705**	**1 010**	**1 303**	**58**	**60**	**346**	**442**	**455**	**3 057**
J01DD01	cefotaxime	120	134	447	703	983	63	6	212	357	408	1 801
J01DD02	ceftazidime	80	57	68	73	78	45	12	40	15	11	751
J01DD04	ceftriaxone	190	177	195	238	244	39	42	95	70	37	505
J01DF	**Monobactams**	**13**	**8**	**9**	**10**	**13**	**46**	**0**	**10**	**<5**	**0**	**504**
J01DF01	aztreonam	13	8	9	10	13	46	0	10	<5	0	504
J01DH	**Carbapenems**	**43**	**53**	**69**	**85**	**65**	**46**	**<5**	**21**	**30**	**12**	**1 112**
J01DH02	meropenem	39	40	58	62	49	49	<5	19	20	8	761
J01DH03	ertapenem	<5	13	10	17	16	38	0	<5	10	<5	347
J01DH04	doripenem	0	0	<5	0	0	–	0	0	0	0	0
J01DH51	imipenem and enzyme inhibitor	<5	<5	<5	7	<5	100	0	<5	0	0	3
J01E	**SULFONAMIDES AND TRIMETHOPRIM**	**117 088**	**116 661**	**114 940**	**116 722**	**121 142**	**73**	**13 956**	**31 330**	**40 653**	**35 203**	**12 787**
J01EA	**Trimethoprim and derivatives**	**86 108**	**84 347**	**80 744**	**78 689**	**76 400**	**85**	**8 073**	**20 674**	**24 443**	**23 210**	**6 980**
J01EA01	trimethoprim	86 108	84 347	80 744	78 689	76 400	85	8 073	20 674	24 443	23 210	6 980
J01EE	**Combinations of sulfonamides and trimethoprim, incl. derivatives**	**34 976**	**36 389**	**38 556**	**42 790**	**49 887**	**55**	**6 455**	**11 552**	**17 793**	**14 087**	**5 807**
J01EE01	sulfamethoxazole and trimethoprim	34 976	36 389	38 556	42 790	49 887	55	6 455	11 552	17 793	14 087	5 807
J01F	**MACROLIDES, LINCOSAMIDES AND STREPTOGRAMINS**	**301 083**	**349 643**	**343 543**	**296 521**	**267 245**	**57**	**34 400**	**116 456**	**89 465**	**26 924**	**41 729**
J01FA	**Macrolides**	**257 943**	**304 755**	**295 755**	**238 975**	**211 897**	**59**	**29 699**	**94 444**	**68 873**	**18 881**	**30 011**
J01FA01	erythromycin	129 188	170 347	152 858	120 963	110 600	59	23 786	42 156	34 168	10 490	15 911
J01FA02	spiramycin	2 794	2 744	2 645	2 018	1 858	60	21	607	968	262	323
J01FA06	roxithromycin	0	0	0	<5	5	100	<5	<5	<5	0	6
J01FA09	clarithromycin	37 830	43 161	48 582	34 941	29 154	57	2 655	10 982	11 563	3 954	4 988
J01FA10	azithromycin	98 413	101 180	105 207	90 289	77 574	60	3 968	44 106	24 710	4 790	8 769
J01FA15	telithromycin	0	0	<5	6	<5	67	0	<5	0	0	14

ATC group J

ATC level		2010	2011	2012	2013	2014		2014				2014
		Number of individuals					Share of women (%)	Number of individuals per age group				Sales in 1000 NOK
								<15	15–44	45–69	≥70	
J01FF	**Lincosamides**	**51 154**	**53 678**	**56 641**	**66 378**	**63 188**	**54**	**5 497**	**25 550**	**23 280**	**8 861**	**11 718**
J01FF01	clindamycin	51 154	53 678	56 641	66 378	63 188	54	5 497	25 550	23 280	8 861	11 718
J01G	**AMINOGLYCOSIDE ANTIBACTERIALS**	**273**	**252**	**255**	**242**	**258**	**47**	**55**	**127**	**48**	**28**	**9 597**
J01GA	**Streptomycins**	**0**	**0**	**0**	**<5**	**<5**	**0**	**0**	**<5**	**0**	**0**	**7**
J01GA01	streptomycin	0	0	0	<5	<5	0	0	<5	0	0	7
J01GB	**Other aminoglycosides**	**273**	**252**	**255**	**241**	**257**	**47**	**55**	**126**	**48**	**28**	**9 589**
J01GB01	tobramycin	250	219	229	211	214	46	47	110	38	19	8 115
J01GB03	gentamicin	16	19	14	21	33	52	8	7	8	10	567
J01GB06	amikacin	10	14	12	9	11	55	0	9	<5	0	908
J01M	**QUINOLONE ANTIBACTERIALS**	**64 703**	**67 271**	**69 685**	**68 203**	**65 073**	**49**	**543**	**15 949**	**27 623**	**20 958**	**15 986**
J01MA	**Fluoroquinolones**	**64 703**	**67 271**	**69 685**	**68 203**	**65 073**	**49**	**543**	**15 949**	**27 623**	**20 958**	**15 986**
J01MA01	ofloxacin	2 516	2 242	2 057	1 647	1 492	34	0	433	634	425	490
J01MA02	ciprofloxacin	62 445	65 193	67 734	66 556	63 282	49	543	15 038	27 081	20 620	14 277
J01MA12	levofloxacin	21	31	20	18	28	61	0	14	12	<5	153
J01MA14	moxifloxacin	142	205	263	290	545	58	0	522	22	<5	1 067
J01X	**OTHER ANTIBACTERIALS**	**54 632**	**58 484**	**59 562**	**61 581**	**63 126**	**85**	**1 446**	**11 884**	**21 923**	**27 873**	**44 118**
J01XA	**Glycopeptide antibacterials**	**23**	**27**	**35**	**29**	**31**	**65**	**5**	**<5**	**8**	**17**	**275**
J01XA01	vancomycin	21	24	35	28	30	67	5	<5	7	17	270
J01XA02	teicoplanin	<5	<5	0	<5	<5	0	0	0	<5	0	5
J01XB	**Polymyxins**	**55**	**63**	**72**	**79**	**88**	**59**	**14**	**40**	**27**	**7**	**3 491**
J01XB01	colistin	55	63	72	79	88	59	14	40	27	7	3 491
J01XC	**Steroid antibacterials**	**757**	**663**	**592**	**646**	**481**	**57**	**19**	**160**	**177**	**125**	**365**
J01XC01	fusidic acid	757	663	592	646	481	57	19	160	177	125	365
J01XD	**Imidazole derivatives**	**24**	**26**	**25**	**28**	**30**	**50**	**<5**	**<5**	**19**	**8**	**53**
J01XD01	metronidazole	24	26	25	28	30	50	<5	<5	19	8	53
J01XE	**Nitrofuran derivatives**	**33 594**	**36 784**	**36 250**	**36 821**	**36 878**	**86**	**1 314**	**8 788**	**12 795**	**13 981**	**4 610**
J01XE01	nitrofurantoin	33 594	36 784	36 250	36 821	36 878	86	1 314	8 788	12 795	13 981	4 610
J01XX	**Other antibacterials**	**24 887**	**25 921**	**28 098**	**29 569**	**31 562**	**85**	**141**	**3 643**	**10 936**	**16 842**	**35 323**
J01XX01	fosfomycin	0	0	<5	6	7	86	0	0	<5	<5	9
J01XX05	methenamine	24 644	25 647	27 852	29 300	31 320	85	137	3 607	10 833	16 743	26 476
J01XX08	linezolid	252	279	252	273	251	41	<5	37	110	100	8 838
J01XX09	daptomycin	0	0	<5	<5	0	–	0	0	0	0	0
J02	**ANTIMYCOTICS FOR SYSTEMIC USE**	**45 330**	**46 501**	**47 777**	**48 187**	**48 587**	**87**	**419**	**30 694**	**14 044**	**3 430**	**32 036**
J02A	**ANTIMYCOTICS FOR SYSTEMIC USE**	**45 330**	**46 501**	**47 777**	**48 187**	**48 587**	**87**	**419**	**30 694**	**14 044**	**3 430**	**32 036**
J02AA	**Antibiotics**	**0**	**<5**	**<5**	**<5**	**<5**	**67**	**<5**	**<5**	**<5**	**0**	**148**

ATC level		2010	2011	2012	2013	2014		2014				2014
		Number of individuals					Share of women (%)	Number of individuals per age group				Sales in 1000 NOK
								<15	15–44	45–69	≥70	
J02AA01	amphotericin B	0	<5	<5	<5	<5	67	<5	<5	<5	0	148
J02AB	**Imidazole derivatives**	**2 163**	**2 227**	**2 264**	**1 716**	**0**	**–**	**0**	**0**	**0**	**0**	**0**
J02AB02	ketoconazole	2 163	2 227	2 264	1 716	0	–	0	0	0	0	0
J02AC	**Triazole derivatives**	**43 283**	**44 379**	**45 621**	**46 571**	**48 584**	**87**	**418**	**30 694**	**14 042**	**3 430**	**28 473**
J02AC01	fluconazole	42 967	43 936	45 311	46 203	48 136	88	410	30 458	13 881	3 387	16 851
J02AC02	itraconazole	471	635	608	576	637	75	6	414	187	30	869
J02AC03	voriconazole	80	80	88	87	85	44	<5	19	42	20	6 152
J02AC04	posaconazole	22	40	55	63	85	38	<5	32	45	5	4 602
J02AX	**Other antimycotics for systemic use**	**<5**	**5**	**6**	**7**	**5**	**100**	**0**	**<5**	**<5**	**0**	**3 416**
J02AX04	caspofungin	<5	<5	<5	<5	<5	100	0	<5	<5	0	301
J02AX05	micafungin	0	<5	<5	<5	<5	100	0	<5	<5	0	3 114
J02AX06	anidulafungin	0	<5	<5	0	0	–	0	0	0	0	0
J04	**ANTIMYCOBACTERIALS**	**1 573**	**1 645**	**1 877**	**1 980**	**2 083**	**49**	**201**	**964**	**562**	**356**	**5 926**
J04A	**DRUGS FOR TREATMENT OF TUBERCULOSIS**	**1 126**	**1 194**	**1 454**	**1 524**	**1 615**	**51**	**189**	**845**	**355**	**226**	**5 557**
J04AB	**Antibiotics**	**444**	**474**	**621**	**563**	**654**	**50**	**103**	**155**	**200**	**196**	**1 203**
J04AB02	rifampicin	422	458	608	555	643	50	103	150	198	192	1 081
J04AB04	rifabutin	24	17	14	9	11	64	0	5	<5	<5	122
J04AB30	capreomycin	0	0	<5	0	0	0	0	0	0	0	0
J04AC	**Hydrazides**	**75**	**88**	**78**	**95**	**78**	**54**	**28**	**29**	**17**	**<5**	**79**
J04AC01	isoniazid	75	88	78	95	78	54	28	29	17	<5	79
J04AK	**Other drugs for treatment of tuberculosis**	**203**	**207**	**283**	**318**	**292**	**49**	**10**	**171**	**72**	**39**	**1 261**
J04AK01	pyrazinamide	28	37	50	68	59	44	8	38	11	<5	137
J04AK02	ethambutol	198	200	268	304	274	50	6	161	68	39	880
J04AK05	bedaquiline	0	0	0	0	<5	100	0	<5	0	0	243
J04AM	**Combinations of drugs for treatment of tuberculosis**	**645**	**684**	**808**	**917**	**957**	**51**	**92**	**694**	**142**	**29**	**3 015**
J04AM02	rifampicin and isoniazid	578	619	752	856	892	51	91	649	130	22	2 462
J04AM05	rifampicin, pyrazinamide and isoniazid	138	111	180	225	178	47	<5	125	35	15	426
J04AM06	rifampicin, pyrazinamide, ethambutol and isoniazid	47	47	0	14	54	56	5	38	10	<5	127
J04B	**DRUGS FOR TREATMENT OF LEPRA**	**449**	**454**	**423**	**457**	**469**	**43**	**12**	**119**	**208**	**130**	**369**
J04BA	**Drugs for treatment of lepra**	**449**	**454**	**423**	**457**	**469**	**43**	**12**	**119**	**208**	**130**	**369**
J04BA02	dapsone	449	454	423	457	469	43	12	119	208	130	369
J05	**ANTIVIRALS FOR SYSTEMIC USE**	**31 034**	**32 722**	**34 845**	**39 342**	**39 576**	**62**	**664**	**19 630**	**14 709**	**4 573**	**657 254**

ATC group J

ATC level		2010	2011	2012	2013	2014		2014				2014
		Number of individuals					Share of women (%)	Number of individuals per age group				Sales in 1000 NOK
								<15	15–44	45–69	≥70	
J05A	**DIRECT ACTING ANTIVIRALS**	**31 034**	**32 722**	**34 845**	**39 342**	**39 576**	**62**	**664**	**19 630**	**14 709**	**4 573**	**657 254**
J05AB	**Nucleosides and nucleotides excl. reverse transcriptase inhibitors**	**24 889**	**27 463**	**30 034**	**32 041**	**34 613**	**65**	**597**	**17 189**	**12 481**	**4 346**	**51 625**
J05AB01	aciclovir	11 316	12 172	12 655	12 598	12 719	69	360	6 845	4 178	1 336	5 326
J05AB04	ribavirin	705	760	900	785	697	37	6	307	380	<5	10 417
J05AB06	ganciclovir	<5	<5	0	<5	<5	100	0	<5	<5	0	17
J05AB09	famciclovir	0	0	<5	<5	<5	25	<5	<5	<5	0	12
J05AB11	valaciclovir	13 096	14 811	16 807	18 985	21 597	64	231	10 401	7 949	3 016	18 714
J05AB14	valganciclovir	283	319	347	365	378	37	13	109	213	43	17 139
J05AD	**Phosphonic acid derivatives**	**0**	**0**	**<5**	**<5**	**<5**	**0**	**<5**	**0**	**0**	**0**	**52**
J05AD01	foscarnet	0	0	<5	<5	<5	0	<5	0	0	0	52
J05AE	**Protease inhibitors**	**860**	**1 105**	**1 557**	**1 551**	**1 506**	**38**	**6**	**749**	**718**	**33**	**91 825**
J05AE01	saquinavir	9	7	7	7	5	20	0	<5	<5	<5	234
J05AE02	indinavir	<5	<5	<5	0	0	–	0	0	0	0	0
J05AE03	ritonavir	604	720	864	963	995	41	<5	579	393	20	3 706
J05AE07	fosamprenavir	<5	<5	<5	<5	0	–	0	0	0	0	0
J05AE08	atazanavir	780	920	1 080	1 140	1 112	40	<5	603	481	26	41 151
J05AE10	darunavir	70	91	132	177	228	33	<5	103	119	5	9 927
J05AE11	telaprevir	0	16	94	85	25	28	0	13	12	0	4 142
J05AE12	boceprevir	0	76	256	161	61	43	<5	20	38	0	6 557
J05AE14	simeprevir	0	0	0	0	94	34	0	20	74	0	26 107
J05AF	**Nucleoside and nucleotide reverse transcriptase inhibitors**	**399**	**420**	**489**	**587**	**660**	**41**	**19**	**324**	**301**	**16**	**24 333**
J05AF01	zidovudine	34	35	30	36	21	52	<5	9	9	<5	100
J05AF02	didanosine	37	22	17	15	11	45	0	<5	7	0	152
J05AF04	stavudine	13	<5	0	0	0	–	0	0	0	0	0
J05AF05	lamivudine	100	93	92	100	88	42	18	19	45	6	931
J05AF06	abacavir	51	54	60	66	58	55	15	20	22	<5	1 413
J05AF07	tenofovir disoproxil	163	191	228	297	352	45	<5	205	139	7	11 984
J05AF08	adefovir dipivoxil	22	15	11	10	10	30	0	<5	7	0	544
J05AF09	emtricitabine	11	9	6	8	7	29	0	<5	6	0	149
J05AF10	entecavir	106	126	160	175	209	34	0	98	108	<5	8 939
J05AF11	telbivudine	5	<5	0	<5	<5	25	0	<5	<5	0	119
J05AG	**Non-nucleoside reverse transcriptase inhibitors**	**529**	**467**	**425**	**398**	**344**	**39**	**12**	**126**	**183**	**23**	**9 526**
J05AG01	nevirapine	191	184	176	164	156	38	<5	56	89	8	4 060

ATC level		2010	2011	2012	2013	2014		2014				2014
		Number of individuals					Share of women (%)	Number of individuals per age group				Sales in 1000 NOK
								<15	15–44	45–69	≥70	
J05AG03	efavirenz	321	258	221	192	147	42	11	54	68	14	3 771
J05AG04	etravirine	23	28	28	35	31	32	0	9	21	<5	1 260
J05AG05	rilpivirine	0	0	<5	12	15	33	0	8	7	0	435
J05AH	**Neuraminidase inhibitors**	**3 860**	**2 646**	**1 808**	**3 993**	**1 094**	**52**	**43**	**495**	**420**	**136**	**274**
J05AH01	zanamivir	35	36	34	85	18	56	0	9	8	<5	5
J05AH02	oseltamivir	3 829	2 612	1 776	3 911	1 076	52	43	486	412	135	269
J05AR	**Antivirals for treatment of HIV infections, combinations**	**2 184**	**2 445**	**2 775**	**3 043**	**3 349**	**35**	**16**	**1 687**	**1 563**	**83**	**229 283**
J05AR01	zidovudine and lamivudine	514	421	350	249	179	43	0	75	93	11	5 674
J05AR02	lamivudine and abacavir	279	290	335	376	419	29	7	156	237	19	16 935
J05AR03	tenofovir disoproxil and emtricitabine	1 065	1 230	1 433	1 526	1 583	41	<5	880	666	36	74 584
J05AR04	zidovudine, lamivudine and abacavir	35	31	23	17	12	67	0	<5	8	<5	701
J05AR06	emtricitabine, tenofovir disoproxil and efavirenz	514	650	767	792	785	28	<5	371	397	15	65 002
J05AR08	emtricitabine, tenofovir disoproxil and rilpivirine	0	0	143	339	512	29	0	283	223	6	42 830
J05AR09	emtricitabine, tenofovir disoproxil, elvitegravir and cobicistat	0	0	0	33	133	29	<5	69	62	<5	10 904
J05AR10	lopinavir and ritonavir	551	510	480	401	298	53	7	169	117	5	9 606
J05AR13	lamivudine, abacavir and dolutegravir	0	0	0	0	91	11	0	30	60	<5	3 047
J05AX	**Other antivirals**	**179**	**271**	**325**	**379**	**1 042**	**36**	**6**	**394**	**627**	**15**	**250 335**
J05AX05	inosine pranobex	31	81	61	45	40	65	<5	26	12	0	140
J05AX08	raltegravir	148	190	264	333	469	36	<5	214	240	11	24 360
J05AX09	maraviroc	7	7	7	8	8	25	0	<5	6	0	678
J05AX12	dolutegravir	0	0	0	0	101	28	0	48	51	<5	3 368
J05AX14	daclatasvir	0	0	0	0	32	31	0	6	26	0	6 949
J05AX15	sofosbuvir	0	0	0	0	450	36	0	110	337	<5	214 840

3.12 ATC group L – Antineoplastic and immunomodulating agents

ATC level		2010	2011	2012	2013	2014		2014				2014
		Number of individuals					Share of women (%)	Number of individuals per age group				Sales in 1000 NOK
								<15	15–44	45–69	≥70	
L	**ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS**	**76 656**	**81 612**	**86 336**	**90 729**	**95 223**	**54**	**1 348**	**20 633**	**45 350**	**27 892**	**3 077 838**
L02	**ENDOCRINE THERAPY**	**24 886**	**25 999**	**26 144**	**26 900**	**26 982**	**52**	**151**	**2 899**	**9 459**	**14 473**	**389 119**
L02A	**HORMONES AND RELATED AGENTS**	**11 009**	**11 761**	**11 175**	**11 171**	**10 472**	**18**	**148**	**1 380**	**1 895**	**7 049**	**90 131**
L02AA	**Estrogens**	**17**	**7**	**<5**	**<5**	**0**	**–**	**0**	**0**	**0**	**0**	**0**
L02AA02	polyestradiol phosphate	17	7	<5	<5	0	–	0	0	0	0	0
L02AB	**Progestogens**	**178**	**202**	**166**	**154**	**142**	**87**	**0**	**<5**	**60**	**78**	**314**
L02AB01	megestrol	178	202	166	154	142	87	0	<5	60	78	314
L02AE	**Gonadotropin releasing hormone analogues**	**10 827**	**11 558**	**11 011**	**11 019**	**10 335**	**17**	**148**	**1 377**	**1 836**	**6 974**	**89 817**
L02AE01	buserelin	1 474	1 898	1 313	1 355	721	100	0	701	20	0	1 122
L02AE02	leuprorelin	3 891	4 012	3 957	3 736	3 480	19	148	428	451	2 453	30 159
L02AE03	goserelin	5 619	5 783	5 861	6 028	6 219	7	0	250	1 388	4 581	58 400
L02AE04	triptorelin	<5	12	13	13	22	100	0	16	6	0	68
L02AE05	histrelin	0	12	20	20	6	0	0	0	0	6	68
L02B	**HORMONE ANTAGONISTS AND RELATED AGENTS**	**17 127**	**17 878**	**18 866**	**19 816**	**20 712**	**60**	**<5**	**1 565**	**8 626**	**10 517**	**298 988**
L02BA	**Anti-estrogens**	**4 109**	**3 861**	**3 999**	**4 250**	**4 418**	**97**	**<5**	**764**	**2 708**	**943**	**12 862**
L02BA01	tamoxifen	3 893	3 597	3 766	4 036	4 182	96	<5	758	2 579	842	4 118
L02BA03	fulvestrant	242	296	267	246	263	99	0	6	144	113	8 745
L02BB	**Anti-androgens**	**6 641**	**7 008**	**6 983**	**6 964**	**7 077**	**0**	**0**	**<5**	**1 429**	**5 647**	**89 136**
L02BB01	flutamide	305	253	248	202	136	1	0	<5	10	125	697
L02BB03	bicalutamide	6 362	6 775	6 765	6 720	6 479	0	0	0	1 289	5 190	27 890
L02BB04	enzalutamide	0	0	0	85	517	0	0	0	144	373	60 549
L02BG	**Aromatase inhibitors**	**7 219**	**7 378**	**7 777**	**8 322**	**8 906**	**98**	**<5**	**820**	**4 643**	**3 442**	**31 226**
L02BG03	anastrozole	2 901	2 331	1 857	1 537	1 281	88	0	110	640	531	4 911
L02BG04	letrozole	3 478	4 365	5 300	6 155	7 001	99	<5	701	3 656	2 643	22 753
L02BG06	exemestane	1 108	929	809	901	911	99	0	17	514	380	3 561
L02BX	**Other hormone antagonists and related agents**	**89**	**377**	**836**	**1 182**	**1 380**	**1**	**0**	**<5**	**379**	**999**	**165 764**
L02BX02	degarelix	89	271	380	487	642	1	0	<5	207	433	6 892
L02BX03	abiraterone	0	107	484	762	804	0	0	0	201	603	158 873
L03	**IMMUNOSTIMULANTS**	**5 883**	**6 294**	**6 765**	**6 747**	**6 492**	**61**	**46**	**1 901**	**3 781**	**764**	**277 017**
L03A	**IMMUNOSTIMULANTS**	**5 883**	**6 294**	**6 765**	**6 747**	**6 492**	**61**	**46**	**1 901**	**3 781**	**764**	**277 017**
L03AA	**Colony stimulating factors**	**2 222**	**2 426**	**2 691**	**2 831**	**3 314**	**61**	**32**	**502**	**2 085**	**695**	**105 139**
L03AA02	filgrastim	415	587	599	623	612	42	30	121	348	113	9 764
L03AA13	pegfilgrastim	1 919	1 958	2 218	2 353	2 734	65	<5	402	1 750	580	93 078

ATC level		2010	2011	2012	2013	2014		2014				2014
		Number of individuals					Share of women (%)	Number of individuals per age group				Sales in 1000 NOK
								<15	15–44	45–69	≥70	
L03AA14	lipegfilgrastim	0	0	0	0	109	59	0	19	67	23	2 297
L03AB	**Interferons**	**2 649**	**2 756**	**2 891**	**2 722**	**2 154**	**57**	**14**	**963**	**1 122**	**55**	**108 002**
L03AB01	interferon alfa natural	11	20	20	14	8	50	0	6	<5	0	1 261
L03AB03	interferon gamma	9	9	10	10	11	73	<5	8	0	<5	1 406
L03AB04	interferon alfa-2a	19	19	23	25	19	53	0	<5	9	8	874
L03AB05	interferon alfa-2b	74	63	49	40	47	34	0	6	27	14	1 179
L03AB07	interferon beta-1a	1 217	1 183	1 178	1 159	872	69	6	364	497	5	65 038
L03AB08	interferon beta-1b	533	637	652	611	490	66	0	242	244	<5	17 386
L03AB10	peginterferon alfa-2b	310	273	337	260	171	37	6	74	83	8	5 633
L03AB11	peginterferon alfa-2a	503	594	687	651	553	38	0	268	270	15	15 146
L03AB13	peginterferon beta-1a	0	0	0	0	<5	50	0	<5	<5	0	80
L03AC	**Interleukins**	**0**	**<5**	**0**	**0**	**0**	**–**	**0**	**0**	**0**	**0**	**0**
L03AC01	aldesleukin	0	<5	0	0	0	–	0	0	0	0	0
L03AX	**Other immunostimulants**	**1 148**	**1 266**	**1 358**	**1 322**	**1 060**	**71**	**0**	**448**	**597**	**15**	**63 876**
L03AX03	BCG vaccine	13	12	10	12	13	15	0	0	6	7	97
L03AX13	glatiramer acetate	1 135	1 254	1 348	1 310	1 047	72	0	448	591	8	63 778
L04	**IMMUNOSUPPRESSANTS**	**39 932**	**42 913**	**46 379**	**49 521**	**53 451**	**55**	**989**	**15 005**	**27 769**	**9 688**	**1 923 421**
L04A	**IMMUNOSUPPRESSANTS**	**39 932**	**42 913**	**46 379**	**49 521**	**53 451**	**55**	**989**	**15 005**	**27 769**	**9 688**	**1 923 421**
L04AA	**Selective immunosuppressants**	**4 910**	**5 466**	**6 255**	**7 280**	**8 531**	**52**	**90**	**2 286**	**4 833**	**1 322**	**353 306**
L04AA06	mycophenolic acid	3 266	3 591	3 926	4 207	4 427	38	79	1 050	2 564	734	39 981
L04AA10	sirolimus	101	130	150	189	215	36	5	30	155	25	6 403
L04AA13	leflunomide	1 458	1 539	1 662	1 785	2 006	69	0	235	1 265	506	10 992
L04AA18	everolimus	294	336	402	449	474	30	9	61	278	126	29 629
L04AA23	natalizumab	49	0	0	0	0	–	0	0	0	0	0
L04AA24	abatacept	<5	0	0	72	144	78	0	23	87	34	8 263
L04AA25	eculizumab	<5	5	8	10	11	55	<5	5	<5	<5	33 955
L04AA27	fingolimod	0	186	487	896	1 111	71	0	639	471	<5	175 923
L04AA31	teriflunomide	0	0	0	140	638	71	0	319	316	<5	48 046
L04AA33	vedolizumab	0	0	0	0	<5	50	0	<5	0	0	113
L04AB	**Tumor necrosis factor alpha (TNF-) inhibitors**	**9 649**	**11 057**	**12 629**	**13 980**	**15 156**	**53**	**207**	**5 640**	**7 960**	**1 349**	**1 236 979**
L04AB01	etanercept	5 078	6 122	6 948	6 521	5 970	54	123	1 812	3 347	688	492 348
L04AB02	infliximab	<5	0	0	<5	0	–	0	0	0	0	0
L04AB04	adalimumab	3 993	4 121	4 589	4 962	5 078	49	87	2 305	2 347	339	473 168
L04AB05	certolizumab pegol	135	314	606	1 232	3 021	61	0	1 071	1 676	274	114 024
L04AB06	golimumab	1 038	1 208	1 219	2 145	2 086	49	<5	861	1 115	108	157 439

ATC group L

ATC level		2010	2011	2012	2013	2014		2014				2014
		Number of individuals					Share of women (%)	Number of individuals per age group				Sales in 1000 NOK
								<15	15–44	45–69	≥70	
L04AC	**Interleukin inhibitors**	**127**	**180**	**293**	**436**	**821**	**48**	**17**	**307**	**442**	**55**	**74 821**
L04AC03	anakinra	75	85	121	125	148	47	13	55	63	17	9 481
L04AC05	ustekinumab	50	92	166	304	555	43	<5	218	313	23	52 001
L04AC07	tocilizumab	0	0	0	<5	113	78	0	31	67	15	2 587
L04AC08	canakinumab	<5	6	7	6	11	27	7	<5	<5	0	10 752
L04AD	**Calcineurin inhibitors**	**4 799**	**5 027**	**5 288**	**5 524**	**5 733**	**39**	**170**	**1 532**	**3 164**	**867**	**119 797**
L04AD01	ciclosporin	3 307	3 332	3 274	3 199	3 155	38	78	724	1 735	618	58 688
L04AD02	tacrolimus	1 570	1 770	2 092	2 381	2 645	39	97	828	1 464	256	61 109
L04AX	**Other immunosuppressants**	**28 382**	**29 767**	**31 228**	**32 173**	**33 663**	**58**	**684**	**8 069**	**17 371**	**7 539**	**138 518**
L04AX01	azathioprine	6 390	6 714	7 087	7 362	7 653	52	252	3 515	3 156	730	6 981
L04AX02	thalidomide	348	320	330	295	246	51	<5	8	65	172	7 731
L04AX03	methotrexate	21 622	22 692	23 702	24 355	25 501	60	432	4 580	14 016	6 473	11 649
L04AX04	lenalidomide	157	171	236	257	308	45	0	5	145	158	71 973
L04AX05	pirfenidone	0	0	21	50	58	26	0	0	35	23	12 313
L04AX06	pomalidomide	0	0	0	0	74	46	0	0	51	23	27 871

3.13 ATC group M – Musculo-skeletal system

ATC level		2010	2011	2012	2013	2014	Share of women (%)	2014				2014
		Number of individuals						Number of individuals per age group				Sales in 1000 NOK
								<15	15–44	45–69	≥70	
M	**MUSCULO-SKELETAL SYSTEM**	**901 910**	**927 355**	**937 937**	**925 319**	**928 041**	**57**	**14 840**	**324 466**	**430 134**	**158 601**	**366 238**
M01	**ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS**	**824 208**	**833 848**	**838 542**	**821 122**	**817 632**	**57**	**12 827**	**313 761**	**389 381**	**101 663**	**226 135**
M01A	**ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS**	**824 121**	**833 776**	**838 491**	**821 087**	**817 607**	**57**	**12 827**	**313 756**	**389 375**	**101 649**	**225 763**
M01AB	**Acetic acid derivatives and related substances**	**505 424**	**508 808**	**485 786**	**439 563**	**391 804**	**54**	**6 095**	**166 562**	**182 687**	**36 460**	**52 423**
M01AB01	indometacin	2 710	1 116	1 153	1 129	1 160	61	20	447	576	117	946
M01AB02	sulindac	16	0	0	0	0	–	0	0	0	0	0
M01AB05	diclofenac[1)]	481 108	483 169	461 621	417 775	372 017	54	6 053	162 300	171 931	31 733	42 234
M01AB15	ketorolac	27	23	9	12	27	48	0	12	11	<5	7
M01AB55	diclofenac, combinations	29 244	31 576	29 001	25 182	22 218	62	27	4 841	12 235	5 115	9 236
M01AC	**Oxicams**	**76 309**	**69 293**	**59 451**	**52 902**	**48 214**	**54**	**207**	**15 518**	**25 916**	**6 573**	**12 377**
M01AC01	piroxicam	51 627	47 991	43 612	39 641	36 959	51	183	13 176	19 848	3 752	9 176
M01AC06	meloxicam	25 438	21 952	16 207	13 527	11 450	61	25	2 401	6 174	2 850	3 202
M01AE	**Propionic acid derivatives**	**276 001**	**294 401**	**332 774**	**343 199**	**373 510**	**60**	**6 692**	**141 385**	**178 950**	**46 483**	**91 804**
M01AE01	ibuprofen[1)]	215 745	226 838	225 258	217 264	223 845	61	5 498	93 190	103 085	22 072	32 847
M01AE02	naproxen[1)]	58 354	62 549	65 207	72 012	86 234	57	1 156	32 114	40 459	12 505	23 633
M01AE03	ketoprofen	7 478	7 396	6 735	5 438	4 973	59	21	1 044	2 840	1 068	2 407
M01AE14	dexibuprofen	1 025	881	707	637	540	58	<5	238	223	78	138
M01AE17	dexketoprofen	0	0	0	<5	11	64	0	9	<5	0	2
M01AE52	naproxen and esomeprazole	0	5 217	50 859	64 416	77 494	63	103	21 723	42 756	12 912	32 777
M01AG	**Fenamates**	**106**	**304**	**309**	**337**	**367**	**83**	**0**	**218**	**143**	**6**	**309**
M01AG02	tolfenamic acid	106	304	309	337	367	83	0	218	143	6	309
M01AH	**Coxibs**	**35 999**	**36 515**	**43 619**	**72 688**	**92 038**	**56**	**135**	**28 686**	**48 794**	**14 423**	**52 086**
M01AH01	celecoxib	7 851	7 720	9 983	16 437	15 177	61	29	3 965	8 022	3 161	12 236
M01AH04	parecoxib	0	0	<5	<5	<5	100	0	<5	0	0	2
M01AH05	etoricoxib	28 365	29 013	34 034	57 270	77 833	55	106	24 974	41 319	11 434	39 849
M01AX	**Other antiinflammatory and antirheumatic agents, non-steroids**	**48 137**	**41 749**	**37 374**	**34 782**	**32 644**	**66**	**12**	**2 113**	**17 898**	**12 621**	**16 763**
M01AX01	nabumetone	7 343	6 378	4 799	3 773	3 180	65	<5	613	1 738	827	1 654
M01AX05	glucosamine[1)]	40 410	34 884	31 959	30 393	28 805	66	10	1 445	15 833	11 517	13 729
M01C	**SPECIFIC ANTIRHEUMATIC AGENTS**	**242**	**208**	**133**	**99**	**77**	**75**	**0**	**10**	**41**	**26**	**371**
M01CB	**Gold preparations**	**199**	**171**	**100**	**71**	**61**	**87**	**0**	**7**	**35**	**19**	**251**
M01CB01	sodium aurothiomalate	36	30	26	19	17	59	0	<5	6	9	61

[1)] The ATC level comprises OTC medicinal products. The number of individuals is registered for prescription sales only.

ATC group M

ATC level		2010	2011	2012	2013	2014		2014				2014
		Number of individuals					Share of women (%)	Number of individuals per age group				Sales in 1000 NOK
								<15	15–44	45–69	≥70	
M01CB03	auranofin	163	141	74	52	44	98	0	5	29	10	191
M01CC	**Penicillamine and similar agents**	**14**	**13**	**12**	**12**	**9**	**22**	**0**	**<5**	**5**	**<5**	**40**
M01CC01	penicillamine	14	13	12	12	9	22	0	<5	5	<5	40
M01CX	**Other specific antirheumatic agents**	**30**	**24**	**21**	**16**	**7**	**43**	**0**	**0**	**<5**	**6**	**80**
M02	**TOPICAL PRODUCTS FOR JOINT AND MUSCULAR PAIN**	**24 394**	**53 477**	**59 206**	**60 159**	**64 489**	**60**	**2 428**	**19 801**	**26 926**	**15 334**	**7 980**
M02A	**TOPICAL PRODUCTS FOR JOINT AND MUSCULAR PAIN**	**24 394**	**53 477**	**59 206**	**60 157**	**64 482**	**60**	**2 428**	**19 799**	**26 925**	**15 330**	**7 979**
M02AA	**Antiinflammatory preparations, non-steroids for topical use**	**24 200**	**53 269**	**59 087**	**60 050**	**64 414**	**60**	**2 426**	**19 773**	**26 908**	**15 307**	**7 949**
M02AA10	ketoprofen	20 122	47 409	51 291	51 649	51 377	60	1 866	15 810	21 797	11 904	5 028
M02AA13	ibuprofen[1)]	3 998	4 923	5 837	5 818	5 795	60	339	1 714	2 064	1 678	1 029
M02AA15	diclofenac[1)]	167	1 322	2 402	2 890	7 763	58	224	2 372	3 243	1 924	1 893
M02AB	**Capsaicin and similar agents**	**6**	**6**	**8**	**5**	**<5**	**50**	**0**	**<5**	**<5**	**0**	**20**
M02AB01	capsaicin	6	6	8	5	<5	50	0	<5	<5	0	20
M02AC	**Preparations with salicylic acid derivatives**	**189**	**207**	**124**	**119**	**73**	**64**	**<5**	**26**	**20**	**25**	**9**
M02AX	**Other topical products for joint and muscular pain**	**13**	**9**	**5**	**8**	**5**	**60**	**0**	**<5**	**<5**	**<5**	**1**
M02AX10	various	13	9	5	8	5	60	0	<5	<5	<5	1
M03	**MUSCLE RELAXANTS**	**5 918**	**6 009**	**5 939**	**6 104**	**6 870**	**59**	**119**	**1 968**	**3 869**	**914**	**19 828**
M03B	**MUSCLE RELAXANTS, CENTRALLY ACTING AGENTS**	**5 657**	**5 654**	**5 586**	**5 630**	**5 779**	**54**	**118**	**1 395**	**3 385**	**881**	**9 684**
M03BA	**Carbamic acid esters**	**1 097**	**1 030**	**911**	**745**	**635**	**68**	**0**	**130**	**446**	**59**	**1 716**
M03BA02	carisoprodol	1 097	1 030	911	745	635	68	0	130	446	59	1 716
M03BB	**Oxazol, thiazine, and triazine derivatives**	**0**	**<5**	**0**	**<5**	**20**	**30**	**0**	**6**	**10**	**<5**	**20**
M03BB03	chlorzoxazone	0	<5	0	<5	20	30	0	6	10	<5	20
M03BC	**Ethers, chemically close to antihistamines**	**<5**	**0**	**0**	**0**	**0**	**–**	**0**	**0**	**0**	**0**	**0**
M03BC51	orphenadrine, combinations	<5	0	0	0	0	–	0	0	0	0	0
M03BX	**Other centrally acting agents**	**4 583**	**4 652**	**4 696**	**4 901**	**5 146**	**52**	**118**	**1 263**	**2 946**	**819**	**7 948**
M03BX01	baclofen	4 544	4 608	4 650	4 850	5 081	52	118	1 241	2 909	813	7 584
M03BX02	tizanidine	59	71	75	78	90	40	0	27	56	7	364
M03C	**MUSCLE RELAXANTS, DIRECTLY ACTING AGENTS**	**0**	**<5**	**0**	**0**	**0**	**–**	**0**	**0**	**0**	**0**	**0**

[1)] The ATC level comprises OTC medicinal products. The number of individuals is registered for prescription sales only.

ATC level		2010	2011	2012	2013	2014		2014				2014
		Number of individuals					Share of women (%)	Number of individuals per age group				Sales in 1000 NOK
								<15	15–44	45–69	≥70	
M03CA	**Dantrolene and derivatives**	**0**	**<5**	**0**	**0**	**0**	**–**	**0**	**0**	**0**	**0**	**0**
M03CA01	dantrolene	0	<5	0	0	0	–	0	0	0	0	0
M04	**ANTIGOUT PREPARATIONS**	**40 882**	**43 057**	**45 482**	**47 763**	**50 830**	**28**	**21**	**3 248**	**21 704**	**25 857**	**26 094**
M04A	**ANTIGOUT PREPARATIONS**	**40 882**	**43 057**	**45 482**	**47 763**	**50 830**	**28**	**21**	**3 248**	**21 704**	**25 857**	**26 094**
M04AA	**Preparations inhibiting uric acid production**	**37 670**	**39 470**	**41 688**	**43 558**	**46 068**	**28**	**8**	**2 730**	**19 631**	**23 699**	**20 575**
M04AA01	allopurinol	37 661	39 441	41 625	43 473	45 940	28	8	2 717	19 573	23 642	16 375
M04AA03	febuxostat	9	33	75	105	147	23	0	16	66	65	4 200
M04AB	**Preparations increasing uric acid excretion**	**2 062**	**2 072**	**2 041**	**1 970**	**1 942**	**31**	**<5**	**129**	**847**	**964**	**2 661**
M04AB01	probenecid	2 062	2 072	2 041	1 970	1 942	31	<5	129	847	964	2 661
M04AC	**Preparations with no effect on uric acid metabolism**	**3 070**	**3 688**	**4 213**	**5 085**	**6 206**	**22**	**11**	**692**	**2 821**	**2 682**	**2 858**
M04AC01	colchicine	3 070	3 688	4 213	5 085	6 206	22	11	692	2 821	2 682	2 858
M05	**DRUGS FOR TREATMENT OF BONE DISEASES**	**57 597**	**58 371**	**59 962**	**61 037**	**61 693**	**87**	**<5**	**744**	**23 016**	**37 929**	**85 716**
M05B	**DRUGS AFFECTING BONE STRUCTURE AND MINERALIZATION**	**57 597**	**58 371**	**59 962**	**61 037**	**61 693**	**87**	**<5**	**744**	**23 016**	**37 929**	**85 716**
M05BA	**Bisphosphonates**	**55 785**	**56 550**	**57 193**	**58 056**	**57 775**	**88**	**<5**	**685**	**21 976**	**35 110**	**47 702**
M05BA01	etidronic acid	240	205	151	22	0	–	0	0	0	0	0
M05BA02	clodronic acid	48	48	41	34	13	69	0	0	5	8	227
M05BA03	pamidronic acid	21	19	16	18	16	63	0	0	7	9	95
M05BA04	alendronic acid	52 702	52 893	53 133	53 858	53 147	87	<5	574	19 720	32 849	32 030
M05BA06	ibandronic acid	696	668	653	664	658	93	0	5	286	367	2 025
M05BA07	risedronic acid	1 097	948	832	639	481	93	0	5	161	315	1 267
M05BA08	zoledronic acid	1 584	2 329	2 908	3 378	3 967	89	0	113	2 082	1 772	12 057
M05BB	**Bisphosphonates, combinations**	**1 950**	**1 659**	**1 434**	**668**	**<5**	**100**	**0**	**0**	**0**	**<5**	**2**
M05BB01	etidronic acid and calcium, sequential	1 950	1 659	1 434	668	<5	100	0	0	0	<5	2
M05BX	**Other drugs affecting bone structure and mineralization**	**27**	**398**	**1 851**	**3 212**	**4 412**	**82**	**0**	**60**	**1 126**	**3 226**	**38 011**
M05BX04	denosumab	27	398	1 851	3 212	4 412	82	0	60	1 126	3 226	38 011
M09	**OTHER DRUGS FOR DISORDERS OF THE MUSCULOSKELETAL SYSTEM**	**0**	**0**	**31**	**76**	**40**	**5**	**0**	**<5**	**28**	**10**	**485**
M09A	**OTHER DRUGS FOR DISORDERS OF THE MUSCULOSKELETAL SYSTEM**	**0**	**0**	**31**	**76**	**40**	**5**	**0**	**<5**	**28**	**10**	**485**
M09AB	**Enzymes**	**0**	**0**	**31**	**76**	**40**	**5**	**0**	**<5**	**28**	**10**	**485**
M09AB02	collagenase clostridium histolyticum	0	0	31	76	40	5	0	<5	28	10	485

3.14 ATC group N – Nervous system

ATC level		2010	2011	2012	2013	2014		2014				2014
		Number of individuals					Share of women (%)	Number of individuals per age group				Sales in 1000 NOK
								<15	15–44	45–69	≥70	
N	**NERVOUS SYSTEM**	**1 248 505**	**1 279 676**	**1 304 345**	**1 327 510**	**1 352 454**	**59**	**29 691**	**428 315**	**590 539**	**303 909**	**2 824 945**
N02	**ANALGESICS**	**710 536**	**739 147**	**766 791**	**790 759**	**817 528**	**61**	**8 135**	**259 986**	**366 736**	**182 671**	**692 759**
N02A	**OPIOIDS**	**491 941**	**500 644**	**514 434**	**528 298**	**537 365**	**56**	**2 717**	**176 156**	**241 617**	**116 875**	**407 288**
N02AA	**Natural opium alkaloids**	**401 941**	**403 516**	**404 550**	**404 507**	**397 218**	**56**	**2 405**	**135 730**	**177 847**	**81 236**	**239 377**
N02AA01	morphine	7 000	6 790	6 820	6 852	7 042	49	24	889	3 335	2 794	15 192
N02AA03	hydromorphone	40	48	68	95	130	48	0	21	80	29	10 096
N02AA05	oxycodone	19 067	20 444	22 975	26 884	30 554	54	19	5 076	13 978	11 481	55 095
N02AA08	dihydrocodeine	47	52	47	53	45	80	0	12	30	<5	282
N02AA55	oxycodone, combinations	1 001	1 831	2 874	4 069	5 033	58	<5	506	2 054	2 470	15 386
N02AA59	codeine, combinations excl. psycholeptics	387 507	387 930	387 038	383 925	373 320	56	2 371	132 443	167 317	71 189	143 326
N02AB	**Phenylpiperidine derivatives**	**11 167**	**11 306**	**11 506**	**12 148**	**12 588**	**59**	**9**	**2 106**	**5 314**	**5 159**	**45 356**
N02AB01	ketobemidone	3 994	3 972	3 993	4 143	4 339	54	<5	1 261	2 152	922	4 810
N02AB02	pethidine	1 343	1 243	1 201	1 281	1 230	63	<5	368	685	175	2 651
N02AB03	fentanyl	6 331	6 583	6 785	7 173	7 488	62	<5	592	2 720	4 173	37 895
N02AC	**Diphenylpropylamine derivatives**	**4 700**	**30**	**15**	**12**	**7**	**71**	**0**	**<5**	**<5**	**<5**	**26**
N02AC04	dextropropoxyphene	0	9	15	12	7	71	0	<5	<5	<5	26
N02AC54	dextropropoxyphene, combinations excl. psycholeptics	4 700	22	0	0	0	–	0	0	0	0	0
N02AD	**Benzomorphan derivatives**	**41**	**35**	**30**	**24**	**24**	**42**	**0**	**<5**	**15**	**7**	**324**
N02AD01	pentazocine	41	35	30	24	24	42	0	<5	15	7	324
N02AE	**Oripavine derivatives**	**13 189**	**14 009**	**15 272**	**15 863**	**16 725**	**72**	**5**	**1 291**	**4 483**	**10 946**	**52 564**
N02AE01	buprenorphine	13 189	14 009	15 272	15 863	16 725	72	5	1 291	4 483	10 946	52 564
N02AG	**Opioids in combination with antispasmodics**	**1 840**	**1 776**	**1 959**	**1 895**	**1 808**	**59**	**0**	**536**	**937**	**335**	**1 827**
N02AG01	morphine and antispasmodics	263	310	384	314	133	54	0	<5	24	107	24
N02AG02	ketobemidone and antispasmodics	1 584	1 470	1 577	1 586	1 678	59	0	534	913	231	1 803
N02AX	**Other opioids**	**127 986**	**138 495**	**155 617**	**172 547**	**193 009**	**58**	**342**	**57 762**	**89 852**	**45 053**	**67 814**
N02AX02	tramadol	127 986	138 478	155 326	172 161	187 091	58	324	55 683	87 141	43 943	62 611
N02AX06	tapentadol	0	31	495	615	851	59	0	197	448	206	3 715
N02AX52	tramadol, combinations	0	0	0	0	6 827	64	20	2 419	3 100	1 288	1 489
N02B	**OTHER ANALGESICS AND ANTIPYRETICS**	**305 897**	**337 952**	**363 609**	**386 155**	**416 625**	**64**	**3 887**	**97 262**	**188 920**	**126 556**	**94 803**
N02BA	**Salicylic acid and derivatives**	**840**	**883**	**797**	**938**	**1 008**	**58**	**265**	**350**	**262**	**131**	**312**
N02BA01	acetylsalicylic acid[1)]	836	879	791	931	1 003	58	265	349	260	129	285

[1)] The ATC level comprises OTC medicinal products. The number of individuals is registered for prescription sales only.

ATC level		2010	2011	2012	2013	2014		2014				2014
		Number of individuals					Share of women (%)	Number of individuals per age group				Sales in 1000 NOK
								<15	15–44	45–69	≥70	
N02BA11	diflunisal	<5	<5	<5	<5	<5	100	0	0	0	<5	9
N02BA51	acetylsalicylic acid, combinations excl. psycholeptics	<5	<5	<5	<5	<5	50	0	<5	<5	<5	18
N02BB	**Pyrazolones**	**887**	**891**	**970**	**1 051**	**1 030**	**66**	**10**	**493**	**348**	**179**	**307**
N02BB02	metamizole sodium	12	5	13	18	41	68	<5	8	20	12	39
N02BB51	phenazone, combinations excl. psycholeptics	875	886	957	1 033	989	66	9	485	328	167	268
N02BE	**Anilides**	**304 673**	**336 641**	**362 291**	**384 456**	**414 889**	**64**	**3 615**	**96 538**	**188 366**	**126 370**	**86 534**
N02BE01	paracetamol[1)]	304 673	336 641	362 291	384 388	414 747	64	3 612	96 470	188 307	126 358	86 488
N02BE51	paracetamol, combinations excl. psycholeptics[1)]	0	0	0	134	241	70	<5	91	102	45	45
N02BG	**Other analgesics and antipyretics**	**0**	**<5**	**68**	**404**	**366**	**52**	**<5**	**100**	**240**	**24**	**7 650**
N02BG07	flupirtine	0	0	<5	<5	<5	100	0	0	<5	0	1
N02BG08	ziconotide	0	<5	0	0	0	–	0	0	0	0	0
N02BG10	cannabinoids	0	<5	67	402	365	52	<5	100	239	24	7 649
N02C	**ANTIMIGRAINE PREPARATIONS**	**88 921**	**91 693**	**94 417**	**97 251**	**101 242**	**80**	**2 181**	**48 045**	**46 962**	**4 054**	**190 668**
N02CA	**Ergot alkaloids**	**3 072**	**2 918**	**2 496**	**877**	**443**	**84**	**0**	**60**	**260**	**123**	**496**
N02CA04	methysergide	6	9	7	<5	0	–	0	0	0	0	0
N02CA52	ergotamine, combinations excl. psycholeptics	15	15	12	21	8	75	0	<5	<5	<5	14
N02CA72	ergotamine, combinations with psycholeptics	3 053	2 895	2 477	856	435	84	0	58	257	120	482
N02CC	**Selective serotonin ($5HT_1$) agonists**	**83 476**	**85 970**	**89 144**	**93 214**	**97 122**	**80**	**2 108**	**47 066**	**44 320**	**3 628**	**187 418**
N02CC01	sumatriptan	41 843	43 349	45 284	47 946	50 689	78	1 829	26 929	20 167	1 764	79 971
N02CC02	naratriptan	1 501	1 581	1 651	1 707	1 941	87	<5	899	959	79	5 497
N02CC03	zolmitriptan	14 230	14 481	14 789	15 150	15 845	82	168	7 066	7 974	637	30 257
N02CC04	rizatriptan	22 398	23 373	24 259	25 269	26 831	82	273	13 418	12 233	907	27 235
N02CC05	almotriptan	3 053	2 936	2 939	2 988	3 058	84	7	1 490	1 464	97	6 319
N02CC06	eletriptan	11 289	11 403	11 471	11 735	11 874	83	35	5 106	6 384	349	38 126
N02CC07	frovatriptan	6	5	7	8	18	94	0	9	8	<5	12
N02CX	**Other antimigraine preparations**	**3 418**	**3 920**	**3 949**	**4 271**	**4 523**	**79**	**79**	**1 195**	**2 914**	**335**	**2 754**
N02CX01	pizotifen	61	60	78	72	62	85	0	21	32	9	194
N02CX02	clonidine	3 357	3 861	3 874	4 199	4 462	79	79	1 174	2 883	326	2 560
N03	**ANTIEPILEPTICS**	**103 954**	**108 555**	**113 451**	**116 903**	**118 788**	**56**	**3 516**	**36 075**	**55 839**	**23 358**	**406 071**
N03A	**ANTIEPILEPTICS**	**103 954**	**108 555**	**113 451**	**116 903**	**118 788**	**56**	**3 516**	**36 075**	**55 839**	**23 358**	**406 071**

[1)] The ATC level comprises OTC medicinal products. The number of individuals is registered for prescription sales only.

ATC group N

ATC level		2010	2011	2012	2013	2014	Share of women (%)	2014				2014
		Number of individuals						Number of individuals per age group				Sales in 1000 NOK
								<15	15–44	45–69	≥70	
N03AA	**Barbiturates and derivatives**	**2 700**	**2 544**	**2 430**	**2 361**	**2 236**	**52**	**42**	**216**	**1 194**	**784**	**1 908**
N03AA02	phenobarbital	2 426	2 270	2 149	2 064	1 915	52	41	180	1 041	653	1 375
N03AA03	primidone	288	287	293	309	332	48	<5	36	157	138	533
N03AB	**Hydantoin derivatives**	**2 051**	**1 938**	**1 798**	**1 704**	**1 541**	**42**	**13**	**153**	**849**	**526**	**1 214**
N03AB02	phenytoin	2 051	1 937	1 798	1 704	1 541	42	13	153	849	526	1 210
N03AB05	fosphenytoin	0	<5	0	0	<5	0	0	0	0	<5	4
N03AD	**Succinimide derivatives**	**149**	**173**	**183**	**206**	**227**	**63**	**116**	**84**	**24**	**<5**	**2 109**
N03AD01	ethosuximide	149	173	183	206	227	63	116	84	24	<5	2 109
N03AE	**Benzodiazepine derivatives**	**13 528**	**13 006**	**12 558**	**11 748**	**10 909**	**55**	**131**	**2 727**	**5 752**	**2 299**	**5 344**
N03AE01	clonazepam	13 528	13 006	12 558	11 748	10 909	55	131	2 727	5 752	2 299	5 344
N03AF	**Carboxamide derivatives**	**19 238**	**18 449**	**17 652**	**16 961**	**16 206**	**47**	**717**	**4 235**	**8 147**	**3 107**	**33 528**
N03AF01	carbamazepine	16 830	15 931	15 023	14 205	13 395	47	224	3 159	7 211	2 801	13 069
N03AF02	oxcarbazepine	2 298	2 375	2 426	2 526	2 520	45	485	888	847	300	10 314
N03AF03	rufinamide	96	97	99	100	98	32	22	66	9	<5	2 178
N03AF04	eslicarbazepine	205	213	233	294	332	52	<5	182	126	21	7 966
N03AG	**Fatty acid derivatives**	**14 184**	**14 347**	**14 693**	**15 127**	**15 288**	**45**	**1 640**	**5 945**	**6 325**	**1 378**	**36 884**
N03AG01	valproic acid	14 111	14 279	14 623	15 047	15 203	45	1 617	5 917	6 297	1 372	36 043
N03AG03	aminobutyric acid	0	0	7	16	20	80	0	12	7	<5	19
N03AG04	vigabatrin	100	88	90	94	90	54	40	22	22	6	593
N03AG06	tiagabine	11	13	10	10	9	56	0	<5	6	<5	229
N03AX	**Other antiepileptics**	**66 054**	**71 880**	**77 827**	**82 517**	**85 805**	**59**	**1 886**	**27 447**	**39 533**	**16 939**	**325 083**
N03AX03	sultiame	98	130	161	206	239	44	194	43	<5	0	1 467
N03AX09	lamotrigine	23 711	24 878	26 197	27 013	27 568	60	936	13 342	10 773	2 517	88 703
N03AX10	felbamate	23	21	21	20	17	35	0	14	<5	0	343
N03AX11	topiramate	3 060	3 047	3 127	3 230	3 649	73	237	1 988	1 294	130	10 870
N03AX12	gabapentin	24 447	26 611	28 936	30 998	32 205	60	53	6 653	16 798	8 701	49 001
N03AX14	levetiracetam	5 539	6 101	6 784	7 307	7 936	48	632	2 882	2 857	1 565	40 479
N03AX15	zonisamide	457	473	520	611	634	54	85	339	178	32	8 261
N03AX16	pregabalin	15 264	16 892	18 332	19 654	20 227	59	13	4 593	10 594	5 027	114 779
N03AX17	stiripentol	33	30	24	21	25	44	14	10	0	<5	1 467
N03AX18	lacosamide	262	341	411	445	500	53	24	269	183	24	6 409
N03AX21	retigabine	0	18	138	103	36	61	0	21	12	<5	319
N03AX22	perampanel	0	0	0	149	221	50	6	136	70	9	2 986
N04	**ANTI-PARKINSON DRUGS**	**17 787**	**18 178**	**18 653**	**19 088**	**20 067**	**51**	**23**	**1 636**	**8 617**	**9 791**	**139 588**
N04A	**ANTICHOLINERGIC AGENTS**	**2 915**	**2 808**	**2 667**	**2 481**	**2 345**	**49**	**14**	**517**	**1 466**	**348**	**1 520**
N04AA	**Tertiary amines**	**2 880**	**2 773**	**2 635**	**2 448**	**2 322**	**49**	**14**	**514**	**1 451**	**343**	**1 477**

ATC level		2010	2011	2012	2013	2014		2014				2014
		Number of individuals					Share of women (%)	Number of individuals per age group				Sales in 1000 NOK
								<15	15–44	45–69	≥70	
N04AA01	trihexyphenidyl	22	23	20	27	41	39	13	14	13	<5	240
N04AA02	biperiden	2 854	2 747	2 611	2 418	2 279	49	<5	500	1 438	340	1 229
N04AA04	procyclidine	<5	<5	<5	<5	<5	33	0	0	<5	<5	8
N04AB	**Ethers chemically close to antihistamines**	**40**	**38**	**37**	**34**	**29**	**69**	**0**	**<5**	**21**	**5**	**43**
N04AB02	orphenadrine (chloride)	40	38	37	34	29	69	0	<5	21	5	43
N04B	**DOPAMINERGIC AGENTS**	**14 940**	**15 436**	**16 047**	**16 673**	**17 783**	**51**	**11**	**1 125**	**7 189**	**9 458**	**138 069**
N04BA	**Dopa and dopa derivatives**	**7 906**	**8 015**	**8 279**	**8 579**	**9 034**	**43**	**8**	**140**	**2 707**	**6 179**	**76 362**
N04BA02	levodopa and decarboxylase inhibitor	7 180	7 277	7 562	7 860	8 340	44	8	137	2 429	5 766	58 535
N04BA03	levodopa, decarboxylase inhibitor and COMT inhibitor	1 448	1 395	1 415	1 399	1 391	36	0	11	587	793	17 827
N04BB	**Adamantane derivatives**	**114**	**123**	**142**	**161**	**152**	**70**	**<5**	**36**	**90**	**25**	**476**
N04BB01	amantadine	114	123	142	161	152	70	<5	36	90	25	476
N04BC	**Dopamine agonists**	**9 442**	**9 976**	**10 381**	**10 874**	**11 678**	**54**	**<5**	**973**	**5 838**	**4 865**	**39 830**
N04BC01	bromocriptine	<5	<5	<5	<5	<5	0	0	0	<5	<5	28
N04BC04	ropinirole	2 665	2 667	2 676	2 729	2 869	45	0	171	1 551	1 147	14 262
N04BC05	pramipexole	6 501	6 946	7 350	7 750	8 470	57	<5	802	4 163	3 503	16 824
N04BC06	cabergoline	209	177	142	121	109	50	0	7	36	66	318
N04BC07	apomorphine	18	21	19	18	26	35	0	0	15	11	2 150
N04BC09	rotigotine	517	541	528	573	560	45	0	30	267	263	6 249
N04BD	**Monoamine oxidase B inhibitors**	**3 184**	**3 339**	**3 519**	**3 652**	**3 869**	**38**	**0**	**46**	**1 897**	**1 926**	**20 400**
N04BD01	selegiline	2 126	2 087	2 138	2 183	2 257	38	0	29	1 125	1 103	3 255
N04BD02	rasagiline	1 183	1 329	1 460	1 530	1 649	37	0	17	790	842	17 145
N04BX	**Other dopaminergic agents**	**192**	**152**	**160**	**119**	**111**	**53**	**0**	**0**	**49**	**62**	**1 000**
N04BX01	tolcapone	11	11	9	8	6	50	0	0	<5	<5	82
N04BX02	entacapone	181	141	151	111	105	53	0	0	45	60	918
N05	**PSYCHOLEPTICS**	**614 376**	**618 313**	**616 277**	**619 567**	**627 568**	**63**	**9 673**	**143 988**	**282 892**	**191 015**	**620 435**
N05A	**ANTIPSYCHOTICS**	**104 077**	**104 361**	**106 114**	**106 651**	**109 224**	**55**	**912**	**38 693**	**49 273**	**20 346**	**316 133**
N05AA	**Phenothiazines with aliphatic side-chain**	**24 617**	**23 180**	**21 794**	**20 118**	**18 907**	**57**	**11**	**4 702**	**10 227**	**3 967**	**7 418**
N05AA01	chlorpromazine	439	389	280	222	196	59	0	78	88	30	663
N05AA02	levomepromazine	24 212	22 826	21 541	19 912	18 729	57	11	4 631	10 148	3 939	6 755
N05AB	**Phenothiazines with piperazine structure**	**18 276**	**17 128**	**15 768**	**13 470**	**11 061**	**71**	**12**	**2 253**	**4 572**	**4 224**	**6 562**
N05AB01	dixyrazine	32	<5	0	0	0	–	0	0	0	0	0
N05AB02	fluphenazine	22	20	15	14	16	50	0	0	7	9	56
N05AB03	perphenazine	5 423	5 084	4 728	3 506	1 716	58	0	289	1 100	327	4 588

ATC group N

ATC level		2010	2011	2012	2013	2014		2014				2014
		Number of individuals					Share of women (%)	Number of individuals per age group				Sales in 1000 NOK
								<15	15–44	45–69	≥70	
N05AB04	prochlorperazine	12 860	12 078	11 063	10 061	9 345	73	12	1 968	3 476	3 889	1 916
N05AB06	trifluoperazine	<5	<5	<5	<5	<5	50	0	0	<5	<5	3
N05AC	**Phenothiazines with piperidine structure**	**62**	**61**	**50**	**54**	**46**	**48**	**0**	**<5**	**30**	**14**	**157**
N05AC01	periciazine	<5	<5	<5	<5	<5	100	0	0	<5	0	2
N05AC02	thioridazine	58	57	47	49	43	47	0	<5	28	13	117
N05AC04	pipotiazine	<5	<5	<5	<5	<5	50	0	0	<5	<5	38
N05AD	**Butyrophenone derivatives**	**4 277**	**4 089**	**4 023**	**3 966**	**4 027**	**53**	**<5**	**394**	**1 573**	**2 056**	**1 328**
N05AD01	haloperidol	4 270	4 082	4 014	3 959	4 020	53	<5	391	1 571	2 054	1 305
N05AD03	melperone	6	6	6	7	6	50	0	<5	<5	<5	10
N05AD08	droperidol	<5	<5	<5	<5	<5	0	0	0	0	<5	13
N05AE	**Indole derivatives**	**1 164**	**1 033**	**957**	**902**	**870**	**59**	**<5**	**385**	**448**	**35**	**7 148**
N05AE03	sertindole	161	138	127	125	100	60	0	56	43	<5	1 176
N05AE04	ziprasidone	1 006	897	831	778	766	59	<5	327	403	34	5 950
N05AE05	lurasidone	0	0	0	0	5	40	0	<5	<5	0	22
N05AF	**Thioxanthene derivatives**	**23 752**	**22 935**	**22 560**	**22 303**	**21 603**	**56**	**25**	**7 128**	**10 966**	**3 484**	**12 339**
N05AF01	flupentixol	4 918	4 621	4 478	4 351	4 187	66	<5	1 038	2 171	977	2 122
N05AF03	chlorprothixene	16 658	16 269	16 097	15 541	15 116	54	23	5 611	7 409	2 073	6 921
N05AF05	zuclopenthixol	2 822	2 661	2 581	3 044	2 916	51	<5	696	1 718	501	3 296
N05AG	**Diphenylbutylpiperidine derivatives**	**135**	**139**	**128**	**117**	**114**	**34**	**<5**	**63**	**35**	**12**	**305**
N05AG02	pimozide	118	117	111	115	114	34	<5	63	35	12	305
N05AG03	penfluridol	17	22	17	<5	0	–	0	0	0	0	0
N05AH	**Diazepines, oxazepines, thiazepines and oxepines**	**31 688**	**35 237**	**39 939**	**44 837**	**50 419**	**53**	**112**	**23 209**	**21 805**	**5 293**	**136 269**
N05AH02	clozapine	2 362	2 398	2 459	2 533	2 572	37	<5	1 160	1 323	88	9 929
N05AH03	olanzapine	15 799	15 754	16 072	16 385	16 710	47	29	6 508	7 872	2 301	52 259
N05AH04	quetiapine	15 094	18 864	23 376	28 125	33 555	56	84	16 809	13 597	3 065	73 432
N05AH05	asenapine	0	0	117	87	50	64	0	27	23	0	649
N05AL	**Benzamides**	**548**	**527**	**566**	**569**	**600**	**47**	**0**	**303**	**273**	**24**	**3 740**
N05AL03	tiapride	7	7	7	5	<5	0	0	<5	0	0	22
N05AL05	amisulpride	541	520	559	564	597	47	0	300	273	24	3 718
N05AN	**Lithium**	**7 877**	**7 727**	**7 792**	**7 682**	**7 559**	**57**	**<5**	**2 202**	**4 178**	**1 177**	**14 470**
N05AN01	lithium	7 877	7 727	7 792	7 682	7 559	57	<5	2 202	4 178	1 177	14 470
N05AX	**Other antipsychotics**	**12 299**	**12 804**	**13 193**	**13 752**	**14 030**	**48**	**779**	**6 166**	**4 998**	**2 087**	**126 398**
N05AX07	prothipendyl	0	<5	<5	<5	<5	100	0	<5	<5	0	2
N05AX08	risperidone	8 255	8 366	8 303	8 392	8 336	46	666	2 879	2 934	1 857	34 252
N05AX12	aripiprazole	4 379	4 744	4 916	5 143	5 402	51	152	3 136	1 904	210	65 074

ATC level		2010	2011	2012	2013	2014	Share of women (%)	2014				2014
		Number of individuals						Number of individuals per age group				Sales in 1000 NOK
								<15	15–44	45–69	≥70	
N05AX13	paliperidone	0	37	512	782	833	40	0	484	320	29	27 069
N05B	**ANXIOLYTICS**	**277 880**	**273 985**	**273 911**	**270 647**	**267 752**	**64**	**3 103**	**61 176**	**125 524**	**77 949**	**108 755**
N05BA	**Benzodiazepine derivatives**	**255 446**	**250 055**	**249 597**	**245 061**	**241 323**	**65**	**2 736**	**51 044**	**114 987**	**72 556**	**94 279**
N05BA01	diazepam	132 588	128 283	125 831	120 562	116 548	62	2 531	24 647	55 771	33 599	44 563
N05BA02	chlordiazepoxide	<5	<5	<5	<5	0	–	0	0	0	0	0
N05BA04	oxazepam	133 963	131 939	134 353	134 612	134 613	67	67	28 830	63 789	41 927	43 133
N05BA06	lorazepam	21	30	31	48	51	57	<5	19	27	<5	139
N05BA08	bromazepam	5	6	7	8	6	67	0	0	<5	<5	24
N05BA09	clobazam	615	645	706	710	752	51	243	371	129	9	1 949
N05BA12	alprazolam	4 340	4 024	4 133	3 851	3 535	46	<5	1 357	1 769	408	4 470
N05BB	**Diphenylmethane derivatives**	**30 163**	**31 960**	**32 347**	**33 868**	**34 724**	**62**	**371**	**12 495**	**14 562**	**7 296**	**10 135**
N05BB01	hydroxyzine	30 163	31 960	32 347	33 868	34 724	62	371	12 495	14 562	7 296	10 135
N05BC	**Carbamates**	**6**	**7**	**6**	**<5**	**0**	**–**	**0**	**0**	**0**	**0**	**0**
N05BC01	meprobamate	6	7	6	<5	0	–	0	0	0	0	0
N05BE	**Azaspirodecanedione derivatives**	**2 345**	**2 371**	**2 580**	**2 403**	**2 228**	**59**	**5**	**794**	**1 117**	**312**	**4 341**
N05BE01	buspirone	2 345	2 371	2 580	2 403	2 228	59	5	794	1 117	312	4 341
N05C	**HYPNOTICS AND SEDATIVES**	**406 162**	**411 062**	**407 120**	**410 808**	**420 453**	**65**	**6 648**	**81 363**	**188 423**	**144 019**	**195 547**
N05CA	**Barbiturates, plain**	**<5**	**<5**	**0**	**0**	**<5**	**0**	**0**	**0**	**<5**	**0**	**1**
N05CA04	barbital	<5	<5	0	0	<5	0	0	0	<5	0	1
N05CC	**Aldehydes and derivatives**	**0**	**0**	**0**	**5**	**6**	**67**	**<5**	**<5**	**<5**	**0**	**21**
N05CC01	chloral hydrate	0	0	0	5	6	67	<5	<5	<5	0	21
N05CD	**Benzodiazepine derivatives**	**41 807**	**39 255**	**34 101**	**28 367**	**28 229**	**57**	**1 678**	**5 614**	**11 152**	**9 785**	**20 961**
N05CD01	flurazepam	17	16	16	16	17	47	0	0	8	9	46
N05CD02	nitrazepam	33 406	31 315	27 880	24 446	23 298	59	297	4 191	9 903	8 907	8 291
N05CD03	flunitrazepam	7 690	6 971	5 780	1 185	1 089	47	0	230	574	285	2 553
N05CD05	triazolam	115	98	107	91	74	58	0	22	24	28	83
N05CD08	midazolam	1 493	1 759	2 255	3 117	4 236	47	1 523	1 328	761	624	9 988
N05CF	**Benzodiazepine related drugs**	**349 542**	**352 287**	**355 331**	**355 049**	**358 339**	**66**	**64**	**57 916**	**167 872**	**132 487**	**128 529**
N05CF01	zopiclone	305 048	306 107	306 438	303 992	304 096	66	46	44 833	141 532	117 685	107 463
N05CF02	zolpidem	55 244	56 956	61 114	62 261	65 767	66	21	15 919	31 589	18 238	21 066
N05CF03	zaleplon	<5	0	0	0	0	–	0	0	0	0	0
N05CH	**Melatonin receptor agonists**	**42 795**	**48 436**	**53 571**	**56 177**	**64 516**	**61**	**5 196**	**26 107**	**24 090**	**9 123**	**43 359**
N05CH01	melatonin	42 795	48 436	53 571	56 177	64 516	61	5 196	26 107	24 090	9 123	43 359
N05CM	**Other hypnotics and sedatives**	**2 109**	**2 131**	**2 141**	**2 087**	**2 147**	**48**	**0**	**169**	**579**	**1 399**	**2 677**

ATC group N

ATC level		2010	2011	2012	2013	2014		2014				2014
		Number of individuals					Share of women (%)	Number of individuals per age group				Sales in 1000 NOK
								<15	15–44	45–69	≥70	
N05CM02	clomethiazole	2 048	2 057	2 007	1 986	1 937	48	0	134	499	1 304	2 292
N05CM05	scopolamine	65	75	89	65	110	45	0	<5	23	85	289
N05CM06	propiomazine	0	0	15	38	99	62	0	33	58	8	95
N05CM09	Valerianae radix[1)]	0	0	33	<5	5	80	0	0	<5	<5	2
N05CM11	bromides	0	<5	<5	0	0	–	0	0	0	0	0
N06	**PSYCHOANALEPTICS**	**333 134**	**341 017**	**349 413**	**353 980**	**360 055**	**63**	**11 327**	**121 351**	**150 427**	**76 950**	**567 411**
N06A	**ANTIDEPRESSANTS**	**297 124**	**303 747**	**310 242**	**313 336**	**317 319**	**66**	**625**	**102 875**	**146 770**	**67 049**	**281 852**
N06AA	**Non-selective monoamine reuptake inhibitors**	**61 908**	**63 098**	**64 758**	**65 888**	**67 305**	**72**	**90**	**17 133**	**35 980**	**14 102**	**28 340**
N06AA02	imipramine	26	22	19	21	16	56	<5	<5	6	7	45
N06AA04	clomipramine	3 080	2 907	2 714	2 602	2 489	69	9	417	1 410	653	2 002
N06AA05	opipramol	6	6	9	5	8	50	0	<5	<5	5	12
N06AA06	trimipramine	11 431	10 943	10 553	9 890	9 407	70	<5	1 751	4 783	2 869	6 122
N06AA07	lofepramine	13	12	11	9	6	67	0	<5	<5	<5	39
N06AA09	amitriptyline	43 086	45 318	47 831	49 857	51 948	73	74	14 420	28 354	9 100	17 861
N06AA10	nortriptyline	2 104	1 983	1 980	1 996	2 180	69	<5	643	1 021	514	763
N06AA12	doxepin	3 017	2 749	2 496	2 280	2 016	70	0	128	803	1 085	1 494
N06AA21	maprotiline	<5	<5	<5	0	<5	100	0	0	<5	0	2
N06AB	**Selective serotonin reuptake inhibitors**	**180 612**	**184 013**	**186 449**	**185 672**	**185 976**	**66**	**504**	**66 300**	**81 576**	**37 596**	**140 634**
N06AB03	fluoxetine	9 289	9 634	10 578	10 750	11 118	76	158	6 454	3 778	728	15 281
N06AB04	citalopram	30 680	29 143	27 158	25 200	23 520	69	6	5 168	11 817	6 529	14 213
N06AB05	paroxetine	16 895	16 172	15 536	14 828	14 252	69	<5	2 889	7 762	3 599	12 155
N06AB06	sertraline	26 384	27 181	28 814	29 740	30 858	66	335	12 582	12 526	5 415	27 562
N06AB08	fluvoxamine	603	586	552	559	543	54	0	208	255	80	1 014
N06AB10	escitalopram	102 626	107 172	109 487	109 896	110 848	65	30	41 332	47 304	22 182	70 409
N06AF	**Monoamine oxidase inhibitors, non-selective**	**111**	**102**	**95**	**97**	**89**	**64**	**0**	**23**	**43**	**23**	**1 773**
N06AF03	phenelzine	102	94	88	91	83	63	0	21	40	22	606
N06AF04	tranylcypromine	9	9	7	6	7	86	0	<5	<5	<5	1 167
N06AG	**Monoamine oxidase A inhibitors**	**880**	**853**	**758**	**738**	**708**	**64**	**0**	**154**	**403**	**151**	**1 561**
N06AG02	moclobemide	880	853	758	738	708	64	0	154	403	151	1 561
N06AX	**Other antidepressants**	**92 850**	**95 460**	**98 898**	**101 299**	**103 358**	**61**	**46**	**31 480**	**47 469**	**24 363**	**109 544**
N06AX01	oxitriptan	261	308	293	276	279	80	<5	146	116	13	358
N06AX02	tryptophan	<5	<5	6	8	18	78	0	8	10	0	33
N06AX03	mianserin	30 307	29 477	28 143	27 133	26 403	62	11	5 740	12 640	8 012	10 313
N06AX05	trazodone	<5	<5	<5	12	17	71	0	7	10	0	33

[1)] The ATC level comprises OTC medicinal products. The number of individuals is registered for prescription sales only.

ATC level		2010	2011	2012	2013	2014		2014				2014
		Number of individuals					Share of women (%)	Number of individuals per age group				Sales in 1000 NOK
								<15	15–44	45–69	≥70	
N06AX06	nefazodone	42	36	36	30	30	50	0	<5	26	<5	307
N06AX11	mirtazapine	31 458	33 331	35 820	36 953	38 642	58	14	10 224	16 290	12 114	31 103
N06AX12	bupropion	7 641	8 808	10 205	11 330	11 701	59	<5	5 771	5 066	860	23 554
N06AX14	tianeptine	<5	<5	<5	<5	0	–	0	0	0	0	0
N06AX16	venlafaxine	28 791	29 240	30 295	31 108	31 331	63	12	11 143	15 358	4 818	30 318
N06AX18	reboxetine	512	424	413	383	338	67	0	150	156	32	747
N06AX21	duloxetine	2 804	3 021	3 203	3 503	3 961	69	<5	1 213	2 177	570	12 560
N06AX22	agomelatine	28	22	15	18	17	59	0	6	11	0	185
N06AX25	Hyperici herba[1)]	0	0	<5	0	0	–	0	0	0	0	0
N06AX26	vortioxetine	0	0	0	0	25	60	0	8	15	<5	32
N06B	**PSYCHOSTIMULANTS, AGENTS USED FOR ADHD AND NOOTROPICS**	**30 080**	**31 221**	**33 009**	**34 763**	**37 110**	**39**	**10 852**	**22 183**	**3 916**	**159**	**231 857**
N06BA	**Centrally acting sympathomimetics**	**29 711**	**30 821**	**32 609**	**34 369**	**36 723**	**39**	**10 848**	**21 974**	**3 788**	**113**	**231 129**
N06BA01	amfetamine	303	336	383	402	421	46	29	263	115	14	11 482
N06BA02	dexamfetamine	1 167	1 285	1 473	1 691	1 885	44	47	1 305	511	22	25 855
N06BA04	methylphenidate	26 471	27 302	28 993	30 397	32 347	39	10 156	19 156	2 973	62	154 520
N06BA07	modafinil	329	349	366	436	486	59	22	306	141	17	5 411
N06BA09	atomoxetine	3 055	3 108	3 036	3 282	3 636	37	1 267	2 114	255	0	31 925
N06BA12	lisdexamfetamine	0	0	<5	26	386	36	171	188	26	<5	1 936
N06BC	**Xanthine derivatives**	**285**	**326**	**322**	**309**	**311**	**50**	**<5**	**176**	**102**	**32**	**181**
N06BC01	caffeine	285	326	322	309	311	50	<5	176	102	32	181
N06BX	**Other psychostimulants and nootropics**	**102**	**86**	**88**	**95**	**88**	**43**	**<5**	**43**	**28**	**14**	**546**
N06BX03	piracetam	77	70	77	84	72	40	<5	29	28	14	268
N06BX13	idebenone	8	10	11	11	16	56	<5	14	0	0	278
N06BX17	adrafinil	18	6	0	0	0	–	0	0	0	0	0
N06C	**PSYCHOLEPTICS AND PSYCHOANALEPTICS IN COMBINATION**	**0**	**0**	**<5**	**0**	**0**	**–**	**0**	**0**	**0**	**0**	**0**
N06CA	**Antidepressants in combination with psycholeptics**	**0**	**0**	**<5**	**0**	**0**	**–**	**0**	**0**	**0**	**0**	**0**
N06CA02	melitracen and psycholeptics	0	0	<5	0	0	–	0	0	0	0	0
N06D	**ANTI-DEMENTIA DRUGS**	**14 174**	**14 759**	**15 519**	**15 483**	**15 426**	**62**	**0**	**17**	**1 542**	**13 867**	**53 702**
N06DA	Anticholinesterases	12 920	12 850	13 047	12 995	12 805	62	0	8	1 318	11 479	43 091
N06DA02	donepezil	8 920	8 530	8 320	7 960	7 701	64	0	<5	766	6 931	20 095
N06DA03	rivastigmine	3 935	4 303	4 776	5 146	5 212	60	0	<5	570	4 638	20 991
N06DA04	galantamine	502	395	347	301	257	56	0	0	28	229	2 005
N06DX	**Other anti-dementia drugs**	**1 969**	**3 030**	**3 598**	**3 682**	**3 728**	**60**	**0**	**9**	**446**	**3 273**	**10 611**

[1)] The ATC level comprises OTC medicinal products. The number of individuals is registered for prescription sales only.

ATC g roup N

ATC level		2010	2011	2012	2013	2014	Share of women (%)	2014				2014
		Number of individuals						Number of individuals per age group				Sales in 1000 NOK
								<15	15–44	45–69	≥70	
N06DX01	memantine	1 816	2 837	3 467	3 645	3 728	60	0	9	446	3 273	10 611
N06DX02	Ginkgo folium[1)]	153	193	131	37	0	–	0	0	0	0	0
N07	**OTHER NERVOUS SYSTEM DRUGS**	**47 182**	**48 455**	**45 131**	**50 686**	**45 472**	**53**	**60**	**15 303**	**26 750**	**3 359**	**385 867**
N07A	**PARASYMPATHOMIMETICS**	**660**	**684**	**733**	**747**	**782**	**66**	**5**	**125**	**375**	**277**	**2 479**
N07AA	**Anticholinesterases**	**509**	**523**	**568**	**591**	**619**	**60**	**5**	**106**	**275**	**233**	**1 284**
N07AA01	neostigmine	0	0	0	<5	0	–	0	0	0	0	0
N07AA02	pyridostigmine	505	519	566	588	617	60	5	105	275	232	1 280
N07AA30	ambenonium	<5	<5	<5	<5	<5	100	0	<5	<5	0	3
N07AA51	neostigmine, combinations	<5	<5	0	0	<5	100	0	0	0	<5	1
N07AB	**Choline esters**	**22**	**33**	**30**	**29**	**30**	**57**	**0**	**8**	**15**	**7**	**26**
N07AB01	carbachol	22	33	30	29	30	57	0	8	15	7	26
N07AX	**Other parasympathomimetics**	**130**	**131**	**138**	**131**	**134**	**94**	**0**	**11**	**86**	**37**	**1 170**
N07AX01	pilocarpine	130	131	138	131	134	94	0	11	86	37	1 170
N07B	**DRUGS USED IN ADDICTIVE DISORDERS**	**45 745**	**46 701**	**41 867**	**47 793**	**41 496**	**52**	**38**	**14 228**	**24 571**	**2 659**	**208 872**
N07BA	**Drugs used in nicotine dependence**	**34 822**	**35 032**	**29 885**	**23 082**	**17 792**	**55**	**<5**	**5 193**	**11 259**	**1 339**	**27 000**
N07BA01	nicotine[1)]	906	1 000	916	928	931	48	<5	97	565	268	590
N07BA03	varenicline	34 002	34 123	29 045	22 201	16 909	56	0	5 104	10 723	1 082	26 410
N07BB	**Drugs used in alcohol dependence**	**4 866**	**4 953**	**4 948**	**17 479**	**16 382**	**58**	**34**	**5 100**	**9 977**	**1 271**	**16 714**
N07BB01	disulfiram	4 450	4 541	4 523	4 315	4 235	29	0	1 362	2 614	259	2 913
N07BB03	acamprosate	526	543	588	580	469	31	0	136	300	33	809
N07BB04	naltrexone	19	17	14	11 314	10 472	74	34	3 287	6 260	891	11 430
N07BB05	nalmefene	0	0	0	1 722	1 614	31	<5	444	1 066	103	1 562
N07BC	**Drugs used in opioid dependence**	**6 368**	**7 048**	**7 353**	**7 736**	**7 674**	**31**	**<5**	**4 051**	**3 560**	**60**	**165 159**
N07BC01	buprenorphine	2 133	2 270	2 465	2 650	2 751	30	0	1 600	1 145	6	52 085
N07BC02	methadone[2)]	3 337	3 636	3 631	3 718	3 441	34	<5	1 450	1 936	52	79 117
N07BC05	levomethadone	0	0	0	0	<5	100	0	<5	0	0	1
N07BC51	buprenorphine, combinations	1 562	1 759	1 925	2 012	2 187	25	0	1 494	690	<5	33 956
N07C	**ANTIVERTIGO PREPARATIONS**	**424**	**454**	**531**	**555**	**672**	**64**	**<5**	**150**	**354**	**167**	**1 593**
N07CA	**Antivertigo preparations**	**424**	**454**	**531**	**555**	**672**	**64**	**<5**	**150**	**354**	**167**	**1 593**
N07CA01	betahistine	413	438	512	535	643	63	0	130	346	167	1 553
N07CA03	flunarizine	11	16	19	20	29	76	<5	20	8	0	40

[1)] The ATC level comprises OTC medicinal products. The number of individuals is registered for prescription sales only.

[2)] The figures only include methadone dispensed from the pharmacies. Patients may also receive this drug dispensed according to special arrangements in the health regions.

ATC level		2010	2011	2012	2013	2014		2014				2014
		Number of individuals					Share of women (%)	Number of individuals per age group				Sales in 1000 NOK
								<15	15–44	45–69	≥70	
N07X	**OTHER NERVOUS SYSTEM DRUGS**	**366**	**644**	**2 061**	**2 114**	**3 057**	**64**	**16**	**897**	**1 859**	**285**	**172 922**
N07XX	**Other nervous system drugs**	**366**	**644**	**2 061**	**2 114**	**3 057**	**64**	**16**	**897**	**1 859**	**285**	**172 922**
N07XX02	riluzole	278	294	297	285	289	38	0	12	158	119	3 545
N07XX04	sodium oxybate	49	58	63	84	96	59	13	63	17	<5	7 852
N07XX05	amifampridine	0	0	<5	<5	7	29	<5	<5	<5	<5	3 216
N07XX06	tetrabenazine	37	35	41	43	52	48	<5	8	33	9	802
N07XX07	fampridine	<5	257	1 659	1 692	1 632	64	0	193	1 288	151	66 288
N07XX09	dimethyl fumarate	0	0	0	8	1 055	73	0	640	412	<5	91 219

3.15 ATC group P – Antiparasitic products, insecticides and repellents

ATC level		2010	2011	2012	2013	2014		2014				2014
		Number of individuals					Share of women (%)	Number of individuals per age group				Sales in 1000 NOK
								<15	15–44	45–69	≥70	
P	**ANTIPARASITIC PRODUCTS, INSECTICIDES AND REPELLENTS**	**88 743**	**92 296**	**95 141**	**96 547**	**97 439**	**62**	**3 922**	**43 819**	**38 212**	**11 486**	**29 812**
P01	**ANTIPROTOZOALS**	**85 626**	**88 926**	**91 618**	**92 720**	**92 801**	**62**	**2 432**	**41 563**	**37 489**	**11 317**	**27 270**
P01A	**AGENTS AGAINST AMOEBIASIS AND OTHER PROTOZOAL DISEASES**	**55 588**	**57 290**	**58 106**	**58 337**	**59 207**	**64**	**689**	**25 016**	**24 620**	**8 882**	**6 716**
P01AB	**Nitroimidazole derivatives**	**55 587**	**57 289**	**58 103**	**58 335**	**59 205**	**64**	**689**	**25 015**	**24 619**	**8 882**	**6 704**
P01AB01	metronidazole	55 540	57 236	58 039	58 227	59 185	64	689	25 003	24 611	8 882	6 657
P01AB02	tinidazole	6	9	124	149	26	54	0	16	9	<5	45
P01AB03	ornidazole	46	73	9	0	0	–	0	0	0	0	0
P01AB06	nimorazole	0	0	<5	<5	<5	0	0	0	<5	0	2
P01AC	**Dichloroacetamide derivatives**	**<5**	**11**	**12**	**9**	**5**	**60**	**0**	**<5**	**<5**	**<5**	**12**
P01AC01	diloxanide	<5	11	12	9	5	60	0	<5	<5	<5	12
P01AX	**Other agents against amoebiasis and other protozoal diseases**	**<5**	**0**	**0**	**0**	**0**	**–**	**0**	**0**	**0**	**0**	**0**
P01AX11	nitazoxanide	<5	0	0	0	0	–	0	0	0	0	0
P01B	**ANTIMALARIALS**	**30 716**	**32 446**	**34 304**	**35 069**	**34 169**	**59**	**1 746**	**16 830**	**13 109**	**2 484**	**20 546**
P01BA	**Aminoquinolines**	**5 684**	**5 912**	**6 128**	**6 131**	**6 041**	**82**	**39**	**1 571**	**3 304**	**1 127**	**3 723**
P01BA01	chloroquine	21	17	22	14	13	77	0	<5	8	<5	17
P01BA02	hydroxychloroquine	5 661	5 897	6 107	6 112	6 020	82	36	1 566	3 293	1 125	3 693
P01BA03	primaquine	<5	0	0	6	9	44	<5	<5	<5	0	13
P01BB	**Biguanides**	**20 468**	**21 918**	**23 899**	**24 803**	**25 213**	**54**	**1 338**	**13 899**	**8 925**	**1 051**	**15 464**
P01BB01	proguanil	11	7	<5	<5	<5	33	0	<5	0	<5	3
P01BB51	proguanil, combinations	20 459	21 913	23 898	24 799	25 211	54	1 338	13 898	8 925	1 050	15 461
P01BC	**Methanolquinolines**	**4 802**	**4 841**	**4 473**	**4 312**	**3 073**	**57**	**371**	**1 461**	**928**	**313**	**1 357**
P01BC01	quinine	569	473	439	396	350	68	0	10	135	205	259
P01BC02	mefloquine	4 235	4 368	4 035	3 917	2 724	56	371	1 452	793	108	1 098
P01BD	**Diaminopyrimidines**	**<5**	**0**	**0**	**0**	**0**	**–**	**0**	**0**	**0**	**0**	**0**
P01BD01	pyrimethamine	<5	0	0	0	0	–	0	0	0	0	0
P01BE	**Artemisinin and derivatives, plain**	**0**	**0**	**<5**	**<5**	**0**	**–**	**0**	**0**	**0**	**0**	**0**
P01BE03	artesunate	0	0	<5	<5	0	–	0	0	0	0	0
P01BF	**Artemisinin and derivatives, combinations**	**<5**	**<5**	**<5**	**<5**	**<5**	**0**	**0**	**0**	**<5**	**0**	**2**
P01BF01	artemether and lumefantrine	<5	<5	<5	<5	<5	0	0	0	<5	0	2
P01C	**AGENTS AGAINST LEISHMANIASIS AND TRYPANOSOMIASIS**	**<5**	**0**	**<5**	**<5**	**<5**	**0**	**0**	**0**	**<5**	**0**	**8**

ATC level		2010	2011	2012	2013	2014		2014				2014
		Number of individuals					Share of women (%)	Number of individuals per age group				Sales in 1000 NOK
								<15	15–44	45–69	≥70	
P01CX	**Other agents against leishmaniasis and trypanosomiasis**	**<5**	**0**	**<5**	**<5**	**<5**	**0**	**0**	**0**	**<5**	**0**	**8**
P01CX01	pentamidine isethionate	<5	0	<5	<5	<5	0	0	0	<5	0	8
P02	**ANTHELMINTICS**	**2 107**	**2 224**	**2 315**	**2 388**	**2 743**	**57**	**1 241**	**996**	**422**	**84**	**1 329**
P02B	**ANTITREMATODALS**	**26**	**41**	**50**	**55**	**45**	**42**	**<5**	**35**	**9**	**0**	**407**
P02BA	**Quinoline derivatives and related substances**	**26**	**41**	**50**	**55**	**45**	**42**	**<5**	**35**	**9**	**0**	**407**
P02BA01	praziquantel	26	41	50	55	45	42	<5	35	9	0	407
P02C	**ANTINEMATODAL AGENTS**	**2 068**	**2 171**	**2 262**	**2 330**	**2 688**	**58**	**1 240**	**952**	**412**	**84**	**912**
P02CA	**Benzimidazole derivatives**	**1 900**	**2 004**	**2 070**	**2 127**	**2 414**	**57**	**1 164**	**810**	**363**	**77**	**768**
P02CA01	mebendazole	1 877	1 960	2 006	1 993	2 265	56	1 120	742	326	77	445
P02CA03	albendazole	23	45	70	140	160	69	44	71	43	<5	324
P02CF	**Avermectines**	**62**	**58**	**80**	**86**	**119**	**55**	**18**	**62**	**35**	**<5**	**118**
P02CF01	ivermectin	62	58	80	86	119	55	18	62	35	<5	118
P02CX	**Other antinematodals**	**120**	**119**	**128**	**139**	**174**	**74**	**61**	**90**	**17**	**6**	**26**
P02CX01	pyrvinium	120	119	128	139	174	74	61	90	17	6	26
P02D	**ANTICESTODALS**	**18**	**26**	**13**	**16**	**17**	**35**	**<5**	**12**	**<5**	**0**	**11**
P02DA	**Salicylic acid derivatives**	**18**	**26**	**13**	**16**	**17**	**35**	**<5**	**12**	**<5**	**0**	**11**
P02DA01	niclosamide	18	26	13	16	17	35	<5	12	<5	0	11
P03	**ECTOPARASITICIDES, INCL. SCABICIDES, INSECTICIDES AND REPELLENTS**	**1 176**	**1 297**	**1 374**	**1 688**	**2 157**	**51**	**280**	**1 404**	**383**	**90**	**1 213**
P03A	**ECTOPARASITICIDES, INCL. SCABICIDES**	**1 176**	**1 297**	**1 374**	**1 688**	**2 157**	**51**	**280**	**1 404**	**383**	**90**	**1 213**
P03AC	**Pyrethrines, incl. synthetic compounds**	**1 093**	**1 222**	**1 298**	**1 618**	**2 091**	**50**	**264**	**1 367**	**371**	**89**	**1 191**
P03AC04	permethrin[1)]	1 093	1 222	1 298	1 618	2 091	50	264	1 367	371	89	1 191
P03AX	**Other ectoparasiticides, incl. scabicides**	**86**	**82**	**84**	**80**	**73**	**64**	**18**	**38**	**16**	**<5**	**22**
P03AX01	benzyl benzoate[1)]	24	28	21	34	32	59	8	15	9	0	10
P03AX03	malathion[1)]	62	54	63	47	42	69	10	23	8	<5	12

[1)] The ATC level comprises OTC medicinal products. The number of individuals is registered for prescription sales only.

3.16 ATC group R – Respiratory system

ATC level		2010	2011	2012	2013	2014	Share of women (%)	2014				2014
		Number of individuals						Number of individuals per age group				Sales in 1000 NOK
								<15	15–44	45–69	≥70	
R	**RESPIRATORY SYSTEM**	**1 183 735**	**1 223 490**	**1 239 078**	**1 220 116**	**1 258 951**	**56**	**166 570**	**461 617**	**455 301**	**175 463**	**1 456 546**
R01	**NASAL PREPARATIONS**	**353 908**	**364 669**	**376 523**	**376 766**	**405 269**	**57**	**36 505**	**189 499**	**144 602**	**34 663**	**111 140**
R01A	**DECONGESTANTS AND OTHER NASAL PREPARATIONS FOR TOPICAL USE**	**297 143**	**307 141**	**316 067**	**316 889**	**349 472**	**55**	**35 354**	**159 190**	**123 208**	**31 720**	**100 889**
R01AA	**Sympathomimetics, plain**	**4 017**	**3 672**	**3 650**	**3 520**	**3 587**	**53**	**1 306**	**1 173**	**791**	**317**	**259**
R01AA05	oxymetazoline[1)]	1 802	1 781	1 847	1 824	1 982	52	1 016	562	297	107	134
R01AA07	xylometazoline[1)]	2 233	1 899	1 812	1 700	1 617	55	296	613	496	212	125
R01AB	**Sympathomimetics, combinations excl. corticosteroids**	**602**	**603**	**468**	**387**	**427**	**55**	**11**	**173**	**160**	**83**	**62**
R01AB06	xylometazoline[1)]	602	603	468	387	427	55	11	173	160	83	62
R01AC	**Antiallergic agents, excl. corticosteroids**	**39 407**	**40 956**	**39 433**	**38 277**	**47 305**	**55**	**12 743**	**22 546**	**10 201**	**1 815**	**12 465**
R01AC01	cromoglicic acid[1)]	8 772	8 705	7 943	7 646	8 647	58	2 041	3 988	2 225	393	2 250
R01AC02	levocabastine[1)]	30 659	32 377	31 556	30 702	38 745	54	10 802	18 557	7 965	1 421	10 165
R01AC03	azelastine[1)]	198	127	151	132	214	52	31	115	57	11	50
R01AD	**Corticosteroids**	**259 097**	**267 954**	**278 421**	**279 941**	**305 176**	**55**	**22 804**	**138 919**	**113 844**	**29 609**	**87 460**
R01AD01	beclometasone	11	<5	0	0	0	–	0	0	0	0	0
R01AD04	flunisolide	11	9	10	10	12	58	0	<5	7	<5	20
R01AD05	budesonide	34 996	32 644	31 215	28 699	28 574	56	1 418	10 675	12 914	3 567	10 687
R01AD08	fluticasone	24 352	22 518	21 931	21 129	21 837	54	1 013	8 040	9 919	2 865	10 433
R01AD09	mometasone	141 114	144 414	151 022	152 995	160 704	55	10 555	71 683	61 779	16 687	41 240
R01AD11	triamcinolone	9 687	8 713	7 889	6 924	6 972	57	293	2 791	3 062	826	2 895
R01AD12	fluticasone furoate	60 417	70 241	77 348	79 316	92 046	55	9 758	47 311	28 687	6 290	18 992
R01AD58	fluticasone, combinations	0	0	0	1 551	7 852	54	334	4 316	2 580	622	3 192
R01AX	**Other nasal preparations**	**630**	**728**	**836**	**1 000**	**1 120**	**55**	**71**	**316**	**337**	**396**	**643**
R01AX03	ipratropium bromide	355	422	469	534	615	54	5	70	205	335	494
R01AX06	mupirocin	276	306	367	466	505	56	66	246	132	61	149
R01B	**NASAL DECONGESTANTS FOR SYSTEMIC USE**	**81 771**	**83 161**	**88 700**	**89 209**	**84 741**	**67**	**1 583**	**45 957**	**32 754**	**4 447**	**10 250**
R01BA	**Sympathomimetics**	**81 771**	**83 161**	**88 700**	**89 209**	**84 741**	**67**	**1 583**	**45 957**	**32 754**	**4 447**	**10 250**
R01BA01	phenylpropanolamine	81 771	83 161	88 700	89 207	84 737	67	1 583	45 956	32 751	4 447	10 213
R01BA52	pseudoephedrine, combinations	0	0	0	<5	<5	50	0	<5	<5	0	38
R03	**DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES**	**423 205**	**418 109**	**420 887**	**418 306**	**429 977**	**54**	**82 114**	**111 127**	**156 474**	**80 262**	**1 066 937**
R03A	**ADRENERGICS, INHALANTS**	**335 492**	**347 921**	**354 853**	**357 307**	**370 746**	**54**	**59 566**	**101 530**	**139 900**	**69 750**	**712 224**
R03AA	**Alpha- and beta-adrenoreceptor agonists**	**209**	**246**	**251**	**201**	**147**	**33**	**132**	**12**	**<5**	**0**	**118**
R03AA01	epinephrine	209	246	251	201	147	33	132	12	<5	0	118

[1)] The ATC level comprises OTC medicinal products. The number of individuals is registered for prescription sales only.

ATC level		2010	2011	2012	2013	2014		2014				2014
		Number of individuals					Share of women (%)	Number of individuals per age group				Sales in 1000 NOK
								<15	15–44	45–69	≥70	
R03AC	**Selective beta-2-adrenoreceptor agonists**	**249 080**	**258 858**	**265 033**	**266 976**	**278 591**	**54**	**57 193**	**79 067**	**96 561**	**45 770**	**142 571**
R03AC02	salbutamol	198 277	208 540	216 082	219 571	231 782	54	55 978	66 315	75 564	33 925	76 289
R03AC03	terbutaline	35 556	34 151	32 149	29 979	29 669	57	1 182	11 102	12 581	4 804	11 194
R03AC04	fenoterol	17	16	12	14	12	58	0	<5	10	<5	20
R03AC12	salmeterol	10 563	9 699	9 202	8 885	8 619	57	241	965	3 983	3 430	14 759
R03AC13	formoterol	16 627	15 456	14 434	13 601	12 924	56	247	2 540	6 328	3 809	17 167
R03AC18	indacaterol	713	4 814	7 450	9 343	9 393	46	0	167	4 767	4 459	23 051
R03AC19	olodaterol	0	0	0	0	131	44	0	<5	62	66	91
R03AK	**Adrenergics in combination with corticosteroids or other drugs, excl. anticholinergics**	**168 449**	**175 117**	**178 269**	**180 135**	**183 337**	**55**	**8 639**	**47 458**	**83 139**	**44 101**	**554 386**
R03AK06	salmeterol and fluticasone	90 997	94 190	95 885	94 551	92 183	55	7 004	21 613	39 519	24 047	287 516
R03AK07	formoterol and budesonide	79 114	82 417	83 238	83 758	83 667	56	1 407	23 084	40 071	19 105	240 636
R03AK08	formoterol and beclometasone	1 783	1 942	2 795	4 443	5 529	59	47	1 726	2 777	979	10 238
R03AK10	vilanterol and fluticasone furoate	0	0	0	0	5 051	54	155	1 386	2 444	1 066	8 854
R03AK11	formoterol and fluticasone	0	0	0	2 239	3 732	57	149	1 314	1 697	572	7 142
R03AL	**Adrenergics in combination with anticholinergics**	**<5**	**0**	**0**	**0**	**4 849**	**46**	**0**	**80**	**2 486**	**2 283**	**15 148**
R03AL02	salbutamol and ipratropium bromide	<5	0	0	0	0	–	0	0	0	0	0
R03AL03	vilanterol and umeclidinium bromide	0	0	0	0	137	50	0	<5	76	58	210
R03AL04	indacaterol and glycopyrronium bromide	0	0	0	0	4 720	46	0	77	2 412	2 231	14 938
R03B	**OTHER DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES, INHALANTS**	**146 450**	**149 797**	**152 867**	**153 128**	**158 979**	**51**	**42 846**	**23 029**	**53 046**	**40 058**	**273 691**
R03BA	**Glucocorticoids**	**91 633**	**92 760**	**94 053**	**91 993**	**96 548**	**51**	**42 505**	**19 776**	**23 948**	**10 319**	**79 790**
R03BA01	beclometasone	4 380	4 075	4 021	3 713	3 821	56	794	943	1 397	687	3 175
R03BA02	budesonide	25 066	23 194	21 290	19 625	18 783	57	2 210	4 964	7 581	4 028	23 348
R03BA05	fluticasone	62 013	64 095	63 972	61 703	64 135	48	39 643	10 405	10 125	3 962	41 200
R03BA07	mometasone	<5	0	546	703	578	54	55	237	222	64	853
R03BA08	ciclesonide	1 874	3 476	6 104	8 080	11 094	59	688	3 609	5 080	1 717	11 214
R03BB	**Anticholinergics**	**60 133**	**62 625**	**64 442**	**66 894**	**68 510**	**52**	**804**	**4 078**	**31 721**	**31 907**	**193 648**
R03BB01	ipratropium bromide	38 289	35 884	32 181	28 751	28 636	58	800	3 502	12 437	11 897	22 103
R03BB04	tiotropium bromide	27 429	32 809	39 704	41 458	40 771	49	10	556	19 317	20 888	158 164
R03BB05	aclidinium bromide	0	0	0	1 518	2 631	48	0	64	1 293	1 274	6 415
R03BB06	glycopyrronium bromide	0	0	0	1 899	2 873	48	0	56	1 523	1 294	6 966
R03BC	**Antiallergic agents, excl. corticosteroids**	**454**	**430**	**383**	**345**	**362**	**59**	**24**	**118**	**171**	**49**	**252**

ATC group R

ATC level		2010	2011	2012	2013	2014	Share of women (%)	2014 Number of individuals per age group				2014 Sales in 1000 NOK
		Number of individuals						<15	15–44	45–69	≥70	
R03BC01	cromoglicic acid	454	430	383	345	362	59	24	118	171	49	252
R03C	**ADRENERGICS FOR SYSTEMIC USE**	**63 272**	**40 582**	**33 966**	**27 069**	**23 135**	**49**	**17 138**	**2 212**	**2 768**	**1 017**	**3 251**
R03CA	**Alpha- and beta-adrenoreceptor agonists**	**49 364**	**23 993**	**17 522**	**12 615**	**8 810**	**51**	**5 278**	**1 404**	**1 660**	**468**	**1 629**
R03CA02	ephedrine	49 364	23 993	17 522	12 615	8 810	51	5 278	1 404	1 660	468	1 629
R03CC	**Selective beta-2-adrenoreceptor agonists**	**16 917**	**17 886**	**17 339**	**14 953**	**14 722**	**48**	**12 233**	**817**	**1 120**	**552**	**1 622**
R03CC02	salbutamol	4 731	4 844	4 351	3 497	3 122	48	2 550	216	240	116	250
R03CC03	terbutaline	12 109	12 968	12 926	11 371	11 491	47	9 781	580	774	356	1 140
R03CC12	bambuterol	245	210	219	206	219	57	0	22	116	81	233
R03D	**OTHER SYSTEMIC DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES**	**41 123**	**42 178**	**42 327**	**41 450**	**40 863**	**56**	**7 462**	**10 257**	**16 309**	**6 835**	**77 772**
R03DA	**Xanthines**	**4 785**	**4 300**	**3 856**	**3 431**	**3 047**	**59**	**<5**	**166**	**1 499**	**1 379**	**3 682**
R03DA02	choline theophyllinate	10	6	8	7	6	100	0	<5	5	0	22
R03DA04	theophylline	4 768	4 288	3 844	3 417	3 038	59	<5	163	1 493	1 379	3 607
R03DA05	aminophylline	19	19	14	17	10	70	0	<5	8	0	54
R03DC	**Leukotriene receptor antagonists**	**37 220**	**38 267**	**38 587**	**37 874**	**37 483**	**56**	**7 448**	**10 013**	**14 778**	**5 244**	**31 200**
R03DC01	zafirlukast	22	22	21	19	18	61	0	<5	9	8	182
R03DC03	montelukast	37 199	38 245	38 567	37 857	37 465	56	7 448	10 012	14 769	5 236	31 018
R03DX	**Other systemic drugs for obstructive airway diseases**	**145**	**751**	**1 058**	**1 303**	**1 453**	**50**	**22**	**239**	**680**	**512**	**42 889**
R03DX05	omalizumab	84	133	175	256	415	62	22	230	156	7	38 968
R03DX07	roflumilast	61	620	885	1 049	1 038	46	0	9	524	505	3 921
R05	**COUGH AND COLD PREPARATIONS**	**382 371**	**422 433**	**413 274**	**375 144**	**355 911**	**59**	**26 121**	**113 982**	**147 371**	**68 437**	**74 082**
R05C	**EXPECTORANTS, EXCL. COMBINATIONS WITH COUGH SUPPRESSANTS**	**135 840**	**147 156**	**135 972**	**113 567**	**104 452**	**57**	**6 031**	**20 758**	**42 974**	**34 689**	**35 565**
R05CA	**Expectorants**	**3 671**	**4 351**	**3 935**	**3 977**	**5 164**	**56**	**2 190**	**1 191**	**1 126**	**657**	**398**
R05CA10	combinations[1)]	3 671	4 351	3 935	3 977	5 164	56	2 190	1 191	1 126	657	398
R05CB	**Mucolytics**	**132 821**	**143 557**	**132 685**	**110 178**	**99 999**	**57**	**3 914**	**19 718**	**42 135**	**34 232**	**35 167**
R05CB01	acetylcysteine[1)]	128 953	139 329	128 839	106 696	96 305	57	2 209	19 095	41 346	33 655	27 028
R05CB02	bromhexine[1)]	4 658	4 974	4 549	4 134	4 337	53	1 701	715	1 055	866	702
R05CB12	tiopronin	5	<5	<5	<5	<5	50	0	<5	<5	0	42
R05CB13	dornase alfa (desoxyribonuclease)	118	128	130	129	146	54	48	85	12	<5	7 395
R05D	**COUGH SUPPRESSANTS, EXCL. COMBINATIONS WITH EXPECTORANTS**	**254 586**	**283 928**	**281 002**	**259 319**	**246 860**	**60**	**18 410**	**87 908**	**104 240**	**36 302**	**33 984**

[1)] The ATC level comprises OTC medicinal products. The number of individuals is registered for prescription sales only.

ATC level		2010	2011	2012	2013	2014	Share of women (%)	2014				2014
		Number of individuals						Number of individuals per age group				Sales in 1000 NOK
								<15	15–44	45–69	≥70	
R05DA	**Opium alkaloids and derivatives**	**254 586**	**283 928**	**281 002**	**259 319**	**246 860**	**60**	**18 410**	**87 908**	**104 240**	**36 302**	**33 984**
R05DA01	ethylmorphine	245 677	274 413	271 657	250 796	238 475	60	17 988	85 190	100 496	34 801	31 140
R05DA03	hydrocodone	592	592	543	514	442	61	<5	83	233	125	165
R05DA04	codeine	7 203	7 752	7 704	6 904	6 711	64	57	2 377	3 107	1 170	1 866
R05DA07	noscapine[1)]	1 880	1 952	1 664	1 636	1 769	60	379	569	589	232	168
R05DA09	dextromethorphan	<5	0	<5	<5	0	–	0	0	0	0	0
R05DA20	combinations	2 836	2 918	2 979	2 631	2 618	61	38	770	1 317	493	647
R05F	**COUGH SUPPRESSANTS AND EXPECTORANTS, COMBINATIONS**	**41 844**	**48 192**	**49 235**	**46 193**	**44 507**	**62**	**2 734**	**16 302**	**18 782**	**6 689**	**4 532**
R05FA	**Opium derivatives and expectorants**	**41 844**	**48 192**	**49 235**	**46 193**	**44 507**	**62**	**2 734**	**16 302**	**18 782**	**6 689**	**4 532**
R05FA02	opium derivatives and expectorants	41 844	48 192	49 235	46 193	44 507	62	2 734	16 302	18 782	6 689	4 532
R06	**ANTIHISTAMINES FOR SYSTEMIC USE**	**511 537**	**529 217**	**544 575**	**555 485**	**615 083**	**58**	**80 488**	**256 810**	**215 914**	**61 871**	**188 886**
R06A	**ANTIHISTAMINES FOR SYSTEMIC USE**	**511 537**	**529 217**	**544 575**	**555 485**	**615 083**	**58**	**80 488**	**256 810**	**215 914**	**61 871**	**188 886**
R06AA	**Aminoalkyl ethers**	**15**	**14**	**23**	**29**	**44**	**70**	**<5**	**10**	**20**	**12**	**134**
R06AA02	diphenhydramine	<5	0	6	11	5	40	0	<5	<5	0	6
R06AA04	clemastine	14	14	17	18	20	75	<5	<5	9	5	30
R06AA52	diphenhydramine, combinations	0	0	0	0	19	74	0	<5	10	7	97
R06AB	**Substituted alkylamines**	**25 263**	**22 719**	**20 363**	**19 417**	**17 795**	**66**	**4 005**	**6 396**	**5 057**	**2 337**	**6 619**
R06AB02	dexchlorpheniramine	25 263	22 719	20 363	19 417	17 795	66	4 005	6 396	5 057	2 337	6 619
R06AD	**Phenothiazine derivatives**	**64 453**	**65 875**	**66 127**	**66 678**	**69 781**	**62**	**3 692**	**25 060**	**30 730**	**10 299**	**39 211**
R06AD01	alimemazine	57 913	59 728	60 223	60 961	63 794	62	3 644	22 557	28 242	9 351	36 435
R06AD02	promethazine	7 154	6 719	6 464	6 242	6 509	69	52	2 710	2 749	998	2 766
R06AD03	thiethylperazine	5	<5	5	6	5	80	0	<5	0	<5	10
R06AE	**Piperazine derivatives**	**285 404**	**293 955**	**285 833**	**277 991**	**297 573**	**58**	**39 502**	**118 180**	**106 405**	**33 486**	**64 902**
R06AE03	cyclizine[1)]	737	759	731	774	835	71	26	246	357	206	437
R06AE05	meclozine[1)]	2 031	2 165	2 271	2 613	2 982	89	78	2 277	388	239	283
R06AE07	cetirizine[1)]	282 294	290 730	282 583	274 382	293 591	58	39 395	115 649	105 517	33 030	63 642
R06AE09	levocetirizine	703	661	611	572	619	63	18	272	272	57	539
R06AX	**Other antihistamines for systemic use**	**169 564**	**178 145**	**206 281**	**223 948**	**268 330**	**58**	**38 033**	**123 310**	**87 551**	**19 436**	**78 021**
R06AX02	cyproheptadine	40	17	24	31	32	72	5	8	10	9	34
R06AX13	loratadine[1)]	83 864	82 823	71 385	61 729	62 748	60	2 922	28 591	24 510	6 725	17 154
R06AX17	ketotifen	7	10	9	10	7	57	0	<5	<5	<5	12
R06AX22	ebastine[1)]	10 315	10 432	9 816	9 205	9 556	65	104	4 055	4 457	940	6 490

[1)] The ATC level comprises OTC medicinal products. The number of individuals is registered for prescription sales only.

ATC group R

ATC level		2010	2011	2012	2013	2014		2014				2014
		Number of individuals					Share of women (%)	Number of individuals per age group				Sales in 1000 NOK
								<15	15–44	45–69	≥70	
R06AX26	fexofenadine	27 017	30 412	29 345	29 771	34 437	62	751	17 802	12 932	2 952	11 943
R06AX27	desloratadine	55 048	60 505	103 482	129 266	168 993	56	34 641	76 917	48 167	9 268	42 388
R06AX29	bilastine	0	0	0	0	<5	67	0	0	<5	0	1
R07	**OTHER RESPIRATORY SYSTEM PRODUCTS**	**0**	**0**	**<5**	**12**	**15**	**53**	**<5**	**8**	**<5**	**0**	**15 500**
R07A	**OTHER RESPIRATORY SYSTEM PRODUCTS**	**0**	**0**	**<5**	**12**	**15**	**53**	**<5**	**8**	**<5**	**0**	**15 500**
R07AX	**Other respiratory system products**	**0**	**0**	**<5**	**9**	**8**	**38**	**<5**	**6**	**0**	**0**	**15 426**
R07AX02	ivacaftor	0	0	<5	9	8	38	<5	6	0	0	15 426

3.17 ATC group S – Sensory organs

ATC level		2010	2011	2012	2013	2014		2014				2014
		Number of individuals					Share of women (%)	Number of individuals per age group				Sales in 1000 NOK
								<15	15–44	45–69	≥70	
S	**SENSORY ORGANS**	**609 467**	**617 742**	**618 314**	**612 715**	**652 081**	**57**	**117 478**	**191 918**	**204 888**	**137 797**	**334 902**
S01	**OPHTHALMOLOGICALS**	**538 818**	**549 815**	**547 600**	**540 362**	**576 833**	**57**	**103 206**	**168 019**	**177 150**	**128 458**	**318 051**
S01A	**ANTIINFECTIVES**	**269 034**	**266 933**	**262 214**	**249 591**	**251 061**	**55**	**69 026**	**72 644**	**72 927**	**36 464**	**46 875**
S01AA	**Antibiotics**	**266 185**	**264 028**	**259 211**	**246 579**	**247 984**	**55**	**68 902**	**71 609**	**71 706**	**35 767**	**45 325**
S01AA01	chloramphenicol	197 212	200 731	197 307	185 720	191 810	55	46 324	58 031	58 766	28 689	38 296
S01AA02	chlortetracycline	<5	<5	<5	0	6	83	0	<5	<5	<5	2
S01AA11	gentamicin	1 702	1 597	1 252	111	41	66	<5	15	18	7	13
S01AA12	tobramycin	2 302	2 322	2 028	1 783	1 625	58	204	497	553	371	168
S01AA13	fusidic acid	82 810	75 325	71 484	64 306	60 601	57	25 803	14 261	13 312	7 225	5 264
S01AA26	azithromycin	0	0	2 795	8 981	6 921	60	2 256	2 001	1 864	800	775
S01AA30	combinations of different antibiotics	5 105	5 269	4 340	4 797	5 572	58	274	1 228	2 134	1 936	807
S01AD	**Antivirals**	**3 266**	**3 171**	**3 399**	**3 230**	**3 288**	**57**	**128**	**895**	**1 337**	**928**	**864**
S01AD03	aciclovir	3 266	3 171	3 399	3 230	3 288	57	128	895	1 337	928	864
S01AE	**Fluoroquinolones**	**2 138**	**2 327**	**2 468**	**2 613**	**2 667**	**56**	**138**	**1 068**	**979**	**482**	**664**
S01AE03	ciprofloxacin	2 138	2 327	2 468	2 613	2 667	56	138	1 068	979	482	664
S01AX	**Other antiinfectives**	**<5**	**<5**	**<5**	**<5**	**7**	**43**	**0**	**5**	**<5**	**0**	**22**
S01AX09	chlorhexidine	0	0	0	<5	<5	50	0	<5	<5	0	8
S01AX15	propamidine	0	<5	<5	<5	<5	50	0	<5	<5	0	1
S01AX18	povidone-iodine	0	0	0	0	<5	50	0	<5	0	0	0
S01B	**ANTIINFLAMMATORY AGENTS**	**45 945**	**46 769**	**49 872**	**51 179**	**53 569**	**58**	**2 037**	**9 428**	**19 587**	**22 517**	**18 126**
S01BA	**Corticosteroids, plain**	**30 638**	**31 478**	**33 551**	**33 532**	**35 388**	**58**	**1 978**	**8 517**	**13 945**	**10 948**	**11 578**
S01BA01	dexamethasone	18 993	20 148	20 502	20 553	21 826	55	560	4 725	9 240	7 301	8 009
S01BA04	prednisolone	11 840	10 925	13 613	13 742	14 639	59	1 379	4 585	5 546	3 129	2 362
S01BA07	fluorometholone	16	12	12	7	9	56	0	<5	<5	<5	9
S01BA09	clobetasone	16	13	16	15	13	54	0	<5	6	<5	30
S01BA13	rimexolone	4 351	4 414	4 285	4 162	4 096	57	207	948	1 578	1 363	1 169
S01BB	**Corticosteroids and mydriatics in combination**	**<5**	**<5**	**<5**	**<5**	**0**	**–**	**0**	**0**	**0**	**0**	**0**
S01BB03	fluorometholone andmydriatics	<5	<5	<5	<5	0	–	0	0	0	0	0
S01BC	**Antiinflammatory agents, non-steroids**	**17 141**	**17 568**	**18 734**	**20 187**	**21 192**	**57**	**73**	**1 387**	**6 733**	**12 999**	**6 549**
S01BC03	diclofenac	15 814	11 689	7 413	6 137	6 018	56	50	855	2 167	2 946	1 350
S01BC10	nepafenac	1 528	6 095	10 294	9 113	9 780	58	10	218	2 947	6 605	3 922
S01BC11	bromfenac	0	0	1 372	5 325	5 708	56	13	328	1 734	3 633	1 277
S01C	**ANTIINFLAMMATORY AGENTS AND ANTIINFECTIVES IN COMBINATION**	**56 906**	**57 674**	**57 855**	**57 314**	**58 514**	**57**	**1 269**	**8 823**	**20 944**	**27 478**	**11 647**

ATC group S

ATC level		2010	2011	2012	2013	2014		2014				2014
		Number of individuals					Share of women (%)	Number of individuals per age group				Sales in 1000 NOK
								<15	15–44	45–69	≥70	
S01CA	**Corticosteroids and antiinfectives in combination**	**56 906**	**57 674**	**57 855**	**57 314**	**58 514**	**57**	**1 269**	**8 823**	**20 944**	**27 478**	**11 647**
S01CA01	dexamethasone and antiinfectives	56 906	57 674	57 855	57 314	58 514	57	1 269	8 823	20 944	27 478	11 647
S01E	**ANTIGLAUCOMA PREPARATIONS AND MIOTICS**	**70 039**	**70 786**	**71 402**	**72 192**	**72 795**	**56**	**257**	**2 157**	**21 627**	**48 754**	**136 344**
S01EA	**Sympathomimetics in glaucoma therapy**	**4 077**	**4 222**	**4 446**	**4 920**	**5 139**	**52**	**<5**	**203**	**1 384**	**3 549**	**4 804**
S01EA01	epinephrine	<5	<5	<5	<5	0	–	0	0	0	0	0
S01EA02	dipivefrine	9	<5	0	0	0	–	0	0	0	0	0
S01EA03	apraclonidine	115	122	145	155	192	48	<5	21	61	108	137
S01EA05	brimonidine	3 983	4 122	4 351	4 805	4 997	53	<5	186	1 334	3 476	4 667
S01EB	**Parasympathomimetics**	**1 291**	**1 254**	**1 179**	**1 012**	**922**	**60**	**5**	**53**	**263**	**601**	**948**
S01EB01	pilocarpine	1 289	1 253	1 178	1 012	922	60	5	53	263	601	948
S01EB02	carbachol	<5	<5	<5	<5	0	–	0	0	0	0	0
S01EC	**Carbonic anhydrase inhibitors**	**10 040**	**10 322**	**10 647**	**10 892**	**11 047**	**56**	**142**	**685**	**2 831**	**7 389**	**13 886**
S01EC01	acetazolamide	1 699	1 828	1 926	1 840	1 766	55	58	502	622	584	1 401
S01EC03	dorzolamide	2 503	2 393	2 342	2 357	2 434	58	15	63	580	1 776	3 207
S01EC04	brinzolamide	6 195	6 452	6 759	7 109	7 267	56	76	135	1 740	5 316	9 275
S01EC05	methazolamide	0	0	0	0	<5	100	0	<5	0	<5	3
S01ED	**Beta blocking agents**	**48 841**	**49 028**	**49 468**	**49 878**	**50 189**	**55**	**167**	**1 209**	**14 917**	**33 896**	**65 796**
S01ED01	timolol	22 326	21 731	21 600	21 606	21 488	56	140	529	7 163	13 656	22 969
S01ED02	betaxolol	1 778	1 587	1 433	1 247	1 149	65	6	20	250	873	792
S01ED51	timolol, combinations	27 060	27 984	28 616	29 164	29 550	54	36	723	8 173	20 618	42 034
S01EE	**Prostaglandin analogues**	**36 697**	**37 171**	**37 056**	**37 446**	**37 945**	**57**	**34**	**724**	**10 518**	**26 669**	**50 910**
S01EE01	latanoprost	27 890	26 156	24 231	23 338	23 690	57	13	408	6 279	16 990	20 227
S01EE03	bimatoprost	1 867	1 871	2 061	2 247	2 343	57	<5	67	674	1 600	3 563
S01EE04	travoprost	5 035	6 464	7 197	7 095	6 455	54	<5	114	1 729	4 611	10 623
S01EE05	tafluprost	3 068	4 029	4 999	5 994	6 577	62	20	169	2 179	4 209	16 497
S01F	**MYDRIATICS AND CYCLOPLEGICS**	**5 066**	**5 041**	**5 318**	**5 318**	**5 334**	**47**	**409**	**1 291**	**2 369**	**1 265**	**985**
S01FA	**Anticholinergics**	**5 062**	**5 038**	**5 312**	**5 311**	**5 320**	**47**	**408**	**1 286**	**2 365**	**1 261**	**977**
S01FA01	atropine	2 549	2 323	2 323	2 185	2 002	46	329	431	808	434	381
S01FA02	scopolamine	0	0	0	0	<5	100	0	0	<5	0	29
S01FA04	cyclopentolate	2 546	2 746	3 069	3 177	3 367	47	76	881	1 572	838	533
S01FA06	tropicamide	189	164	140	139	167	49	13	66	74	14	34
S01FA54	cyclopentolate, combinations	0	0	0	<5	0	–	0	0	0	0	0

ATC level		2010	2011	2012	2013	2014		2014				2014
		Number of individuals					Share of women (%)	Number of individuals per age group				Sales in 1000 NOK
								<15	15–44	45–69	≥70	
S01FB	**Sympathomimetics excl. antiglaucoma preparations**	**29**	**35**	**33**	**28**	**46**	**46**	**<5**	**15**	**23**	**7**	**8**
S01FB01	phenylephrine	29	35	33	28	46	46	<5	15	23	7	8
S01G	**DECONGESTANTS AND ANTIALLERGICS**	**158 625**	**167 530**	**163 501**	**163 518**	**195 537**	**58**	**35 102**	**88 307**	**58 126**	**14 002**	**56 137**
S01GA	**Sympathomimetics used as decongestants**	**20 728**	**21 288**	**20 300**	**19 136**	**21 903**	**60**	**2 476**	**10 030**	**7 587**	**1 810**	**6 472**
S01GA51	naphazoline, combinations	<5	6	<5	0	0	–	0	0	0	0	0
S01GA52	tetryzoline, combinations	20 725	21 283	20 297	19 136	21 903	60	2 476	10 030	7 587	1 810	6 472
S01GX	**Other antiallergics**	**141 091**	**149 662**	**146 552**	**147 512**	**177 563**	**58**	**33 350**	**80 115**	**51 691**	**12 407**	**49 665**
S01GX01	cromoglicic acid[1)]	22 551	23 401	22 545	21 636	25 240	61	3 782	10 882	8 501	2 075	6 210
S01GX02	levocabastine[1)]	70 567	75 499	73 827	75 061	91 745	57	18 643	41 545	25 672	5 885	22 726
S01GX04	nedocromil	1 777	1 702	1 442	1 395	1 167	58	114	576	403	74	217
S01GX06	emedastine	379	384	376	345	384	63	59	144	137	44	139
S01GX07	azelastine	580	553	531	508	616	59	91	265	183	77	144
S01GX08	ketotifen[1)]	16 305	17 279	16 686	17 238	21 001	58	3 850	9 391	6 277	1 483	8 239
S01GX09	olopatadine	32 856	35 349	35 456	35 267	43 202	56	8 429	19 590	12 024	3 159	11 991
S01X	**OTHER OPHTHALMOLOGICALS**	**26 371**	**34 504**	**40 602**	**45 774**	**52 948**	**75**	**438**	**5 176**	**22 163**	**25 171**	**47 825**
S01XA	**Other ophthalmologicals**	**26 371**	**34 504**	**40 602**	**45 774**	**52 948**	**75**	**438**	**5 176**	**22 163**	**25 171**	**47 825**
S01XA03	sodium chloride, hypertonic	15	17	10	15	21	57	0	0	<5	17	24
S01XA18	ciclosporin	70	112	252	474	601	75	19	130	315	137	9 891
S01XA20	artificial tears and other indifferent preparations[1)]	26 329	34 451	40 510	45 650	52 762	75	422	5 136	22 077	25 127	37 910
S02	**OTOLOGICALS**	**14 933**	**20 226**	**18 711**	**20 091**	**22 983**	**53**	**3 728**	**6 264**	**9 196**	**3 795**	**4 549**
S02A	**ANTIINFECTIVES**	**7 346**	**10 565**	**9 590**	**8 282**	**7 548**	**47**	**2 701**	**2 214**	**1 981**	**652**	**1 359**
S02AA	**Antiinfectives**	**7 346**	**10 565**	**9 590**	**8 282**	**7 548**	**47**	**2 701**	**2 214**	**1 981**	**652**	**1 359**
S02AA01	chloramphenicol	75	75	17	11	11	36	<5	<5	<5	<5	15
S02AA03	boric acid	0	0	0	7	<5	0	<5	0	<5	0	2
S02AA15	ciprofloxacin	7 290	10 501	9 576	8 264	7 536	47	2 698	2 212	1 976	650	1 342
S02B	**CORTICOSTEROIDS**	**7 847**	**10 185**	**9 549**	**10 784**	**10 852**	**60**	**221**	**2 629**	**5 593**	**2 409**	**2 192**
S02BA	**Corticosteroids**	**7 847**	**10 185**	**9 549**	**10 784**	**10 852**	**60**	**221**	**2 629**	**5 593**	**2 409**	**2 192**
S02BA07	betamethasone	7 847	10 185	9 549	10 784	10 852	60	221	2 629	5 593	2 409	2 192
S02C	**CORTICOSTEROIDS AND ANTIINFECTIVES IN COMBINATION**	**66**	**104**	**91**	**1 764**	**5 606**	**50**	**943**	**1 748**	**2 043**	**872**	**999**
S02CA	**Corticosteroids and antiinfectives in combination**	**66**	**104**	**91**	**1 764**	**5 606**	**50**	**943**	**1 748**	**2 043**	**872**	**999**
S02CA02	flumetasone and antiinfectives	66	104	91	64	44	52	5	8	22	9	8

[1)] The ATC level comprises OTC medicinal products. The number of individuals is registered for prescription sales only.

ATC group S

ATC level		2010	2011	2012	2013	2014		2014				2014
		Number of individuals					Share of women (%)	Number of individuals per age group				Sales in 1000 NOK
								<15	15–44	45–69	≥70	
S02CA05	fluocinolone acetonide and antiinfectives	0	0	0	1 702	5 564	50	938	1 740	2 023	863	991
S03	**OPHTHALMOLOGICAL AND OTOLOGICAL PREPARATIONS**	**77 041**	**68 909**	**73 479**	**73 853**	**75 886**	**54**	**14 942**	**23 484**	**26 889**	**10 571**	**12 302**
S03C	**CORTICOSTEROIDS AND ANTIINFECTIVES IN COMBINATION**	**77 041**	**68 909**	**73 479**	**73 853**	**75 886**	**54**	**14 942**	**23 484**	**26 889**	**10 571**	**12 302**
S03CA	**Corticosteroids and antiinfectives in combination**	**77 041**	**68 909**	**73 479**	**73 853**	**75 886**	**54**	**14 942**	**23 484**	**26 889**	**10 571**	**12 302**
S03CA01	dexamethasone and antiinfectives	14 416	24 937	11 256	12 789	12 872	56	1 644	3 624	5 317	2 287	1 669
S03CA04	hydrocortisone and antiinfectives	65 038	47 812	64 616	63 093	64 974	53	13 555	20 401	22 436	8 582	10 633

3.18 ATC group V – Various

ATC level		2010	2011	2012	2013	2014		2014				2014
		Number of individuals					Share of women (%)	Number of individuals per age group				Sales in 1000 NOK
								<15	15–44	45–69	≥70	
V	**VARIOUS**	**15 898**	**18 601**	**21 869**	**23 890**	**27 402**	**51**	**3 455**	**8 839**	**9 572**	**5 536**	**108 419**
V01	**ALLERGENS**	**7 289**	**8 273**	**8 927**	**9 462**	**10 346**	**47**	**1 913**	**6 582**	**1 802**	**49**	**59 183**
V01A	**ALLERGENS**	**7 289**	**8 273**	**8 927**	**9 462**	**10 346**	**47**	**1 913**	**6 582**	**1 802**	**49**	**59 183**
V01AA	**Allergen extracts**	**7 289**	**8 273**	**8 927**	**9 462**	**10 346**	**47**	**1 913**	**6 582**	**1 802**	**49**	**59 183**
V01AA02	grass pollen	5 033	5 758	6 330	6 829	7 481	45	1 253	5 085	1 127	16	33 838
V01AA03	house dust mites	349	426	488	539	551	46	111	349	87	<5	3 405
V01AA05	tree pollen	4 150	4 670	4 874	4 896	5 288	50	1 002	3 255	1 004	27	16 776
V01AA07	insects	183	181	156	160	148	53	13	42	83	10	843
V01AA10	flowers	108	141	149	149	118	59	7	71	40	0	586
V01AA11	animals	288	382	425	494	525	54	94	318	112	<5	3 735

Noen forkortelser og definisjoner / Some abbreviations and definitions

ATC	Anatomisk Terapeutisk Kjemisk (klassifikasjonssystem for legemidler)	Anatomical Therapeutical Chemical (classification system for medicines)
DDD	Definert døgndose	Defined Daily Doses
EEA	–	European Economic Association
EØS	Europeisk økonomisk samarbeid	–
FHI	Folkehelseinstituttet	–
GP	–	General Practitioner
ICD -10	–	International Classification of Diseases version 10
ICPC-2	–	International Classification of Primary Care version 2
MA	Markedsføringstillatelse	Marketing Authorisation
NIPH	–	Norwegian Institute of Public Health
NMD	Norsk Medisinaldepot	Norwegian Medicinal Depot (wholesaler)
NOK	Norske kroner	Norwegian kroner
NorPD	Reseptregisteret	Norwegian Prescription Database
NSAID	Ikke-steroid antiinflammatorisk legemiddel	Non Steroidal Anti-Inflammatory Drug
OTC	Reseptfritt	Over The Counter, non prescription drugs
SPC	–	Summary of Product Characteristics
SSB	Statistisk sentralbyrå	Statistics Norway
WHO	Verdens helseorganisasjon	World Health Organization

Definisjoner

Prevalens
Brukere (individer) defineres som personer som har hentet minst én resept på apotek i perioden. Prevalens er definert som antall brukere per 100 innbyggere (%) i det definerte befolkningsutvalget.

Insidens (nye brukere)
Insidens er antall brukere av et bestemt legemiddel eller en legemiddelgruppe i en definert tidsperiode som ikke var brukere i en tidligere, definert periode. Insidens kan også uttrykkes som andel (%) i forhold til antallet potensielle nye brukere i det definerte befolkningsutvalget.

Definitions

Prevalence
Users (individuals) are defined as persons who had at least one prescription dispensed at pharmacies in the period. Prevalence is defined as the number of users per 100 inhabitants (%) in the defined population sample.

Incidence (new users)
Incidence is the number of users of a particular drug or drug group in a defined time period who were not users in a previous, defined time period. Incidence can be expressed as a percentage relative to the number of potential users in the defined population sample.

Folkemengde i Norge 2010–2014 (per 1. juli)/ Population in Norway 2010–2014 (as of 1st July)

Year	2010	2011	2012	2013	2014
Population	4 888 946	4 953 217	5 018 415	5 080 148	5 137 321

Folkemengde etter alder i 2014 (per 1. juli)/ Population by age in 2014 (as of 1st July)

Age groups	<15	15–44	45–69	≥70
Population	899 798	2 071 907	1 593 451	572 166

Kilde: Statistisk sentralbyrå / Source: Statistics Norway

Liste over publikasjoner basert på data fra Reseptregisteret per mars 2015 / List of publications based on data from the Norwegian Prescription Database (NorPD) as of March 2015

2015:

Berg C, Skurtveit S, Sakshaug S, Hjellvik V, Handal M. Reduced Prescribing of Benzodiazepines in Denmark and Norway. Basic Clin Pharmacol Toxicol. 2015 Jan 23;[Epub ahead of print]. doi: 10.1111/bcpt.12377.

Engeland A, Bjorge T, Klungsoyr K, Skjaerven R, Skurtveit S, Furu K. Preeclampsia in pregnancy and later use of antihypertensive drugs. Eur J Epidemiol. 2015 Mar 18;[Epub ahead of print]. doi: 10.1007/s10654–015 – 0018–5.

Foshaug M, Vandbakk-Ruther M, Skaare D, Grude N, Lindbaek M. Mycoplasma pneumoniae detection causes excess antibiotic use in Norwegian general practice: a retrospective case-control study. Br J GenPract. 2015 Feb;65:e82–8.

Fredheim OM, Mahic M, Skurtveit S, Borchgrevink PC. Use of nasal fentanyl for cancer pain: A pharmacoepidemiological study. PalliatMed. 2015 Mar 11;[Epub ahead of print]. doi: 10.1177/0269216315575252

Hermann M, Waade RB, Molden E. Therapeutic drug monitoring of selective serotonin reuptake inhibitors in elderly patients. Ther Drug Monit. 2015 Jan 6;[Epub ahead of print]. doi: 10.1097/FTD.0000000000000169.

Magnus MC, Haberg SE, Karlstad O, Nafstad P, London SJ, Nystad W. Grandmother's smoking when pregnant with the mother and asthma in the grandchild: the Norwegian Mother and Child Cohort Study. Thorax. 2015;70:237–43.

Skrede S, Tvete IF, Tanum L, Steen VM, Bramness JG. Incident users of antipsychotic agents and future use of cholesterol-lowering drugs: an observational, pharmacoepidemiologic study. J Clin Psychiatry. 2015;76:e111–6.

2014:

Andersen JB, Heldal AT, Engeland A, Gilhus NE. Myasthenia gravis epidemiology in a national cohort; combining multiple disease registries. Acta Neurol Scand Suppl. 2014;129:26-31

Andersen JB, Owe JF, Engeland A, Gilhus NE. Total drug treatment and comorbidity in myasthenia gravis: a population-based cohort study. Eur J Neurol 2014;21:948-955

Bakken MS, Engeland A, Engesæter LB, Ranhoff AH, Hunskaar S, Ruths S. Risk of hip fracture among older people using anxiolytic and hypnotic drugs: a nationwide prospective cohort study. Eur J Clin Pharmacol 2014;70:873-880

Berg-Hansen P, Moen S, Harbo H, Celius E. High prevalence and no latitude gradient of multiple sclerosis in Norway. Mult Scler 2014;20:1780-1782

Blix HS, Vestrheim DF, Hjellvik V, Skaare D, Christensen A, Steinbakk M. Antibiotic prescriptions and cycles of Mycoplasma pneumoniae infections in Norway: can a nationwide prescription register be used for surveillance? Epidemiol Infect. 2014 Nov 12;[Epub ahead of print]. doi: 10.1017/S0950268814002908.

Ferrer P, Rafaniello C, Sabate M, Ballarin E, Coma A, Zara C, et al. Cross-national comparison of antiepileptic drug use: Catalonia, Denmark and Norway, 2007-2011. Epidemiology Biostatistics and Public Health. 2014;11:e9405–1.

Fredheim OM, Mahic M, Skurtveit S, Dale O, Romundstad P, Borchgrevink PC. Chronic pain and use of opioids: a population based pharmacoepidemiological study from the Norwegian prescription database and the Nord-Trøndelag health study (HUNT). Pain 2014;155:1213-1221

Gjelsvik B, Heyerdahl F, Lunn D, Hawton K. Change in access to prescribed medication following an episode of deliberate self-poisoning: a multilevel approach. PLoS One. 2014;e98086.

Grytli HH, Fagerland MW, Fosså SD, Taskén KA. Association Between Use of b-Blockers and Prostate Cancer-Specific Survival: A Cohort Study of 3561 Prostate Cancer Patients with High-Risk or Metastatic Disease. European Urology 2014;65:635-641.

Halvorsen T, Martinussen PE. The geography of chronic obstructive pulmonary disease: A population-based study of Norway. Soc Sci Med 2014;21:25-34.

Jensen E, Daniels J, Sturmer T, Robinson W, Williams C, Vejrup K, et al. Hormonal contraceptive use before and after conception in relation to preterm birth and small for gestational age: an observational cohort study. BJOG. 2014 Oct 16;[Epub ahead of print]. doi: 10.1111/1471–0528.13114.

Jensen ET, Daniels JL, Sturmer T, Robinson WR, Williams CJ, Moster D, et al. Maternal hormonal contraceptive use and offspring overweight or obesity. Int J Obes. 2014;38:1275–81.

Kalseth J, Halvorsen T, Kalseth B, Sarheim Anthun K, Peltola M, Kautiainen K, Häkkinen U, Medin E, Lundgren J, Rehnberg C, Másdóttir BB, Heimisdottir M, Bjarnadóttir HH, Køtlum JE, Kilsmark J, Halsteinli V. Cross-country comparisons of health-care costs: The case of cancer treatment in the Nordic countries. Health Policy 2014:115;172-179.

Kann IC, Lundqvist C, Luras H. Prescription of addictive and non-addictive drugs to home-dwelling elderly. Drugs Aging. 2014 Jun;31(6):453–9.

Karlstad Ø, Furu K, Skurtveit S, Selmer R. Prescribing of Drugs for Attention-Deficit Hyperactivity Disorder in Opioid Maintenance Treatment Patients in Norway. Eur Addict Res 2014;20:59-65.

Kieler H, Malm H, Artama M, Engeland A, Furu K, Gissler M, et al. Use of antidepressants and association with elective termination of pregnancy: population based case-control study. BJOG. 2014 Nov 14;[Epub ahead of print]:doi: 10.1111/1471–0528.13164.

Kielland KB, Amundsen EJ, Dalgard O. HCV treatment uptake in people who have injected drugs - observations in a large cohort that received addiction treatment 1970-1984. Scand J Gastroenterol. 2014 Dec;49(12):1465–72.

Langballe EM, Engdahl B, Nordeng H, Ballard C, Aarsland D, Selbaek G. Short- and Long-Term Mortality Risk Associated with the Use of Antipsychotics Among 26,940 Dementia Outpatients: A Population-Based Study. Am J Geriatr Psychiatry 2014;22:321-331.

Mahic M, Fredheim OM, Borchgrevink PC, Skurtveit S. Use of prescribed opioids by children and adolescents: Differences between Denmark, Norway and Sweden. Eur J Pain. 2014 Nov 20;[Epub ahead of print]: doi 10.1002/ejp.632.

Mellbye A, Karlstad O, Skurtveit S, Borchgrevink PC, Fredheim OM. Co-morbidity in persistent opioid users with chronic non-malignant pain in Norway. Eur J Pain. 2014;18:1083-1093

Neutel CI, Skurtveit S, Berg C, Sakshaug S. Trends in prescription of strong opioids for 41-80 year old Norwegians, 2005-2010. Eur J Pain. 2014 Mar;18(3):438–46.

Nordfjærn T, Bjerkeset O, Bratberg G, Moylan S, Berk M, Grawe R. Socio-demographic, lifestyle and psychological predictors of benzodiazepine and z-hypnotic use patterns. Nord J Psychiatry 2014;68:107-116.

Norum J, Olsen AI, Nohr FI, Heyd A, Totth A. Medical treatment of children and youths with attention-deficit/hyperactivity disorder (ADHD): a Norwegian Prescription Registry Based Study. GlobJ Health Sci. 2014 Jul;6(4):155–62.

Omland G, Ruths S, Diaz E. Use of hormonal contraceptives among immigrants and native women in Norway: data from the Norwegian Prescription Database. BJOG 2014;121:1221-1228

Riska BS, Skurtveit S, Furu K, Engeland A, Handal M. Dispensing of benzodiazepines and benzodiazepine-related drugs to pregnant women: a population-based cohort study. Eur J Clin Pharmacol. 2014 Nov;70(11):1367–74.

Skrivarhaug T, Stene LC, Drivvoll AK, Strom H, Joner G. Incidence of type 1 diabetes in Norway among children aged 0-14 years between 1989 and 2012: has the incidence stopped rising? Results from the Norwegian Childhood Diabetes Registry. Diabetologia 2014;57:57-62.

Skurtveit S, Selmer R, Odsbu I, Handal M. Self-reported data on medicine use in the Norwegian mother and child cohort study compared to data from the Norwegian prescription database. Norsk Epidemiologi. 2014;24(1-2).

Soraas A, Sundsfjord A, Jorgensen SB, Liestol K, Jenum PA. High rate of per oral mecillinam treatment failure in community-acquired urinary tract infections caused by ESBL-producing Escherichia coli. PLoS One. 2014;9:e85889.

Strom H, Selmer R, Birkeland KI, Schirmer H, Berg TJ, Jenum AK, et al. No increase in new users of blood glucose-lowering drugs in Norway 2006-2011: a nationwide prescription database study. BMC Public Health. 2014;14:520.

Svendsen K, Fredheim OM, Romundstad P, Borchgrevink PC, Skurtveit S. Persistent opioid use and socio-economic factors: a population-based study in Norway. Acta Anaesthesiol Scand. 2014;58:437-445.

Søraas A, Sundsfjord A, Jørgensen SB, Liestøl K, Jenum PA. High rate of per oral mecillinam treatment failure in community-acquired urinary tract infections caused by ESBL-producing Escherichia coli. PLoS One. 2014:9;e85889.

2013:

Bakken MS, Engeland A, Engesaeter LB, Ranhoff AH, Hunskaar S, Ruths S. Increased risk of hip fracture among older people using antidepressant drugs: data from the Norwegian Prescription Database and the Norwegian Hip Fracture Registry. Age Ageing 2013;42:514-20.

Berge LI, Riise T, Iversen M. Co-morbidity between diabetes, migraine and depression. Norsk Epidemiologi 2013;23:2013.

Berge LI, Riise T, Fasmer OB, Hundal O, Oedegaard KJ, Midthjell K, et al. Does diabetes have a protective effect on migraine? Epidemiology 2013;24:129-34.

Bjorner T, Tvete IF, Aursnes I, Skomedal T. [Dispensing of benzodiazepines and Z drugs by Norwegian pharmacies 2004-2011]. Tidsskr Nor Laegeforen 2013;133:2149-53.

Brelin S, Loge JH, Skurtveit S, Johannesen TB, Aass N, Ottesen S, et al. Antidepressants to cancer patients during the last year of life--a population-based study. Psychooncology 2013;22:506-14.

Devold HM, Sogaard AJ, Tverdal A, Falch JA, Furu K, Meyer HE. Hip fracture and other predictors of anti-osteoporosis drug use in Norway. Osteoporos Int 2013;24:1225-33.

Engeland A, Bjørge T, Daltveit AK, Skurtveit S, Vangen S, Vollset SE, et al. Effects of preconceptional paternal drug exposure on birth outcomes: Cohort study of 340000 pregnancies using Norwegian population-based databases. British Journal of Clinical Pharmacology 2013;75:1134-41.

Fossum GH, Lindbaek M, Gjelstad S, Dalen I, Kvaerner KJ. Are children carrying the burden of broad-spectrum antibiotics in general practice? Prescription pattern for paediatric outpatients with respiratory tract infections in Norway. BMJ Open 2013;3:e002285.

Fredheim OM, Borchgrevink PC, Mahic M, Skurtveit S. A pharmacoepidemiological cohort study of subjects starting strong opioids for nonmalignant pain: a study from the Norwegian Prescription Database. Pain 201;154:2487-93.

Holdø I, Handal M, Skurtveit S, Bramness JG. Association between prescribing hypnotics for parents and children in Norway. Arch Dis Child 2013;98:732-6.

Hoye S, Gjelstad S, Lindbaek M. Effects on antibiotic dispensing rates of interventions to promote delayed prescribing for respiratory tract infections in primary care. Br J GenPract. 2013;63:e777–86.

Jonasson C, Tvete IF, Hatlebakk JG. Patterns of proton pump inhibitor utilization in gastroesophageal reflux disease and the effect of restrictions on reimbursement: a nationwide prescription database study. Scand J Gastroenterol 2013;48:1010-7.

Klovstad H, Natas O, Tverdal A, Aavitsland P. Systematic screening with information and home sampling for genital Chlamydia trachomatis infections in young men and women in Norway: a randomized controlled trial. BMC Infectious Diseases 2013;13:30.

Kravdal O. The poorer cancer survival among the unmarried in Norway: Is much explained by comorbidities? Social Science and Medicine 2013;81:42-52.

Kvaale MK, Grave K, Kristoffersen AB, Norstrom M. The prescription rate of antibacterial agents in dogs in Norway - geographical patterns and trends during the period 2004-2008. J Vet Pharmacol Ther 2013;36:285-91.

Kyrdalen AE, Dahl AA, Hernes E, Smastuen MC, Fossa SD. A national study of adverse effects and global quality of life among candidates for curative treatment for prostate cancer. BJU Int 2013;111:221-32.

Lillefjell M, Haugan T, Martinussen P, Halvorsen T. Treatment outcomes among individuals in a musculoskeletal pain rehabilitation program related to the prevalence and trends in the dispensing of prescribed medications. Journal of Musculoskeletal Pain 2013;21:311-319.

Log T, Skurtveit S, Selmer R, Tverdal A, Furu K, Hartz I. The association between prescribed opioid use for mothers and children: a record-linkage study. Eur J Clin Pharmacol 2013;69:111-8.

Lund IO, Skurtveit S, Engeland A, Furu K, Ravndal E, Handal M. Prescription drug use among pregnant women in opioid Maintenance Treatment. Addiction 2013;108:367-76.

Mauseth SA, Skurtveit S, Spigset O. Adherence, persistence and switch rates for anticholinergic drugs used for overactive bladder in women: data from the Norwegian Prescription Database. Acta Obstet Gynecol Scand 2013;92:1208-1215.

Neutel CI, Skurtveit S, Berg C, Sakshaug S. Multiple prescribers in older frequent opioid users--does it mean abuse? J Popul Ther Clin Pharmacol 2013;20:e397-e405.

Nezvalova-Henriksen K, Spigset O, Nordeng H. Triptan safety during pregnancy: a Norwegian population registry study. Eur J Epidemiol 2013;28:759-69.

Nordeng H, Lupattelli A, Romøren M, Koren G. Neonatal outcomes after gestational exposure to nitrofurantoin. Obstetrics and Gynecology 2013;121:306-13.

Nordfjaern T, Bjerkeset O, Moylan S, Berk M, Grawe RW. Clusters of personality traits and psychological symptoms associated with later benzodiazepine prescriptions in the general population: The HUNT Cohort Study. Addict Behav 2013;38:2575-80.

Nordfjaern T. Prospective associations between benzodiazepine use and later life satisfaction, somatic pain and psychological health among the elderly. Hum Psychopharmacol 2013;28:248-57.

Persheim MS, Helland A, Spigset O, Slordal L. Potensielt vanedannende legemidler på blåresept ved kroniske sterke smerter. [Potentially addictive drugs on reimbursable prescription for chronic severe pain]. Tidsskrift for den Norske Laegeforening 2013;133:150-4.

Rognstad S, Brekke M, Fetveit A, Dalen I, Straand J. Prescription peer academic detailing to reduce inappropriate prescribing for older patients: a cluster randomised controlled trial. Br J GenPract. 2013;63:e554–62.

Skogar O, Nilsson M, Tornhage CJ, Lokk J. National surveys: a way to manage treatment strategies in Parkinson's disease? Pharmaceutical prescribing patterns and patient experiences of symptom control and their impact on disease. J Multidiscip Healthc 2013;6:239-47.

Skollerud LM, Fredheim OM, Svendsen K, Skurtveit S, Borchgrevink PC. Laxative prescriptions to cancer outpatients receiving opioids: A study from the Norwegian prescription database. Supportive Care in Cancer 2013;21:67-73.

Skurtveit S, Selmer R, Tverdal A, Furu K, Nystad W, Handal M. Drug exposure: inclusion of dispensed drugs before pregnancy may lead to underestimation of risk associations. J Clin Epidemiol 2013;66:964-72.

Stene LE, Jacobsen GW, Dyb G, Tverdal A, Schei B. Intimate partner violence and cardiovascular risk in women: A population-based cohort study. Journal of Women's Health 2013;22:250-8.

Stephansson O, Kieler H, Haglund B, Artama M, Engeland A, Furu K, et al. Selective serotonin reuptake inhibitors during pregnancy and risk of stillbirth and infant mortality. JAMA 2013;309:48-54.

Thelle DS, Selmer R, Gjesdal K, Sakshaug S, Jugessur A, Graff-Iversen S, et al. Resting heart rate and physical activity as risk factors for lone atrial fibrillation: a prospective study of 309,540 men and women. Heart 2013;99:1755-60.

Tvete IF, Bjorner T, Aursnes IA, Skomedal T. A 3-year survey quantifying the risk of dose escalation of benzodiazepines and congeners to identify risk factors to aid doctors to more rationale prescribing. BMJ Open 2013;3:e003296.

Westin AA, Bramness JG, Chalabianloo F, Rygnestad T, Slordal L. [Pregabalin should be moved to the prescription group B]. Tidsskr Nor Laegeforen 2013;133:615-6.

2012:

Berge LI, Riise T, Fasmer OB, Lund A, Oedegaard KJ, Hundal O. Risk of depression in diabetes is highest for young persons using oral anti-diabetic agents. Diabet Med 2012;29:509-14.

Blix HS, Hjellvik V. Økt bruk av antibiotika blant 19-åringer i mai. [Increased use of antibiotics among nineteen-year-olds in May]. Tidsskr Nor Laegeforen 2012;132:1084-8.

Blix HS, Landmark K, Selmer R, Reikvam Å. Forskrivning av antihypertensive legemidler 1975-2010. [Patterns in the prescription of antihypertensive drugs in Norway, 1975 – 2010] Tidsskr Nor Laegeforen 2012;132:1224-8.

Bramness JG, Furu K, Skurtveit S, Engeland A. Effect of withdrawal of carisoprodol on use of other prescribed drugs with abuse potential. Clin Pharmacol Therap 2012;91:438-41.

Bramness JG, Skurtveit S, Mørland J, Engeland A. An increased risk of motor vehicle accidents after prescription of methadone. Addiction 2012;107:967-72.

Devold H, Furu K, Skurtveit S, Tverdal A, Falck JA, Søgård AJ. Influence of socioeconomic factors on the adherence of alendronate treatment in incident users in Norway. Pharmacoepidemiol Drug Saf 2012;21:297-304.

Devold HM, Søgaard AJ, Tverdal A, Falch JA, Furu K, Meyer HE. Hip fracture and other predictors of anti-osteoporosis drug use in Norway. Osteoporosis International 2012;24:1225-33.

Fasmer OB, Riise T, Lund A, Dilsaver SC, Hundal O, Ødegaard KJ. Comorbidity of migraine with ADHD. J Attend Disord 2012;16:339-45.

Fredheim OMS, Moksnes K, Borchgrevink PC, Skurtveit S. Opioid switching to methadone: A pharmacoepidemiological study from a national prescription database. Palliative Medicine 2012;26:804-12.

Fredheim OM, Moksnes K, Borchgrevink PC, Skurtveit S. Opoid switching to methadone: a pharmacoepidemiological study from a national prescription database. Palliat Med 2012;26;804-812.

Gedde-Dahl A, Devold HM, Molden E. Statin medication in patients treated with antiepileptic drugs in Norway. Pharmacoepidemiol Drug Saf 2012;21:881-5.

Gjelsvik B, Heyerdahl F, Hawton K. Prescribed medication availability and deliberate self-poisoning: a longitudinal study. J Clin Psychiatry. 2012;73:e548-54.

Handal M, Skurtveit S, Mørland JG. Samtidig bruk av ulike benzodiazepiner. [Co-medication with benzodiazepines]. Tidsskr Nor Laegeforen. 2012;132:526-30.

Hartz I, Furu K, Bratlid T, Handal M, Skurtveit S. Hypnotic drug use among 0-17 year olds during 2004-2011: A nationwide prescription database study. Scandinavian Journal of Public Health 2012;40:704-11.

Hjellvik V, Mahic M, Tverdal A. Utdanning og legemiddelbruk. [Education and use of drugs in Norway]. Tidsskr Nor Laegeforen 2012;132:2166-70.

Karlstad O, Nafstad P, Tverdal A, Skurtveit S, Furu K. Comorbidities in an asthma population 8-29 years old: A study from the Norwegian Prescription Database. Pharmacoepidemiol Drug Saf 2012;21:1045-52.

Kieler H, Artama M, Engeland A, Ericsson O, Furu K, Gissler M, Nørgaard M, Nielsen RB, Stephansson O, Valdimarsdottir U, Zoega H, Haglund B. Selective serotonin-reuptake inhibitors during pregnancy and risks of persistent pulmonary hypertension of the newborn: population based cohort study from the five Nordic countries BMJ 2012;344:d8012.

Kjome RL, Roraas T, Granas AG, Sandberg S. [Regional differences in sales of glucometer strips and antidiabetics]. Tidsskr Nor Laegeforen 2012;132:1453-7.

Kjosavik SR, Ruths S, Hunskår S. Use of addictive anxiolytics and hypnotics in a national cohort of incident users in Norway. Eur J Clin Pharmacol 2012;68:311-9.

Langhammer A, Krokstad S, Romundstad P, Heggland J, Holmen J. The HUNT study: Participation is associated with survival and depends on socioeconomic status, diseases and symptoms. BMC Medical Research Methodology 2012;12:143.

Lillemoen PKS, Kjosavik SR, Hunskår S, Ruths S. [Prescriptions for ADHD medication, 2004 – 08]. Tidsskr Nor Laegeforen 2012;132:1856-60.

Mellbye A, Svendsen K, Borchgrevink PC, Skurtveit S, Fredheim OMS. Concomitant medication among persistent opioid users with chronic non-malignant pain. Acta Anaesthesiologica Scandinavica 2012;56:1267-76.

Neutel CI, Skurtveit S, Berg C. What is the point of guidelines? Benzodiazepine and z-hypnotic use by an elderly population. Sleep Medicine 2012;13:893-7.

Neutel I, Skurtveit S, Berg C. Polypharmacy of potentially addictive medication in the older persons - quantifying usage. Pharmacoepidemiol Drug Saf 2012;21:199-206

Neutel CI, Skurtveit S, Berg C. Benzodiazepine and z-hypnotic use in Norwegian elderly, aged 65-79. Norsk Epidemiologi 2012;22:203-8.

Nordbø A, Skurtveit S, Borchgrevink PC, Kaasa S, Fredheim OM. Low-dose transdermal buprenorphine - long-term use and co-medication with other potentially addictive drugs. Acta Anaesthesiol Scand. 2012;56:88-94.

Nordfjærn T. A population-based cohort study of anxiety, depression, sleep and alcohol outcomes among benzodiazepine and z-hypnotic users. Addictive Behaviors 2012;37:1151-7.

Nyborg G, Straand J, Brekke M. Inappropriate prescribing for the elderly - A modern epidemic? European Journal of Clinical Pharmacology 2012;68:1085-94.

Pedersen L, Hansen AB, Svendsen K, Skurtveit S, Borchgrevink PC, Fredheim OMS. [Reimbursement of analgesics for chronic pain]. Tidsskr Nor Laegeforen 2012;132:2489-93.

Romoren M, Lindbaek M, Nordeng H. Pregnancy outcome after gestational exposure to erythromycin - a population-based register study from Norway. British Journal of Clinical Pharmacology 2012;74:1053-62.

Rønning PA, Helseth E, Meling TR, Johannesen TB. A population-based study on the effect of temozolomide in the treatment of glioblastoma multiforme. Neuro-Oncology 2012;14:1178-84.

Selmer R, Blix HS, Landmark K, Reikvam Å. Choice of initial antihypertensive drugs and persistence of drug use--a 4-year follow-up of 78,453 incident users. Eur J Clin Pharmacol 2012;68:1435-42.

Skjeldestad FE. [Prescribing contraception for young women]. Tidsskr Nor Laegeforen. 2012;132:292-4.

Steffenak AKM, Wilde-Larsson B, Skurtveit S, Furu K, Nordström G, Hartz I. Mental distress and subsequent use of psychotropic drugs among adolescents - a prospective register linkage study. J Adolescent Health 2012;50:578-87

Steffenak AKM, Wilde-Larsson B, Nordstrom G, Skurtveit S, Hartz I. Increase in psychotropic drug use between 2006 and 2010 among adolescents in Norway: A nationwide prescription database study. Clinical Epidemiology 2012;4:225-31.

Stene LE, Dyb G, Tverdal A, Jacobsen GW, Schei B. Intimate partner violence and prescription of potentially addictive drugs: prospective cohort study of women in the Oslo Health Study. BMJ Open. 2012 Apr 5;2(2):e000614.

Svendal G, Fasmer OB, Engeland A, Berk M, Lund A. Co-prescription of medication for bipolar disorder and diabetes mellitus: A nationwide population-based study with focus on gender differences. BMC Medicine 2012;10:148.

Svendsen K, Skurtveit S, Romundstad P, Borchgrevink PC, Fredheim OM. Differential patterns of opioid use: defining persistent opioid use in a prescription database. Eur J Pain 2012;16:359-69.

Viktil KK, Engeland A, Furu K. Outcomes after antirheumatic drug use before and during pregnancy - a cohort study among 150 000 pregnant women and expectant fathers. Scand J Rheum 2012;41:196-201.

Von Soest T, Bramness JG, Pedersen W, Wichstrøm L. The relationship between socio-economic status and antidepressant prescription: A longitudinal survey and register study of young adults. Epidemiology and Psychiatric Sciences 2012;21:87-95.

Åsvold BO, Vatten LJ, Midthjell K, Bjøro T. Serum TSH within the reference range as a predictor of future hypothyroidism and hyperthyroidism: 11-year follow-up of the HUNT Study in Norway. J Clin Endocrinol Metab. 2012;97:93-9.

2011:

Berg C, Sakshaug S, Handal M, Skurtveit S. Z-hypnotika - Sovemidlene som dominerer markedet i Norge. Norsk Farmaceutisk Tidsskrift 2011;4:20-23.

Blix H, Hjellvik V, Litleskare I, Rønning M, Tverdal A. Cigarette smoking and risk of subsequent use of antibacterials: a follow-up of 365 117 men and women. J Antimicrob Chemother 2011;66:2159-67.

Bramness JG, Sexton JA. The basic pharmacoepidemiology of benzodiazepine use in Norway 2004-9. Norsk Epidemiologi 2011; 21: 35-42

Brekke M, Straand J. Does present use of cardiovascular medication reflect elevated cardiovascular risk scores estimated ten years ago? A population based longitudinal observation study. BMC Public Health. 2011;11:144.

Dalen DM, Furu K, Locatelli M, Strøm S. Generic substitution: micro evidence from register data in Norway. Eur J Health Econ 2011;12:49-59.

Engeland A, Bjørge T, Daltveit AK, Skurtveit S, Vangen S, Vollset SE, Furu K. Risk of diabetes after gestational diabetes and preeclampsia. A registry-based study of 230.000 women in Norway. Eur J Epidemiol 2011;26:157-63.

Espnes MG, Bjørge T, Engeland A. Comparison of recorded medication use in the Medical Birth Registry of Norway with prescribed medicines registered in the Norwegian Prescription Database. Pharmacoepidemiol Drug Saf 2011;20:243-8.

Fasmer OB, Riise T, Eagan TM, Lund A, Dilsaver SC, Hundal Ø, Ødegaard KJ. Comorbidity of asthma with ADHD. J Atten Disord 2011;15:564-71.

Fredheim OM, Borchgrevink P, Nordstrand B, Clausen T, Skurtveit S. Prescription of analgesics to patients in opioid maintenance therapy: A pharmacoepidemiological study. Drug Alcohol Depend 2011;116:158-62.

Furu K, Karlstad Ø, Skurtveit S, Håberg SE, Nafstad P, London SJ, Nystad W. High validity of mother-reported use of antiasthmatics among children: a comparison with a population-based prescription database. J Clin Epidemiol 2011;64:878-84.

Furu K, Skurtveit S. Legemidler forskrevet til barn og ungdom i alderen 0-17 år i Norge. En studie basert på data fra Reseptregisteret. Norsk Farmaceutisk Tidsskrift 2011;119:14-7.

Ghaderi S, Nordbø SA, Bakken IJ. Chlamydiainfeksjon i Sør-Trøndelag – behandling og oppfølging. [Chlamydia infections in South Trøndelag – treatment and follow-up]. Tidsskr Nor Laegeforen 2011;131:461-3.

Godman B, Sakshaug S, Berg C, Wettermark B, Haycox A. Combination of prescribing restrictions and policies to engineer low prices to reduce reimbursement costs. Expert Rev Pharmacoecon Outcomes Res. 2011;11:121-9.

Godman B, Shrank W, Andersen M, Berg C, Bishop I, Burkhardt T, Garuoliene K, Herholz H, Joppi R, Kalaba M, Laius O, Lonsdale J, Malmström R, Martikainen J, Samaluk V, Sermet C, Schwabe U, Teixeira I, Tilson L, Tulunay F, Vlahovic-Palcevski V, Wendykowska K, Wettermark B, Zara Corinne Gustafsson L. Policies to enchance prescribing effiency in Europe: findings and future implications. Front Pharmacol 2011;1:141.

Gjelstad S, Straand J, Dalen I, Fetveit A, Strøm H, Lindbæk M. Do general practitioners' consultation rates influence their prescribing patterns of antibiotics for acute respiratory tract infections? J Antimicrob Chemother 2011;66:2425-33.

Hancock D, Håberg SE, Furu K, Whitworth KV, Nafstad P, Nystad W, London SJ. Oral contraceptive pill use before pregnancy and respiratory outcomes in early childhood. Pediatr Allergy Immunol 2011;22:528-36.

Handal M, Engeland A, Rønning M, Skurtveit S, Furu K. Use of prescribed opioid analgesics and co-medication with benzodiazepines in women before, during and after pregnancy. A population based cohort study. Eur J Clin Pharmacol 2011;67:953-60

Harman C, Reid M, Thomas KV.In situ calibration of a passive sampling device for selected illicit drugs and their metabolites in wastewater, and subsequent year-long assessment of community drug usage. Environ Sci Technol. 2011;45:5676-82.

Hartz I, Bramness JG, Skurtveit S. Prescription of antidepressants to patients on opioid maintenance therapy – a pharmacoepidemiological study Norsk Epidemiologi 2011;21:77-83.

Hartz I, Tverdal, Aa, Skurtveit S. Langtidsbruk av benzodiazepiner i kombinasjon med opioider og z-hypnotika blant uføretrygdede i Norge. Norsk Farmaceutisk Tidsskrift 2011; 119, 24-28

Hjellvik V, Tverdal A, Strøm H. Boiled coffee intake and subsequent risk for Type 2 Diabetes. Epidemiology 2011;22:418-21.

Hofvind S, Sakshaug S, Ursin G, Graff-Iversen S. Breast cancer incidence trends in Norway –explained by hormone therapy or mammographic screening? International Journal of Cancer 2011;95:51-9.

Karlstad Ø, Tverdal A, Skurtveit S, Nafstad P, Furu K. A prospective study of asthma and subsequent use of hypnotics in young adults. Pharmacoepidemiol Drug Saf 2011;20:370-7

Kjosavik SR, Hunskaar S, Aarsland D, Ruths S. Initial prescription of antipsychotics and antidepressants in general practice and specialist care in Norway. Acta Psychiatr Scand 2011;123:459-65.

Kvaale MK, Grave K, Bangen M, Norström M. Forskrivning av antibakterielle midler til hund og katt i Norge i perioden 2005-2008. Norsk Veterinærtidsskrift 2011;123:76-79.

Landmark CJ, Fossmark H, Larsson PG, Rytter E, Johannessen SI. Prescription patterns of antiepileptic drugs in patients with epilepsy in a nation-wide population. Epilepsy Res. 2011;95:51-9.

Langballe EM, Engdahl B, Selbaek G, Nordeng H. Concomitant use of anti-dementia drugs with psychotropic drugs in Norway--a population-based study. Pharmacoepidemiol Drug Saf. 2011;20:1319-26

Log T, Hartz I, Handal M, Tverdal A, Furu K, Skurtveit S. The association between smoking and subsequent repeated use of prescribed opioids among adolescents and young adults – a population-based cohort study. Pharmacoepidemiol Drug Saf 2011;20:90-8.

Log T, Skurtveit S, Tverdal A, Furu K, Hartz I. Dispensing of prescribed analgesics in Norway among young people with foreign- or Norwegian-born parents. Scand J Pain 2011;2:36-44.

Mahic M, Skurtveit S, Selmer R, Rønning M, Furu K. Prevalence, incidence and persistence of etanercept and adalimimab in Norway 2005-2009. Pharmacoepidemiol Drug Saf. 2011;20:457-63.

Neubert A, Hsia Y, de Jong-van den Berg LT, Janhsen K, Glaeske G, Furu K, Kieler H, Nørgaard M, Clavenna A, Wong IC. Comparison of anti-diabetic drug prescribing in children and adolescents in seven European countries. Br J Clin Pharmacol. 2011;72:969-77.

Skurtveit S, Furu K, Handal M, Borchgrevink P, Fredheim O. To what extent does a cohort of new users of weak opioids develop persistent or probable problematic opioid use? Pain 2011;152:1555-61.

Zoega H, Furu K, Halldórsson M, Thomsen PH, Sourander A, Martikainen JE.Use of ADHD drugs in the Nordic countries: A population-based comparison study. Acta Psychiatr Scand 2011;123:360-7.

Ødegaard KJ, Dilsaver SC, Hundal O, Riise T, Lund A, Akiskal HS, Fasmer OB. Are migraine and bipolar disorders comorbid phenomena?: findings from a pharmacoepidemiological study using the Norwegian Prescription Database. J Clin Psychopharmacol. 2011;31:734-9.

Ødegaard KJ, Riise T, Dilsaver S, Lund A, Akiskal H, Fasmer OB, Hundal Ø. A pharmaco-epidemiological study of migraine and antidepressant medications: Complete one year data from the Norwegian population. J Affective Disorders 2011;129:198-204.

2010:

Amundsen MO, Engdahl B, Berg C, Nordeng H. Cardiovascular co-medication among users of antiobesity drugs: a population-based study. Pharm World Sci. 2010;32:752-8.

Amundsen MO, Engdahl B, Berg C, Nordeng H. Use of psychotropic drugs and analgesics among users of antiobesity drugs--a population based study. Pharmacoepidemiol Drug Saf 2010;19:273-9.

Andersen JB, Engeland A, Owe JF, Gilhus NE. Myasthenia gravis requiring pyridostigmine treatment in a national population cohort. Eur J Neurol 2010;17:1445-50.

Berg A, Furu K, Einen, M, Spigseth O: Bør barn behandles med efedrin mikstur? [Should children be treated with ephedrine mixture?]. Tidsskr Nor Lægeforen 2010;24: 2474-5.

Berge HM, Gjelstad S, Furu K, Straand J. Glukosaminbruk reduserer ikke behovet for analgetika [Use of glucosamine does not reduce the need for other pain-relieving drugs]. Tidsskr Nor Laegeforen 2010;130:1463-6.

Bramness JG, Rossow I. Can the total consumption of a medicinal drug be used as an indicator of excessive use? The case of carisoprodol. Drugs: Education, Prevention, and Policy 2010;17:168-80

Bramness J, Sandvik P, Engeland A, Skurtveit S. Does pregabalin (Lyrica) help patients reduce their use of benzodiazepines? A comparison with gabapentin using the Norwegian Prescription Database. Basic Clin Pharmacol Toxicol 2010;107:883-6

Devold HM, Doung GM, Tverdal A, Furu K, Meyer HE, Falch JA, Søgaard AJ. Prescription of anti-osteoporosis drugs during 2004-2007 – a nationwide register study in Norway. Eur J Clin Pharmacol 2010;66:299-306.

Fredheim OM, Skurtveit S, Breivik H, Borchgrevink P. Increasing use of opoids from 2004 to 2007 – Pharmacoepidemiological data from a complete national prescription database in Norway. Eur J Pain 2010;14:289-294.

Fredheim OM, Log T, Olsen W, Skurtveit S, Sagen Ø, Borchgrevink P. Prescription of opioids to children and adolescents; a study from a national prescription database in Norway. Pediatric Anesthesia 2010;20:537-544.

Furu K, Skurtveit S, Strøm H, Rønning M. Reseptregisteret 2004-2009 - en kilde til informasjon. Norsk Farmaceutisk Tidsskrift 2010;12:29-31.

Furu K, Wettermark B, Andersen M, Martikainen JE, Almarsdottir AB, Sørensen HT. The Nordic Countries as a cohort for pharmacoepidemiological research. Basic Clin Pharmacol Toxicol 2010;106:86-94.

Gjerden P, Slørdal L, Bramness JG. Prescription persistence and safety of antipsychotic medication: a national registry-based 3-year follow-up. Eur J Clin Pharmacol 2010;66:911-7.

Hartz I, Tverdal A, Skille E, Skurtveit S. Disability pension as a predictor of later use of benzodiazepines among benzodiazepines users. Soc Sci Med 2010;70:921-5.

Hausken AM, Furu K, Tverdal A, Skurtveit S. Mental distress and subsequent use of anxiolytic drugs - a prospective population-based cohort study of 16 000 individuals. Scand J Public Health 2010;38:465-73.

Hjellvik V, Tverdal A, Furu K. Body mass index as predictor for asthma: a cohort study of 118 723 males and females. Eur Resp J 2010;35:1235-42.

Hunskaar S, Welle-Nilsen LK. The market lifecycle of duloxetine for urinary incontinence in Norway. Acta Obstet Gynecol Scand. 2010;89:217-22

Kann IC, Biørn E, Lurås H. Competition in general practice: prescriptions to the elderly in a list patient system. J Health Econ. 2010;29:751-64

Karlstad Ø, Nafstad P, Tverdal A, Skurtveit S, Furu K. Prevalence, incidence and persistence of anti-asthma medication use in 2- to 29-year-olds: a nationwide prescription study. Eur J Clin Pharmacol 2010;66:399-406.

Karouni M, Arulthas S, Larsson PG, Rytter E, Johannessen SI, Landmark CJ. Psychiatric comorbidity in patients with epilepsy: a population-based study. Eur J Clin Pharmacol 2010;66:1151-60.

Kjome RL, Granas AG, Nerhus K, Roraas TH, Sandberg S. The prevalence of self-monitoring of blood glucose and costs of glucometer strips in a nationwide cohort. Diabetes Technol Ther 2010;12:701-5.

Kornør H, Pedersen W, von Soest T, Rossow I, Bramness JG. Bruk av benzodiazepiner og cannabis blant unge voksne [Use of benzodiazepines and cannabis in young adults]. Tidsskr Nor Laegeforen 2010 ;130:928-31.

Skurtveit S, Furu K, Bramness J, Selmer R, Tverdal A. Benzodiazepines predict use of opioids– a follow-up study of 17 074 men and women. Pain Med 2010;11:805-14.

Skurtveit S, Furu K, Selmer R, Handal M, Tverdal A. Nicotine dependence predicts repeated use of prescribed opioids. Prospective population-based cohort study. Ann Epidemiol 2010;20:890-7.

Vandraas K, Spigset O, Mahic M, Slørdal S. Non-steroidal anti-inflammatory drugs: use and co-treatment with potentially interacting medications in the elderly. Eur J Clin Pharmacol 2010;66:823-9.

2009:

Bachs LC, Engeland A, Mørland JG, Skurtveit S. The risk of motor vehicle accidents involving drivers with prescriptions for codeine or tramadol. Clin Pharmacol Ther 2009;85:596-9.

Bramness JG. Bruk av litium i Oslo og i Sogn og Fjordane [Use of lithium in the Norwegian counties Oslo and Sogn og Fjordane]. Tidsskr Nor Laegeforen 2009;129:855-7.

Bramness JG. Ungdom og dagliglivets smerter. [Adolescents and everyday life pains]. Tidsskr Nor Laegeforen 2009; 129:1444.

Bramness JG, Grøholt B, Engeland A, Furu K. The use of lithium, valproate or lamotrigine for psychiatric conditions in children and adolescents in Norway 2004-2007 – a prescription database study. J Affect Disord 2009; 117:208-11.

Bramness JG, Skurtveit S, Neutel I, Mørland J, Engeland A. An increased risk of road traffic accidents after prescriptions of lithium or valproate? Pharmacoepidemiol Drug Saf 2009;18:492-6.

Bramness JG, Weitoft GR, Hallas J. Use of lithium in the adult populations of Denmark, Norway and Sweden. J Affect Disord 2009;118:224-8.

Devold H, Molden E, Skurtveit S, Furu K. Co-medication of statins and CYP3A4 inhibitors before and after introduction of new reimbursement policy. Brit J Clin Pharmacol 2009;67:234-41.

Engeland A, Bjørge T, Daltveit AK, Vollset SE, Furu K. Validation of disease registration in pregnant women in the Medical Birth Registry of Norway. Acta Obstet Gynecol Scand 2009;88:1083-9.

Fredheim OM, Skurtveit S, Moroz A, Breivik H, Borchgrevink P. Prescription pattern of codeine for non-malignant pain in Norway- a pharmacoepidemiological study from The Norwegian Prescription Database. Acta Anaesthesiol Scand 2009;53:627-33.

Gjerden P, Bramness JG, Slørdal L. The use and potential abuse of anticholinergic antiparkinson drugs in Norway: a pharmacoepidemiological study. Br J Clin Pharmacol 2009;67:228-33.

Gjerden P, Slørdal L, Bramness JG. Association between the use of anticholinergic antiparkinson drugs and safety and receptor drug-binding profiles of antipsychotic agents. Eur J Clin Pharmacol 2009;65:1229-35.

Gjerden P, Slørdal L, Bramness JG. The use of antipsychotic and anticholinergic antiparkinson drugs in Norway after the withdrawal of orphenadrine. Br J Clin Pharmacol 2009;68:238-42.

Hartz I, Lundesgaard E, Tverdal A, Skurtveit S. Disability pension is associated with the use of benzodiazepines 20 years later: A prospective study. Scand J Public Health 2009;37:320-6.

Hartz I, Tverdal A, Skurtveit S. A comparison of self-reported data on disability pension status with data from a nationwide administrative register. Nor J Epidemiol 2009;19:169-172.

Hartz I, Tverdal A, Skurtveit S. Social inequalities in use of potentially addictive drugs in Norway – use among disability pensioners. Nor J Epidemiol 2009;19:209-218.

Hauge S, Blix HS, Borgen K, Hungnes O, Dudman SG, Aavitsland P. Sales of oseltamivir in Norway prior to the emergence of oseltamivir resistant influenza A(H1N1) viruses in 2007-08. Virol J 2009;6:54.

Hausken AM, Furu K, Skurtveit S, Engeland A, Bramness JG. Starting insomnia treatment: the use of benzodiazepines versus z-hypnotics. A prescription database study of predictors. Eur J Clin Pharmacol 2009;65:295-301.

Håkonsen GD, Pettersen MH, Skurtveit S, Giverhaug T. Samtidig bruk av warfarin, analgetika og antiinflammatoriske midler. [Concomitant use of warfarin, analgesics and anti-inflammatory drugs]. Tidsskr Nor Laegeforen 2009;129:1217-20.

Kjosavik SR, Ruths S, Hunskaar S. Psychotropic drug use in the Norwegian general population in 2005: data from the Norwegian Prescription Database Pharmacoepidemiol Drug Saf 2009;18:572-8.

Landmark CJ, Larsson P, Rytter E, Johannessen SI. Antiepileptic drugs in epilepsy and other disorders - a population-based study of prescriptions. Epilepsy Res 2009; 87: 31-9.

Selmer R, Sakshaug S, Skurtveit S, Furu K, Tverdal A. Statin treatment in a cohort of 20 212 men and women in Norway according to cardiovascular risk factors and level of education. Brit J Clin Pharmacol 2009;67:355-62.

Skurtveit S, Furu K, Kaasa S, Borchgrevink P. Introduction of low dose transdermal buprenorphine - did it influence use of potentially addictive drugs in chronic non-malignant pain patients? Eur J Pain 2009;13:949-53.

Skurtveit S, Strøm H, Skrivarhaug T, Mørland J, Bramness J, Engeland A. Road traffic accident risk in patients with diabetes mellitus, receiving blood glucose-lowering drugs. Prospective follow-up study. Diabet Med 2009; 26:404-08.

Viktil K, Engeland A, Furu K. Use of antirheumatic drugs in mothers and fathers before and during pregnancy – a population-based cohort study Pharmacoepidemiol Drug Saf 2009;18:737-42.

Winther RB, Bramness JG. Legemiddelshopping av vanedannende medikamenter i Norge [Prescription shopping of addictive drugs in Norway]. Tidsskr Nor Laegeforen 2009;129:517-20.

2008:

Bachs LC, Bramness JG, Engeland A, Skurtveit S. Repeated dispensing of codeine is associated with high consumption of benzodiazepines. Nor J Epidemiol 2008;18:185-90.

Berg A, Furu K, Spigset O. Slimhinneavsvellende nesedråper og nesespray hos barn [Nasal decongestants and nasal sprays in children].Tidsskr Nor Laegeforen 2008;128:2582-3.

Bramness JG, Buajordet I, Skurtveit S. The role of pharmacoepidemiological studies in the market withdrawal of carisoprodol (Somadril®) in Europe. Nor J Epidemiol 2008;18:167-72.

Bramness JG, Skurtveit S. Carisoprodol should be taken of the market. South Med J 2008;101:1074-5.

Bramness JG , Skurtveit S, Neutel CI, Mørland J, Engeland A. Minor increase in risk of road traffic accidents after prescriptions of antidepressants. J Clin Psych 2008; 69:1099-1103.

Brekke M, Rognstad, Straand J, Furu K, Gjelstad S, Bjørner T, Dalen I. Pharmacologically inappropriate prescriptions for elderly patients in general practice: How common? Baseline data from The Prescription Peer Academic Detailing (Rx-PAD) study. Scand J Prim Health Care 2008;26:80-5.

Engeland A, Bramness JG, Daltveit AK, Rønning M, Skurtveit S, Furu K. Prescription druguse among fathers and mothers before and during pregnancy. A population-based cohort study of 106,000 pregnancies in Norway 2004-06. Br J Clin Pharmacol 2008;65:653-60.

Engeland A, Bramness JG, Mørland J, Skurtveit S. Veitrafikkulykker knyttet til forskrivning av legemidler: en registerbasert kohortstudie. [Traffic accident risks associated with the prescription of medicinal drugs: a registry-based cohort study] Nor J Epidemiol 2008;18: 159-66.

Furu K. Establishment of the nationwide Norwegian Prescription Database (NorPD) - New opportunities for research in pharmacoepidemiology in Norway. Nor J Epidemiol 2008; 18:129-36.

Gustavsen I, Bramness JG, Skurtveit S, Engeland A, Neutel CI, Mørland J. Road traffic accident risk related to prescriptions of the hypnotics zopiclone, zolpidem, flunitrazepam and nitrazepam. Sleep Med 2008;9:818-22.

Hagen K. Stovner LJ. Skorpen F. Pettersen E. Zwart JA. COMT genotypes and use of antipsychotic medication: linking population-based prescription database to the HUNT study. Pharmacoepidemiol Drug Saf 2008;17:372-7.

Litleskare I, Blix H, Rønning M. Antibiotikaforbruk i Norge [Antibiotic use in Norway]. Tidsskr Nor Laegeforen 2008;128:2324-9.

Olsen AS, Ottesen S. Varierende forskrivning av opioider til norske kreftpasienter [Variable prescription of opioids to cancer patients in Norway]. Tidsskr Nor Laegeforen 2008;128:1271-4.

Skurtveit S, Furu K, Bramness JG, Tverdal A. Benzodiazepine use in all alcohol consumers predicts use of opioids in patients 20 years later – a follow-up study of 13 390 men and women aged 40-42 years. Pharmacoepidemiol Drug Saf 2008;17:926-933.

Skurtveit S, Selmer R, Tverdal A, Furu K. The validity of self-reported prescription medication use among adolescents varied by therapeutic class. J Clin Epidemiol 2008;61:714-17.

Strøm H, Sakshaug S, Skurtveit S. Use of statins in patients receiving oral blood glucose-lowering drugs. Nor J Epidemiol 2008;18:191-94.

2007:

Al-Haroni M, Skaug N. Incidence of antibiotic prescribing in dental practice in Norway and its contribution to national consumption. J Antimicrob Chemother 2007;59:1161-6.

Blix HS, Engeland A, Litleskare I, Rønning M. Age- and gender-specific antibacterial prescribing in Norway. J Antimicrob Chemother 2007;59:971-6.

Bramness JG, Engeland A, Furu K. Antidepressiver hos barn og ungdom – førte advarsler til færre forskrivninger? [The use of antidepressants amongst children and adolescents – did the warnings lead to fewer prescriptions?] Tidsskr Nor Laegeforen 2007;127:2653-5.

Bramness JG, Furu K, Engeland A, Skurtveit S. Carisoprodol use and abuse in Norway. A pharmacoepidemiological study. Br J Clin Pharmacol 2007;64: 210-8.

Bramness JG, Kornør H. Benzodiazepine prescription for patients in opioid maintenance treatment in Norway. Drug Alcohol Depend 2007;90:203-9.

Bramness JG, Skurtveit S, Mørland J, Engeland A. The risk of road traffic accidents after prescriptions of carisoprodol. Accid Anal Prev 2007;39:1050-5.

Engeland A, Skurtveit S, Mørland J. Risk of road traffic accidents associated with the prescription of medicinal drugs: a registry-based cohort study. Ann Epidemiol 2007;17:597-602.

Furu K, Skurtveit S, Langhammer A, Nafstad P. Use of anti-asthmatic medications as a proxy for prevalence of asthma in children and adolescents in Norway: a nationwide prescription database analysis. Eur J Clin Pharmacol 2007;63:693-8.

Hartz I, Sakshaug S, Furu K, Engeland A, Eggen AE, Njolstad I, Skurtveit S. Aspects of statin prescribing in Norwegian counties with high, average and low statin consumption - an individual-level prescription database study. BMC Clin Pharmacol 2007;7:14.

Nygard K, Schimmer B, Sobstad O, Walde A, Tveit I, Langeland N, Hausken T, Aavitsland P. A large community outbreak of waterborne giardiasis-delayed detection in a non-endemic urban area. BMC Public Health 2006;6:141.

Sakshaug S, Furu K, Karlstad Ø, Rønning M, Skurtveit S. Switching statins in Norway after new reimbursement policy - a nationwide prescription study. Br J Clin Pharmacol 2007;64:476-81.

Torkildsen O, Grytten N, Myhr KM. Immunomodulatory treatment of multiple sclerosis in Norway. Acta Neurol Scand Suppl 2007;187:46-50.

Åsheim H, Nilsen KB, Johansen K, Furu K. Forskrivning av sentralstimulerende legemidler ved ADHD i Nordland. [Prescribing of stimulants for ADHD in Nordland county]. Tidsskr Nor Laegeforen 2007;127:2360-2.

2006:
Bramness JG, Skurtveit S, Furu K, Engeland A, Sakshaug S, Rønning M. Endringer i salg og bruk av flunitrazepam etter 1999. [Changes in the sale and use of

Gjelstad S, Fetveit A, Straand J, Dalen I, Rognstad S, Lindback M. Can antibiotic prescriptions in respiratory tract infections be improved? A cluster-randomized educational intervention in general practice--the Prescription Peer Academic Detailing (Rx-PAD) Study [NCT00272155]. BMC Health Serv Res 2006;6:75.

Mellingsæter T, Bramness JG, Slørdal L. Benzodiazepinlignende z-hypnotika: bedre og tryggere søvnmidler? [Are z-hypnotics better and safer sleeping pills than benzodiazepines?] Tidsskr Nor Laegeforen 2006; 126: 2954-6.

Straand J, Fetveit A, Rognstad S, Gjelstad S, Brekke M, Dalen I. A cluster-randomized flunitrazepam in Norway, 1999 – 2004]. Tidsskr Nor Laegeforen 2006;126:589-90. educational intervention to reduce inappropriate prescription patterns for elderly patients in general practice--The Prescription Peer Academic Detailing (Rx-PAD) study [NCT00281450]. BMC Health Serv Res 2006;6:72.

Strøm H, Engeland A, Eriksen E, Sakshaug S, Rønning M. Hvor mange og hvem behandles medikamentelt for diabetes mellitus? [How many and who are receiving medication for diabetes mellitus?] Tidsskr Nor Laegeforen 2006;126:768-70.

2005:
Bramness JG, Hausken AM, Sakshaug S, Skurtveit S, Rønning M. Forskrivning av selektive serotoninreopptakshemmere 1990 – 2004. [Prescription of selective serotonin reuptake inhibitors 1990-2004]. Tidsskr Nor Laegeforen 2005;125:2470-3.

2004:
Strøm H. Reseptbasert legemiddelregister: Et viktig verktøy for å oppnå detaljert legemiddelstatistikk [The Norwegian Prescription Database: An important tool for detailed information on drug use]. Nor J Epidemiol 2004;14:53-56.

2001:
Furu K. Drug utilisation in a public health perspective: Establishing a national prescription register in Norway. Nor J Epidemiol 2001;11:55-60.

Utgitt av Nasjonalt folkehelseinstitutt
Published by Norwegian Institute of Public Health

Bestilling/Order:
E-mail:publikasjon@fhi.no
Telephone: +47 21 07 82 00
Telefax: +47 21 07 81 05

ISSN: 1890-9647
ISBN: 978-82-8082-665-7 trykt utgave /printed version
ISBN: 978-82-8082-666-4 elektronisk utgave /electronic version